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What’s New in the Guidelines?  (Last updated April 8, 2015; last reviewed
April 8, 2015)
Revisions to the May 1, 2014, version of the guidelines include key updates to several existing sections and
the addition of two new tables. Significant updates are highlighted throughout the document.
Key Updates
The following are key updates to existing sections of the guidelines.
What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient
Since the last version of these guidelines, data from clinical trials and cohort studies, as well as experience in
clinical practice, have prompted significant changes to the list of Recommended, Alternative, and Other
regimens for treatment-naive patients (Table 6). Additionally, a new table, titled “Antiretroviral (ARV)
Regimen Considerations as Initial Therapy Based on Specific Clinical Scenarios,” has been created to guide
clinicians on the selection of an initial ARV regimen based on specific clinical scenarios and ARV-related
considerations (Table 7).
•     There are now five Recommended regimens for antiretroviral therapy (ART)-naive patients—four
integrase strand transfer inhibitor (INSTI)-based regimens and one ritonavir-boosted protease inhibitor
(PI/r)-based regimen, as listed below:
INSTI-Based Regimens:
            • Dolutegravir/abacavir/lamivudine (DTG/ABC/3TC)—only for patients who are HLA-B*5701
negative (AI)
            • DTG plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (AI)
            • Elvitegravir/cobicistat/TDF/FTC (EVG/c/TDF/FTC)—only for patients with pre-ART CrCl >70
mL/min (AI)
            • Raltegravir (RAL) plus TDF/FTC (AI)
PI/r-Based Regimen:
            • Darunavir/ritonavir (DRV/r) plus TDF/FTC (AI)
•     Two regimens previously classified as Recommended regimens have been moved to the Alternative
regimens category, with the rationale stated below:
            • Atazanavir/ritonavir (ATV/r) plus TDF/FTC (BI)—Based on the results of a large comparative
clinical trial showing a greater rate of discontinuation with ATV/r plus TDF/FTC because of
toxicities when compared to (DRV/r or RAL) plus TDF/FTC
            • Efavirenz/TDF/FTC (EFV/TDF/FTC) (BI)—Based on concerns about the tolerability of EFV in
clinical trials and practice, especially the high rate of central nervous system (CNS)-related
toxicities and a possible association with suicidality
•     Three regimens (ATV/r plus ABC/3TC, EFV plus ABC/3TC, and rilpivirine/TDF/FTC) that were
previously listed as Recommended regimens for baseline HIV RNA <100,000 copies/mL or CD4 T
lymphocyte (CD4) count >200 cells/mm3 are now in the Alternative or Other category, with the same
caveat about limiting their use in these populations.
•     Two regimens that use fewer than two nucleoside reverse transcriptase inhibitors (DRV/r plus RAL and
lopinavir/ritonavir plus 3TC) are now listed among the Other regimens, with the caveat that their use
would be limited to those patients who cannot take either TDF or ABC.
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•     Coformulations of atazanavir (ATV) and darunavir (DRV) with the pharmacokinetic (PK) enhancer
cobicistat (COBI) have been added to the Alternative regimen options.
Virologic Failure
The following key updates have been made to this section:
•     The Management of Virologic Failure in Different Clinical Scenarios subsection has been expanded to
provide guidance on the management of patients failing first and second ART regimens.
•     A new subsection on Isolated CNS Virologic Failure and New Onset Neurologic Symptoms has been added.
•     The Suboptimal Immunologic Response Despite Viral Suppression subsection has been moved from this
section to become a stand-alone section (see below). 
Poor CD4 Cell Recovery and Persistent Inflammation Despite Viral Suppression
•     This new section describes the role of persistently low CD4 cell count (<200 cells/mm3) and persistent
inflammation/immune activation on the increased risk of AIDS- and non-AIDS-related morbidity.
•     The Panel emphasizes that currently no therapeutic intervention designed to improve CD4 cell recovery
or immune activation has been proven to improve health.
Acute/Early HIV Infection
•     This section has been updated to include the 2014 Centers for Disease Control and Prevention’s
recommendation for diagnosis of HIV infection, including in individuals with acute/early HIV infection.
HIV-2 Infection
•     This section has been updated with the most recent literature on ARV use in HIV-2-infected patients.
HIV/Hepatitis C Virus (HCV) Coinfection
•     The text and table (Table 12) in this section have been updated with information on the concomitant use
of different ARV drugs with the new HCV drug combination of ombitasvir, paritaprevir, ritonavir, and
dasabuvir.
Drug Interaction
•     The text of this section has been updated to focus on mechanisms of interaction of ARV drugs.
•     A new table, titled “Mechanisms of Antiretroviral Associated Drug Interactions,” has been developed to
provide clinicians with information on clinically relevant mechanisms of PK-associated interactions for
individual ARV drugs (Table 17).
•     All the Drug Interaction tables have been updated; in particular, interactions related to ATV/c, DRV/c,
and EVG plus PI/r have been added to these tables (see Tables 19a–e, 20a, and 20b).
Additional Updates
Minor revisions have also been made to the following sections:
•     Discontinuation or Interruption of Antiretroviral Therapy
•     Exposure-Response Relationship and Therapeutic Drug Monitoring (TDM) for Antiretroviral Agents
•     Monthly Average Wholesale Price of Antiretroviral Drugs (Table 16)
•     Drug Characteristics tables (Appendix B, Tables 1–7)
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Introduction  (Last updated February 12, 2013; last reviewed February 12, 2013)
Antiretroviral therapy (ART) for the treatment of HIV infection has improved steadily since the advent of
potent combination therapy in 1996. New drugs that offer new mechanisms of action, improvements in
potency and activity even against multidrug-resistant viruses, dosing convenience, and tolerability have been
approved. ART has dramatically reduced HIV-associated morbidity and mortality and has transformed HIV
disease into a chronic, manageable condition. In addition, effective treatment of HIV-infected individuals
with ART is highly effective at preventing transmission to sexual partners.1 However, less than one-third of
HIV-infected individuals in the United States have suppressed viral loads,2 which is mostly a result of
undiagnosed HIV infection and failure to link or retain diagnosed patients in care. Despite remarkable
improvements in HIV treatment and prevention, economic and social barriers that result in continued
morbidity, mortality, and new HIV infections persist.
The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and
Adolescents (the Panel) is a working group of the Office of AIDS Research Advisory Council (OARAC).
The primary goal of the Panel is to provide HIV care practitioners with recommendations based on current
knowledge of antiretroviral (ARV) drugs used to treat adults and adolescents with HIV infection in the
United States. The Panel reviews new evidence and updates recommendations in these guidelines when
needed. The Panel’s primary areas of attention have included baseline assessment, treatment goals,
indications for initiation of ART, choice of the initial regimen for ART-naive patients, drugs or combinations
to avoid, management of adverse effects and drug interactions, management of treatment failure, and special
ART-related considerations in specific patient populations. For recommendations related to pre-exposure
HIV prophylaxis (PrEP) for HIV-uninfected persons, please refer to recommendations from the Centers for
Disease Control and Prevention (CDC).3, 4
These guidelines generally represent the state of knowledge regarding the use of ARV agents. However,
because the science of HIV evolves rapidly, the availability of new agents and new clinical data may change
therapeutic options and preferences. Information included in these guidelines may not be consistent with
approved labeling for the particular products or indications in question, and the use of the terms “safe” and
“effective” may not be synonymous with the Food and Drug Administration (FDA)-defined legal standards
for product approval. The Panel frequently updates the guidelines (current and archived versions of the
guidelines are available on the AIDSinfo website at http://www.aidsinfo.nih.gov). However, the guidelines
cannot always be updated apace with the rapid evolution of new data in the field of HIV and cannot offer
guidance on care for all patients. Clinicians should exercise clinical judgment in management decisions
tailored to unique patient circumstances.
The Panel recognizes the importance of clinical research in generating evidence to address unanswered
questions related to the optimal safety and efficacy of ART. The Panel encourages both the development of
protocols and patient participation in well-designed, Institutional Review Board (IRB)-approved clinical
trials.
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Guidelines Development Process
Table 1. Outline of the Guidelines Development Process
Topic Comment
Goal of the
guidelines
Provide guidance to HIV care practitioners on the optimal use of antiretroviral (ARV) agents for the treatment of
HIV infection in adults and adolescents in the United States.
Panel members The Panel is composed of approximately 40 voting members who have expertise in HIV care and research. The
Panel includes at least one representative from each of the following U.S. Department of Health and Human Services
(HHS) agencies: Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), Health
Resource Services Administration (HRSA), and National Institutes of Health (NIH). Approximately two-thirds of the
Panel members are non-governmental scientific members. The Panel also includes four to five community members
with knowledge in HIV treatment and care. The U.S. government representatives are appointed by their respective
agencies; other Panel members are selected after an open announcement to call for nominations. Each member
serves on the Panel for a 4-year term with an option for reappointment for an additional term. A list of current
members can be found in the Panel Roster.
Financial
disclosure
All members of the Panel submit financial disclosure in writing annually, reporting any association with manufacturers
of ARV drugs or diagnostics used for management of HIV infections. A list of the latest disclosures is available on the
AIDSinfo website (http://aidsinfo.nih.gov/contentfiles/AA_financialDisclosures.pdf).
Users of the
guidelines
HIV treatment providers
Developer Panel on Antiretroviral Guidelines for Adults and Adolescents—a working group of the Office of AIDS Research
Advisory Council (OARAC)
Funding source Office of AIDS Research, NIH
Evidence
collection
The recommendations in the guidelines are generally based on studies published in peer-reviewed journals. On
some occasions, particularly when new information may affect patient safety, unpublished data presented at
major conferences or prepared by the FDA and/or manufacturers as warnings to the public may be used as
evidence to revise the guidelines.
Recommendation
grading
As described in Table 2
Method of
synthesizing data
Each section of the guidelines is assigned to a working group of Panel members with expertise in the area of
interest. The working groups synthesize the available data and propose recommendations to the Panel. The
Panel discusses all proposals during monthly teleconferences. Recommendations endorsed by the Panel are
included in the guidelines as official recommendations. 
Other guidelines These guidelines focus on treatment for HIV-infected adults and adolescents. Included is a brief discussion on the
management of women of reproductive age and pregnant women. For more detailed and up-to-date discussion
on the use of antiretroviral therapy (ART) for these women, as well as for children, and other special populations,
please refer to guidelines specific to these groups. The guidelines are also available on the AIDSinfo website
(http://www.aidsinfo.nih.gov).
Update plan The Panel meets monthly by teleconference to review data that may warrant modification of the guidelines.
Updates may be prompted by new drug approvals (or new indications, dosing formulations, or frequency of
dosing), new significant safety or efficacy data, or other information that may have a significant impact on the
clinical care of patients. In the event of significant new data that may affect patient safety, the Panel may post a
warning announcement with recommendations on the AIDSinfo website in the interim until the guidelines can be
updated with the appropriate changes. Updated guidelines are available on the AIDSinfo website
(http://www.aidsinfo.nih.gov).
Public comments A 2-week public comment period follows release of the updated guidelines on the AIDSinfo website. The Panel
reviews comments received to determine whether additional revisions to the guidelines are indicated. The public
may also submit comments to the Panel at any time at contactus@aidsinfo.nih.gov.
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Basis for Recommendations
Recommendations in these guidelines are based upon scientific evidence and expert opinion. Each
recommended statement includes a letter (A, B, or C) that represents the strength of the recommendation and
with a Roman numeral (I, II, or III) that represents the quality of the evidence that supports the
recommendation (see Table 2).
Table 2. Rating Scheme for Recommendations 
HIV Expertise in Clinical Care
Many studies have demonstrated that outcomes achieved in HIV-infected outpatients are better when care is
delivered by a clinician with HIV expertise,5-10 which reflects the complexity of HIV infection and its
treatment. Thus, appropriate training and experience, as well as ongoing continuing education, are important
components of optimal care. Primary care providers without HIV experience, such as those who provide
service in rural or underserved areas, should identify experts in their regions who will be available for
consultation when needed.
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Strength of Recommendation Quality of Evidence for Recommendation
A: Strong recommendation for the statement
B: Moderate recommendation for the statement
C: Optional recommendation for the statement
I: One or more randomized trials with clinical outcomes and/or
validated laboratory endpoints
II: One or more well-designed, non-randomized trials or
observational cohort studies with long-term clinical
outcomes
III: Expert opinion
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Baseline Evaluation  (Last updated May 1, 2014; last reviewed May 1, 2014)
Every HIV-infected patient entering into care should have a complete medical history, physical examination,
and laboratory evaluation and should be counseled regarding the implications of HIV infection. The goals of
the initial evaluation are to confirm the diagnosis of HIV infection, obtain appropriate baseline historical and
laboratory data, ensure patient understanding about HIV infection and its transmission, and to initiate care as
recommended in HIV primary care guidelines1 and guidelines for prevention and treatment of HIV-associated
opportunistic infections.2 The initial evaluation also should include introductory discussion on the benefits of
antiretroviral therapy (ART) for the patient’s health and to prevent HIV transmission. Baseline information
then can be used to define management goals and plans. In the case of previously treated patients who
present for an initial evaluation with a new health care provider, it is critical to obtain a complete
antiretroviral (ARV) history (including drug-resistance testing results, if available), preferably through the
review of past medical records. Newly diagnosed patients should also be asked about any prior use of ARV
agents for prevention of HIV infection.
The following laboratory tests performed during initial patient visits can be used to stage HIV disease and to
assist in the selection of ARV drug regimens:
•     HIV antibody testing (if prior documentation is not available or if HIV RNA is below the assay’s limit of
detection) (AI);
•     CD4 T-cell count (CD4 count) (AI);
•     Plasma HIV RNA (viral load) (AI);
•     Complete blood count, chemistry profile, transaminase levels, blood urea nitrogen (BUN), and creatinine,
urinalysis, and serologies for hepatitis A, B, and C viruses (AIII);
•     Fasting blood glucose and serum lipids (AIII); and
•     Genotypic resistance testing at entry into care, regardless of whether ART will be initiated immediately
(AII). For patients who have HIV RNA levels <500 to 1,000 copies/mL, viral amplification for resistance
testing may not always be successful (BII).
In addition, other tests (including screening tests for sexually transmitted infections and tests for determining
the risk of opportunistic infections and need for prophylaxis) should be performed as recommended in HIV
primary care and opportunistic infections guidelines.1, 2
Patients living with HIV infection often must cope with many social, psychiatric, and medical issues that are
best addressed through a patient-centered, multi-disciplinary approach to the disease. The baseline evaluation
should include an evaluation of the patient’s readiness for ART, including an assessment of high-risk behaviors,
substance abuse, social support, mental illness, comorbidities, economic factors (e.g., unstable housing),
medical insurance status and adequacy of coverage, and other factors that are known to impair adherence to
ART and increase the risk of HIV transmission. Once evaluated, these factors should be managed accordingly.
The baseline evaluation should also include a discussion of risk reduction and disclosure to sexual and/or
needle sharing partners, especially with untreated patients who are still at high risk of HIV transmission.
Education about HIV risk behaviors and effective strategies to prevent HIV transmission should be provided
at each patient visit (see Preventing Secondary Transmission of HIV).
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Laboratory Testing
Laboratory Testing for Initial Assessment and Monitoring of HIV-Infected Patients on
Antiretroviral Therapy  (Last updated May 1, 2014; last reviewed May 1, 2014)
A number of laboratory tests are important for initial evaluation of HIV-infected patients upon entry into
care; during follow-up if antiretroviral therapy (ART) is not initiated; and before and after initiation or
modification of therapy to assess the virologic and immunologic efficacy of ART and to monitor for
laboratory abnormalities that may be associated with antiretroviral (ARV) drugs. Table 3 outlines the Panel’s
recommendations on the frequency of testing. As noted in the table, some tests may be repeated more
frequently if clinically indicated.
Two surrogate markers are used routinely to assess immune function and level of HIV viremia: CD4 T-cell
count (CD4 count) and plasma HIV RNA (viral load), respectively. Resistance testing should be used to
guide selection of an ARV regimen. A viral tropism assay should be performed before initiation of a CCR5
antagonist or at the time of virologic failure that occurs while a patient is receiving a CCR5 antagonist. HLA-
B*5701 testing should be performed before initiation of abacavir (ABC). The rationale for and utility of
these laboratory tests are discussed in the corresponding sections of the guidelines.
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Table 3. Laboratory Monitoring Schedule for HIV-Infected Patients Before and After Initiation of
Antiretroviral Therapya (page 1 of 2)
Laboratory
Test
Timepoint/Frequency of Testing
Entry into
Care
Follow Up
Before
Initiation of
ART
ART Initiation
or
Modificationb
Follow-Up 2
to 8 Weeks
After ART
Initiation or
Modification
Every 3 to 6
Months
Every 6
Months
Every 12
Months
Treatment
Failure
Clinically
Indicated
HIV
Serology
√
If HIV
diagnosis
has not been
confirmed
CD4 Count √ √
Every 3–6
months
√ √
During first 2
years of ART
or if viremia
develops
while patient
on ART or
CD4 count
<300 cells/
mm3
√
After 2 years on
ART with
consistently
suppressed viral
load:
CD4 Count 300–
500 cells/mm3:
• Every 12
months
CD4 Count
>500 cells/mm3:
• CD4
monitoring is
optional
√ √
HIV Viral
Load
√ Repeat
testing is
optional
√ √c √d √d √ √
Resistance
Testing
√ √e √ √
HLA-
B*5701
Testing
√
If considering
ABC
Tropism
Testing
√
If considering a
CCR5
antagonist
√
If
considering
a CCR5
antagonist
or for
failure of
CCR5
antagonist-
based
regimen
√
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Table 3. Laboratory Monitoring Schedule for HIV-Infected Patients Before and After Initiation of
Antiretroviral Therapya (page 2 of 2)
Laboratory
Test
Timepoint/Frequency of Testing
Entry into
Care
Follow Up
Before
Initiation of
ART
ART Initiation
or
Modificationb
Follow-Up 2
to 8 Weeks
After ART
Initiation or
Modification
Every 3 to 6
Months
Every 6
Months
Every 12
Months
Treatment
Failure
Clinically
Indicated
Hepatitis B
Serologyf
√ √
May repeat if
HBsAg (-) and
HBsAb (-) at
baseline
√
Hepatitis C
Serology,
with
Confirmation
of Positive
Results
√ √
Basic
Chemistryg,h
√ √
Every 6–12
months
√ √ √ √
ALT, AST, T.
bilirubin
√ √
Every 6–12
months
√ √ √ √
CBC with
Differential
√ √
Every 3–6
months
√ √
If on ZDV
√ √
Fasting Lipid
Profile
√ √
If normal,
annually
√ √
Consider 4–8
weeks after
starting new
ART regimen
that affects
lipids
√
If abnormal
at last
measure-
ment
√
If normal at last
measurement
√
Fasting
Glucose or
Hemoglobin
A1C
√ √
If normal,
annually
√ √
If abnormal
at last
measure-
ment
√
If normal at last
measurement
√
Urinalysisg √ √ √
If on TDFi
√ √
Pregnancy
Test
√
In women with
child-bearing
potential
√
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aThis table pertains to laboratory tests done to select an ARV regimen and monitor for treatment responses or ART toxicities. Please refer
to the HIV Primary Care guidelines for guidance on other laboratory tests generally recommended for primary health care maintenance of
HIV patients.1
b ART may be modified because of treatment failure, adverse effects, or for regimen simplification.
c If HIV RNA is detectable at 2 to 8 weeks, repeat every 4 to 8 weeks until viral load is suppressed to <200 copies/mL, and thereafter, every
3 to 6 months.
d In patients on ART, viral load typically is measured every 3 to 4 months. However, for adherent patients with consistently suppressed viral
load and stable immunologic status for more than 2 years, monitoring can be extended to 6 month intervals.
e In ART-naive patients, if resistance testing was performed at entry into care, repeat testing before initiation of ART is optional. The
exception is pregnant women; repeat testing is recommended in this case. In virologically suppressed patients who are switching therapy
because of toxicity or for convenience, viral amplification will not be possible; therefore, resistance testing should not be performed.
Results from prior resistance testing can be helpful in constructing a new regimen.
f If HBsAg is positive at baseline or before initiation of ART, TDF plus either FTC or 3TC should be used as part of the ARV regimen to treat
both HBV and HIV infections. If HBsAg, and HBsAb, and anti-HBc are negative at baseline, hepatitis B vaccine series should be
administered. Refer to HIV Primary Care guidelines for more detailed recommendations.1
g Serum Na, K, HCO3, Cl, BUN, creatinine, glucose (preferably fasting). Some experts suggest monitoring the phosphorus levels of
patients on TDF. Determination of renal function should include estimation of CrCl using the Cockcroft-Gault equation or estimation of
glomerular filtration rate using the MDRD equation.
h For patients with renal disease, consult the Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients:
Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.2
i More frequent monitoring may be indicated for patients with evidence of kidney disease (e.g., proteinuria, decreased glomerular
dysfunction) or increased risk of renal insufficiency (e.g., patients with diabetes, hypertension).
Key to Acronyms: 3TC = lamivudine, ABC = abacavir, ALT = alanine aminotransferase, ART = antiretroviral therapy, AST = aspartate
aminotranserase, CBC = complete blood count, CrCl = creatinine clearance, EFV = efavirenz, FTC = emtricitabine, HBsAb = hepatitis B
surface antibody, HBsAg = hepatitis B surface antigen, HBV = hepatitis B virus, MDRD = modification of diet in renal disease (equation),
TDF = tenofovir, ZDV = zidovudine
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Plasma HIV-1 RNA (Viral Load) and CD4 Count Monitoring  (Last updated May 1, 2014; last
reviewed May 1, 2014)
HIV RNA (viral load) and CD4 T lymphocyte (CD4) cell count are the two surrogate markers of
antiretroviral treatment (ART) responses and HIV disease progression that have been used for decades to
manage and monitor HIV infection.
Viral load is a marker of response to ART. A patient’s pre-ART viral load level and the magnitude of viral
load decline after initiation of ART provide prognostic information about the probability of disease
progression.1 The key goal of ART is to achieve and maintain durable viral suppression. Thus, the most
important use of the viral load is to monitor the effectiveness of therapy after initiation of ART.
Measurement of CD4 count is particularly useful before initiation of ART. The CD4 cell count provides
information on the overall immune function of an HIV-infected patient. The measurement is critical in
establishing thresholds for the initiation and discontinuation of opportunistic infection (OI) prophylaxis and
in assessing the urgency to initiate ART.
The management of HIV-infected patients has changed substantially with the availability of newer, more
potent, and less toxic antiretroviral (ARV) agents. In the United States, ART is now recommended for all
HIV-infected patients regardless of their viral load or CD4 count. In the past, clinical practice, which was
supported by treatment guidelines, was generally to monitor both CD4 cell count and viral load concurrently.
However, because most HIV-infected patients in care now receive ART, the rationale for frequent CD4
monitoring is weaker. The roles and usefulness of these two tests in clinical practice are discussed in the
following sections.
Plasma HIV-1 RNA (Viral Load) Monitoring
Viral load is the most important indicator of initial and sustained response to ART (AI) and should be
measured in all HIV-infected patients at entry into care (AIII), at initiation of therapy (AIII), and on a
regular basis thereafter. For those patients who choose to delay therapy, repeat viral load testing while not on
ART is optional (CIII). Pre-treatment viral load level is also an important factor in the selection of an initial
ARV regimen because several currently approved ARV drugs or regimens have been associated with poorer
responses in patients with high baseline viral load (see What to Start). Commercially available HIV-1 RNA
assays do not detect HIV-2 viral load. For further discussion on HIV-2 RNA monitoring in patients with HIV-
1/HIV-2 co-infection or HIV-2 mono-infection, see HIV-2 Infection.
Several systematic reviews of data from clinical trials involving thousands of participants have established that
decreases in viral load following initiation of ART are associated with reduced risk of progression to AIDS or
death.1-3 Thus, viral load testing is an established surrogate marker for treatment response.4 The minimal
change in viral load considered to be statistically significant (2 standard deviations) is a three-fold change
(equivalent to a 0.5 log10 copies/mL change). Optimal viral suppression is defined generally as a viral load
persistently below the level of detection (HIV RNA <20 to 75 copies/mL, depending on the assay used).
However, isolated blips (viral loads transiently detectable at low levels, typically HIV RNA <400 copies/mL)
are not uncommon in successfully treated patients and are not predictive of virologic failure.5 Furthermore, the
data on the association between persistently low level but quantifiable viremia (HIV RNA <200 copies/mL)
and virologic failure is conflicting. One recent study showed an increased risk of subsequent failure at this level
of viremia; however, the association was not observed in other studies.6-9 These guidelines and the AIDS
Clinical Trials Group (ACTG) now define virologic failure as a confirmed viral load >200 copies/mL—a
threshold that eliminates most cases of apparent viremia caused by viral load blips or assay variability10 (see
Virologic Failure and Suboptimal Immunologic Response).
Individuals who are adherent to their ARV regimens and do not harbor resistance mutations to the component
drugs can generally achieve viral suppression 8 to 24 weeks after ART initiation; rarely, in some patients it
Downloaded from http://aidsinfo.nih.gov/guidelines on 9/16/2015
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents                                   C-6
may take longer. Recommendations on the frequency of viral load monitoring are summarized below:
• After initiation of ART or modification of therapy because of virologic failure. Plasma viral load
should be measured before initiation of ART and within 2 to 4 weeks but no later than 8 weeks after
treatment initiation or modification (AIII). The purpose of the measurements is to confirm an adequate
initial virologic response to ART, indicating appropriate regimen selection and patient adherence to
therapy. Repeat viral load measurement should be performed at 4- to 8-week intervals until the level falls
below the assay’s limit of detection (BIII).
• In virologically suppressed patients in whom ART was modified because of drug toxicity or for
regimen simplification. Viral load measurement should be performed within 4 to 8 weeks after changing
therapy (AIII). The purpose of viral load monitoring at this point is to confirm the effectiveness of the
new regimen. 
• In patients on a stable, suppressive ARV regimen. Viral load should be repeated every 3 to 4 months
(AIII) or as clinically indicated to confirm continuous viral suppression. Clinicians may extend the
interval to 6 months for adherent patients whose viral load has been suppressed for more than 2 years and
whose clinical and immunologic status is stable (AIII). 
• In patients with suboptimal response. The frequency of viral load monitoring will depend on clinical
circumstances, such as adherence and availability of further treatment options. In addition to viral load
monitoring, a number of additional factors, such as patient adherence to prescribed medications,
suboptimal drug exposure, or drug interactions, should be assessed. Patients who fail to achieve viral
suppression should undergo resistance testing to aid in the selection of an alternative regimen (see Drug-
Resistance Testing and Virologic Failure and Suboptimal Immunologic Response sections).
CD4 Count Monitoring
The CD4 count is the most important laboratory indicator of immune function in HIV-infected patients. It is
also the strongest predictor of subsequent disease progression and survival according to findings from
clinical trials and cohort studies.11,12 CD4 counts are highly variable; a significant change (2 standard
deviations) between 2 tests is approximately a 30% change in the absolute count, or an increase or decrease
in CD4 percentage by 3 percentage points. Monitoring of lymphocyte subsets other than CD4 (e.g., CD8,
CD19) has not proven clinically useful, is more expensive, and is not routinely recommended (BIII).
Use of CD4 Count for Initial Assessment
CD4 count should be measured in all patients at entry into care (AI). It is the key factor in determining the
need to initiate OI prophylaxis (see the Adult Opportunistic Infection Guidelines)13 and the urgency to
initiate ART (AI) (see the Initiating Antiretroviral Therapy in Antiretroviral-Naive Patients section of these
guidelines). Although most OIs occur in patients with CD4 counts <200 cells/mm3, some OIs can occur in
patients with higher CD4 counts.14
Use of CD4 Count for Monitoring Therapeutic Response
The CD4 count is used to assess a patient’s immunologic response to ART. It is also used to determine
whether prophylaxis for OIs can be discontinued (see the Adult Opportunistic Infection Guidelines)13. For
most patients on therapy, an adequate response is defined as an increase in CD4 count in the range of 50 to
150 cells/mm3 during the first year of ART, generally with an accelerated response in the first 3 months of
treatment. Subsequent increases average approximately 50 to 100 cells/mm3 per year until a steady state level
is reached.15 Patients who initiate therapy with a low CD4 count16 or at an older age17 may have a blunted
increase in their counts despite virologic suppression. 
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Frequency of CD4 Count Monitoring
ART is now recommended for all HIV-infected patients. In patients who remain untreated for whatever
reason, CD4 counts should be monitored every 3 to 6 months to assess the urgency of ART initiation and the
need for OI prophylaxis (AIII).
A repeat CD4 count 3 months after ART initiation will provide information regarding the magnitude of immune
reconstitution (AIII). This repeat measurement is most important in patients who initiate ART with more
advanced disease and require OI prophylaxis or treatment. In these patients, the magnitude and duration of
CD4 count increase can be used to determine whether to discontinue OI prophylaxis and/or treatment as
recommended in the guidelines for treatment and prophylaxis of opportunistic infections.13 In this setting, and
in the first 2 years following ART initiation, CD4 count can be monitored at 3- to 6-month intervals (BII).
The CD4 count response to ART varies widely, but a poor CD4 response in a patient with viral suppression is
rarely an indication for modifying an ARV regimen. In patients with consistently suppressed viral loads who
have already experienced ART-related immune reconstitution, the CD4 count provides limited information.
Frequent testing is unnecessary because the results rarely lead to a change in clinical management. One
retrospective study found that declines in CD4 count to <200 cells/mm3 are rare in patients with viral
suppression and CD4 counts >300 cells/mm3.18 Similarly, the ARTEMIS trial found that CD4 monitoring had
no clinical benefit in patients who had suppressed viral loads and CD4 counts >200 cells/mm3 after 48 weeks
of therapy.19 Furthermore, the risk of Pneumocystis jirovecii pneumonia is extremely low in patients on
suppressive ART who have CD4 counts between 100 and 200 cells/mm3.20 Although uncommon, CD4 count
declines can occur in a small percentage of virologically suppressed patients and may be associated with
adverse clinical outcomes such as cardiovascular disease, malignancy, and death.21 An analysis of costs
associated with CD4 monitoring in the United States estimated that reducing CD4 monitoring in treated
patients from every 6 months to every 12 months could result in annual savings of approximately $10 million.22
For the patient on a suppressive regimen whose CD4 count has consistently ranged between 300 and 500 cells/
mm3 for at least 2 years, the Panel recommends CD4 monitoring on an annual basis (BII). Continued CD4
monitoring for virologically suppressed patients whose CD4 counts have been consistently >500 cells/mm3 for
at least 2 years may be considered optional (CIII). The CD4 count should be monitored more frequently, as
clinically indicated, when there are changes in a patient’s clinical status that may decrease CD4 count and thus
prompt OI prophylaxis. Examples of such changes include the appearance of new HIV-associated clinical
symptoms or initiation of treatment known to reduce CD4 cell count (e.g., interferon, chronic corticosteroids,
or anti-neoplastic agents) (AIII). In patients who fail to maintain viral suppression while on ART, the Panel
recommends CD4 count monitoring every 3 to 6 months (AIII) (see Virologic Failure and Suboptimal
Immunologic Response section).
Factors that Affect Absolute CD4 Count
The absolute CD4 count is a calculated value based on the total white blood cell (WBC) count and the
percentages of total and CD4+ T lymphocytes. This absolute number may fluctuate in individuals or may be
influenced by factors that may affect the total WBC count and lymphocyte percentages, such as use of bone
marrow-suppressive medications or the presence of acute infections. Splenectomy23,24 or co-infection with
human T-lymphotropic virus type I (HTLV-1)25 may cause misleadingly elevated CD4 counts. Alpha-interferon
may reduce the absolute CD4 count without changing the CD4 percentage.26 In all these settings, CD4
percentage remains stable and may be a more appropriate parameter to assess a patient’s immune function.
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Table 4. Recommendations on the Indications and Frequency of Viral Load and CD4 Count Monitoringa
Clinical Scenario Viral Load Monitoring CD4 Count Monitoring
Before initiating ART At entry into care (AIII)
If ART initiation is deferred, repeat before
initiating ART (AIII).
In patients not initiating ART, repeat testing is
optional (CIII).
At entry into care (AI)
If ART is deferred, every 3 to 6 months
(AIII).b
After initiating ART Preferably within 2 to 4 weeks (and no later
than 8 weeks) after initiation of ART (AIII);
thereafter, every 4 to 8 weeks until viral load
suppressed (BIII). 
3 months after initiation of ART (AIII)
After modifying ART because of drug
toxicities or for regimen simplification in a
patient with viral suppression
4 to 8 weeks after modification of ART to
confirm effectiveness of new regimen (AIII).
Monitor according to prior CD4 count and
duration on ART, as outlined below.
After modifying ART because of virologic
failure
Preferably within 2 to 4 weeks (and no later
than 8 weeks) after modification (AIII);
thereafter, every 4 to 8 weeks until viral load
suppressed (BIII). If viral suppression is not
possible, repeat viral load every 3 months or
more frequently if indicated (AIII). 
Every 3 to 6 months (AI)
During the first 2 years of ART Every 3 to 4 months (AIII) Every 3 to 6 monthsa (BII)
After 2 years of ART (VL consistently
suppressed, CD4 consistently 300-
500 cells/mm3) Can extend to every 6 months for patients
with consistent viral suppression for ≥2 years
(AIII).
Every 12 months (BII)
After 2 years of ART (VL consistently
suppressed, CD4 consistently >500 cells/
mm3)
Optional (CIII)
While on ART with detectable viremia (VL
repeatedly >200 copies/mL) 
Every 3 months (AIII) or more frequently if
clinically indicated. (See Virologic Failure and
Suboptimal Immunologic Response section)
Every 3 to 6 months (AIII)
Change in clinical status (e.g., new HIV
clinical symptom or initiation of interferon,
chronic systemic corticosteroids, or
antineoplastic therapy)
Every 3 months (AIII) Perform CD4 count and repeat as clinically
indicatedc (AIII)
a Monitoring of lymphocyte subsets other than CD4 (e.g., CD8, CD19) has not proven clinically useful, adds to costs, and is not routinely
recommended (BIII).
b Some experts may repeat CD4 count every 3 months in patients with low baseline CD4 count (<200–300 cells/mm3) before ART but
every 6 months in those who initiated ART at higher CD4 cell count (e.g., >300 cells/mm3).
c The following are examples of clinically indicated scenarios: changes in a patient’s clinical status that may decrease CD4 count and thus
prompt initiation of prophylaxis for opportunistic infections (OI), such as new HIV-associated symptoms, or initiation of treatment with
medications which are known to reduce CD4 cell count.
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Drug-Resistance Testing (Last updated May 1, 2014; last reviewed May 1, 2014)
Genotypic and Phenotypic Resistance Assays
Genotypic and phenotypic resistance assays are used to assess viral strains and inform selection of treatment
strategies. Standard assays provide information on resistance to nucleoside reverse transcriptase inhibitors
(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). Testing for
integrase and fusion inhibitor resistance can also be ordered separately from several commercial laboratories.
Co-receptor tropism assays should be performed whenever the use of a CCR5 antagonist is being considered.
Phenotypic co-receptor tropism assays have been used in clinical practice. A genotypic assay to predict co-
receptor use is now commercially available (see Co-receptor Tropism Assays).
Genotypic Assays
Genotypic assays detect drug-resistance mutations present in relevant viral genes. Most genotypic assays
involve sequencing of the RT and PR genes to detect mutations that are known to confer drug resistance.
Genotypic assays that assess mutations in the integrase and gp41 (envelope) genes are also commercially
available. Genotypic assays can be performed rapidly and results are available within 1 to 2 weeks of sample
collection. Interpretation of test results requires knowledge of the mutations selected by different
antiretroviral (ARV) drugs and of the potential for cross resistance to other drugs conferred by certain
mutations. The International AIDS Society-USA (IAS-USA) maintains an updated list of significant
resistance-associated mutations in the RT, PR, integrase, and envelope genes (see
Panel’s Recommendations
• HIV drug-resistance testing is recommended in persons with HIV infection at entry into care regardless of whether antiretroviral
therapy (ART) will be initiated immediately or deferred (AII). If therapy is deferred, repeat testing should be considered at the time of
ART initiation (CIII).
• Genotypic testing is recommended as the preferred resistance testing to guide therapy in antiretroviral (ARV)-naive patients (AIII).
• Standard genotypic drug-resistance testing in ARV-naive persons involves testing for mutations in the reverse transcriptase (RT) and
protease (PR) genes. If transmitted integrase strand transfer inhibitor (INSTI) resistance is a concern, providers may wish to
supplement standard genotypic resistance testing with an INSTI genotype test (CIII).
• HIV drug-resistance testing should be performed to assist in the selection of active drugs when changing ARV regimens in persons
with virologic failure and HIV RNA levels >1,000 copies/mL (AI). In persons with HIV RNA levels >500 but <1,000 copies/mL, testing
may be unsuccessful but should still be considered (BII).
• Drug-resistance testing should also be performed when managing suboptimal viral load reduction (AII).
• In persons failing INSTI-based regimens, genotypic testing for INSTI resistance should be performed to determine whether to include
a drug from this class in subsequent regimens (AII).
• Drug-resistance testing in the setting of virologic failure should be performed while the person is taking prescribed ARV drugs or, if
not possible, within 4 weeks after discontinuing therapy (AII). If greater than 4 weeks has lapsed since the ARVs were discontinued,
resistance testing may still provide useful information to guide therapy, recognizing that previously selected resistance mutations can
be missed (CIII).
• Genotypic testing is recommended as the preferred resistance testing to guide therapy in patients with suboptimal virologic
responses or virologic failure while on first or second regimens (AII).
• The addition of phenotypic to genotypic testing is generally preferred for persons with known or suspected complex drug-resistance
mutation patterns, particularly to protease inhibitors (PIs) (BIII).
• Genotypic resistance testing is recommended for all pregnant women before initiation of ART (AIII) and for those entering pregnancy
with detectable HIV RNA levels while on therapy (AI) (see the Perinatal Treatment Guidelines for more detailed discussion).
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
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http://www.iasusa.org/resistance_mutations).1 The Stanford University HIV Drug Resistance Database
(http://hivdb.stanford.edu) also provides helpful guidance for interpreting genotypic resistance test results.
Various tools to assist the provider in interpreting genotypic test results are now available.2-5 Clinical trials
have demonstrated that consultation with specialists in HIV drug resistance improves virologic outcomes.6
Clinicians are thus encouraged to consult a specialist to facilitate interpretation of genotypic test results and
design of an optimal new regimen.
Phenotypic Assays
Phenotypic assays measure the ability of a virus to grow in different concentrations of ARV drugs. RT and
PR gene sequences and, more recently, integrase and envelope sequences derived from patient plasma HIV
RNA are inserted into the backbone of a laboratory clone of HIV or used to generate pseudotyped viruses
that express the patient-derived HIV genes of interest. Replication of these viruses at different drug
concentrations is monitored by expression of a reporter gene and is compared with replication of a reference
HIV strain. The drug concentration that inhibits viral replication by 50% (i.e., the median inhibitory
concentration [IC50]) is calculated, and the ratio of the IC50 of test and reference viruses is reported as the
fold increase in IC50 (i.e., fold resistance). 
Automated phenotypic assays that can produce results in 2 to 3 weeks are commercially available, but they
cost more to perform than genotypic assays. In addition, interpretation of phenotypic assay results is
complicated by incomplete information regarding the specific resistance level (i.e., fold increase in IC50) that
is associated with drug failure, although clinically significant fold increase cutoffs are now available for
some drugs.7-11 Again, consultation with a specialist to interpret test results can be helpful.
Further limitations of both genotypic and phenotypic assays include lack of uniform quality assurance testing
for all available assays, relatively high cost, and insensitivity to minor viral species. Despite being present,
drug-resistant viruses that constitute less than 10% to 20% of the circulating virus population will probably
not be detected by commercially available assays. This limitation is important because after drugs exerting
selective pressure on drug-resistant populations are discontinued, a wild-type virus often re-emerges as the
predominant population in the plasma. As a consequence, the proportion of virus with resistance mutations
decreases to below the 10% to 20% threshold.12-14 In the case of some drugs, this reversion to predominantly
wild-type virus can occur in the first 4 to 6 weeks after the drugs are discontinued. Prospective clinical
studies have shown that despite this plasma reversion, re-initiation of the same ARV agents (or those sharing
similar resistance pathways) is usually associated with early drug failure, and that the virus present at failure
is derived from previously archived resistant virus.15 Therefore, resistance testing is of greatest value when
performed before or within 4 weeks after drugs are discontinued (AII). Because resistant virus may persist in
the plasma of some patients for longer periods of time, resistance testing done 4 to 6 weeks after
discontinuation of drugs may still detect mutations. However, the absence of detectable resistance in such
patients must be interpreted with caution when designing subsequent ARV regimens.
Use of Resistance Assays in Clinical Practice (See Table 5)
Use of Resistance Assays in Determining Initial Treatment
Transmission of drug-resistant HIV strains is well documented and associated with suboptimal virologic
response to initial antiretroviral therapy (ART).16-19 The likelihood that a patient will acquire drug-resistant
virus is related to the prevalence of drug resistance in HIV-infected persons engaging in high-risk behaviors
in the community. In the United States and Europe, recent studies suggest that the risk that transmitted virus
will be resistant to at least one ARV drug is in the range of 6% to 16%.20-25 Up to 8%, but generally less than
5% of transmitted viruses will exhibit resistance to drugs from more than one class.24, 26-28
If the decision is made to initiate therapy in a person with early HIV infection, resistance testing at baseline
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can guide regimen selection to optimize virologic response. Therefore, resistance testing in this situation is
recommended (AII). A genotypic assay is preferred for this purpose (AIII). In this setting, treatment
initiation should not be delayed pending resistance testing results. Once results are obtained, the treatment
regimen can be modified if warranted (see Acute and Recent HIV Infection). In the absence of therapy,
resistant viruses may decline over time to less than the detection limit of standard resistance tests, but when
therapy is eventually initiated, resistant viruses even at a low level may still increase the risk of treatment
failure.29-31 Therefore, if therapy is deferred, resistance testing should still be done during acute HIV infection
(AIII). In this situation, the genotypic resistance test result may be kept on record until the patient is to be
started on ART. Repeat resistance testing at the time treatment is started should be considered because it is
possible for a patient to acquire drug-resistant virus (i.e., superinfection) between entry into care and
initiation of ART (CIII).
Performing drug-resistance testing before ART initiation in patients with chronic HIV infection is less
straightforward. The rate at which transmitted resistance-associated mutations revert to wild-type virus has
not been completely delineated, but mutations present at the time of HIV transmission are more stable than
those selected under drug pressure. It is often possible to detect resistance-associated mutations in viruses
that were transmitted several years earlier.32-34 No prospective trial has addressed whether drug-resistance
testing before initiation of therapy confers benefit in this population. However, data from several, but not all,
studies suggest that virologic responses in persons with baseline resistance mutations are suboptimal.16-19, 35-37
In addition, a cost-effectiveness analysis of early genotypic resistance testing suggests that baseline testing in
this population should be performed.38 Therefore, resistance testing in chronically infected persons is
recommended at the time of entry into HIV care (AII). Although no definitive prospective data exist to
support the choice of one type of resistance testing over another, genotypic testing is generally preferred in
this situation because of lower cost, more rapid turnaround time, the assay’s ability to detect mixtures of
wild-type and resistant virus, and the relative ease of interpreting test results (AIII). If therapy is deferred,
repeat testing soon before initiation of ART should be considered because the patient may have acquired
drug-resistant virus (i.e., superinfection) (CIII).
Standard genotypic drug-resistance testing in ARV-naive persons involves testing for mutations in the RT and
PR genes. Although transmission of integrase strand transfer inhibitor (INSTI)-resistant virus has rarely been
reported, as use of INSTIs increases, the potential for transmission of INSTI-resistant virus may also
increase. Therefore, when INSTI resistance is suspected, providers may wish to supplement standard
baseline genotypic resistance testing with genotypic testing for resistance to this class of drugs (CIII).
Use of Resistance Assays in the Event of Virologic Failure
Resistance assays are useful in guiding treatment decisions for patients who experience virologic failure
while on ART. Several prospective studies assessed the utility of resistance testing to guide ARV drug
selection in patients with virologic failure. These studies involved genotypic assays, phenotypic assays, or
both.6, 39-45 In general, these studies found that changes in therapy that were informed by resistance testing
results produced better early virologic response to salvage regimens than regimen changes guided only by
clinical judgment.
In addition, one observational cohort study found that performance of genotypic drug-resistance testing in
ART-experienced patients with detectable plasma HIV RNA was independently associated with improved
survival.46 Thus, resistance testing is recommended as a tool in selecting active drugs when changing ARV
regimens because of virologic failure in persons with HIV RNA >1,000 copies/mL (AI) (see Virologic
Failure and Suboptimal Immunologic Response). In persons with HIV RNA >500 copies/mL but <1,000
copies/mL, testing may be unsuccessful but should still be considered (BII). Drug-resistance testing in
persons with a plasma viral load <500 copies/mL is not usually recommended because resistance assays
cannot be consistently performed given low HIV RNA levels (AIII).
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Resistance testing also can help guide treatment decisions for patients with suboptimal viral load reduction
(AII). Virologic failure in the setting of combination ART is, for certain patients, associated with resistance
to only one component of the regimen.47-49 In this situation, substituting individual drugs in a failing regimen
may be a possible option, but this concept will require clinical validation (see Virologic Failure and
Suboptimal Immunologic Response).
In patients who are on a failing first or second ARV drug regimen and experiencing virologic failure or
suboptimal viral load reduction, genotypic testing is generally preferred for resistance testing (AII). This is
based on the fact that, when compared with phenotypic testing, genotypic testing costs less to perform, has a
faster turnaround time, and greater sensitivity for detecting mixtures of wild-type and resistant virus. In
addition, observations show that the assays are comparable predictors of virologic response to subsequent
ART regimens.50
Addition of phenotypic to genotypic testing is generally preferred for persons with known or suspected
complex drug-resistance mutation patterns, particularly to PIs (BIII).
In patients failing INSTI-based regimens, testing for INSTI resistance should be performed to determine
whether to include drugs from this class in subsequent regimens (AII); genotypic testing is preferred for this
purpose. 
When the use of a CCR5 antagonist is being considered, a co-receptor tropism assay should be performed
(AI). Phenotypic co-receptor tropism assays have been used in clinical practice. A genotypic assay to predict
co-receptor use is now commercially available and is less expensive than phenotypic assays. Evaluation of
genotypic assays is ongoing, but current data suggest that such testing should be considered as an alternative
assay. The same principles regarding testing for co-receptor use also apply to testing when patients exhibit
virologic failure on a CCR5 antagonist.51 Resistance to CCR5 antagonists in the absence of detectable
CXCR4-using virus has been reported, but such resistance is uncommon (see Co-receptor Tropism Assays).
Use of Resistance Assays in Pregnant Women
In pregnant women, the goal of ART is to maximally reduce plasma HIV RNA to provide optimal maternal
therapy and to prevent perinatal transmission of HIV. Genotypic resistance testing is recommended for all
pregnant women before initiation of therapy (AIII) and for those entering pregnancy with detectable HIV
RNA levels while on therapy (AI). Phenotypic testing in those found to have complex drug-resistance
mutation patterns, particularly to PIs, may provide additional information (BIII). Optimal prevention of
perinatal transmission may require initiation of ART pending resistance testing results. Once the results are
available, the ARV regimen can be changed as needed.
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Clinical Setting/Recommendation Rationale
Drug-resistance assay recommended
In acute HIV infection: Drug-resistance testing is recommended
regardless of whether antiretroviral therapy (ART) is initiated
immediately or deferred (AII). A genotypic assay is generally preferred
(AIII).
If ART is initiated immediately, drug-resistance testing can
determine whether drug-resistant virus was transmitted. Test
results will help in the design of initial regimens or to modify or
change regimens if results are obtained after treatment initiation.
Genotypic testing is preferred to phenotypic testing because of
lower cost, faster turnaround time, and greater sensitivity for
detecting mixtures of wild-type and resistant virus.
If ART is deferred, repeat resistance testing should be considered at
the time therapy is initiated (CIII). A genotypic assay generally is
preferred (AIII).
If ART is deferred, testing should still be performed because of
the greater likelihood that transmitted resistance-associated
mutations will be detected earlier in the course of HIV infection.
Results of resistance testing may be important when treatment
is initiated. Repeat testing at the time ART is initiated should be
considered because the patient may have acquired a drug-
resistant virus (i.e., superinfection).
In ART-naive patients with chronic HIV infection: Drug-resistance
testing is recommended at entry into HIV care, regardless of whether
therapy is initiated immediately or deferred (AII). A genotypic assay is
generally preferred (AIII).
If therapy is deferred, repeat resistance testing should be considered
before initiation of ART (CIII). A genotypic assay is generally preferred
(AIII).
If an INSTI is considered for an ART-naive patient and transmitted
INSTI resistance is a concern, providers may supplement standard
resistance testing with a specific INSTI genotypic resistance assay
(CIII).
If use of a CCR5 antagonist is being considered, a co-receptor tropism
assay should be performed (AI) (see Co-receptor Tropism Assays)
Transmitted HIV with baseline resistance to at least 1 drug is
seen in 6% to 16% of patients, and suboptimal virologic
responses may be seen in patients with baseline resistant
mutations. Some drug-resistance mutations can remain
detectable for years in untreated, chronically infected patients.
Repeat testing before initiation of ART should be considered
because the patient may have acquired a drug-resistant virus
(i.e., a superinfection).
Genotypic testing is preferred to phenotypic testing because of
lower cost, faster turnaround time, and greater sensitivity for
detecting mixtures of wild-type and resistant virus.
Standard genotypic drug-resistance assays test only for
mutations in the RT and PR genes.
(see Co-receptor Tropism Assays)
In patients with virologic failure: Drug-resistance testing is
recommended in patients on combination ART with HIV RNA levels
>1,000 copies/mL (AI). In patients with HIV RNA levels >500
copies/mL but <1,000 copies/mL, testing may not be successful but
should still be considered (BII).
A standard genotypic resistance assay is generally preferred for patients
experiencing virologic failure on their first or second regimens (AII).
In patients failing INSTI-based regimens, genotypic testing for INSTI
resistance should be performed to determine whether to include drugs
from this class in subsequent regimens (AII).
If use of a CCR5 antagonist is being considered, a co-receptor tropism
assay should be performed (AI) (see Co-receptor Tropism Assays).
Addition of phenotypic assay to genotypic assay is generally preferred
in patients with known or suspected complex drug-resistance patterns,
particularly to protease inhibitors (PIs) (BIII).
Testing can help determine the role of resistance in drug failure
and maximize the clinician’s ability to select active drugs for the
new regimen. Drug-resistance testing should be performed while
the patient is taking prescribed ARV drugs or, if not possible,
within 4 weeks after discontinuing therapy.
Genotypic testing is preferred to phenotypic testing because of
lower cost, faster turnaround time, and greater sensitivity for
detecting mixtures of wild-type and resistant HIV.
Standard genotypic drug-resistance assays test only for
mutations in the RT and PR genes.
Phenotypic testing can provide additional useful information in
patients with complex drug-resistance mutation patterns,
particularly to PIs.
Table 5. Recommendations for Using Drug-Resistance Assays (page 1 of 2)
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Clinical Setting/Recommendation Rationale
Drug-resistance assay recommended
In patients with suboptimal suppression of viral load: Drug-
resistance testing is recommended in patients with suboptimal
suppression of viral load after initiation of ART (AII).
Testing can help determine the role of resistance and thus
assist the clinician in identifying the number of active drugs
available for a new regimen.
In HIV-infected pregnant women: Genotypic resistance testing is
recommended for all pregnant women before initiation of ART
(AIII) and for those entering pregnancy with detectable HIV RNA
levels while on therapy (AI).
The goal of ART in HIV-infected pregnant women is to achieve
maximal viral suppression for treatment of maternal HIV infection
and for prevention of perinatal transmission of HIV. Genotypic
resistance testing will assist the clinician in selecting the optimal
regimen for the patient.
Drug-resistance assay not usually recommended
After therapy is discontinued: Drug-resistance testing is not
usually recommended more than 4 weeks after discontinuation of
ARV drugs (BIII).
Drug-resistance mutations may become minor species in the
absence of selective drug pressure, and available assays may not
detect minor drug-resistant species. If testing is performed in this
setting, the detection of drug resistance may be of value; however,
the absence of resistance does not rule out the presence of minor
drug-resistant species.
In patients with low HIV RNA levels: Drug-resistance testing is
not usually recommended in patients with a plasma viral load <500
copies/mL (AIII).
Resistance assays cannot be consistently performed given low
HIV RNA levels.
Table 5. Recommendations for Using Drug-Resistance Assays (page 2 of 2)
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Co-Receptor Tropism Assays  (Last updated February 12, 2013; last reviewed February 12, 2013)
HIV enters cells by a complex process that involves sequential attachment to the CD4 receptor followed by
binding to either the CCR5 or CXCR4 molecules and fusion of the viral and cellular membranes.1 CCR5 co-
receptor antagonists prevent HIV entry into target cells by binding to the CCR5 receptors.2 Phenotypic and, to
a lesser degree, genotypic assays have been developed that can determine or predict the co-receptor tropism
(i.e., CCR5, CXCR4, or both) of the patient’s dominant virus population. An older generation assay (Trofile,
Monogram Biosciences, Inc., South San Francisco, CA) was used to screen patients who were participating in
clinical trials that led to the approval of maraviroc (MVC), the only CCR5 antagonist currently available. The
assay has been improved and is now available with enhanced sensitivity. In addition, a genotypic assay to
predict co-receptor usage is now commercially available.
During acute/recent infection, the vast majority of patients harbor a CCR5-utilizing virus (R5 virus), which
suggests that the R5 variant is preferentially transmitted. Viruses in many untreated patients eventually exhibit
a shift in co-receptor tropism from CCR5 usage to either CXCR4 or both CCR5 and CXCR4 tropism (i.e.,
dual- or mixed-tropic; D/M-tropic). This shift is temporally associated with a more rapid decline in CD4 T-cell
counts,3, 4 but whether this tropism shift is a cause or a consequence of progressive immunodeficiency remains
undetermined.1 Antiretroviral (ARV)-treated patients with extensive drug resistance are more likely to harbor
X4- or D/M-tropic variants than untreated patients with comparable CD4 counts.5 The prevalence of X4- or
D/M-tropic variants increases to more than 50% in treated patients who have CD4 counts <100 cells/mm3.5, 6
Phenotypic Assays
Phenotypic assays characterize the co-receptor usage of plasma-derived virus. These assays involve the
generation of laboratory viruses that express patient-derived envelope proteins (i.e., gp120 and gp41). These
pseudoviruses, which are replication-defective, are used to infect target cell lines that express either CCR5 or
CXCR4.7, 8 Using the Trofile assay, the co-receptor tropism of the patient-derived virus is confirmed by testing
the susceptibility of the virus to specific CCR5 or CXCR4 inhibitors in vitro. This assay takes about 2 weeks
to perform and requires a plasma HIV RNA level ≥1,000 copies/mL. 
The performance characteristics of these assays have evolved. Most, if not all, patients enrolled in pre-
marketing clinical trials of MVC and other CCR5 antagonists were screened with an earlier, less sensitive
version of the Trofile assay.8 This earlier assay failed to routinely detect low levels of CXCR4-utilizing
variants. As a consequence, some patients enrolled in these clinical trials harbored low levels of CXCR4-
utilizing virus at baseline that were below the assay limit of detection and exhibited rapid virologic failure
after initiation of a CCR5 antagonist.9 The assay has been revised and is now able to detect lower levels of
CXCR4-utlizing viruses. In vitro, the assay can detect CXCR4-utilizing clones with 100% sensitivity when
those clones represent 0.3% or more of the virus population.10 Although this more sensitive assay has had
limited use in prospective clinical trials, it is now the only one that is commercially available. For unclear
Panel’s Recommendations
• A co-receptor tropism assay should be performed whenever the use of a CCR5 co-receptor antagonist is being considered (AI).
• Co-receptor tropism testing is also recommended for patients who exhibit virologic failure on a CCR5 antagonist (BIII).
• A phenotypic tropism assay is preferred to determine HIV-1 co-receptor usage (AI).
• A genotypic tropism assay should be considered as an alternative test to predict HIV-1 co-receptor usage (BII). 
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
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reasons, a minority of samples cannot be successfully phenotyped with either generation of the Trofile assay. 
In patients with plasma HIV-1 RNA below the limit of detection, co-receptor usage can be determined from
proviral DNA obtained from peripheral blood mononuclear cells; however, the clinical utility of this assay
remains to be determined.11
Genotypic Assays
Genotypic determination of HIV-1 co-receptor usage is based on sequencing of the V3-coding region of HIV-
1 env, the principal determinant of co-receptor usage. A variety of algorithms and bioinformatics programs
can be used to predict co-receptor usage from the V3 sequence. When compared to the phenotypic assay,
genotypic methods show high specificity (~90%) but only modest sensitivity (~50%–70%) for the presence
of a CXCR4-utilizing virus. Given these performance characteristics, these assays may not be sufficiently
robust to completely rule out the presence of an X4 or D/M variant.12
Studies in which V3 genotyping was performed on samples from patients screened for clinical trials of MVC
suggest that genotyping performed as well as phenotyping in predicting the response to MVC.13-15 On the
basis of these data, accessibility, and cost, European guidelines currently favor genotypic testing to determine
co-receptor usage.16 An important caveat to these results is that the majority of patients who received MVC
were first shown to have R5 virus by a phenotypic assay (Trofile). Consequently, the opportunity to assess
treatment response to MVC in patients whose virus was considered R5 by genotype but D/M or X4 by
phenotype was limited to a relatively small number of patients. 
Use of Assays to Determine Co-Receptor Usage in Clinical Practice
An assay for HIV-1 co-receptor usage should be performed whenever the use of a CCR5 antagonist is being
considered (AI). In addition, because virologic failure may occur due to a shift from CCR5-using to CXCR4-
using virus, testing for co-receptor usage is recommended in patients who exhibit virologic failure on a
CCR5 antagonist (BIII). Virologic failure also may be caused by resistance of a CCR5-using virus to a
CCR5 antagonist, but such resistance is uncommon. Compared to genotypic testing, phenotypic testing has
more evidence supporting its usefulness. Therefore, a phenotypic test for co-receptor usage is generally
preferred (AI). However, because phenotypic testing is more expensive and requires more time to perform, a
genotypic test to predict HIV-1 co-receptor usage should be considered as an alternative test (BII).
A tropism assay may potentially be used in clinical practice for prognostic purposes or to assess tropism
before starting ART if future use of a CCR5 antagonist is anticipated (e.g., a regimen change for toxicity).
Currently, sufficient data do not exist to support these uses.
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HLA-B*5701 Screening (Last updated December 1, 2007; last reviewed January 10, 2011)
The ABC HSR is a multiorgan clinical syndrome typically seen within the initial 6 weeks of ABC treatment.
This reaction has been reported in 5%–8% of patients participating in clinical trials when using clinical
criteria for the diagnosis, and it is the major reason for early discontinuation of ABC. Discontinuing ABC
usually promptly reverses HSR, whereas subsequent rechallenge can cause a rapid, severe, and even life-
threatening recurrence.1
Studies that evaluated demographic risk factors for ABC HSR have shown racial background as a risk factor,
with white patients generally having a higher risk (5%–8%) than black patients (2%–3%). Several groups
reported a highly significant association between ABC HSR and the presence of the major histocompatibility
complex (MHC) class I allele HLA-B*5701.2-3 Because the clinical criteria used for ABC HSR are overly
sensitive and may lead to false-positive ABC HSR diagnoses, an ABC skin patch test (SPT) was developed
as a research tool to immunologically confirm ABC HSR.4 A positive ABC SPT is an ABC-specific delayed
HSR that results in redness and swelling at the skin site of application. All ABC SPT–positive patients
studied were also positive for the HLA-B*5701 allele.5 The ABC SPT could be falsely negative for some
patients with ABC HSR and, at this point, is not recommended for use as a clinical tool. The PREDICT-1
study randomized patients before starting ABC either to be prospectively screened for HLA-B*5701 (with
HLA-B*5701–positive patients not offered ABC) or to standard of care at the time of the study (i.e., no HLA
screening, with all patients receiving ABC).6 The overall HLA-B*5701 prevalence in this predominately
white population was 5.6%. In this cohort, screening for HLA-B*5701 eliminated immunologic ABC HSR
(defined as ABC SPT positive) compared with standard of care (0% vs. 2.7%), yielding a 100% negative
predictive value with respect to SPT and significantly decreasing the rate of clinically suspected ABC HSR
(3.4% vs. 7.8%). The SHAPE study corroborated the low rate of immunologically validated ABC HSR in
black patients and confirmed the utility of HLA-B*5701 screening for the risk of ABC HSR (100%
sensitivity in black and white populations).7
On the basis of the results of these studies, the Panel recommends screening for HLA-B*5701 before starting
patients on an ABC-containing regimen (AI). HLA-B*5701–positive patients should not be prescribed ABC
(AI), and the positive status should be recorded as an ABC allergy in the patient’s medical record (AII).
HLA-B*5701 testing is needed only once in a patient’s lifetime; thus, efforts to carefully record and maintain
the test result and to educate the patient about its implications are important. The specificity of the HLA-
B*5701 test in predicting ABC HSR is lower than the sensitivity (i.e., 33%–50% of HLA-B*5701–positive
patients would likely not develop confirmed ABC HSR if exposed to ABC). HLA-B*5701 should not be
used as a substitute for clinical judgment or pharmacovigilance, because a negative HLA-B*5701 result does
not absolutely rule out the possibility of some form of ABC HSR. When HLA-B*5701 screening is not
Panel’s Recommendations
• The Panel recommends screening for HLA-B*5701 before starting patients on an abacavir (ABC)-containing regimen to reduce the
risk of hypersensitivity reaction (HSR) (AI).
• HLA-B*5701-positive patients should not be prescribed ABC (AI).
• The positive status should be recorded as an ABC allergy in the patient’s medical record (AII).
• When HLA-B*5701 screening is not readily available, it remains reasonable to initiate ABC with appropriate clinical counseling and
monitoring for any signs of HSR (CIII).
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
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readily available, it remains reasonable to initiate ABC with appropriate clinical counseling and monitoring
for any signs of ABC HSR (CIII).
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Treatment Goals (Last updated March 27, 2012; last reviewed March 27, 2012)
Eradication of HIV infection cannot be achieved with available antiretroviral (ARV) regimens even when
new, potent drugs are added to a regimen that is already suppressing plasma viral load below the limits of
detection of commercially available assays.1 This is chiefly because the pool of latently infected CD4 T cells
is established during the earliest stages of acute HIV infection2 and persists with a long half-life, despite
prolonged suppression of plasma viremia.3-7 Therefore the primary goals for initiating antiretroviral therapy
(ART) are to:
•     reduce HIV-associated morbidity and prolong the duration and quality of survival,
•     restore and preserve immunologic function,
•     maximally and durably suppress plasma HIV viral load (see Plasma HIV RNA Testing), and
•     prevent HIV transmission.
ART has reduced HIV-related morbidity and mortality8-11 and has reduced perinatal12 and behavior-associated
transmission of HIV.13-17 HIV suppression with ART may also decrease inflammation and immune activation
thought to contribute to higher rates of cardiovascular and other end-organ damage reported in HIV-infected
cohorts. (See Initiating Antiretroviral Therapy.) Maximal and durable suppression of plasma viremia delays
or prevents the selection of drug-resistance mutations, preserves CD4 T-cell numbers, and confers substantial
clinical benefits, all of which are important treatment goals.18-19
Achieving viral suppression requires the use of ARV regimens with at least two, and preferably three, active
drugs from two or more drug classes. Baseline resistance testing and patient characteristics should guide
design of the specific regimen. (See What to Start: Initial Combination Regimens for the Antiretroviral-
Naive Patient.) When initial suppression is not achieved or is lost, rapidly changing to a new regimen with at
least two active drugs is required. (See Virologic Failure and Suboptimal Immunologic Response.) The
increasing number of drugs and drug classes makes viral suppression below detection limits an appropriate
goal in all patients.
Viral load reduction to below limits of assay detection in an ART-naive patient usually occurs within the first
12–24 weeks of therapy. Predictors of virologic success include:
•     high potency of ARV regimen,
•     excellent adherence to treatment regimen,20
•     low baseline viremia,21
•     higher baseline CD4 count (>200 cells/mm3),22 and
•     rapid reduction of viremia in response to treatment.21,23
Successful outcomes are usually observed, although adherence difficulties may lower the success rate in
clinical practice to below the 90% rate commonly seen in clinical trials.24
Strategies to Achieve Treatment Goals
Achieving treatment goals requires a balance of sometimes competing considerations, outlined below.
Providers and patients must work together to define individualized strategies to achieve treatment goals.
Selection of Initial Combination Regimen
Several preferred and alternative ARV regimens are recommended for use. (See What to Start.) Many of
these regimens have comparable efficacy but vary to some degree in dosing frequency and symmetry, pill
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burden, drug interactions, and potential side effects. Regimens should be tailored for the individual patient to
enhance adherence and thus improve long-term treatment success. Individual regimen choice is based on
such considerations as expected side effects, convenience, comorbidities, interactions with concomitant
medications, and results of pretreatment genotypic drug-resistance testing.
Pretreatment Drug-Resistance Testing
Current studies suggest a 6%–16% prevalence of HIV drug resistance in ART-naive patients,25-29 and some
studies suggest that the presence of transmitted drug-resistant viruses may lead to suboptimal virologic
responses.30 Therefore, pretreatment genotypic resistance testing should be used to guide selection of the
most optimal initial ARV regimen. (See Drug-Resistance Testing.)
Improving Adherence
Suboptimal adherence may result in reduced treatment response. Incomplete adherence can result from
complex medication regimens; patient factors, such as active substance abuse and depression; and health
system issues, including interruptions in patient access to medication and inadequate treatment education and
support. Conditions that promote adherence should be maximized before and after initiation of ART. (See
Adherence to Antiretroviral Therapy.)
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Initiating Antiretroviral Therapy in Treatment-Naive Patients  (Last
updated May 1, 2014; last reviewed May 1, 2014)
Introduction
Without treatment, most HIV-infected individuals will eventually develop progressive immunosuppression,
as evident by CD4 T lymphocyte (CD4) cell depletion, leading to AIDS-defining illnesses and premature
death. The primary goal of ART is to prevent HIV-associated morbidity and mortality. This goal is best
accomplished by using effective ART to maximally inhibit HIV replication so that plasma HIV RNA (viral
load) remains below levels detectable by commercially available assays. Durable viral suppression improves
immune function and overall quality of life, lowers the risk of both AIDS-defining and non-AIDS-defining
complications, and prolongs life.
Furthermore, high plasma HIV RNA is a major risk factor for HIV transmission, and effective antiretroviral
therapy (ART) can reduce viremia and transmission of HIV to sexual partners by more than 96%.1,2
Modelling studies suggest that expanded use of ART may result in lower incidence and, eventually,
prevalence of HIV on a community or population level.3 Thus, a secondary goal of ART is to reduce the risk
of HIV transmission.
Historically, HIV-infected individuals have had low CD4 counts at presentation to care.4 However, there have
been concerted efforts to increase testing of at-risk patients and to link these patients to medical care before
they have advanced HIV disease. Deferring ART until CD4 count declines put an individual at risk of AIDS-
defining conditions has been associated with higher risk of morbidity and mortality (as discussed below).
Furthermore, the magnitude of CD4 recovery is directly correlated with CD4 count at ART initiation.
Consequently, many individuals who start treatment with CD4 counts <350 cells/mm3 never achieve counts
>500 cells/mm3 after up to 6 years on ART.5
The recommendation to initiate ART in individuals with high CD4 cell counts—whose short-term risk for
death and development of AIDS-defining illness is low6,7—is based on growing evidence that untreated HIV
infection or uncontrolled viremia is associated with development of non-AIDS-defining diseases, including
cardiovascular disease (CVD), kidney disease, liver disease, neurologic complications, and malignancies.
Furthermore, newer ART regimens are more effective, more convenient, and better tolerated than regimens
used in the past.
Panel’s Recommendations
• Antiretroviral therapy (ART) is recommended for all HIV-infected individuals to reduce the risk of disease progression.
The strength of and evidence for this recommendation vary by pretreatment CD4 T lymphocyte (CD4) cell count: CD4 count 
<350 cells/mm3 (AI); CD4 count 350 to 500 cells/mm3 (AII); CD4 count >500 cells/mm3 (BIII).
• ART is also recommended for HIV-infected individuals to prevent of transmission of HIV. 
The strength of and evidence for this recommendation vary by transmission risks: perinatal transmission (AI); heterosexual
transmission (AI); other transmission risk groups (AIII). 
• Patients starting ART should be willing and able to commit to treatment and understand the benefits and risks of therapy and the
importance of adherence (AIII). Patients may choose to postpone therapy, and providers, on a case-by-case basis, may elect to
defer therapy on the basis of clinical and/or psychosocial factors.
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
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Regardless of CD4 count, the decision to initiate ART should always include consideration of a patient’s
comorbid conditions, his or her willingness and readiness to initiate therapy, and available resources. In
settings where there are insufficient resources to initiate ART in all patients, treatment should be prioritized
for patients with the following clinical conditions: pregnancy; CD4 count <200 cells/mm3 or history of an
AIDS-defining illness including HIV-associated dementia, HIV-associated nephropathy (HIVAN), or
hepatitis B virus (HBV); and acute HIV infection. 
Tempering the enthusiasm to treat all patients regardless of CD4 count is the absence of randomized trial
data that demonstrate a definitive clinical benefit of ART in patients with higher CD4 counts (e.g., >350
cells/ mm3) and mixed results from observational cohort studies as to the definitive benefits of early ART
(i.e., when CD4 count >500 cells/mm3). For some asymptomatic patients, the potential risks of short- or
long-term drug-related complications and non-adherence to long-term therapy may offset possible benefits of
earlier initiation of therapy. An ongoing randomized controlled trial evaluating the role of immediate versus
delayed ART in patients with CD4 counts >500 cells/mm3 (see Strategic Timing of Antiretroviral Treatment
(START); ClinicalTrials.gov identifier NCT00867048) should help to further define the role of ART in this
patient population.
The known and potential benefits and limitations of ART in general, and in different patient populations are
discussed below.
Benefits of Antiretroviral Therapy
Reduction in Mortality and/or AIDS-Related Morbidity According to Pretreatment CD4
Cell Count
Patients with a History of an AIDS-Defining Illness or CD4 Count <350 cells/mm3
HIV-infected patients with CD4 counts <200 cells/mm3 are at higher risk of opportunistic diseases, non-
AIDS morbidity, and death than HIV-infected patients with higher CD4 counts. Randomized controlled trials
in patients with CD4 counts <200 cells/mm3 and/or a history of an AIDS-defining condition provide strong
evidence that ART improves survival and delays disease progression in these patients.8-10 Long-term data
from multiple observational cohort studies comparing earlier ART (i.e., initiated at CD4 count >200
cells/mm3) with later treatment (i.e., initiated at CD4 count <200 cells/mm3) have also provided strong
support for these findings.11-16
Few large, randomized controlled trials address when to start therapy in patients with CD4 counts >200
cells/mm3. CIPRA HT-001, a randomized clinical trial conducted in Haiti, enrolled 816 participants without
AIDS. Participants were randomized to start ART with CD4 counts in the 200 to 350 cells/mm3 range or to
defer treatment until their CD4 counts dropped to <200 cells/mm3 or they developed an AIDS-defining
condition. The study was terminated when an interim analysis showed a survival benefit in the early
treatment arm. When compared with participants who began ART with CD4 counts in the 200 to 350
cells/mm3 range, patients who deferred therapy had a higher mortality rate (23 versus 6 deaths; hazard ratio
[HR] = 4.0; 95% confidence interval [CI], 1.6–9.8) and a higher rate of incident tuberculosis (TB) (HR = 2.0;
95% CI, 1.2–3.6).17
Collectively, these studies support the Panel’s recommendation that ART should be initiated in patients with
a history of an AIDS-defining illness or with a CD4 count <350 cells/mm3 (AI).
Patients with CD4 Counts Between 350 and 500 cells/mm3
Data supporting initiation of ART in patients with CD4 counts ranging from 350 cells/mm3 to 500 cells/mm3
are from large observational studies conducted in North America, Europe, and Australia and from secondary
analysis of randomized controlled trials. Findings from the observational studies were analyzed using
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advanced statistical methods that minimize the bias and confounding that arise when observational data are
used to address the question of when to start ART. However, unmeasured confounders for which adjustment
was not possible may have influenced the analysis.
Among the cohort studies analyzed, the ART Cohort Collaboration (ART-CC) included 45,691 patients from
18 cohort studies conducted primarily in North America and Europe. Data from ART-CC showed that the rate
of progression to AIDS and/or death was higher in participants who delayed ART initiation until their CD4
counts fell to 251 to 350 cells/mm3 than in those who initiated ART at CD4 count level of 351 to 450
cells/mm3 (risk ratio: 1.28; 95% CI, 1.04–1.57).13 When analysis of the data was restricted to mortality alone,
the difference between the 2 strategies was weaker and not statistically significant (risk ratio: 1.13; 95% CI,
0.80–1.60).
The NA-ACCORD cohort evaluated patients regardless whether they had started therapy. The 6,278 patients
who deferred therapy until their CD4 counts fell to <350 cells/mm3 had a greater risk of death than the 2,084
patients who initiated therapy with CD4 counts between 351 cells/mm3 and 500 cells/mm3 (risk ratio: 1.69;
95% CI, 1.26–2.26) after adjustment for other factors that differed between these 2 groups.18
The HIV-CAUSAL cohort evaluated 8,392 ART-naive patients with initial CD4 counts >500 cells/mm3 that
declined to <500 cells/mm3.16 The study estimated that delaying initiation of ART until CD4 count fell to
<350 cells/mm3 was associated with a greater risk of AIDS-defining illness or death than initiating ART with
CD4 count between 350 cells/mm3 and 500 cells/mm3 (HR: 1.38; 95% CI, 1.23–1.56). However, there was
no difference in mortality between the 2 groups (HR: 1.01; 95% CI, 0.84–1.22).
The CASCADE cohort included 5,527 ART-naive patients with CD4 counts in the 350 to 499 cells/mm3
range. Compared with patients who deferred therapy until their CD4 counts fell to <350 cells/mm3, patients
who started ART immediately had a marginally lower risk of AIDS-defining illness or death (HR: 0.75; 95%
CI, 0.49–1.14) and a lower risk of death (HR: 0.51; 95% CI,98 0.33–0.80).19
Randomized data showing clinical evidence that supports ART for patients with higher CD4 cell counts came
from two studies. In the SMART trial, HIV-infected participants with CD4 counts >350 cells/mm3 were
randomized to continuous ART or to treatment interruption until their CD4 counts fell to <250 cells/mm3. In
the subgroup of 249 participants who were ART naive at enrollment (median CD4 count: 437 cells/mm3),
those who deferred ART until their CD4 counts dropped to <250 cells/mm3 had a greater risk of serious
AIDS- and non-AIDS-related events than those who initiated therapy immediately (7 vs. 2 events; HR: 4.6;
95% CI, 1.0–22.2).20 HPTN 052 was a large multi-continent randomized trial that examined whether
treatment of HIV-infected individuals reduces transmission to their uninfected sexual partners.2 A secondary
objective of the study was to determine whether ART reduces clinical events in the HIV-infected participants.
This trial enrolled 1,763 HIV infected participants with CD4 counts between 350 and 550 cells/mm3 and
their HIV uninfected partners. The infected participants were randomized to initiate ART immediately or to
delay initiation until they had 2 consecutive CD4 counts <250 cells/mm3. At a median follow-up of 2.1 years,
there were 57 primary events in the early therapy arm versus 77 events in the delayed therapy arm (HR: 0.73;
95% CI, 0.52–1.03). The most frequent event was tuberculosis (17 cases in the early therapy arm and 34
cases in the delayed therapy arm); deaths were relatively rare (11 cases in the early therapy arm and 15 cases
in the delayed therapy arm).21,22
Collectively, these studies suggest that initiating ART in patients with CD4 counts between 350 and 500
cells/mm3 reduces HIV-related disease progression; whether there is a corresponding reduction in mortality is
unclear. This benefit supports the Panel’s recommendation that ART should be initiated in patients with CD4
counts 350 to 500 cells/mm3 (AII). Recent evidence demonstrating the public health benefit of earlier
initiation of ART in reducing HIV transmission further supports the strength of this recommendation (see
Prevention of Sexual Transmission).
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Patients with CD4 Counts >500 cells/mm3
An analysis of the risks of HIV-associated disease progression in ART-naive patients with CD4 cell counts
>500 cells/mm3 is difficult because only a small proportion of individuals present for clinical care with CD4
cell counts at this level.4,23 However, studies have demonstrated a gradient of increased risk of AIDS and
death when ART is initiated at lower CD4 cell count levels and have provided no evidence of a safe CD4
count level.6,24,25
To date, questions regarding the risks and benefits of starting ART in patients with CD4 cell counts >500
cells/mm3 as compared to deferring initiation until CD4 cell counts are lower have not yet been answered in
a definitive randomized clinical trial. Evidence supporting early initiation comes from an observational
study. The NA-ACCORD study observed patients who started ART with CD4 counts >500 cells/mm3 or after
their CD4 counts dropped below this threshold. The adjusted mortality rates were significantly higher in the
6,935 patients who deferred therapy until their CD4 counts fell to <500 cells/mm3 than in the 2,200 patients
who started therapy with CD4 counts >500 cells/mm3 (risk ratio: 1.94; 95% CI, 1.37–2.79).18
In contrast, in an analysis of the ART-CC cohort,13 the rate of progression to AIDS/death associated with
deferral of therapy until CD4 counts fell to the 351 to 450 cells/mm3 range was similar to the rate with
initiation of therapy with CD4 counts in the 451 to 550 cells/mm3 range (HR: 0.99; 95% CI, 0.76–1.29). The
analysis showed no significant difference in rate of death in the immediate and deferred therapy groups (HR:
0.93; 95% CI, 0.60–1.44). In the CASCADE Collaboration,19 among the 5,162 patients with CD4 counts in
the 500 to 799 cells/mm3 range, compared with patients who deferred therapy, those who started ART
immediately did not experience a significant reduction in the composite outcome of progression to
AIDS/death (HR: 1.10; 95% CI, 0.67–1.79) or death (HR: 1.02; 95% CI, 0.49–2.12).
Although not a clinical endpoint study, a recent clinical trial (Setpoint Study) randomized patients within 6
months of HIV seroconversion to receive either immediate ART for 36 weeks or deferred treatment. More
than 57% of the study participants had CD4 counts >500 cells/mm3. The deferred treatment group had a
statistically higher risk of meeting study defined ART initiation criteria than the immediate treatment group.
The study was halted early, showing that the time from diagnosis of early infection and the need for initiation
of ART was shorter than anticipated in the deferral therapy group. Fully half of the participants in the deferral
group met the criteria for treatment initiation by week 72.26
Another recent study provides evidence that early treatment enhances recovery of CD4 counts to levels >900
cells/mm3.27 Among individuals who were identified during primary infection, those who initiated ART
within 4 months after the estimated date of infection were more likely to have CD4 cell recovery and had a
faster rate of recovery than those initiating ART at 4 to 12 months or >12 months after the estimated date of
infection. However, even among participants who started ART earlier, those who initiated ART with lower
CD4 counts were less likely to have CD4 cell recovery and had a lower rate of recovery than those who
initiated ART with higher CD4 counts.
With a better understanding of the pathogenesis of HIV infection, the growing awareness that untreated HIV
infection increases the risk of many non-AIDS-defining diseases (as discussed below), and the benefit of
ART in reducing transmission of HIV, the Panel recommends initiation of ART in patients with CD4 counts
>500 cells/mm3 (BIII). 
When discussing initiation of ART at high CD4 cell counts (>500 cells/mm3), clinicians should inform
patients that data on the clinical benefit of starting treatment at such levels are not conclusive, especially for
patients with very high CD4 counts. Clinicians should also inform patients that viral suppression from
effective ART can reduce the risk of sexual transmission. Lastly, patients should be informed that untreated
HIV infection will eventually lead to immunological deterioration and increased risk of clinical disease and
death. Therefore, if therapy is not initiated, continued monitoring and close follow-up are necessary. 
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Further ongoing research (both randomized clinical trials and cohort studies) to assess the short- and long-
term clinical and public health benefits and cost effectiveness of starting therapy at higher CD4 counts is
needed. Findings from such research will provide further evidence to help the Panel make future
recommendations.
Effects of Viral Replication on HIV-Related Morbidity
Since the mid-1990s, it has been known that measures of viral replication predict HIV disease progression.
Among untreated HIV-infected individuals, time to clinical progression and mortality is fastest in those with
higher viral loads.28 This finding is confirmed across the spectrum of HIV-infected patient populations, such
as injection drug users (IDUs),29 women,30 and individuals with hemophilia.31 Several studies have shown the
prognostic value of pre-treatment viral load for predicting post-therapy response.32,33 Once therapy has been
initiated, failure to achieve viral suppression34-36 and viral load at the time of treatment failure37 are predictive
of clinical disease progression.
More recent studies have examined the impact of ongoing viral replication for both longer durations and at
higher CD4 cell counts. Using viremia copy-years, a novel metric for quantifying viral load over time, the
Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort found that cumulative
exposure to replicating virus is independently associated with mortality. Using viremia copy-years, the HR
for mortality was 1.81 per log10 copy-year/mL (95% CI, 1.51–2.18), which was the only viral load-related
variable that retained statistical significance in the multivariable model (HR 1.44 per log10 copy-year/mL;
95% CI, 1.07–1.94). These findings support the concept that unchecked viral replication, which occurs in the
absence of effective ART, is a factor in disease progression and death independent of CD4 count.38
The EuroSIDA collaboration evaluated HIV-infected individuals with CD4 counts >350 cells/mm3
segregated by three viral load strata (<500 copies/mL, 500–9,999 copies/mL, and ≥10,000 copies/mL) to
determine the impact of viral load on rates of fatal and nonfatal AIDS-related and non-AIDS-related events.
The lower viral load stratum included more participants on ART (92%) than the middle (62%) and high
(31%) viral load strata. After adjustment for age, region, and ART, the rates of non-AIDS events were 61%
(P = 0.001) and 66% (P = 0.004) higher in participants with viral loads 500 to 9,999 copies/mL and >10,000
copies/mL, respectively, than in individuals with viral loads <500 copies/mL. These data further confirm that
unchecked viral replication is associated with adverse clinical outcomes in individuals with CD4 counts
>350 cells/mm3.39
Collectively, these data show that the harm of ongoing viral replication affects both untreated patients and
those who are on ART but remain viremic. The harm of ongoing viral replication in patients on ART is
compounded by the risk of emergence of drug-resistant virus. Therefore, all patients on ART should be
carefully monitored and counseled on the importance of adherence to therapy. 
Effects of Antiretroviral Therapy on HIV-Related Morbidity
HIV-associated immune deficiency, the direct effects of HIV on end organs, and the indirect effects of HIV-
associated inflammation on these organs all likely contribute to HIV-related morbidity and mortality. In
general, the available data demonstrate the following:
• Untreated HIV infection (ongoing viral replication) may have negative effects at all stages of infection.
• Earlier treatment may prevent the damage associated with HIV replication during early stages of
infection.
• ART is beneficial even when initiated later in infection; however, later therapy may not repair damage
associated with viral replication during early stages of infection.
• Sustaining viral suppression and maintaining higher CD4 count levels, mostly as a result of effective
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combination ART, may delay, prevent, or reverse some non-AIDS-defining complications, such as HIV-
associated kidney disease, liver disease, CVD, neurologic complications, and malignancies, as discussed
below.
HIV-Associated Nephropathy 
HIVAN is the most common cause of chronic kidney disease in HIV-infected individuals that may lead to
end-stage kidney disease.40 HIVAN is almost exclusively seen in black patients and can occur at any CD4
count. Ongoing viral replication appears to be directly involved in renal injury;41 HIVAN is extremely
uncommon in virologically suppressed patients.42 ART in patients with HIVAN has been associated with both
preserved renal function and prolonged survival.43-45 Therefore, regardless of CD4 count, ART should be
started in all patients with HIVAN at the earliest sign of renal dysfunction (AII).
Coinfection with Hepatitis B Virus and/or Hepatitis C Virus 
HIV infection is associated with more rapid progression of viral hepatitis-related liver disease, including
cirrhosis, end-stage liver disease, hepatocellular carcinoma, and fatal hepatic failure.46 48 The pathogenesis of
accelerated liver disease in HIV-infected patients has not been fully elucidated, but HIV-related
immunodeficiency and a direct interaction between HIV and hepatic stellate and Kupffer cells have been
implicated.49-52 In individuals co-infected with HBV and/or hepatitis C virus (HCV), ART may attenuate liver
disease progression by preserving or restoring immune function and reducing HIV-related immune activation
and inflammation.53-55 Antiretroviral (ARV) drugs active against both HIV and HBV (such as tenofovir
disoproxil fumarate [TDF], lamivudine [3TC], and emtricitabine [FTC]) also may prevent development of
significant liver disease by directly suppressing HBV replication.56,57 Although ARV drugs do not inhibit
HCV replication directly, HCV treatment outcomes typically improve when HIV replication is controlled or
CD4 counts increase.58 In one prospective cohort, after controlling for liver and HIV disease stage, HCV co-
infected patients receiving ART were approximately 66% less likely to experience end-stage liver disease,
hepatocellular carcinoma, and fatal hepatic failure than patients not receiving ART.59 While some studies
have shown that chronic viral hepatitis increases the risk of ART-induced liver injury, the majority of
coinfected persons do not develop clinically significant liver injury60-62 and the rate of hepatotoxicity may be
greater in persons with more advanced HIV disease. Collectively, these data suggest that earlier treatment of
HIV infection in persons coinfected with HBV (and likely HCV) may reduce the risk of liver disease
progression. ART is recommended for patients coinfected with HBV, and the ART regimen should include
drugs with activity against both HIV and HBV (AII) (also see Hepatitis B Virus/HIV Coinfection). ART is
also recommended for most patients coinfected with HCV (BII), including those with high CD4 counts and
those with cirrhosis. This recommendation is based on findings from retrospective and prospective cohort
studies that indicated that the receipt of ART is associated with slower progression of hepatic fibrosis and
reduced risk of liver disease outcomes.59,63-65 Combined treatment of HIV and HCV can be complicated by
large pill burden, drug interactions, and overlapping toxicities; however, the complexity of treatment depends
on the HCV regimen selected. ART should be considered for HIV/HCV-coinfected patients regardless of
CD4 cell count. However, for patients with CD4 counts >500 cells/mm3 and also infected with HCV
genotype 1, if treatment is to include an HCV protease inhibitor, some clinicians may choose to defer ART
until HCV treatment is completed (also see HIV/Hepatitis C Virus Co-Infection).
Cardiovascular Disease 
In HIV-infected patients, CVD is a major cause of morbidity and mortality, accounting for one-third of
serious non-AIDS conditions and at least 10% of deaths.66-68 A number of studies have found that, over time,
HIV-infected persons are at greater risk for CVD events than age-matched uninfected individuals. 
Persons living with HIV infection have higher rates of established CVD risk factors, particularly smoking
and dyslipidemia, than HIV-uninfected individuals. In the Data Collection on Adverse Events of Anti-HIV
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Drugs (D:A:D) cohort study such factors, including age, male gender, obesity, smoking, family history of
CVD, diabetes, and dyslipidemia, were each independently associated with risk of myocardial infarction
(MI).69 This study also found that the risk of CVD was greater with exposure to some ARV drugs, including
certain PIs (ritonavir-boosted lopinavir and ritonavir-boosted fosamprenavir) and abacavir, than with
exposure to other ARV drugs.69,70
In terms of preventing the progression to CVD events, it has not been determined whether delaying ART
initiation is preferable to immediate treatment. In the meta-analysis mentioned above, the risk of CVD in
HIV-infected individuals was 1.5 times higher in those treated with ART than in those not treated with
ART.63 These analyses were limited by concern that the treated individuals may have been infected for longer
periods of time and had prior episodes of untreated HIV disease, as well as the fact that the untreated people
were at higher risk for competing events, including death. Furthermore, there is evidence that untreated HIV
infection may also be associated with an increased risk of CVD. In the SMART study, the risk of
cardiovascular events was greater in participants randomized to CD4-guided treatment interruption than in
participants who received continuous ART.71 In other studies, ART resulted in marked improvement in
parameters associated with CVD, including markers of inflammation (such as interleukin 6 [IL-6]), immune
dysfunction (e.g., T cell activation, T cell senescence), monocyte activation (e.g., IL-6, soluble CD14 and
CD163), hyper-coagulation (e.g., D-dimers) and, most importantly, endothelial dysfunction.72,73 Low nadir
and/or proximal on-therapy CD4 cell count has been linked to CVD (MI and/or stroke),74-76 suggesting that
low CD4 count might result in increased risk of CVD. 
Collectively, the increased risk of cardiovascular events with treatment interruption, the effects of ART on
markers of inflammation and endothelial dysfunction, and the association between CVD and CD4 cell
depletion suggest that early control of HIV replication with ART can be used as a strategy to reduce risk of
CVD, particularly if drugs with potential cardiovascular toxicity are avoided. However, no study has
demonstrated that initiation of ART prevents CVD. Therefore, a role for early ART in preventing CVD
remains to be established. For HIV-infected individuals with a significant risk of CVD, as assessed by
medical history and estimated risk calculations, risk of CVD should be considered when selecting a specific
ART regimen.
Malignancies
HIV-infected individuals are at increased risk for developing several cancers and human papilloma virus
(HPV)-related pre-malignant intraepithelial neoplasia.77,78 Increased rates of Kaposi sarcoma and non-
Hodgkin lymphoma in patients with advanced HIV infection have been noted since early in the AIDS
epidemic, and, together with cervical cancer, both diseases have been defined as AIDS-defining
malignancies (ADMs) for public health surveillance purposes. HIV infection and associated
immunosuppression increase the risk of several cancers identified as non-AIDS-defining malignancies
(NADMs). Importantly, the incidence of lung, anal, oropharyngeal, liver and skin cancers, Hodgkin
lymphoma, and melanoma, is higher in HIV-infected individuals than in matched HIV-uninfected controls,79-
81 and the burden of these NADMs continued to increase in the United States between 1996 and 2007.82
Incidental cancers that occur in HIV-infected individuals are becoming more common, which is due to the
aging of the HIV population rather than to HIV-associated risks of malignancies. These cancers are also
sometimes considered NADMs. Most cancers with increased incidence are either virally related (i.e.,
Hodgkin lymphoma, anal cancer, liver cancer) or smoking related (lung cancer), although HIV remains an
independent risk factor for the later.83
Large cohort studies enrolling mainly patients receiving ART have reported a consistent link between low
CD4 counts (<350 to 500 cells/mm3) and the risk of ADMs and/or NADMs.14,76,84-87 The ANRS C04 Study
demonstrated that, in contrast to patients with CD4 counts >500 cells/mm3, patients with CD4 counts <500
cells/mm3 had a statistically significant relative risk of all cancers evaluated (except for anal carcinoma). The
Downloaded from http://aidsinfo.nih.gov/guidelines on 9/16/2015
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents                                   E-8
study also showed an increased risk of anal cancer based on extent of time with CD4 counts <200 cells/mm3,
and that, regardless of CD4 count, ART has a protective effect for HIV-associated malignancies.84 This
potential effect of HIV-associated immunodeficiency is striking particularly with regard to cancers and pre-
malignant diseases associated with chronic viral infections such as HBV, HCV, HPV, Epstein-Barr virus, and
human herpes virus-8.88,89 For some cancers, risk is related to HIV viremia. Cumulative HIV viremia,
independent of other factors, is associated with increased risk of non-Hodgkin lymphoma and other
ADM.87,90 In the SMART study,91 patients randomized to the drug conservation arm (ART interruption with
re-initiation if CD4 count fell to <250 cells/mm3) had a higher incidence of ADM but not NADM, although
increased NADM was noted in non-smokers in the drug-conservation arm.
From the early 1990s through 2000, incidence rates for many cancers occurring with advanced
immunosuppression, including Kaposi sarcoma, diffuse large B-cell lymphoma, and primary central nervous
system (CNS) lymphoma, declined markedly in HIV-infected individuals in the United States, with more
gradual declines noted after 2000.92 However, for other ADMs and NADMs, such as Burkitt lymphoma,
Hodgkin lymphoma, cervical cancer, and anal cancer, similar reductions in incidence have not been
observed.92,93 Declines in competing causes of mortality (e.g., opportunistic infections [OIs]) and concurrent
cancer risk factors such as smoking or aging of HIV-infected cohorts, may confound a full assessment of the
relative impact of ART on cancer prevention for NADMs.82,94
Additionally, data from the era of potent combination ART suggest that overall survival in HIV-infected
patients who develop ADMs or NADMs also depends on immune status as measured by CD4 count.85,95,96
For non-Hodgkin lymphoma, data from the Center for AIDS Research Network of Integrated Clinical
Systems Cohort shows that across CD4 strata, the level of HIV viremia 6 months after the diagnosis of
lymphoma (including Hodgkin lymphoma) is associated with an increased risk of death.95
Together this evidence suggests that initiating ART to suppress HIV replication, maximize immune
reconstitution, and maintain CD4 counts at levels >350 to 500 cells/mm3 reduces the overall incidence of
ADMs and may reduce the risk of some NADMs as well. The effect of ART on cancer incidence and
mortality in patients with cancer95,97 is likely to be heterogeneous across various cancer types.
Neurological Complications
In the untreated HIV-infected patient, CNS involvement is a nearly universal facet of systemic HIV infection
as evident by detection of HIV RNA in cerebrospinal fluid (CSF).98-101 The CNS is an important target of
ART, not only to treat neurologically symptomatic infection but also to prevent later development of virus-
related brain injury, which can range from severe and debilitating encephalopathy to milder and more
insidious cognitive and motor dysfunction.102-104
Like systemic infection, CNS virus populations and the character of CNS infection can evolve within
individual patients. Characteristically during the earliest phases of systemic infection, CSF viral isolates are
similar to those found in blood and likely reflect transfer of blood populations across CNS barriers in T
lymphocytes.105 Over time CSF isolates may exhibit increasing compartmentalization that reflect divergence
from the predominant blood populations, a transformation most notable in patients with frank HIV
encephalitis presenting with HIV-associated dementia (HAD).106 Combination ART usually reduces CSF
HIV RNA to below the level of detection,99,107 largely preventing this development, and consequently,
reducing the incidence of severe HIV-related brain disease in virologically suppressed patients.108-110 Hence,
prevention of HAD is among the arguments for early ART, although the CD4 threshold for treatment to
prevent this disorder is not established. Additionally, treatment of patients presenting with HAD—usually
seen in the context of late HIV presentation—can arrest and variably reverse neurological abnormalities;111
therefore, the diagnosis of HAD is an indication for rapid initiation of ART (AI).
With the successful control of HAD with ART, attention has shifted to milder forms of neurocognitive
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impairment in HIV infection, largely recognized by reduced neuropsychological test performance.104,112
These milder forms of impairment are categorized in two groups: asymptomatic neurocognitive impairment
and mild neurocognitive disorder. Although patients with either form exhibit the same degree of impairment
on neuropsychological tests (<1 SD below normative performance in two neurocognitive domains), they
differ as to the absence or presence of symptoms or mild functional impairment in everyday activities.103
Even after exclusion of confounding conditions, the prevalence of these milder forms of neurocognitive
impairment appears to be substantial, including in treated patients with plasma viral suppression.104,112 Less
certain is the extent to which these impairments are the consequence of earlier mild or subclinical brain
injury sustained before ART initiation, or alternatively, reflect ongoing injury despite ART and plasma viral
suppression. Association of these milder deficits with nadir CD4 count may favor the role of earlier
injury,100,113-115 providing further argument for early treatment.
Peripheral neuropathies are a second category of important HIV-associated neurological disease.116 In the
early decades of the discovery of HIV infection and the use of some nucleoside analogs, painful distal
sensory neuropathy was particularly common and a difficult problem that did not respond to ART.117
Although some reports suggest that the incidence of this HIV-associated neuropathy remains high, clinical
experience suggests that the condition mainly affects patients with longer duration of HIV infection who
initiated ART late in the course of the disease.118 There appears to be a reduced incidence of neuropathies as
more patients begin treatment at earlier stages of HIV infection. 
Overall, effective ART may be beneficial in preventing and treating symptomatic and subclinical CNS HIV
infection and the CNS and peripheral nervous system consequences of infection.
Age and Treatment-Related Immune Reconstitution 
Also see HIV and the Older Patient.
The CD4 cell response to ART is an important predictor of short- and long-term morbidity and mortality. In
most, but not all studies, treatment initiation at an older age has been associated with a less robust CD4 count
response; starting therapy at a younger age may result in better immunologic and perhaps clinical
outcomes.4,119-122
Persistent Inflammation and Immunodeficiency During Antiretroviral Therapy
Untreated HIV infection is associated with chronic inflammation, as defined by the frequency of activated T
cells and monocyte/macrophages and levels of a number of pro-inflammatory cytokines (e.g., IL-6, CRP,
soluble CD14). Effective ART decreases levels of most of these inflammatory markers, but the effect is often
incomplete, with levels in many of those on ART remaining higher than those observed in age-matched
uninfected adults.123,124 Chronic inflammation during both untreated and treated disease is strongly associated
with risk of non-AIDS defining morbidity and all-cause mortality.125-128 Because HIV replication contributes
to this inflammatory state through both direct and indirect mechanisms, earlier use of ART to blunt this
process may be beneficial. However, there are no data showing that ART-mediated changes in any
inflammatory biomarker are associated with reduced morbidity and mortality.
Immune function as defined by the peripheral CD4 cell count is also an important determinant of health.
Although effective ART results in a sustained and beneficial increase in CD4 cell counts, this effect is often
incomplete. Patients who delay therapy to the point of advanced immunodeficiency may require several
years of ART to normalize their peripheral CD4 cell counts,129 and some patients may never achieve a normal
level.130 A lower CD4 count on therapy is associated with higher risk of developing cancer, liver disease,
cardiovascular disease and death.14 In some studies a history of low CD4 counts is associated with risk of
morbidity and mortality during subsequent effective therapy.131,132
Collectively, these observations support earlier use of ART. Treatment decreases the level of inflammation,
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which may be associated with reduced short-term risk of AIDS- and non-AIDS-related morbidity and
mortality.125,133,134 ART also prevents progressive loss of CD4 cells, thus reducing risk of immunodeficiency
and its related complications. Some studies have shown that a patient’s pre-therapy CD4 cell count nadir is
predictive of the degree of residual inflammation and/or T-cell dysfunction during ART.123,135,136 Thus, earlier
ART may result in less residual immunological perturbations during treatment, which theoretically may
result in reduced risk of disease during the decades that a patient requires ART (CIII).
Antiretroviral Therapy for Prevention of HIV Transmission
Prevention of Perinatal Transmission
Effective ART reduces transmission of HIV. The most dramatic and well-established example of this effect is
the use of ART in pregnant women to prevent perinatal transmission of HIV. Effective suppression of HIV
replication, as reflected in plasma HIV RNA, is a key determinant in reducing perinatal transmission. In the
setting of ART initiation before 28 weeks’ gestation and an HIV RNA level <50 copies/mL near delivery, use
of combination ART during pregnancy has reduced the rate of perinatal transmission of HIV from
approximately 20% to 30% to 0.1% to 0.5%.137,138 Thus, use of combination ART drug regimens is
recommended for all HIV-infected pregnant women (AI). Following delivery, in the absence of
breastfeeding, considerations regarding continuation of the ARV regimen for maternal therapeutic indications
are the same as those regarding ART for other non-pregnant individuals. For detailed recommendations, see
the Perinatal Guidelines.139
Prevention of Sexual Transmission
A number of investigations, including biological, ecological and epidemiological studies and one randomized
clinical trial, provide strong support for the premise that treatment of the HIV-infected individual can
significantly reduce sexual transmission of HIV. Lower plasma HIV RNA levels are associated with
decreases in the concentration of the virus in genital secretions.140,141 Studies of HIV-serodiscordant
heterosexual couples have demonstrated a relationship between level of plasma viremia and risk of
transmission of HIV—when plasma HIV RNA levels are lower, transmission events are less common.1,142-145
A study conducted in KwaZulu-Natal, South Africa, used geospatial techniques to assess the relationship
between ART use and HIV incidence in an observational cohort of more than 16,000 study participants living
in many different communities.146 After adjustment for sexual behavior and prevalent HIV cases, each
percentage point increase in ART coverage of HIV-infected persons lowered the HIV infection risk in a
community by 1.7%. 
Most significantly, the multi-continental HPTN 052 trial enrolled 1,763 HIV-serodiscordant couples in which
the HIV-infected partner was ART naive with a CD4 count of 350 to 550 cells/mm3 at enrollment to compare
the effect of immediate ART versus delayed therapy (not started until CD4 count <250 cells/mm3) on HIV
transmission to the HIV-infected partner.2 At study entry, 97% of the participants were in heterosexual
monogamous relationships. All study participants were counseled on behavioral modification and condom
use. Twenty-eight linked HIV transmission events were identified during the study period, but only 1 event
occurred in the early therapy arm. This 96% reduction in transmission associated with early ART was
statistically significant (HR 0.04; 95% CI, 0.01–0.27; P <0.001). These results show that early ART is more
effective at preventing transmission of HIV than all other behavioral and biomedical prevention interventions
studied. This study, as well as other observational studies and modeling analyses showing a decreased rate of
HIV transmission among serodiscordant heterosexual couples following the introduction of ART,
demonstrate that suppression of viremia in ART-adherent patients with no concomitant sexually transmitted
diseases (STDs) substantially reduces the risk of transmission of HIV.3,144,145,147-149 HPTN 052 was conducted
in heterosexual couples and not in populations at risk of transmission via homosexual exposure or needle
sharing. In addition, in this clinical trial, adherence to ART was well supported and near complete. However,
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the prevention benefits of effective ART observed in HPTN 052 can reasonably be presumed to apply
broadly. Therefore, the Panel recommends that ART be offered to patients who are at risk of transmitting
HIV to sexual partners (the strength of this recommendation varies according to mode of sexual
transmission: AI for heterosexual transmission and AIII for male-to-male and other modes of sexual
transmission). Clinicians should discuss with patients the potential individual and public health benefits of
therapy and the need for adherence to the prescribed regimen and counsel patients that ART is not a
substitute for condom use and behavioral modification and that ART does not protect against other STDs (see
Preventing Secondary Transmission of HIV).
Concerns Regarding Earlier Initiation of Therapy
Despite increasing evidence showing the benefits of earlier initiation of ART, four areas of concern remain as
reasons for deferral of HIV therapy. 
ARV Drug Toxicities Have an Adverse Effect on Quality of Life and Adherence
Earlier initiation of ART extends exposure to ARV agents by several years. The D:A:D study found an
increased incidence of CVD associated with cumulative exposure to some drugs in the nucleoside reverse
transcriptase inhibitor and protease inhibitor (PI) drug classes.69,150 Renal and bone health are also of
concern. Aging coupled with long term use of tenofovir may increase risk of significant renal dysfunction.151-
153 In the SMART study, compared with interruption or deferral of therapy, continuous exposure to ART was
associated with significantly greater loss of bone density.71 There may be unknown complications related to
cumulative use of ARV drugs for many decades. A list of known ARV-associated toxicities can be found in
Adverse Effects of Antiretroviral Agents.
ART frequently improves quality of life for symptomatic patients. However, some side effects of ART may
impair quality of life for some patients, especially those who are asymptomatic at initiation of therapy and at
low risk of AIDS events. For example, efavirenz can cause neurocognitive or psychiatric side effects and PIs
have been associated with gastrointestinal side effects. As noted above, some therapies may increase the risk
of CVD. Patients who find that the inconvenience of taking medication every day outweighs the overall
benefit of early ART may choose to delay therapy. 
ARV Non-Adherence May Have an Impact on Virologic Response.
At any CD4 count, adherence to therapy is essential to achieve viral suppression and prevent emergence of
drug-resistance mutations. Several clinical, behavioral, and social factors associated with poor adherence, such
as untreated major psychiatric disorders, active substance abuse, unfavorable social circumstances, patient
concerns about side effects, and poor adherence to clinic visits, have been identified. Clinicians should identify
areas where additional intervention is needed to improve adherence both before and after initiation of therapy.
Some strategies to improve adherence are discussed in Adherence to Antiretroviral Therapy. 
Earlier Development of Resistance may Reduce Future Therapeutic Options. 
Non-adherence and subsequent virologic failure may promote emergence of drug resistance mutations and
limit subsequent treatment options. Despite concerns about the development of resistance to ARV drugs, the
evidence thus far indicates that resistance occurs more frequently in individuals who initiate therapy later in
the course of infection than in those who initiate ART earlier.154 Furthermore, recent data have indicated a
slight increase in the prevalence of 2-drug class resistance from 2000 to 2005.155
Cost may be a Barrier to Early Initiation of Therapy.
In resource-rich countries, the cost of ART exceeds $10,000 per year (see Cost Considerations and
Antiretroviral Therapy). Several modeling studies support the cost effectiveness of HIV therapy initiated
soon after diagnosis.156-158 One study reported that the annual cost of care is 2.5 times higher for patients with
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CD4 counts <50 cells/mm3 than for patients with CD4 counts >350 cells/mm3.159 Much of the health care
expenditure in patients with advanced infection is from non-ARV drugs and hospitalization. However, there
are no comparisons of the cost of earlier ART initiation (i.e., CD4 count 350–500 cells/mm3) versus later
initiation (i.e., CD4 count >500 cells/ mm3). As generic formulations for more ARV drugs become available
in the next several years, the cost of ART may decline. However, despite any significant cost savings,
decisions regarding which ARVs to select for system-wide HIV programs must be based on rigorous cost-
effectiveness assessments (see Cost section).160
Conditions Favoring More Urgent Initiation of Therapy 
Several conditions increase the urgency for therapy, including:
• Pregnancy (AI). Clinicians should refer to the Perinatal Guidelines for more detailed recommendations
on the management of HIV-infected pregnant women.139
• AIDS-defining conditions, including HAD (AI)
• Acute OIs (see discussion below)
• Lower CD4 counts (e.g., <200 cells/mm3) (AI)
• HIVAN (AII)
• Acute/Early Infection (BII). See more discussion in the Acute/Early Infection section.
• HIV/HBV coinfection (AII)
• HIV/HCV coinfection (BII)
• Rapidly declining CD4 counts (e.g., >100 cells/mm3 decrease per year) (AIII)
• Higher viral loads (e.g., >100,000 copies/mL) (BII)
Acute Opportunistic Infections
In patients who have opportunistic diseases for which no effective therapy exists (e.g., cryptosporidiosis,
microsporidiosis, progressive multifocal leukoencephalopathy), but in whom ART may improve outcomes by
improving immune responses, treatment should be started as soon as possible (AIII). For patients with mild
to moderate cutaneous Kaposi’s sarcoma (KS), prompt initiation of ART alone without chemotherapy has
been associated with improvement of the KS lesions, even though initial transient progression of KS lesion
as a manifestation of immune reconstitution inflammatory syndrome (IRIS) can also occur.161
In the setting of some OIs, such as cryptococcal meningitis, for which immediate therapy may increase the
risk of serious immune reconstitution inflammatory syndrome (IRIS), a short delay before initiating ART
may be warranted.162-164 In the setting of other OIs, such as Pneumocystis jirovecii pneumonia, early initiation
of ART is associated with increased survival;10 therefore, therapy should not be delayed (AI).
In patients who have active TB, initiating ART during treatment for TB confers a significant survival
advantage;165-169 therefore, ART should be initiated as recommended in Mycobacterium Tuberculosis Disease
with HIV Coinfection.
Clinicians should refer to the Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-
Infected Adults and Adolescents161 for more detailed discussion on when to initiate ART in the setting of a
specific OI.
Conditions Where Deferral of Therapy May be Considered
Some patients and their clinicians may decide to defer therapy on the basis of clinical or personal
circumstances. Deferring therapy for the reasons discussed below may be reasonable in patients with high
CD4 counts (e.g., >500 cells/mm3), but deferring therapy in patients with much lower CD4 counts (e.g.,
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<200 cells/mm3) should be considered only in rare situations and should be undertaken with close clinical
follow-up. Briefly delaying therapy to allow a patient more time to prepare for lifelong treatment may be
considered.
When There are Significant Barriers to Adherence 
Also see Adherence to Antiretroviral Therapy.
In patients with higher CD4 counts who are at risk of poor adherence, it may be prudent to defer treatment
while addressing the barriers to adherence. However, in patients with conditions that require urgent initiation
of ART (see above), therapy should be started while simultaneously addressing the barriers to adherence.
Several methods are available to assess adherence. When the most feasible measure of adherence is self-
report, this assessment should be completed at each clinic visit using one of the available reliable and valid
instruments.170,171 If other objective measures (e.g., pharmacy refill data, pill count) are available, these
methods should be used to assess adherence at each follow-up visit.172–174 Continual assessment and
counseling allow the clinician to intervene early to address barriers to adherence occurring at any point
during treatment (see Adherence to Antiretroviral Therapy).
Presence of Comorbidities that Complicate or Prohibit Antiretroviral Therapy
Deferral of ART may be considered when either the treatment or manifestations of other medical conditions
may complicate the treatment of HIV infection or vice versa. Examples include:
• Surgery that may result in an extended interruption of ART
• Treatment with medications that have clinically significant drug interactions with ART and for which
alternative medications are not available
In each of these circumstances, the assumption is that the situation is temporary and that ART will be
initiated after the conflicting condition has resolved.
There are some less common situations that preclude ART at any time while CD4 counts remain high. In
particular, such situations include that of patients who have a poor prognosis because of a concomitant medical
condition and are not expected to gain survival or quality-of-life benefits from ART. Examples include patients
with incurable non-HIV-related malignancies or end-stage liver disease who are not being considered for liver
transplantation. In this setting, deciding to forgo ART may be easier in patients with higher CD4 counts who
are likely asymptomatic for HIV and in whom ART is unlikely to prolong survival. However, it should be noted
that ART may improve outcomes, including survival, in patients with some HIV-associated malignancies (e.g.,
lymphoma, Kaposi sarcoma) and in patients with liver disease due to chronic HBV or HCV.
Long-term Non-Progressors and Elite HIV Controllers
A small subset of HIV-infected individuals (~3% to 5%) can maintain normal CD4 counts for many years
without treatment (long-term non-progressors), and an even smaller subset (~1%) can maintain low to
undetectable HIV RNA levels for years (elite controllers).175,176 Although there is significant overlap in these
clinical phenotypes, many long-term non-progressors have detectable viremia and some controllers progress
immunologically and clinically despite having no detectable viremia. 
There are limited data on how to manage these individuals. Given potential harm associated with
uncontrolled HIV replication, many of the preceding arguments for early therapy likely apply to non-
progressors who have consistently detectable viremia (i.e., HIV RNA >200 to 1000 copies/mL). Given that
ongoing HIV replication occurs even in controllers, ART is also recommended for those rare controllers with
evidence of disease progression, as defined by declining CD4 counts or development of HIV-related
complications (AII). The Panel has no recommendations on managing controllers with high CD4 counts,
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although the fact that ART reduces the level of inflammation in this setting suggests that treatment may be
beneficial.177
The Need for Early Diagnosis of HIV
Fundamental to the earlier initiation of ART recommended in these guidelines is the assumption that patients
will be diagnosed early in the course of HIV infection, making earlier initiation of therapy an option.
Unfortunately, most HIV-infections are diagnosed at later stages of disease,178-181 although in recent years,
HIV is increasingly being detected earlier.4 Despite the recommendations for routine, opt-out HIV screening
in the health care setting regardless of perceptions about a patient’s risk of infection,182 the median CD4
count of newly diagnosed patients remains below 350 cells/mm3, although this number is increasing.4
Diagnosis of HIV infection is delayed more often in nonwhites, IDUs, and older patients than in other
populations, and many individuals in these groups develop AIDS-defining illnesses within 1 year of
diagnosis.178-181 Therefore, to ensure that the current treatment guidelines have maximum impact, routine
HIV screening per current CDC recommendations is essential. It is also critical that all newly diagnosed
patients are educated about HIV disease and linked to care for full evaluation, follow-up, and management.
Once patients are in care, focused effort is required to retain them in the health care system so that both the
infected individuals and their sexual partners can fully benefit from early diagnosis and treatment.
Conclusion
The current recommendations are based on growing evidence supporting earlier initiation of ART and the
lack of demonstrable harm in starting therapy earlier. The strength of each recommendation varies according
to the quality and availability of existing evidence supporting the recommendation. In addition to the benefit
of earlier initiation of therapy for the health of the HIV-infected individual, the reduction in sexual
transmission to HIV-uninfected individuals provides further reason for earlier initiation of ART. The Panel
will continue to monitor and assess the results of ongoing and planned randomized clinical trials and
observational studies, which will provide information to guide future Panel recommendations.
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What to Start: Initial Combination Regimens for the Antiretroviral-
Naive Patient  (Last updated April 8, 2015; last reviewed April 8, 2015)
Introduction
More than 25 antiretroviral (ARV) drugs in 6 mechanistic classes are Food and Drug Administration (FDA)
approved for treatment of HIV infection. These six classes include the nucleoside/nucleotide reverse
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease
inhibitors (PIs), a fusion inhibitor (FI), a CCR5 antagonist, and integrase strand transfer inhibitors (INSTIs).
In addition, two drugs (pharmacokinetic [PK] enhancers or boosters) are used solely to improve the
pharmacokinetic profiles of some ARV drugs (e.g., PIs and the INSTI elvitegravir [EVG]).
The initial ARV regimen for a treatment-naive patient generally consists of two NRTIs, usually abacavir plus
lamivudine (ABC/3TC) or tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC), plus a drug from one
of three drug classes: an INSTI, an NNRTI, or a PK-enhanced PI. As shown in clinical trials and by
retrospective evaluation of cohorts of patients in clinical care, this strategy for initial treatment has resulted
in HIV RNA decreases and CD4 T lymphocyte (CD4) cell increases in most patients.1-3
Data Used for Making Recommendations
The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel)’s recommendations are
primarily based on clinical trial data published in peer-reviewed journals and data prepared by manufacturers
for FDA review. In select cases, the Panel considers data presented in abstract format at major scientific
meetings. The Panel’s first criterion for selection of evidence on which to base recommendations is published
information from a randomized, prospective clinical trial with an adequate sample size that demonstrates that
an ARV regimen has shown high rates of viral suppression, increased CD4 cell count, and has a favorable
Panel’s Recommendations
• An antiretroviral regimen for a treatment-naive patient generally consists of two nucleoside reverse transcriptase inhibitors in
combination with a third active antiretroviral drug from one of three drug classes: an integrase strand transfer inhibitor, a non-
nucleoside reverse transcriptase inhibitor, or a protease inhibitor with a pharmacokinetic enhancer (cobicistat or ritonavir).
• The Panel classifies the following regimens as Recommended regimens for antiretroviral-naive patients: 
Integrase Strand Transfer Inhibitor-Based Regimens:
• Dolutegravir/abacavir/lamivudinea—only for patients who are HLA-B*5701 negative (AI)
• Dolutegravir plus tenofovir disoproxil fumarate (tenofovir)/emtricitabinea (AI)
• Elvitegravir/cobicistat/tenofovir/emtricitabine—only for patients with pre-antiretroviral therapy CrCl >70 mL/min (AI)
• Raltegravir plus tenofovir/emtricitabinea (AI)
Protease Inhibitor-Based Regimen:
• Darunavir/ritonavir plus tenofovir/emtricitabinea (AI)
• On the basis of individual patient characteristics and needs, an Alternative regimen or; less frequently, an Other regimen; may in
some instances be the optimal regimen for a patient. A list of Alternative and Other regimens can be found in Table 6.
• Given the large number of excellent options for initial therapy, selection of a regimen for a particular patient should be guided by
factors such as virologic efficacy, toxicity, pill burden, dosing frequency, drug-drug interaction potential, resistance testing results,
comorbid conditions, and cost. Table 7 provides guidance on choosing an antiretroviral regimen based on selected clinical case
scenarios. Table 8 highlights the advantages and disadvantages of different components in a regimen.
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational cohort
studies with long-term clinical outcomes; III = Expert Opinion
a Lamivudine may substitute for emtricitabine or vice versa.
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safety profile. Comparative clinical trials of initial treatments generally show no significant differences in
HIV-related clinical endpoints or survival. Thus, assessment of regimen efficacy and safety are primarily
based on surrogate marker endpoints (especially rates of HIV RNA suppression) and the incidence and
severity of adverse events. When developing recommendations, the Panel also considers post-marketing
safety data, observational cohort data published in peer-reviewed publications, and the experience of
clinicians and community members who are actively engaged in patient care.
The Panel reviewed the available data to arrive at Recommended, Alternative, or Other regimens, as specified
in Table 6. Each of the regimens listed in Table 6 has shown potent virologic efficacy as measured by the
proportion of participants in comparative clinical trials able to achieve and maintain viral suppression.
Recommended regimens are those studied in randomized controlled trials and shown to have optimal and
durable virologic efficacy, favorable tolerability and toxicity profiles, and ease of use. Alternative regimens are
those that are effective but have potential disadvantages, limitations for use in certain patient population, or
less supporting data than Recommended regimens. In certain situations, depending on individual patient
characteristics and needs, an Alternative regimen may actually be the optimal regimen for a specific patient.
Some regimens are classified as Other regimens because, compared with Recommended or Alternative
regimens, they have reduced virologic activity, limited supporting data from large comparative clinical trials,
or other factors such as greater toxicities, higher pill burden, drug interaction potential, or limitations for use in
certain patient populations.
In addition to Table 6, a number of tables presented below and at the end of the guidelines provide clinicians
with guidance on selecting and prescribing an optimal regimen for an individual patient. Table 7 lists specific
case scenarios to guide regimen selection for patients with common clinical conditions. Table 8 lists the
potential advantages and disadvantages of the components used in Recommended and Alternative regimens.
Table 9 lists agents or regimens not recommended for initial treatment. Appendix B, Tables 1–6 lists
characteristics of individual ARV agents, such as formulations, dosing recommendations, PKs, and common
adverse effects. Appendix B, Table 7 provides ARV dosing recommendations for patients who have renal or
hepatic insufficiency.
Changes Since the Last Revision of the Guidelines
Since the last revision of these guidelines, new data from clinical trials and cohort studies, as well as
experience in clinical practice, have prompted significant changes to the list of Recommended, Alternative, and
Other regimens for treatment-naive patients (Table 6). Among these changes, the following deserve emphasis:
•     There are now five Recommended regimens for antiretroviral therapy (ART)-naive patients: four INSTI-
based regimens and one ritonavir-boosted PI (PI/r)-based regimen.
•     Results from a large comparative clinical trial comparing atazanavir/ritonavir (ATV/r) plus TDF/FTC to
darunavir/ritonavir (DRV/r) or raltegravir (RAL) plus TDF/FTC showed a greater rate of toxicities-
related discontinuation in the ATV/r arm.4 Therefore, ATV/r plus TDF/FTC has been moved from the
Recommended to the Alternative category. 
•     The Panel has also moved EFV/TDF/FTC from the Recommended to the Alternative category because of
concerns about the tolerability of efavirenz (EFV) in clinical trials and practice, especially the high rate
of central nervous system (CNS) related toxicities, and a possible association with suicidality observed in
one analysis of four clinical trials.5
•     Regimens that were previously listed as Recommended for patients with baseline HIV RNA <100,000
copies/mL or CD4 count >200 cells/mm3 are now in the Alternative or Other category, with the same
caveat to limit their use to patients with the cited HIV RNA and CD4 levels.
•     Two regimens that use fewer than two NRTIs (DRV/r plus RAL and lopinavir/ritonavir [LPV/r] plus
3TC) are listed among the Other regimens, with the caveat that their use be limited to patients who
cannot take either TDF or ABC.
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•     Coformulations of ATV and DRV with the PK enhancer cobicistat (COBI) have been added to the
Alternative regimen options.
Table 6. Recommended, Alternative, and Other Antiretroviral Regimen Options for Treatment-Naive
Patients  (page 1 of 2)
An ARV regimen generally consists of two NRTIs (one of which is FTC or 3TC) plus an INSTI, NNRTI, or PK-
enhanced PI. Selection of a regimen should be individualized on the basis of virologic efficacy, potential adverse
effects, pill burden, dosing frequency, drug-drug interaction potential, a patient’s resistance test results and
comorbid conditions, and cost. Table 7 lists specific case scenarios to guide regimen selection for patients with
common clinical conditions. For more detailed recommendations on ARV choices and dosing in HIV-infected
pregnant women, refer to the latest perinatal guidelines available at http://aidsinfo.nih.gov/guidelines.
Recommended Regimen Options
(Drug classes and regimens within each class are arranged in alphabetical order.)
INSTI-Based Regimens:
• DTG/ABC/3TCa—only for patients who are HLA-B*5701 negative (AI)
• DTG plus TDF/FTCa (AI)
• EVG/c/TDF/FTC—only for patients with pre-treatment estimated CrCl ≥70 mL/min (AI)
• RAL plus TDF/FTCa (AI)
PI-Based Regimens:
• DRV/r plus TDF/FTCa (AI)
Alternative Regimen Options
(Drug classes and regimens within each class are arranged in alphabetical order.)
Regimens that are effective and tolerable, but that have potential disadvantages when compared with the recommended regimens listed
above, have limitations for use in certain patient population, or have less supporting data from randomized clinical trials. An alternative
regimen may be the preferred regimen for some patients.
NNRTI-Based Regimens:
• EFV/TDF/FTCa (BI)
• RPV/TDF/FTCa—only for patients with pre-treatment HIV RNA <100,000 copies/mL and CD4 cell count >200 cells/mm3 (BI)
PI-Based Regimens:
• ATV/c plus TDF/FTCa —only for patients with pre-treatment estimated CrCl ≥70 mL/min (BI)
• ATV/r plus TDF/FTCa (BI)
• (DRV/c or DRV/r) plus ABC/3TCa —only for patients who are HLA-B*5701 negative (BIII for DRV/c and BII for DRV/r)
• DRV/c plus TDF/FTCa —only for patients with pre-treatment estimated CrCl ≥70 mL/min (BII)
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Other Regimen Options
(Drugs classes and regimens within each class are arranged in alphabetical order.)
Regimens that, in comparison with Recommended and Alternative regimens, may have reduced virologic activity, limited supporting data
from large comparative clinical trials, or other factors such as greater toxicities, higher pill burden, drug interaction potential, or
limitations for use in certain patient populations.
INSTI-Based Regimen:
• RAL plus ABC/3TCa—only for patients who are HLA-B*5701 negative (CII)
NNRTI-Based Regimen:
• EFV plus ABC/3TCa—only for patients who are HLA-B*5701 negative and with pre-treatment HIV RNA <100,000 copies/mL (CI)
PI-Based Regimens:
• (ATV/c or ATV/r) plus ABC/3TCa—only for patients who are HLA-B*5701 negative and with pre-treatment HIV RNA <100,000
copies/mL (CIII for ATV/c and CI for ATV/r)
• LPV/r (onceb or twice daily) plus ABC/3TCa—only for patients who are HLA-B*5701 negative (CI)
• LPV/r (onceb or twice daily) plus TDF/FTCa (CI)
Other Regimens When TDF or ABC Cannot be Used:
• DRV/r plus RAL—only for patients with pre-treatment HIV RNA <100,000 copies/mL and CD4 cell count >200 cells/mm3 (CI)
• LPV/r (twice daily) plus 3TC (twice daily) (CI)
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
Table 6. Recommended, Alternative, and Other Antiretroviral Regimen Options for Treatment-Naive
Patients  (page 2 of 2)
a 3TC may be substituted for FTC or vice versa. 
b Once daily LPV/r is not recommended for pregnant patients.
Note: The following are available as co-formulated fixed-dose combination products: ABC/3TC, ATV/c, DRV/c, DTG/ABC/3TC,
EFV/TDF/FTC, EVG/c/TDF/FTC, LPV/r, RPV/TDF/FTC, and TDF/FTC.
Key to Acronyms: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ATV/c = cobicistat-boosted atazanavir; ATV/r = ritonavir-
boosted atazanavir; CrCl = creatinine clearance; DRV/c = cobicistat-boosted darunavir; DRV/r = ritonavir-boosted darunavir; DTG =
dolutegravir; EFV = efavirenz; EVG/c/TDF/FTC = elvitegravir/cobicistat/tenofovir DF/emtricitabine; FTC = emtricitabine; INSTI = integrase
strand transfer inhibitor; LPV/r = ritonavir-boosted lopinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside
reverse transcriptase inhibitor; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; TDF = tenofovir disoproxil
fumarate
Considerations When Selecting A Regimen for Antiretroviral Therapy-Naive Patients
As noted in Table 6, the Recommended Regimens include four INSTI-based regimens and one DRV/r-based
regimen for initial therapy. The INSTI-based regimens were selected because of their high virologic efficacy,
excellent safety and tolerability profiles, and (with RAL and dolutegravir [DTG]) low number of drug-drug
interactions (see the INSTI section for discussion regarding the special characteristics and clinical trial
results for each of the 3 Recommended INSTIs). For patients who are at high risk for intermittent therapy
because of poor adherence or have transmitted NRTI drug resistance, a PI/r-based treatment is preferred
given the PIs high genetic barrier to resistance (see PI section for discussion of the different PK-boosted PIs
recommended by the Panel). In some situations, an NNRTI-based regimen may be a better choice for a
particular patient. Table 7 provides guidance on regimen selection based on various patient- and regimen-
specific characteristics. 
 i  i
i  t t, i  i  it    lt ti  i ,    i l i  ti it , li it  ti  t
f  l  ti  li i l t i l ,  t  f t    t  t i iti , i  ill ,  i t ti  t ti l, 
li it ti  f   i  t i  ti t l ti .
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Factors to Consider When Selecting an Initial Regimen
When selecting a regimen for an individual patient, a number of patient and regimen specific characteristics
should be considered, with the goal of providing a potent, safe, tolerable, and easy to adhere to regimen for
the patient in order to achieve sustained virologic control. Some of the factors can be grouped into the
following categories:
Initial Characteristics of the Patient: 
•     Pre-treatment HIV RNA level (viral load)
•     Pre-treatment CD4 cell count
•     HIV genotypic drug resistance testing results
•     HLA-B*5701 status
•     Patient preferences
•     Patient’s anticipated adherence
Specific Comorbidities or Other Conditions:
•     Cardiovascular disease, hyperlipidemia, renal disease, osteoporosis, psychiatric illness, neurologic
disease, drug abuse or dependency requiring narcotic replacement therapy
•     Pregnancy or pregnancy potential. Clinicians should refer to the latest Perinatal Guidelines for more
detailed recommendations on the safety and effectiveness of ARV drugs during pregnancy.
•     Coinfections: hepatitis C (HCV), hepatitis B (HBV), tuberculosis (TB)
Regimen-Specific Considerations:
•     Regimen’s genetic barrier to resistance
•     Potential adverse drug effects
•     Known or potential drug interactions with other medications
•     Convenience (e.g., pill burden, dosing frequency, availability of fixed-dose combination products, food
requirements)
•     Cost (see Cost Consideration and Antiretroviral Therapy section)
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Table 7. Antiretroviral Regimen Considerations as Initial Therapy based on Specific Clinical Scenarios
(page 1 of 3) 
This table is designed to guide clinicians in choosing an initial ARV regimen according to various patient and
regimen characteristics and specific clinical scenarios. When more than one scenario applies to a patient,
clinicians should review considerations for each relevant scenario and use their clinical judgment to select
the most appropriate regimen. This table is intended to guide the initial choice of regimen. However, if a
patient is doing well on a particular regimen, it is not necessary to switch to another regimen based on the
scenarios outlined in this table.
Please see Table 8 for additional information regarding the advantages and disadvantages of particular ARV
medications. 
Pre-ART
Characteristics
CD4 count <200
cells/mm3
Do Not Use the Following Regimens:
• RPV-based regimens
• DRV/r plus RAL
Higher rate of virologic failure observed
in those with low pre-treatment CD4
cell count
HIV RNA >100,000
copies/mL
Do Not Use the Following Regimens:
• RPV-based regimens
• ABC/3TC with EFV or ATV/r
• DRV/r plus RAL
Higher rates of virologic failure
observed in those with high pre-
treatment HIV RNA 
HLA-B*5701 positive Do not use ABC-containing regimen. Abacavir hypersensitivity, a potentially
fatal reaction, is highly associated with
positivity for the HLA-B*5701 allele.
Must treat before
HIV drug resistance
results available
Avoid NNRTI-based regimen. Transmitted mutations conferring
NNRTI resistance are more likely than
mutations associated with PI or INSTI
resistance.
Some experts avoid using INSTI-
containing regimens in this setting
because of concern regarding their
ability to fully suppress viral replication if
transmitted NRTI mutations are present.
ART Specific
Characteristics
One pill once daily
regimen desired
ART Options Include:
• DTG/ABC/3TC
• EFV/TDF/FTC
• EVG/c/TDF/FTC
• RPV/TDF/FTC (if HIV RNA <100,000
copies/mL and CD4 count >200/mm3)
Available as fixed-dose combination
tablets
Food effects Regimens that Should be Taken with Food:
• ATV/r or ATV/c-based regimens
• DRV/r or DRV/c-based regimens
• EVG/c/TDF/FTC
• RPV/TDF/FTC
Regimens that Should be Taken on an
Empty Stomach:
• EFV-based regimens
Food improves absorption of the listed
regimens.
Taking EFV-based regimens with food
increases EFV absorption and may
increase CNS side effects.
Patient or Regimen
Characteristics
Clinical
Scenario Consideration(s) Rationale/Comments
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Table 7. Antiretroviral Regimen Considerations as Initial Therapy based on Specific Clinical Scenarios
(page 2 of 3)
)
Presence of Other
Conditions
Chronic kidney
disease (defined as
eGFR<60 mL/min)
Consider avoiding TDF.
If eGFR is <70 mL/min, Do Not Use:
• EVG/c/TDF/FTC, or
• ATV/c with TDF, or
• DRV/c with TDF 
Options for CKD Patients
Use ABC/3TC if HLA-B*5701 Negative:
• If HIV RNA >100,000 copies/mL, do not
use ABC/3TC with EFV or ATV/r.
• If CrCl <50 mL/min, do not use
coformulated ABC/3TC because 3TC
requires dose adjustment.
Other Options (See Text for Discussion):
• DRV/r plus RAL (if HIV <100,000/mL and
CD4 count >200/mm3), or 
• LPV/r plus 3TC, or
• Modify TDF dose 
TDF has been associated with renal
tubulopathy.
See Appendix B, Table 7 for
recommendations on ARV dose
modification. 
Osteoporosis Consider avoiding TDF.
Use ABC/3TC if HLA-B*5701 negative
If HIV RNA >100,000 copies/mL, do not
use ABC/3TC plus (EFV or ATV/r) 
TDF is associated with greater decrease in
bone mineral density along with renal
tubulopathy, urine phosphate wasting, and
osteomalacia.
Psychiatric
illnesses
Consider avoiding EFV-based regimens. EFV can exacerbate psychiatric symptoms
and may be associated with suicidality.
HIV-associated
dementia (HAD)
Avoid EFV-based regimens if possible.
Favor DRV-based or DTG-based regimen.
EFV neuropsychiatric effects may confound
assessment of the effect of ART on improve-
ment of symptoms associated with HAD.
Theoretical CNS penetration advantage 
Narcotic
replacement
therapy required
If patient receiving methadone, consider
avoiding EFV-based regimen. 
If EFV is used, an increase in methadone
dose may be necessary.
EFV reduces methadone concentrations
and may lead to withdrawal symptoms.
High cardiac risk Consider avoiding ABC- and LPV/r -
based regimens.
Increased cardiovascular risk in some studies
(see ABC discussion in this section)
Hyperlipidemia The Following ARV Drug Classes or Drugs
have been Associated with Deleterious
Effects on Lipids: 
• PI/r
• ABC
• EFV
• EVG/c
TDF has been associated with beneficial
lipid effects, thus it may be preferable to
ABC 
Pregnancy Refer to the Perinatal Antiretroviral Treatment Guidelines.
Patient or Regimen
Characteristics
Clinical
Scenario Consideration(s) Rationale/Comments
Downloaded from http://aidsinfo.nih.gov/guidelines on 9/16/2015
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents                                   F-8
Table 7. Antiretroviral Regimen Considerations as Initial Therapy based on Specific Clinical Scenarios
(page 3 of 3)
Presence of Co-
Infections
HBV infection Use TDF/FTC (or TDF plus 3TC) whenever
possible.
If TDF is Contraindicated:
• For treatment of HBV, use FTC or 3TC
with entecavir or another drug active
against HBV.
TDF, FTC, and 3TC are active against both
HIV and HBV. 3TC- or FTC-associated
HBV mutations can emerge rapidly when
these drugs are used without another HBV-
active agent.
HCV treatment
required
Refer to recommendations in the HIV/HCV co-infection section.
TB infection If Rifampin is Used:
• EFV-based regimens have the least drug-
drug interactions.
• If RAL is used, increase RAL dose to 800
mg BID.
• Use DTG at 50 mg BID dose only in
patients without selected INSTI mutations
(refer to product label).
If using a PI-based regimen, rifabutin
should be used in place of rifampin in the
TB regimen.
• Rifampin is a strong inducer of CYP3A4
and UGT1A1 enzymes, causing
significant decrease in concentrations of
PI, INSTI, and RPV.
• Rifampin has a less significant effect on
EFV concentration than on other NNRTIs,
PIs, and INSTIs
• Rifabutin is a less potent inducer and is a
good option for patients receiving non-
EFV-based regimens
Refer to Tables 19a, b, d and e for dosing
recommendations for rifamycins used with
different ARV agents.
Key to Acronyms: 3TC = lamivudine; ABC = abacavir; ATV/r = ritonavir-boosted atazanavir; ARV = antiretroviral; c = cobicistat; CKD =
chronic kidney disease; CrCl = creatinine clearance; DRV/r = ritonavir- boosted darunavir; DTG = dolutegravir; eGFR = estimated
glomerular filtration rate; EFV = efavirenz; EVG/c/TDF/FTC = elvitegravir/cobicistat/tenofovir/emtricitabine; FDA = Food and Drug
Administration; FTC = emtricitabine; HBV = hepatitis B virus; HCV = hepatitis C virus; INSTI = integrase strand transfer inhibitor; LPV/r =
ritonavir-boosted lopinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI =
protease inhibitor; PI/r = ritonavir-boosted protease inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; TDF = tenofovir disoproxil
fumarate
Selecting an Initial Antiretroviral Regimen 
Initial therapy generally consists of two NRTIs combined with an INSTI, an NNRTI, or a pharmacologically
boosted PI. All Recommended and Alternative regimens include the NRTI combination of TDF/FTC or
ABC/3TC, each combination is available as fixed-dose combination tablets. The choice of NRTI
combination is usually guided by differences between TDF and ABC because FTC and 3TC have few
adverse events and have comparable efficacy. Considerations that are germane to deciding between TDF and
ABC are summarized in Table 8 and in the section on Dual NRTI options (below).
Choosing Between an Integrase Strand Transfer Inhibitor-, A Non-Nucleoside Reverse
Transcriptase Inhibitor-, or A Protease Inhibitor-Based Regimen 
The choice between an INSTI, NNRTI, or PI as the third drug in an initial ARV regimen should be guided by
the regimen’s efficacy, genetic barrier to resistance, adverse effects profile, and convenience; the patient’s co-
morbidities; and concomitant medications and the potential for drug-drug interactions (See Tables 7 and 8 for
guidance). The Panel’s Recommended regimens as listed in Table 6 include an INSTI or DRV/r in combination
Patient or Regimen
Characteristics
Clinical
Scenario Consideration(s) Rationale/Comments
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with 2 NRTIs. For most patients, an INSTI-containing regimen will be highly effective, have few adverse
effects, and (with RAL and DTG) have no significant CYP 3A4-associated drug interactions. In addition, in the
two head-to-head comparisons between DRV/r- and INSTI-containing regimens, the INSTI was better
tolerated, with fewer treatment discontinuations.4,6 For these reasons, all three currently available INSTIs are
included among the Recommended regimens and, in general, should be selected for most patients. An
exception is in those individuals with uncertain adherence or in whom treatment needs to begin before
resistance testing results are available. In this context, DRV/r may have an important role given its high genetic
barrier to resistance and low rate of treatment-emergent resistance during many years of clinical experience.
Alternative Regimens include either an NNRTI-based (EFV or rilpivirine [RPV]) or a PK-enhanced, PI-based
(ATV/r, atazanavir/cobicistat [ATV/c], or darunavir/cobicistat [DRV/c]) regimen. Although the NNRTIs EFV
or RPV are optimal choices for some patients, these drugs have low genetic barriers to resistance, especially in
patients with suboptimal adherence. EFV has a long track record of widespread use in the United States and
globally. Most EFV-based regimens have strong virologic efficacy, including in patients with high HIV RNA
(except when EFV is used with ABC/3TC); however, the relatively high rate of CNS-related side effects makes
the EFV-based regimen less tolerable than other regimens. RPV has fewer adverse effects than EFV, is
available in the smallest coformulated single tablet, and has a favorable lipid profile. However, RPV has lower
virologic efficacy in patients with high baseline HIV RNA (>100,000 copies/mL) and low CD4 count (< 200
cells/mm3). ATV/r has demonstrated excellent virologic efficacy in clinical trials, and has relatively few
metabolic adverse effects in comparison to other boosted PI regimens; however, recent clinical trial data
showed that ATV/r had a higher rate of adverse effect-associated drug discontinuation with than the
comparators (DRV/r and RAL). Thus, despite these favorable attributes, based on the above considerations,
EFV-, RPV-, and ATV/r- containing regimens are no longer Recommended Regimens as initial therapy in all
patients, and are listed as Alternatives. However, based on individual patient characteristics, some Alternative
regimens may actually be the optimal regimen for some patients. Furthermore, patients who are doing well on
EFV-, RPV-, and ATV/r- containing regimens should not necessarily be switched to other agents.
Choosing Among Different Drugs from an Antiretroviral Drug Class 
The sections below provides clinicians with comparisons of different currently recommended ARV drugs
within a drug class, including information related to the safety and virologic efficacy of different drugs based
on clinical trial results and/or post-marketing data, special considerations to take into account, and the
rationales for the Panel’s recommendations.
Dual-Nucleoside Reverse Transcriptase Inhibitor Options A Part of Initial Combination
Therapy 
Summary
TDF/FTC and ABC/3TC are NRTI combinations commonly used for initial therapy. Table 6 provides
recommendations and ratings for the individual regimens. These recommendations are based on the virologic
potency and durability, short- and long-term toxicity, and dosing convenience of these drugs.
Clinical Trials Comparing Abacavir/Lamivudine to Tenofovir/Emtricitabine 
Several randomized controlled trials in ART-naive participants compared ABC/3TC to TDF/FTC, each with
the same7-9 or a different third ARV drug (also see discussion in the DTG section).10
•     The ACTG 5202 study, a randomized controlled trial in more than 1,800 participants, evaluated the
efficacy and safety of ABC/3TC and TDF/FTC when each used in combination with either EFV or ATV/r. 
•     Treatment randomization was stratified on the basis of a screening HIV RNA level <100,000 copies/mL
or ≥100,000 copies/mL. HLA B*5701 testing was not required before study entry. 
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•     A Data Safety Monitoring Board recommended early termination of the ≥100,000 copies/mL
stratification group because of a significantly shorter time to study-defined virologic failure in the
ABC/3TC arm than in the TDF/FTC arm.7 This difference in time to virologic failure between the arms
was observed regardless of whether the third active drug was EFV or ATV/r. 
•     There was no difference between ABC/3TC and TDF/FTC in time to virologic failure for participants
who had plasma HIV RNA <100,000 copies/mL at screening.11
•     The ASSERT study compared open label ABC/3TC with TDF/FTC in 385 HLA B*5701-negative, ART-
naive patients; all participants also received EFV. The primary study endpoint was renal safety of the
regimens. At week 48, the proportion of participants with HIV RNA <50 copies/mL was lower among
ABC/3TC-treated participants than among TDF/FTC-treated participants.8
•     In the HEAT study, 688 participants received ABC/3TC or TDF/FTC in combination with once-daily
LPV/r. Virologic efficacy was similar in the two study arms. In a subgroup analysis of patients with
baseline HIV RNA ≥100,000 copies/mL, the proportion of participants who achieved HIV RNA <50
copies/mL at 96 weeks did not differ between the two regimens.9
Dual-Nucleoside Reverse Transcriptase Inhibitor Choices  
Note: In alphabetical order.
Abacavir/Lamivudine  
ABC plus 3TC has been studied in combination with EFV, several PIs, and DTG in ART-naive patients.10,12-14
Adverse Effects:
Hypersensitivity Reactions:
•     Clinically suspected hypersensitivity reactions (HSRs) were observed in 5% to 8% of individuals who
started ABC in clinical trials conducted before the use of HLA-B*5701 testing. The risk of HSRs is
highly associated with the presence of the HLA-B*5701 allele.15,16 HLA-B*5701 testing should precede
use of ABC. ABC should not be given to patients who test positive for HLA-B*5701 and based on a
positive test result, ABC hypersensitivity should be noted on a patient’s allergy list. Patients who are
HLA-B*5701 negative are far less likely to experience an HSR, but they should be counseled about the
symptoms of the reaction. Patients who discontinue ABC because of a suspected HSR should never be
re-challenged, regardless of their HLA-B*5701 status.
Cardiovascular Risk:
•     An association between ABC use and myocardial infarction (MI) was first reported in the D:A:D study.
This large, multinational observational study group found that recent (within 6 months) or current use of
ABC was associated with an increased risk of MI, particularly in participants with pre-existing cardiac
risk factors.17,18
•     Since the D:A:D report, several studies have evaluated the relationship between ABC therapy and
cardiovascular events. Some studies have found an association;19-22 others, including an FDA meta-
analysis of 26 randomized clinical trials that evaluated ABC, have not.23-27
•     No consensus has been reached on the association between ABC use and MI risk or the mechanism for
such an association.
Other Factors and Considerations:
•     ABC/3TC is available as a co-formulated tablet and as a coformulated single-tablet regimen with DTG.
•     ABC and 3TC are available separately in generic tablet formulations.
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•     ABC does not cause renal dysfunction and is an option for TDF in patients with underlying renal
dysfunction or who are at risk for renal effects. No dosage adjustment is required in patients with renal
dysfunction.
Panel’s Recommendations:
•     ABC should only be prescribed for patients who are HLA B*5701 negative.
•     On the basis of clinical trial safety and efficacy data, experience in clinical practice, and the availability
of ABC/3TC as a component of co-formulated products, the Panel classifies ABC/3TC plus DTG as a
Recommended regimen (AI) (see discussion regarding DTG in this section regarding the clinical efficacy
data for ABC/3TC plus DTG) . 
•     ABC/3TC use with EFV, ATV/r, or ATV/c is only recommended for patients with pre-treatment HIV
RNA <100,000 copies/mL. 
•     ABC/3TC is a part of several Alternative or Other regimens when combined with another ARV drug. See
Table 6 for more detailed recommendations on use of ABC/3TC with other drugs.
•     ABC should be used with caution or avoided in patients with known high cardiovascular risk.
Tenofovir/Emtricitabine  
TDF, with either 3TC or FTC, has been studied in combination with EFV, RPV, several boosted PIs, EVG/c,
RAL, and DTG in randomized clinical trials.28-37
Adverse Effects:
•     New onset or worsening renal impairment has been associated with TDF use.38,39 Risk factors may
include advanced HIV disease; longer treatment history; low body weight, especially in females;40 and
pre-existing renal impairment.41
      •     Concomitant use of a PK-enhanced regimen (with a PI or EVG) can increase TDF concentrations;
studies have suggested a greater risk of renal dysfunction when TDF is used in these regimens.39,42-46
•     While initiation of all NRTI-containing regimens has been associated with a decrease in bone mineral
density (BMD), the loss of BMD is greater with TDF-containing regimens. For example, in two
randomized studies comparing TDF/FTC with ABC/3TC, participants receiving TDF/FTC experienced a
significantly greater decline in bone mineral density than ABC/3TC-treated participants.47,48 Following
an early decline after ART initiation, BMD generally stabilizes.
•     Cases of osteomalacia associated with proximal renal tubulopathy have been reported with the use of
TDF.49
Other Factors and Considerations:
•     TDF/FTC is available in fixed-dose drug combinations with EFV, EVG/c, and RPV, allowing the
regimens to be administered as a single pill, given once daily.
•     Renal function, urine glucose, and urine protein should be assessed before initiating treatment with TDF
and periodically during treatment (see Laboratory Monitoring section). In patients who have pre-existing
renal insufficiency (CrCl <60 mL/min),50 TDF should generally be avoided. If TDF is used, dosage
adjustment is required if the patient’s CrCl falls below 50 mL/min (see Appendix B, Table 7 for dosage
recommendations).
•     Both TDF and FTC are active against HBV. In patients with HIV/HBV coinfection, TDF/FTC should be
used as the NRTI pair of the ART regimen because the drugs have activity against both viruses (also see
HIV/HBV Coinfection section).
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Panel’s Recommendations:
•     On the basis of clinical trial safety and efficacy data, long-term experience in clinical practice, and the
combination’s availability as a component of co-formulated products, the Panel considers TDF/FTC as a
Recommended NRTI combination for initial ART in treatment-naive patients when combined with DTG,
EVG/c, RAL, or DRV/r. See Table 6 for recommendations regarding use of TDF/FTC with other drugs.
•     TDF should be used with caution or avoided in patients with renal disease and osteoporosis.
Integrase Strand Transfer Inhibitor-Based Regimens  
Summary  
Three INSTIs—DTG, EVG, and RAL—are currently approved for HIV-infected, ARV-naive patients. DTG
and EVG are currently available as components of one-tablet once daily complete regimens: DTG is
coformulated with ABC/3TC; EVG is coformulated with a PK enhancer (COBI) and TDF/FTC. EVG is also
available as a single agent designed to be used in combination with PI/r in ART-experienced patients, and is
not recommended for use in treatment-naive patients.
Recommended Integrase Strand Transfer Inhibitor-Based Regimens  
Note: In alphabetical order.
Dolutegravir  
Efficacy in Clinical Trials:
The efficacy of DTG in treatment-naive patients has been evaluated in three fully powered clinical trials,
including two randomized double-blinded clinical trials and one randomized open-label clinical trial. In these
three trials, DTG-based regimens were non-inferior or superior to a comparator INSTI, NNRTI, or PI-based
regimen. The primary efficacy endpoint in these clinical trials was the proportion of participants with plasma
HIV RNA <50 copies/mL.
•     The SPRING-2 trial compared DTG 50 mg once daily to RAL 400 mg twice daily, each in combination
with investigator-selected NRTI ABC/3TC or TDF/FTC, in 822 participants. At week 96, DTG was non-
inferior to RAL.37
•     The SINGLE trial compared DTG 50 mg once daily plus ABC/3TC to EFV/TDF/FTC in 833
participants. At week 48, DTG was superior to EFV, primarily because the study treatment
discontinuation rate was higher in the EFV arm than in the DTG arm.10 At week 144, DTG plus
ABC/3TC remained superior to EFV/TDF/FTC.51
•     The FLAMINGO study, a randomized open-label clinical trial, compared DTG 50 mg once daily to
DRV/r 800 mg/100 mg once daily, each in combination with investigator-selected ABC/3TC or
TDF/FTC. At week 48, DTG was superior to DRV/r because of the higher rate of discontinuation in the
DRV/r arm.6,52 The difference in response rates favoring DTG was greater in patients with pre-treatment
HIV RNA levels >100,000 copies/mL. At week 96, DTG remained superior to DRV/r.53
Adverse Effects:
•     DTG is generally well tolerated. The most common adverse reactions of moderate to severe intensity
with an incidence ≥2% in the clinical trials were insomnia and headache. Cases of hypersensitivity
reactions were reported in <1% of trial participants.
Other Factors and Considerations:
•     In treatment-naive patients, DTG is given once daily, with or without food. 
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•     DTG decreases tubular secretion of creatinine without affecting glomerular function, with increases in
serum creatinine observed within the first 4 weeks of treatment (mean increase in serum creatinine was
0.11 mg/dL after 48 weeks). 
•     DTG has few drug interactions. DTG increases metformin levels approximately two-fold; close
monitoring for metformin adverse effects is advisable. Rifampin decreases DTG levels, therefore, an
increase in dosing of DTG to 50 mg twice daily is required. 
•     DTG absorption may be reduced when the ARV is coadministered with polyvalent cations (see Drug
Interaction section). DTG should be taken at least 2 hours before or 6 hours after cation-containing
antacids or laxatives. Alternatively, DTG and supplements containing calcium or iron can be taken
simultaneously with food.
•     Treatment-emergent mutations that confer DTG resistance have not been reported in patients receiving
DTG for initial therapy, which suggests that DTG has a higher genetic barrier to resistance than other
INSTIs.
Panel’s Recommendation: 
•     On the basis of clinical trial data, the Panel categorizes DTG in combination with either ABC/3TC or
TDF/FTC as a Recommended regimen in ART-naive patients (AI). 
Elvitegravir  
EVG is available as a component of a four-drug, fixed-dose combination product containing EVG, COBI,
TDF, and FTC (EVG/c/TDF/FTC). COBI is a specific, potent CYP3A inhibitor that has no activity against
HIV. It acts as a PK enhancer of EVG, which allows for once daily dosing of the combination.
Efficacy in Clinical Trials:
The efficacy of EVG/c/TDF/FTC in ARV-naive participants has been evaluated in two randomized, double-
blind active-controlled trials.
•     At 144 weeks, EVG/c/TDF/FTC was non-inferior to fixed-dose EFV/TDF/FTC.54
•     EVG/c/TDF/FTC was also found to be non-inferior to a combination containing ATV/r plus TDF/FTC.55
Adverse Effects:
•     The most common adverse events reported with EVG/c/TDF/FTC were diarrhea, nausea, upper
respiratory infection, and headache.54,55
Other Factors and Considerations:
•     EVG is metabolized primarily by CYP3A enzymes; as a result, CYP3A inducers or inhibitors may alter
EVG concentrations. 
•     Because COBI inhibits CYP3A, it interacts with a number of medications that are metabolized by this
enzyme (see Drug-Drug Interactions section).56
•     EVG plasma concentrations are lower when the ARV is administered simultaneously with polyvalent
cation-containing antacids or supplements (see Drug Interaction section). Separate EVG/cobi/TDF/FTC
and polyvalent antacid administration by at least 2 hours; administer polyvalent cation-containing
supplements at least 2 hours before or 6 hours after EVG dosing.
•     COBI inhibits active tubular secretion of creatinine, resulting in increases in serum creatinine and a
reduction in estimated CrCl without reducing glomerular function.57 Patients with a confirmed increase
in serum creatinine greater than 0.4 mg/dL from baseline while taking EVG/c/TDF/FTC should be
closely monitored and evaluated for evidence of TDF-related proximal renal tubulopathy.46
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•     EVG/c/TDF/FTC is not recommended for patients with pre-treatment estimated CrCl <70 mL/min.46
•     At the time of virologic failure, INSTI-associated mutations were detected in some EVG/c/TDF/FTC-
treated patients whose therapy failed.54,55 These mutations conferred cross-resistance to RAL, with most
retaining susceptibility to DTG. 
Panel’s Recommendation: 
•     On the basis of the above factors, the Panel classifies EVG/c/FTC/TDF as a Recommended regimen in
ART-naive patients (AI). 
Raltegravir  
RAL was the first INSTI approved for use in both ARV-naive and ARV-experienced patients.
Efficacy in Clinical Trials: 
The efficacy of RAL (with either TDF/FTC or ABC/3TC) as initial therapy has been evaluated in two
randomized, double-blinded, controlled clinical trials, and a third open-label randomized trial.
•     STARTMRK compared RAL 400 mg twice daily to EFV 600 mg once daily, each in combination with
TDF/FTC. RAL was non-inferior to EFV at 48 weeks.33 RAL was superior to EFV at 4 and 5 years,36,58 in
part because of more frequent discontinuations due to adverse events in the EFV group than in the RAL
group. 
•     The SPRING-2 trial compared DTG 50 mg once daily to RAL 400 mg twice daily, each in combination
with investigator-selected ABC/3TC or TDF/FTC. At week 96, DTG was non-inferior to RAL. 
•     The SPRING-2 trial also provided non-randomized data on the efficacy of RAL plus ABC/3TC. In this
trial, 164 participants (39 and 125 with baseline viral loads ≥100,000 copies/mL and <100,000
copies/mL, respectively) received RAL in combination with ABC/3TC. After 96 weeks, there was no
difference in virologic response between the ABC/3TC and TDF/FTC groups when RAL was given as
the third drug.37
•     ACTG A5257, a large randomized open-label trial, compared 3 NNRTI-sparing regimens containing
RAL, ATV/r, or DRV/r, each given with TDF/FTC. At week 96, all 3 regimens had similar virologic
efficacy, but RAL was superior to both ATV/r and DRV/r for the combined endpoints of virologic
efficacy and tolerability. Lipids increased more in participants in the PI/r arms than in the RAL arm, and
bone mineral density decreased to a greater extent in participants in the PI/r arms than in participants in
the RAL arm.4
Adverse Effects:
•     RAL use has been associated with creatine kinase elevations. Myositis and rhabdomyolysis have been
reported. 
•     Rare cases of severe skin reactions and systemic hypersensitivity reactions in patients who received RAL
have been reported during post-marketing surveillance.59
Other Factors and Considerations:
•     RAL must be administered twice daily—a potential disadvantage when comparing RAL-based treatment
with other Recommended regimens.
•     Coadministration of RAL with aluminum and/or magnesium-containing antacids can reduce absorption
of RAL and is not recommended. Raltegravir may be coadministered with calcium carbonate-containing
antacids. Polyvalent cation-containing supplements may also reduce absorption of RAL; thus, RAL
should be given at least 2 hours before or 6 hours after cation-containing supplements.
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•     RAL has a lower genetic barrier to resistance than RTV-boosted PIs and DTG.
Panel’s Recommendations: 
•     On the basis of these data and long-term clinical experience with RAL, the Panel considers RAL plus
TDF/FTC as a Recommended regimen in ARV-naive patients (AI).
•     Because few patients have received RAL plus ABC/3TC in clinical trials or practice and there has not
been a randomized trial comparing ABC/3TC plus RAL to TDF/FTC plus RAL, the Panel categorizes
RAL plus ABC/3TC as an Other therapy (BII). 
Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens 
Summary 
Five NNRTIs (delavirdine [DLV], EFV, etravirine [ETR], nevirapine [NVP], and RPV) are currently FDA
approved.
NNRTI-based regimens have demonstrated virologic potency and durability. The major disadvantages of
currently available NNRTIs are the prevalence of NNRTI-resistant viral strains in ART-naive patients60 and
the drugs’ low genetic barrier for the development of resistance. Resistance testing should be performed to
guide therapy selection for ART-naive patients (see Drug-Resistance Testing). High-level resistance to all
NNRTIs (except ETR) may occur with a single mutation; within-class cross-resistance is common. In RPV-
treated patients, the presence of RPV resistance mutations at virologic failure may confer cross resistance to
other NNRTIs, including ETR.61,62
Efavirenz  
EFV is an NNRTI approved for use in combination with 2-NRTIs for ART-naive patients. 
Efficacy in Clinical Trials: 
Large randomized, controlled trials and cohort studies in ART-naive patients have demonstrated potent and
durable viral suppression in patients treated with EFV plus two NRTIs. In clinical trials, EFV-based regimens
in ART-naive patients have demonstrated superiority or non-inferiority to several comparator regimens.
•     In ACTG 5142, EFV was superior to LPV/r, although drug resistance was more common after EFV
failure than after LPV/r failure.63
•     In the 2NN study, compared to EFV, NVP did not meet non-inferiority criteria.64
•     In ACTG 5202, EFV was comparable to ATV/r when each was given with either TDF/FTC or
ABC/3TC.65
•     In the ECHO and THRIVE studies, EFV was non-inferior to RPV, with less virologic failure but more
discontinuations due to adverse events. The virologic advantage of EFV was most notable in participants
with pre-ART viral loads >100,000 copies/mL, and NRTI and NNRTI resistance was more frequent with
RPV failure.66
•     In the GS 102 study, EFV/TDF/FTC was non-inferior to EVG/c/TDF/FTC.54
More recently, some regimens have demonstrated superiority to EFV, based primarily on fewer
discontinuations because of adverse events:
•     In the SINGLE trial, a DTG-based regimen was superior to EFV at the primary endpoint of viral
suppression at Week 48.10
•     In the STARTMRK trial, RAL was non-inferior to EFV at 48 weeks.33 RAL was superior to EFV at 4 and
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5 years,36,58 in part because of more frequent discontinuations due to adverse events in the EFV group
than in the RAL group. 
•     In the open-label STaR trial, participants with baseline viral loads ≤100,000 copies/mL had higher rates
of treatment success on RPV than on EFV.67
A recent multinational randomized placebo-controlled trial compared two once daily doses of EFV
(combined with TDF/FTC): EFV 600 mg (standard dose) versus EFV 400 mg (reduced dose). At 48 weeks,
EFV 400 mg was non-inferior to EFV 600 mg for rate of viral suppression.68 Study drug-related adverse
events were less frequent in the EFV 400 mg group than in the 600 mg group. Although there were fewer
self-reported CNS events in the 400 mg group, the two groups had similar rates of psychiatric events. Unlike
the 600 mg dose of EFV, the 400 mg dose is not approved for initial treatment and is not co-formulated as a
component of a single pill regimen.
Adverse Effects:
•     EFV can cause CNS side effects, such as abnormal dreams, dizziness, headache, and depression, which
resolve over a period of days to weeks in most patients. However, more subtle, long-term
neuropsychiatric effects can occur. A recent analysis of 4 AIDS Clinical Trial Group (ACTG)
comparative trials showed a higher rate of suicidality (i.e., reported suicidal ideation or attempted or
completed suicide) among EFV-treated patients than among patients taking comparator regimens.5 This
association, however, was not found in analyses of two large observational cohorts.69,70
•     EFV may cause elevation in LDL cholesterol and triglycerides.
Other Factors and Considerations:
•     EFV is formulated both as a single-drug tablet and in a fixed-dose combination tablet of EFV/TDF/FTC
that allows for once daily dosing. 
•     EFV is a substrate of CYP3A4 and an inducer of CYP3A4 and 2D6 and therefore may potentially
interact with other drugs using the same pathways.
•     EFV has been associated with CNS birth defects in non-human primates, and cases of neural tube defects
have been reported after first trimester exposure in humans.71 Alternative regimens should be considered
in women who are planning to become pregnant or who are sexually active and not using effective
contraception. Because the risk of neural tube defects is restricted to the first 5 to 6 weeks of pregnancy,
before pregnancy is usually recognized, a suppressive EFV-based regimen can be continued in pregnant
women who present for antenatal care in the first trimester, or may be initiated after the first trimester
(see Perinatal Guidelines).
Panel’s Recommendations:
•     Given the availability of regimens with fewer treatment-limiting adverse events with non-inferior or
superior efficacy, the Panel classifies EFV/TDF/FTC as an Alternative regimen for ART-naive patients
(BI).
•     Given virologic and pharmacogenetic parameters that limit its use in some patients, the Panel
recommends EFV with ABC/3TC as an Other regimen, and only for patients with a pre-ART viral load
<100,000 copies/mL and negative HLA B*5701 status (see discussion in ABC/3TC section) (CI). 
•     EFV at a reduced dose has not been studied in the U.S. population. The Panel cannot recommend use of
reduced dose EFV until further data to support its use in the U.S. population are available. 
Rilpivirine  
RPV is an NNRTI approved for use in combination with NRTIs for ART-naive patients with pre-treatment
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viral loads <100,000 copies/mL.
Efficacy in Clinical Trials:
Two Phase 3 randomized, double-blinded clinical trials, ECHO and THRIVE, compared RPV and EFV, each
combined with 2 NRTIs.66 At 96 weeks, the following findings were reported:
•     RPV was non-inferior to EFV overall. 
•     Among participants with a pre-ART viral load >100,000 copies/mL, more RPV-treated than EFV-treated
participants experienced virologic failure. Moreover, in this subgroup of participants with virologic
failure, NNRTI and NRTI resistance was more frequently identified in those treated with RPV. 
•     Among the RPV-treated participants, the rate of virologic failure was greater in those with pre-treatment
CD4 counts <200 cells/mm3 than in those with CD4 counts ≥200 cells/mm3.
STaR, a Phase 3b, open-label study, compared the fixed-dose combinations of RPV/TDF/FTC and
EFV/TDF/FTC in 786 treatment-naive patients. At 96 weeks, the following key findings were reported:67
•     RPV was non-inferior to EFV overall.
•     RPV was superior to EFV in patients with pre-ART viral loads ≤100,000 copies/mL and non-inferior in
those with pre-ART viral loads >100,000 copies/mL. In patients with pre-ART viral loads >500,000
copies/mL., virologic failure was more common in RPV-treated patients than in EFV-treated patients.
•     At 48 weeks, NRTI and NNRTI resistance occurred in 2% and 1% of RPV- and EFV-treated patients,
respectively, with viral loads ≤100,000; in 5% and 0% of RPV- and EFV-treated patients, respectively,
with viral loads 100,000 to 500,000; and in 19% and 4% of RPV- and EFV-treated patients, respectively,
with viral loads >500,000 copies/mL.
Adverse Effects:
•     RPV is generally well tolerated. In the ECHO, THRIVE, and STaR trials, fewer CNS adverse events
(e.g., abnormal dreams, dizziness, psychiatric side effects), skin rash, and dyslipidemia were reported in
the RPV arms than the EFV arms, and fewer patients in the RPV arms discontinued therapy due to
adverse events.
Other Factors and Considerations:
•     RPV is formulated both as a single-drug tablet and in a fixed-dose combination tablet with TDF/FTC.
Among available single pill regimens, it is the smallest tablet.
•     RPV/TDF/FTC is given as a once daily regimen, and must be administered with a meal (at least 400
kcal).
•     The oral drug absorption of RPV can be significantly reduced in the presence of acid-lowering agents.
RPV is contraindicated in patients who are receiving proton pump inhibitors, and should be used with
caution in those receiving H2 antagonists or antacids (see Drug Interaction section for dosing
recommendations).
•     RPV is primarily metabolized in the liver by CYP3A enzyme; its plasma concentration may be affected
in the presence of CYP3A inhibitors or inducers (see Drug Interaction section). 
•     At higher than the approved dose of 25 mg, RPV may cause QTc interval prolongation. RPV should be
used with caution when coadministered with a drug known to increase the risk of Torsades de Pointes.
Panel’s Recommendations:
•     Given the availability of other effective regimens that do not have virologic and immunologic
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prerequisites to initiate treatment, the Panel recommends RPV/TDF/FTC as an Alternative regimen.
•     Use of RPV with TDF/FTC should be limited to ART-naive patients with pre-treatment viral load
<100,000 copies/mL and CD4 count >200 cells/mm3 (BI). 
•     Data on RPV with ABC/3TC are insufficient to consider recommending this regimen as a
Recommended, Alternative, or Other regimen.
Protease Inhibitor-Based Regimens  
Summary 
FDA-approved PIs include ATV, ATV/c, DRV, DRV/c, fosamprenavir (FPV), indinavir (IDV), LPV/r,
nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV), and tipranavir (TPV). PI-based regimens (particularly
with PK enhancement) have demonstrated virologic potency and (for those with RTV boosting) durability in
treatment-naive patients and a high genetic barrier to resistance. Few or no PI mutations are detected when a
patient’s first PI-based regimen fails, which is not the case with NNRTI- and some INSTI-based
regimens.72,73 All PIs (PK enhanced by either RTV or COBI) inhibit the cytochrome (CYP) 450 3A
isoenzyme, which may lead to significant drug-drug interactions (see Drug Interactions section). Each PI has
specific characteristics related to its virologic potency, adverse effects profile, and PK properties. The
characteristics of Recommended and Alternative PIs are listed in Table 8 and Appendix B, Table 3.
A number of metabolic abnormalities, including dyslipidemia and insulin resistance, have been associated
with PI use. The currently available PIs differ in their propensity to cause these metabolic complications,
which also depends on the dose of RTV used as a pharmacokinetic enhancing agent. Two large observational
cohort studies suggest that LPV/r, IDV, FPV, or FPV/r may be associated with increased rates of MI or
stroke.18,24 This association was not seen with ATV.74 Because of the limited number of patients receiving
DRV/r, this boosted-PI was not included in the analysis of the two studies.  
Recommended PIs for use in ART-naive patients should have proven virologic efficacy, once daily dosing, a
low pill count, and good tolerability. On the basis of these criteria, the Panel considers once-daily DRV/r plus
TDF/FTC as a Recommended PI. In a large, randomized controlled trial comparing DRV/r, ATV/r, and RAL,
all in combination with TDF/FTC, all three regimens achieved similar virologic suppression rates; however,
the proportion of patients who discontinued their assigned treatment because of adverse effects was greater
in the in the ATV/r arm than in the other two arms.4 Because of its higher rate of adverse effects, the Panel
now classifies ATV/r plus TDF/FTC as an Alternative regimen (BI). ATV/c- and DRV/c-based regimens are
considered Alternative PI regimens for the reasons detailed below.
LPV/r has twice the daily dose of RTV as other PI/r and is associated with more metabolic complications and
gastrointestinal side effects than PK-enhanced ATV or DRV. LPV/r remains as an Other PI/r because it is
currently the only PI co-formulated with RTV and it has extensive experience in clinical trials and practice.
Compared to other PIs, FPV/r, unboosted ATV, and SQV/r have disadvantages such as greater pill burden,
lower efficacy, or increased toxicity, and thus are no longer included as an option for initial therapy.
Nonetheless, patients who are doing well on regimens containing these PIs should not necessarily be
switched to other agents.
Recommended Protease Inhibitor-Based Regimen  
Darunavir/Ritonavir 
Efficacy in Clinical Trials:
•     The ARTEMIS study compared DRV/r (800/100 mg once daily) with LPV/r (800/200 mg once daily or
400/100 mg twice daily), both in combination with TDF/FTC, in a randomized, open-label, non-
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inferiority trial. DRV/r was non-inferior to LPV/r at week 48,31 and superior at week 192.75 Among
participants with baseline HIV RNA levels >100,000 copies/mL, virologic response rates were lower in
the LPV/r arm than in the DRV/r arm. 
•     The FLAMINGO study compared DRV/r with DTG, each in combination with two NRTIs, in 488 ART-
naive participants. The rate of virologic suppression at week 48 was significantly greater among those
who received DTG than in those who received DRV/r, largely because of more drug discontinuations in
the DRV/r group.6
•     A small retrospective study that followed participants for 48 weeks suggested that DRV/r plus ABC/3TC
may be effective in treatment-naive patients.76
•     The ACTG A5257 study showed similar virologic efficacy for DRV/r, ATV/r, and RAL, but more
participants in the ATV/r group discontinued randomized treatment because of adverse events.4
Adverse Effects:
•     In the ARTEMIS Study, grades 2 to 4 adverse events, primarily diarrhea, were seen less frequently in
DRV/r recipients than in LPV/r recipients. 
•     Patients starting DRV/r may develop a skin rash, which is usually mild-to-moderately severe and self-
limited. Treatment discontinuation is necessary on rare occasions when severe rash with fever or elevated
transaminases occur.
Other Factors and Considerations:
•     DRV/r is administered once daily with food in treatment-naive patients.
•     DRV has a sulfonamide moiety, and should be used with caution in patients with severe sulfonamide
allergies. In clinical trials, the incidence and severity of rash were similar in participants who did or did not
have a history of sulfonamide allergy. Most patients with sulfonamide allergy are able to tolerate DRV.
•     DRV/r is a potent CYP3A4 inhibitor, and may lead to significant interactions with other medications
metabolized through this same pathway (see Drug Interactions section).
Panel’s Recommendation:
•     On the basis of efficacy and safety data from clinical trials and clinical experience, the Panel classifies
DRV/r with TDF/FTC as a Recommended regimen (AI). DRV/r with ABC/3TC is considered an
Alternative regimen because there are fewer studies to support its use (BII).
Alternative Protease Inhibitor-Based Regimens 
Atazanavir/Ritonavir or Atazanavir/Cobicistat  
Efficacy in Clinical Trials:
•     The CASTLE study compared once-daily ATV/r (300/100 mg) with twice-daily LPV/r (400/100 mg),
each in combination with TDF/FTC. In this open-label, non-inferiority study, the 2 regimens showed
similar virologic and CD4 responses at 48 weeks30 and at 96 weeks.77
•     The ACTG A5202 study compared open-label ATV/r and EFV, each given in combination with placebo-
controlled TDF/FTC or ABC/3TC. Efficacy was similar in the ATV/r and EFV groups.65 In a separate
analysis, women assigned to ATV/r were found to have a higher risk of virologic failure than women
assigned to EFV or men assigned to ATV/r.78
•     In a study comparing ATV/r plus TDF/FTC to EVG/c/TDF/FTC, virologic suppression rates through 144
weeks were similar in the two groups.55
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•     ACTG A5257, a large randomized open-label trial, compared ATV/r with DRV/r or RAL, each given
with TDF/FTC. At week 96, all 3 regimens had similar virologic efficacy. However, a significantly
higher proportion of patients in the ATV/r arm discontinued randomized treatment because of adverse
events, mostly for elevated indirect bilirubin/jaundice or gastrointestinal toxicities. Lipid changes in
participants in the ATV/r and DRV/r arms were similar. Bone mineral density decreased to a greater
extent in participants in the ATV/r and DRV/r arms than in participants in the RAL arm.4
•     The Gilead Study 114 enrolled 692 treatment-naive patients. All patients received TDF/FTC and ATV,
and were randomized to receive either RTV or COBI as PK enhancers. Both RTV and COBI were given
as a separate pill with matching placebos. At 48 weeks, similar percentages of patients achieved virologic
suppression, had adverse events, and changes in serum creatinine and indirect bilirubin levels.79
Adverse Effects:
•     The main adverse effect associated with ATV/c or ATV/r is reversible indirect hyperbilirubinemia, with
or without jaundice or scleral icterus, but without concomitant hepatic transaminase elevations. 
•     Nephrolithiasis,80-82 nephrotoxicity,83 and cholelithiasis84 have also been reported in patients who
received ATV, with or without RTV.
•     Both ATV/c and ATV/r can cause gastrointestinal side effects including diarrhea.
Other Factors and Considerations:
•     ATV/c and ATV/r are dosed once daily and with food. 
•     ATV requires acidic gastric pH for dissolution. As a result, concomitant use of drugs that raise gastric pH
(e.g., antacids, H2 antagonists, and particularly PPIs) may impair absorption of ATV. Table 19a provides
recommendations for use of ATV/c or ATV/r with these agents.
•     ATV/c and ATV/r are potent CYP3A4 inhibitors and may have significant interactions with other
medications metabolized through this same pathway (see Drug Interaction section).
•     ATV/c coadministered with TDF/FTC is not recommended for patients with CrCl <70 mL/min.
Panel’s Recommendations:
•     On the basis of clinical trial safety and efficacy data, the Panel classifies ATV/r and ATV/c plus
TDF/FTC as Alternative regimens for ART-naive patients regardless of pre-treatment HIV RNA (BI). 
•     Because of an inferior virologic response seen in patients with a high baseline viral load, the Panel
recommends ATV/r or ATV/c plus ABC/3TC as Other regimens. Use of the regimens should be limited
to patients with pre-ART HIV RNA <100,000 copies/mL (CI).
•     As noted earlier, ATV/c plus TDF/FTC is not recommended for patients with CrCl <70 mL/min.
Darunavir/Cobicistat  
A combination of (DRV 800 mg with COBI 150 mg) is bioequivalent to (DRV 800 mg with RTV 100 mg) in
healthy volunteers.85
Efficacy in Clinical Trial:
•     In a single arm trial of treatment-naive (94%) and treatment-experienced (6%) patients, the co-
formulated DRV/c 800 mg/150 mg tablet was evaluated in combination with investigator-selected
NRTI/NtRTI (99% of participants were given TDF/FTC). At week 48, 81% of participants achieved HIV
RNA <50 copies/ml; 5% of participants discontinued treatment because of adverse events.86
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Adverse Effects:
•     In the single arm trial, the most common treatment emergent adverse events were diarrhea, nausea, and
headache.
Other Factors:
•     (DRV 800 mg and COBI 150 mg) is available as a co-formulated tablet.
•     Coadministration with TDF is not recommended in patients with CrCl <70 mL/min.
Panel’s Recommendation:
•     On the basis of the bioequivalence study and the single arm trial, the Panel recommends DRV/c plus
TDF/FTC (BII) and DRV/c plus ABC/3TC (BIII) as Alternative Regimens for ART-naive patients.
•     As noted earlier, DRV/c plus TDF/FTC is not recommended for patients with CrCl <70 mL/min.
Other Protease Inhibitor-Based Regimens 
Lopinavir/Ritonavir  
Efficacy in Clinical Trials:
•     A 7-year follow-up study of LPV/r and 2 NRTIs showed sustained virologic suppression in patients who
were maintained on the originally assigned regimen.87
•     Results of clinical trials that compared LPV/r with ATV/r and DRV/r are discussed above, demonstrating
more favorable safety and tolerability of ATV/r and DRV/r. 
•     In the ACTG 5142 study, at 96 weeks, a smaller proportion of patients who received LPV/r plus 2 NRTIs
achieved viral suppression (HIV RNA <50 copies/mL) than those who received EFV plus 2 NRTIs.
However, the CD4 cell response was greater with LPV/r, and there was less drug resistance associated
with virologic failure.63
•     In the GARDEL study, patients were randomized to 3TC or a 2 NRTI combination, with all study
participants receiving LPV/r. The results demonstrated non-inferiority of the two strategies.88
Adverse Effects:
•     In addition to diarrhea, major adverse effects of LPV/r include insulin resistance and hyperlipidemia,
especially hypertriglyceridemia; these require pharmacologic management in some patients. 
•     In the D:A:D and French observational cohorts, cumulative use of LPV/r was associated with a slightly
increased risk of MI.18,24
•     In another D:A:D study, LPV/r use was also reported as an independent predictor of chronic renal
impairment.83
Other Factors and Considerations:
•     LPV/r must be boosted with 200 mg/day of RTV and is associated with higher rates of GI side effects
and hyperlipidemia than ATV/r and DRV/r, both of which are boosted with 100 mg/day of RTV.
•     LPV/r can be given once or twice daily. 
•     Once-daily dosing should not be used in pregnant women, especially during the third trimester, when
LPV levels are expected to decline (see Perinatal Guidelines).
•     LPV/r is currently the only available PI co-formulated with RTV.
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Panel’s Recommendation:
•     On the basis of greater potential for adverse events and higher RTV dose and pill burden than ATV/r and
DRV/r, the Panel recommends LPV/r plus TDF/FTC or LPV/r plus ABC/3TC as Other regimens (CI). 
Other Antiretroviral Regimens for Initial Therapy When Abacavir or Tenofovir Cannot Be
Used 
All currently Recommended and Alternative regimens consist of two NRTIs plus a third active drug. This
strategy, however, may not be possible or optimal in all patients. In some situations it may be necessary to
avoid both TDF and ABC, such as in the case of a patient with pre-existing renal disease who is HLA
B*5701 positive or at high risk of cardiovascular disease.
Based on these concerns, several clinical studies have evaluated strategies using initial regimens that avoid 2
NRTIs or the NRTI drug class altogether. Many of these studies were not fully powered to permit
comparisons, and regimens from these studies will not be discussed further. However, there are now
sufficient data on two regimens (DRV/r plus RAL and LPV/r plus 3TC) to warrant including them as options
when ABC or TDF cannot be used.
Darunavir/Ritonavir plus Raltegravir 
In the NEAT/ANRS 143 study, 805 treatment-naive participants were randomized to receive either twice-
daily RAL or once-daily TDF/FTC, both with DRV/r (800 mg/100 mg once daily). At week 96, DRV/r plus
RAL was non-inferior to DRV/r plus TDF/FTC based on the primary endpoint of proportion of patients with
virologic or clinical failure. Among those with baseline CD4 cell count <200/mm3, however, there were more
failures in the two-drug arm; a trend towards more failure was also observed for those with pre-treatment
HIV RNA ≥100,000 copies/mL.89 High rates of virologic failure in patients with HIV RNA >100,000
copies/mL were also seen in two smaller studies of DRV/r plus RAL.90,91
On the basis of these study results, the Panel recommends that DRV/r plus RAL be considered for use only in
patients with HIV RNA <100,000 copies/uL and CD4 cell counts >200/mm3, and only in those patients who
cannot take either TDF or ABC (CI).
Lopinavir/Ritonavir plus Lamivudine 
In the GARDEL study, 426 ART-naive patients were randomized to receive twice-daily LPV/r plus either
open-label 3TC (twice daily) or two NRTIs selected by the study investigators. At 48 weeks, a similar
number of patients in each arm had HIV RNA <50 copies/mL, meeting the study’s non-inferiority criteria.
The LPV/r plus 3TC regimen was better tolerated than the LPV/r plus 2 NRTI regimen.88
An important limitation of the GARDEL study is the use of LPV/r, twice daily dosing, and relatively high
pill burden (total of 6 tablets per day). LPV/r is not considered a Recommended or Alternative initial PI
because of its unfavorable adverse event and pill burden characteristics as compared to pharmacokinetically
enhanced ATV and DRV. Given the above limitations, the Panel recommends that LPV/r plus 3TC be
considered for use only in patients who cannot take either TDF or ABC (CI).
In summary, the aggregate results from these two fully powered studies with NRTI-limiting regimens
demonstrate that these initial strategies have significant deficiencies as compared to standard-of-care
treatment approaches, in particular, disadvantages related to pill burden or dosing frequency. In addition,
there are concerns about the virologic efficacy of DRV/r plus RAL in patients with high viral loads or low
CD4 cell counts. The Panel only recommend LPV/r plus 3TC or DRV/r plus RAL for initial therapy when
both TDF and ABC are contraindicated. Other less well-tested NRTI-limiting combinations are not
recommended.
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Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial
Antiretroviral Therapy  (page 1 of 3)
Note: All drugs within an ARV class are listed in alphabetical order. 
ARV
Class
ARV
Agent(s) Advantages Disadvantages
Dual-
NRTI
ABC/3TC • Co-formulated with DTG as an STR • Inferior virologic responses in patients with baseline HIV RNA
≥100,000 copies/mL when given with EFV or ATV/r as compared with
TDF/FTC in ACTG 5202 study. This difference was not seen when
ABC/3TC was used in combination with DTG.
• May cause life-threatening hypersensitivity reaction in patients
positive for the HLA B*5701 allele. As a result, HLA-B*5701 testing
required before use
• ABC use has been associated with cardiac events in some but not all
observational studies.
TDF/FTC • Co-formulated with EFV, EVG/c, and RPV as
a STR
• Active against HBV; recommended dual-NRTI
for HIV/HBV co-infected patients
• Better virologic responses than with ABC/3TC
in patients with baseline viral load ≥100,000
copies/mL when combined with ATV/r or EFV
• Renal toxicity, including proximal tubulopathy and acute or chronic
renal insufficiency
• Decreases BMD more than other NRTI combinations
INSTI 
DTG • Once-daily dosing
• May have higher barrier to resistance than
EVG or RAL
• Co-formulated with ABC and 3TC as an STR
• No food requirement
• No CYP3A4 interactions
• Oral absorption can be reduced by simultaneous administration with
products containing polyvalent cations (e.g., Al, Ca, or Mg-containing
antacids or supplements, or multivitamin tablets with minerals). See
dosing recommendations in Table 19d.
• Inhibits renal tubular secretion of Cr and can increase serum Cr,
without affecting glomerular function
• UGT substrate; potential for drug interactions (see Table 19d)
EVG/c • Co-formulated as a STR with TDF/FTC
• Once daily dosing
• Compared with ATV/r, causes smaller
increases in total and LDL cholesterol
• EVG/c/TDF/FTC is only recommended for patients with baseline CrCl
≥70 mL/min; therapy should be discontinued if CrCl decreases to <50
mL/min.
• COBI is a potent CYP3A4 inhibitor, which can result in significant
interactions with CYP3A substrates.
• Oral absorption of EVG can be reduced by simultaneous
administration with antacids containing polyvalent cations, such as Al,
Ca, or Mg (see dosing recommendations in Table 19d).
• COBI inhibits active tubular secretion of Cr and can increase serum
Cr, without affecting renal glomerular function.
• May have lower genetic barrier to resistance than boosted PI- or
DTG-based regimens
• Food requirement
RAL • Compared to other INSTIs, has longest post
marketing experience 
• No food requirement
• No CYP3A4 interactions
• Twice-daily dosing
• May have lower genetic barrier to resistance than boosted PI- or
DTG-based regimens
• Increases in creatine kinase, myopathy, and rhabdomyolysis have
been reported.
• Rare cases of severe hypersensitivity reactions (including SJS and
TEN) have been reported.
• Oral absorption of RAL can be significantly impaired by antacids
containing Al or Mg; coadministration is not recommended (see
dosing recommendations in Table 19d).
• UGT substrate; potential for drug interactions (see Table 19d)
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Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial
Antiretroviral Therapy  (page 2 of 3)
ARV
Class
ARV
Agent(s) Advantages Disadvantages
NNRTIs
EFV • Once-daily dosing
• Co-formulated with TDF/FTC
• Long term clinical experience
• EFV-based regimens (except for EFV plus
ABC/3TC) have well documented efficacy in
patients with high HIV RNA
• Transmitted resistance more common than with PIs and INSTIs
• Short-and long-term neuropsychiatric (CNS) side effects, including
depression and, in some studies, suicidality
• Teratogenic in non-human primates; avoid use in women who are
trying to conceive or who are sexually active and not using
contraception
• Dyslipidemia
• Greater risk of resistance at the time of treatment failure than with PIs
• Skin rash
• Potential for CYP450 drug interactions (see Tables 18, 19b, and 20a)
• Should be taken on an empty stomach (food increases drug
absorption and CNS toxicities)
RPV • Once-daily dosing
• Co-formulated with TDF/FTC
• Smaller pill size than co-formulated
DTG/ABC/3TC, EFV/TDF/FTC, and
EVG/c/TDF/FTC
• Compared with EFV:
• Fewer discontinuations for CNS adverse
effects
• Fewer lipid effects
• Fewer rashes
• Not recommended in patients with pre-ART HIV RNA >100,000
copies/mL or CD4 count <200 cells/mm3 because of higher rate of
virologic failure in these patients
• Transmitted resistance more common than with PIs and INSTIs
• More NNRTI-, TDF-, and 3TC-associated mutations at virological
failure than with regimen containing EFV and two NRTIs
• Potential for CYP450 drug interactions (see Tables 18, 19b, and 20a)
• Meal requirement (>390 kcal)
• Requires acid for adequate absorption
• Contraindicated with PPIs
• Use with H2 antagonists or antacids with caution (see Table 19a
for detailed dosing information). 
• Use with caution when coadministered with a drug known to increase
the risk of torsades de pointes.
PIs
ATV/c
or
ATV/r
• Once-daily dosing
• Higher genetic barrier to resistance than
NNRTIs, EVG, and RAL
• PI resistance at the time of treatment failure
uncommon with pharmacologically-boosted
PIs
• ATV/c and ATV/r have similar virologic activity
and toxicity profiles
• Commonly causes indirect hyperbilirubinemia, which may manifest
as scleral icterus or jaundice
• Food requirement
• Absorption depends on food and low gastric pH (see Table 20a for
interactions with H2 antagonists, antacids, and PPIs)
• Nephrolithiasis, cholelithiasis, nephrotoxicity
• GI adverse effects
• CYP3A4 inhibitors and substrates: potential for drug interactions (see
Tables 18 and 19a)
ATV/c-
specific
consid-
erations
• Co-formulated tablet • COBI inhibits active tubular secretion of Cr and can increase serum
Cr, without affecting renal glomerular function
• Coadministration with TDF is not recommended in patients with CrCl
<70 mL/min
• Less long term clinical experience than for ATV/r
• COBI is a potent CYP3A4 inhibitor, which can result in significant
interactions with CYP3A substrates.
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Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial
Antiretroviral Therapy  (page 3 of 3)
ARV
Class
ARV
Agent(s) Advantages Disadvantages
PIs
DRV/c 
or 
DRV/r
• Once-daily dosing
• Higher genetic barrier to resistance than
NNRTIs, EVG, and RAL
• PI resistance at the time of treatment failure
uncommon with pharmacokinetically-boosted
PIs
• Skin rash
• Food requirement
• GI adverse effects
• CYP3A4 inhibitors and substrates: potential for drug interactions (see
Tables 18 and 19a)
DRV/c-
specific
consid-
erations
• Co-formulated tablet • Less long-term clinical experience than for DRV/r
• COBI inhibits active tubular secretion of Cr and can increase serum
Cr, without affecting renal glomerular function
• Co-administration with TDF is not recommended in patients with CrCl
<70 mL/min
• Approval primarily based on pharmacokinetic data comparable to that
for DRV/r rather than on trials comparing the efficacy of DRV/c and
DRV/r
• COBI is a potent CYP3A4 inhibitor, which can result in significant
interactions with CYP3A substrates.
LPV/r • Only RTV-coformulated PI
• No food requirement
• Once or twice daily dosing
• Requires 200 mg per day of RTV
• Once-daily dosing not recommended in pregnant women
• Possible higher risk of MI associated with cumulative use of LPV/r
• PR and QT interval prolongation have been reported. Use with
caution in patients at risk of cardiac conduction abnormalities or
receiving other drugs with similar effect
• Possible nephrotoxicity
• CYP3A4 inhibitors and substrates: potential for drug interactions (see
Tables 18 and 19a)
Key to Acronyms: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; Al = aluminum; ARV = antiretroviral; ATV = atazanavir;
ATV/c = cobicistat-boosted atazanavir; ATV/r = ritonavir-boosted atazanavir; BMD = bone mineral density; Ca = calcium; CaCO3 = calcium
carbonate; CNS = central nervous system; COBI= cobicistat; Cr = creatinine; CrCl = creatinine clearance; CYP = cytochrome P; DRV/c =
cobicistat-boosted darunavir; DRV/r = ritonavir-boosted darunavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; FTC =
emtricitabine; GI = gastrointestinal; HBV = hepatitis B virus; HSR = hypersensitivity reaction; INSTI = integrase strand transfer inhibitor;
LPV/r = ritonavir-boosted lopinavir; Mg  = magnesium; MI = myocardial infarction; NNRTI = non-nucleoside reverse transcriptase inhibitor;
NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PPI = proton pump inhibitor; RAL = raltegravir; RPV = rilpivirine;
RTV = ritonavir; SJS = Stevens-Johnson syndrome; STR = single tablet regimen; TDF = tenofovir disoproxil fumarate; TEN = toxic
epidermal necrosis
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Table 9. Antiretroviral Components or Regimens Not Recommended as Initial Therapy  (page 1 of 2)
ARV Drugs or Components Reasons for Not Recommending as Initial Therapy
NRTIs
ABC/3TC/ZDV (Co-Formulated)
As triple-NRTI combination regimen
• Inferior virologic efficacy
ABC plus 3TC plus ZDV plus TDF
As quadruple-NRTI combination regimen
• Inferior virologic efficacy
d4T plus 3TC • Significant toxicities including lipoatrophy; peripheral neuropathy; and
hyperlactatemia, including symptomatic and life-threatening lactic acidosis, hepatic
steatosis, and pancreatitis
ddI plus 3TC (or FTC) • Inferior virologic efficacy
• Limited clinical trial experience in ART-naive patients
• ddI toxicities such as pancreatitis, peripheral neuropathy
ddI plus TDF • High rate of early virologic failure
• Rapid selection of resistance mutations
• Potential for immunologic nonresponse/CD4 cell decline
• Increased ddI drug exposure and toxicities
ZDV/3TC • ZDV/3TC is generally not recommended as initial therapy because greater toxicities
(including bone marrow suppression; GI toxicities; and mitochondrial toxicities such
as lipoatrophy, lactic acidosis, and hepatic steatosis; skeletal muscle myopathy, and
cardiomyopathy) than Recommended NRTIs.
NNRTIs
DLV • Inferior virologic efficacy
• Inconvenient (three times daily) dosing
ETR • Insufficient data in ART-naive patients
NVP •  Associated with serious and potentially fatal toxicity (hepatic events, severe rash,
including SJS and TEN)
• When compared to EFV, NVP did not meet non-inferiority criteria
PIs
ATV (Unboosted) • Less potent than boosted ATV
DRV (Unboosted) • Use without RTV has not been studied
FPV (Unboosted)
or
FPV/r 
• Virologic failure with unboosted FPV-based regimen may result in selection of
mutations that confer resistance to FPV and DRV.
• Less clinical trial data for FPV/r than for other PI/r
IDV (Unboosted) • Inconvenient dosing (three times daily with meal restrictions)
• Fluid requirement
• IDV toxicities such as nephrolithiasis, crystalluria
IDV/r • Fluid requirement
• IDV toxicities such as nephrolithiasis, crystalluria
NFV • Inferior virologic efficacy
• Diarrhea
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Table 9. Antiretroviral Components or Regimens Not Recommended as Initial Therapy  (page 2 of 2)
ARV Drugs or Components Reasons for Not Recommending as Initial Therapy
RTV as sole PI • High pill burden
• GI intolerance
• Metabolic toxicity
SQV (Unboosted) • Inadequate bioavailability
• Inferior virologic efficacy
SQV/r • High pill burden
• Can cause QT and PR prolongation; requires pre-treatment and follow-up ECG
TPV/r • Inferior virologic efficacy
• Higher rate of adverse events than other RTV-boosted PIs
• Higher dose of RTV required for boosting than other RTV-boosted PIs
CCR5 Anagonist
MVC • Requires testing for CCR5 tropism before initiation of therapy
• No virologic benefit when compared with other recommended regimens
• Requires twice-daily dosing
Key to Acronyms: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; ATV = atazanavir; d4T =
stavudine; ddI = didanosine; DLV = delavirdine; DRV = darunavir; ETR = etravirine; FPV = fosamprenavir; FPV/r = ritonavir-boosted
fosamprenavir; FTC = emtricitabine; GI = gastrointestinal; IDV = indinavir; MVC = maraviroc; NFV = nelfinavir; NVP = nevirapine; NRTI =
nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RTV = ritonavir; SJS = Stevens Johnson Syndrome; SQV = saquinavir;
SQV/r = ritonavir-boosted saquinavir; TDF = tenofovir disoproxil fumarate; TEN = toxic epidermal necrolysis; TPV = tipranavir; ZDV =
zidovudine
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What Not to Use (Last updated March 27, 2012; last reviewed March 27, 2012)
Some antiretroviral (ARV) regimens or components are not generally recommended because of suboptimal
antiviral potency, unacceptable toxicities, or pharmacologic concerns. These are summarized below.
Antiretroviral Regimens Not Recommended
Monotherapy with nucleoside reverse transcriptase inhibitor (NRTI). Single-NRTI therapy does not
demonstrate potent and sustained antiviral activity and should not be used (AII). For prevention of mother-
to-child transmission (PMTCT), zidovudine (ZDV) monotherapy is not recommended but might be
considered in certain unusual circumstances in women with HIV RNA <1,000 copies/mL, although the use
of a potent combination regimen is preferred. (See Perinatal Guidelines,1 available at http://aidsinfo.nih.gov.)
Single-drug treatment regimens with a ritonavir (RTV)-boosted protease inhibitor (PI), either lopinavir
(LPV),2 atazanavir (ATV),3 or darunavir (DRV)4-5 are under investigation with mixed results, and cannot be
recommended outside of a clinical trial at this time.
Dual-NRTI regimens. These regimens are not recommended because they have not demonstrated potent
and sustained antiviral activity compared with triple-drug combination regimens (AI).6
Triple-NRTI regimens. In general, triple-NRTI regimens other than abacavir/lamivudine/zidovudine
(ABC/3TC/ZDV) (BI) and possibly lamivudine/zidovudine + tenofovir (3TC/ZDV + TDF) (BII) should not
be used because of suboptimal virologic activity7-9 or lack of data (AI).
Antiretroviral Components Not Recommended
Atazanavir (ATV) + indinavir (IDV). Both of these PIs can cause Grade 3 to 4 hyperbilirubinemia and
jaundice. Additive adverse effects may be possible when these agents are used concomitantly. Therefore,
these two PIs are not recommended for combined use (AIII).
Didanosine (ddI) + stavudine (d4T). The combined use of ddI and d4T as a dual-NRTI backbone can result
in a high incidence of toxicities, particularly peripheral neuropathy, pancreatitis, and lactic acidosis.10-13 This
combination has been implicated in the deaths of several HIV-infected pregnant women secondary to severe
lactic acidosis with or without hepatic steatosis and pancreatitis.14 Therefore, the combined use of ddI and
d4T is not recommended (AII).
Didanosine (ddI) + tenofovir (TDF). Use of ddI + TDF may increase ddI concentrations15 and serious ddI-
associated toxicities including pancreatitis and lactic acidosis.16-17 These toxicities may be lessened by ddI
dose reduction. The use of this combination has also been associated with immunologic nonresponse or CD4
cell decline despite viral suppression,18-19 high rates of early virologic failure,20-21 and rapid selection of
resistance mutations.20-22 Because of these adverse outcomes, this dual-NRTI combination is not generally
recommended (AII). Clinicians caring for patients who are clinically stable on regimens containing ddI +
TDF should consider altering the NRTIs to avoid this combination.
Two-non-nucleoside reverse transcriptase inhibitor (2-NNRTI) combinations. In the 2NN trial, ARV-
naive participants were randomized to receive once- or twice-daily nevirapine (NVP) versus efavirenz (EFV)
versus EFV plus NVP, all combined with d4T and 3TC.23 A higher frequency of clinical adverse events that
led to treatment discontinuation was reported in participants randomized to the two-NNRTI arm. Both EFV
and NVP may induce metabolism of etravirine (ETR), which leads to reduction in ETR drug exposure.24
Based on these findings, the Panel does not recommend using two NNRTIs in combination in any
regimen (AI).
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Efavirenz (EFV) in first trimester of pregnancy and in women with significant childbearing potential.
EFV use was associated with significant teratogenic effects in nonhuman primates at drug exposures similar
to those representing human exposure. Several cases of congenital anomalies have been reported after early
human gestational exposure to EFV.25-26 EFV should be avoided in pregnancy, particularly during the first
trimester, and in women of childbearing potential who are trying to conceive or who are not using effective
and consistent contraception (AIII). If no other ARV options are available for the woman who is pregnant or
at risk of becoming pregnant, the provider should consult with a clinician who has expertise in both HIV
infection and pregnancy. (See Perinatal Guidelines,1 available at http://aidsinfo.nih.gov.)
Emtricitabine (FTC) + lamivudine (3TC). Both of these drugs have similar resistance profiles and have
minimal additive antiviral activity. Inhibition of intracellular phosphorylation may occur in vivo, as seen with
other dual-cytidine analog combinations.27 These two agents should not be used as a dual-NRTI
combination (AIII).
Etravirine (ETR) + unboosted PI. ETR may induce the metabolism and significantly reduce the drug
exposure of unboosted PIs. Appropriate doses of the PIs have not been established24 (AII).
Etravirine (ETR) + ritonavir (RTV)-boosted atazanavir (ATV) or fosamprenavir (FPV). ETR may alter
the concentrations of these PIs. Appropriate doses of the PIs have not been established24 (AII).
Etravirine (ETR) + ritonavir (RTV)-boosted tipranavir (TPV). RTV-boosted TPV significantly reduces
ETR concentrations. These drugs should not be coadministered24 (AII).
Nevirapine (NVP) initiated in ARV-naive women with CD4 counts >250 cells/mm3 or in ARV-naive
men with CD4 counts >400 cells/mm3. Greater risk of symptomatic hepatic events, including serious and
life-threatening events, has been observed in these patient groups. NVP should not be initiated in these
patients (BI) unless the benefit clearly outweighs the risk.28-30 Patients who experience CD4 count increases
to levels above these thresholds as a result of antiretroviral therapy (ART) can be safely switched to NVP.31
Unboosted darunavir (DRV), saquinavir (SQV), or tipranavir (TPV). The virologic benefit of these PIs
has been demonstrated only when they were used with concomitant RTV. Therefore, use of these agents as
part of a combination regimen without RTV is not recommended (AII).
Stavudine (d4T) + zidovudine (ZDV). These two NRTIs should not be used in combination because of
antagonism demonstrated in vitro32 and in vivo33 (AII).
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Table 10. Antiretroviral Regimens or Components That Should Not Be Offered At Any Time (page 1 of 2)
Rationale Exception
Antiretroviral Regimens Not Recommended
Monotherapy with NRTI (AII) • Rapid development of resistance
• Inferior ARV activity when compared with combination
of three or more ARV agents
• No exception
Dual-NRTI regimens (AI) • Rapid development of resistance
• Inferior ARV activity when compared with combination
of three or more ARV agents
• No exception
Triple-NRTI regimens (AI) except for
ABC/ZDV/3TC (BI)
or possibly TDF + ZDV/3TC (BII)
• High rate of early virologic nonresponse seen when
triple-NRTI combinations, including ABC/TDF/3TC and
TDF/ddI/3TC, were used as initial regimen in ART-
naive patients.
• Other triple-NRTI regimens have not been evaluated.
• ABC/ZDV/3TC (BI) and possibly 
TDF + ZDV/3TC (BII) in patients in
whom other combinations are not
desirable
Antiretroviral Components Not Recommended as Part of an Antiretroviral Regimen
ATV + IDV (AIII) • Potential additive hyperbilirubinemia • No exception
ddI + d4T (AII) • High incidence of toxicities: peripheral neuropathy,
pancreatitis, and hyperlactatemia
• Reports of serious, even fatal, cases of lactic acidosis
with hepatic steatosis with or without pancreatitis in
pregnant women
• No exception
ddI + TDF (AII) • Increased ddI concentrations and serious ddI-
associated toxicities
• Potential for immunologic nonresponse and/or CD4 cell
count decline
• High rate of early virologic failure
• Rapid selection of resistance mutations at failure
• Clinicians caring for patients who are
clinically stable on regimens containing
TDF + ddI should consider altering the
NRTIs to avoid this combination.
2-NNRTI combination (AI) • When EFV combined with NVP, higher incidence of
clinical adverse events seen when compared with
either EFV- or NVP-based regimen.
• Both EFV and NVP may induce metabolism and may
lead to reductions in ETR exposure; thus, they should
not be used in combination with ETR.
• No exception
EFV in first trimester of pregnancy
or in women with significant
childbearing potential (AIII)
• Teratogenic in nonhuman primates • When no other ARV options are
available and potential benefits
outweigh the risks (BIII)
FTC + 3TC (AIII) • Similar resistance profiles
• No potential benefit
• No exception
ETR + unboosted PI (AII) • ETR may induce metabolism of these PIs; appropriate
doses not yet established
• No exception
ETR + RTV-boosted ATV or FPV (AII) • ETR may alter the concentrations of these PIs;
appropriate doses not yet established
• No exception
ETR + RTV-boosted TPV (AII) • ETR concentration may be significantly reduced by
RTV-boosted TPV
• No exception
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Rationale Exception
NVP in ARV-naive women with CD4
count >250 cells/mm3 or men with
CD4 count >400 cells/mm3 (BI)
• High incidence of symptomatic hepatotoxicity • If no other ARV option available; if used,
patient should be closely monitored
d4T + ZDV (AII) • Antagonistic effect on HIV-1 • No exception
Unboosted DRV, SQV, or TPV (AII) • Inadequate bioavailability • No exception
Table 10. Antiretroviral Regimens or Components That Should Not Be Offered At Any Time  (page 2 of 2)
Acronyms: 3TC = lamivudine, ABC = abacavir, ATV = atazanavir, d4T = stavudine, ddI = didanosine, DRV = darunavir, EFV = efavirenz,
ETR = etravirine, FPV = fosamprenavir, FTC = emitricitabine, IDV = indinavir, NVP = nevirapine, RTV = ritonavir, SQV = saquinavir, TDF =
tenofovir, TPV = tipranavir, ZDV = zidovudine
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Management of the Treatment-Experienced Patient
Virologic Failure (Last updated April 8, 2015; last reviewed April 8, 2015)
Antiretroviral (ARV) regimens currently recommended for initial therapy of HIV-infected patients have a
high likelihood of achieving and maintaining plasma HIV RNA levels below the lower limits of detection
(LLOD) of currently used assays (see What to Start). Patients on antiretroviral therapy (ART) who do not
achieve this treatment goal or who experience virologic rebound often develop resistance mutations to one or
more components of their regimen. Based on surveillance data for HIV patients in care in selected cities in
the United States in 2009, an estimated 89% of the patients were receiving ART, of whom 72% had viral
loads <200 copies/mL.1 Many patients with detectable viral loads are non-adherent to treatment. Depending
on their treatment histories, some of these patients may have minimal or no drug resistance; others may have
extensive resistance. Managing patients with extensive resistance is complex and usually requires
consultation with an HIV expert. This section of the guidelines defines virologic failure in patients on ART
and discusses strategies to manage these individuals.
Virologic Response Definitions
The following definitions are used in this section to describe the different levels of virologic response to
ART.
Panel’s Recommendations
• Assessing and managing a patient experiencing failure of antiretroviral therapy (ART) is complex. Expert advice is critical and should
be sought.
• Evaluation of virologic failure should include an assessment of adherence, drug-drug or drug-food interactions, drug tolerability, HIV
RNA and CD4 T lymphocyte (CD4) cell count trends over time, treatment history, and prior and current drug-resistance testing
results.
• Drug-resistance testing should be performed while the patient is taking the failing antiretroviral (ARV) regimen (AI) or within 4 weeks
of treatment discontinuation (AII). Even if more than 4 weeks have elapsed since ARVs were discontinued, resistance testing—
although it may not detect previously selected resistance mutations—can still provide useful information to guide therapy (CIII).
• The goal of treatment for ART-experienced patients with drug resistance who are experiencing virologic failure is to establish
virologic suppression (i.e., HIV RNA below the lower limits of detection of currently used assays) (AI).
• A new regimen should include at least two, and preferably three, fully active agents (AI). A fully active agent is one that is expected to
have uncompromised activity on the basis of the patient’s treatment history and drug-resistance testing results and/or the drug’s
novel mechanism of action.
• In general, adding a single ARV agent to a virologically failing regimen is not recommended because this may risk the development
of resistance to all drugs in the regimen (BII). 
• For some highly ART-experienced patients, maximal virologic suppression is not possible. In this case, ART should be continued (AI)
with regimens designed to minimize toxicity, preserve CD4 cell counts, and delay clinical progression.
• When it is not possible to construct a viable suppressive regimen for a patient with multidrug resistant HIV, the clinician should
consider enrolling the patient in a clinical trial of investigational agents or contacting pharmaceutical companies that may have
investigational agents available. 
• Discontinuing or briefly interrupting therapy may lead to a rapid increase in HIV RNA and a decrease in CD4 cell count and increases
the risk of clinical progression. Therefore, this strategy is not recommended in the setting of virologic failure (AI).
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
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Virologic suppression: A confirmed HIV RNA level below the LLOD of available assays
Virologic failure: The inability to achieve or maintain suppression of viral replication to an HIV RNA level
<200 copies/mL
Incomplete virologic response: Two consecutive plasma HIV RNA levels ≥200 copies/mL after 24 weeks
on an ARV regimen in a patient who has not yet had documented virologic suppression on this regimen. A
patient’s baseline HIV RNA level may affect the time course of response, and some regimens will take
longer than others to suppress HIV RNA levels.
Virologic rebound: Confirmed HIV RNA ≥200 copies/mL after virologic suppression
Virologic blip: After virologic suppression, an isolated detectable HIV RNA level that is followed by a
return to virologic suppression
ART Treatment Goals and Virologic Responses
The goal of ART is to suppress HIV replication to a level below which drug-resistance mutations do not
emerge. Although not conclusive, the evidence suggests that selection of drug-resistance mutations does not
occur in patients with HIV RNA levels persistently suppressed to below the LLOD of current assays.2
Viremia “blips”—defined by viral suppression followed by an isolated detectable HIV RNA level and
subsequent return to undetectable levels—are not usually associated with subsequent virologic failure.3 In
contrast, there is controversy regarding the clinical implications of persistent HIV RNA levels between the
LLOD and <200 copies/mL in patients on ART. Furthermore, viremia at this threshold is detected with some
frequency by commonly used real-time polymerase chain reaction (PCR) assays, which are more sensitive
than PCR-based viral load platforms used in the past.4-6 Findings from a large retrospective analysis showed
that, as a threshold for virologic failure, HIV RNA levels of 200 copies/mL and <50 copies/mL had the same
predictive value for subsequent rebound to >200 copies/mL.7 Two other retrospective studies also support the
supposition that virologic rebound is more likely to occur in patients with viral loads >200 copies/mL than in
those with low-level viremia between 50 to 199 copies/mL.8,9 However, other studies have suggested that
viremia at this low level (<200 copies/mL) can be predictive of progressive viral rebound10,11 and can be
associated with the evolution of drug resistance.12
Persistent HIV RNA levels ≥200 copies/mL are often associated with evidence of viral evolution and
accumulation of drug-resistance mutations.13 This association is particularly common when HIV RNA levels
are >500 copies/mL.14 Therefore, persistent plasma HIV RNA levels ≥200 copies/mL should be considered
virologic failure.
Causes of Virologic Failure
Virologic failure can occur for many reasons. Data from patient cohorts in the earlier era of combination
ART suggested that suboptimal adherence and drug intolerance/toxicity accounted for 28% to 40% of
virologic failure and regimen discontinuations.15,16 Presence of pre-existing (transmitted) drug resistance may
also be the cause of virologic failure.17 Virologic failure may be associated with both patient- and regimen-
related factors, as listed below:
•     Patient-Related Factors
      •     Higher pretreatment or baseline HIV RNA level (depending on the specific regimen used)
      •     Lower pretreatment or nadir CD4 T lymphocyte (CD4) cell count (depending on the specific regimen
used)
      •     Comorbidities that may affect adherence (e.g., active substance abuse, psychiatric disease,
neurocognitive deficits)
      •     Presence of drug-resistant virus, either transmitted or acquired
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      •     Prior treatment failure
      •     Incomplete medication adherence and missed clinic appointments
      •     Interruption of or intermittent access to ART
•     ARV Regimen-Related Factors
      •     Drug adverse effects  
      •     Suboptimal pharmacokinetics (variable absorption, metabolism, or possibly penetration into
reservoirs)
      •     Suboptimal virologic potency
      •     Reduced efficacy because of a patient’s prior exposure to suboptimal regimens (e.g., functional
monotherapy)
      •     Food requirements
      •     High pill burden and/or dosing frequency
      •     Adverse drug-drug interactions with concomitant medications
      •     Prescription errors
      •     Cost and affordability of ARVs (i.e., may affect a patient’s ability to access or continue therapy) 
Management of Patients with Virologic Failure
Assessment of Virologic Failure
If virologic failure is suspected or confirmed, a thorough assessment that includes consideration of the
factors listed in the Causes of Virologic Failure section above is indicated. Often the causes of virologic
failure can be identified, but in some cases, the causes are not obvious. It is important to distinguish among
the causes of virologic failure because the approaches to subsequent therapy differ. The following potential
causes of virologic failure should be explored in depth:
•     Suboptimal Adherence. Assess the patient’s adherence to the regimen. Identify and address the
underlying cause(s) for incomplete adherence (e.g., drug intolerance, difficulty accessing
medications, depression, active substance abuse) and, if possible, simplify the regimen (e.g.,
decrease pill count or dosing frequency). (See Adherence.)
•     Medication Intolerance. Assess the patient’s tolerance of the current regimen and the severity and
duration of side effects, keeping in mind that even minor side effects can affect adherence.
Management strategies to address intolerance in the absence of drug resistance may include:
      •     Symptomatic treatment (e.g., antiemetics, antidiarrheals)
      •     A switch from one ARV in a regimen to another agent in the same drug class (see the Adverse
Effects section)
      •     A switch from one drug class to another class (e.g., from a non-nucleoside reverse transcriptase
inhibitor [NNRTI] to a protease inhibitor [PI] or an integrase strand transfer inhibitor [INSTI]), if
necessary (see the Adverse Effects section)
•     Pharmacokinetic Issues
      •     Review food requirement for each medication, and assess whether the patient adheres to the
requirement.
      •     Review the patient’s recent history of gastrointestinal symptoms such as vomiting or diarrhea
that may result in short-term malabsorption. 
      •     Review concomitant medications and dietary supplements for possible adverse drug-drug
interactions (consult the Drug Interactions section and tables for common interactions) and, if
possible, make appropriate substitutions for ARV agents and/or concomitant medications.
      •     Consider therapeutic drug monitoring if pharmacokinetic drug-drug interactions or impaired drug
absorption leading to decreased ARV exposure is suspected (see also Exposure-Response
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Relationship and Therapeutic Drug Monitoring).
•     Suspected Drug Resistance. Perform resistance testing while the patient is still taking the failing
regimen or within 4 weeks of regimen discontinuation if the patient’s plasma HIV RNA level is >1,000
copies/mL (AI), and possibly even if between 500 to 1,000 copies/mL (BII). (See Drug-Resistance
Testing.) In some patients, resistance testing should be considered even after treatment interruptions of
more than 4 weeks, recognizing that the lack of evidence of resistance in this setting does not exclude the
possibility that resistance mutations may be present at low levels (CIII). Evaluate the extent of drug
resistance, taking into account the patient’s past treatment history and prior resistance-test results. Drug
resistance is cumulative; thus, all prior treatment history and resistance test results should be considered
when evaluating resistance. Genotypic or phenotypic testing provides information relevant for selecting
nucleoside reverse transcriptase inhibitors (NRTIs), NNRTIs, PIs, and INSTIs. Additional drug-resistance
tests for patients experiencing failure on a fusion inhibitor (AII) and viral tropism tests for patients
experiencing failure on a CCR5 antagonist (BIII) are also available. (See Drug-Resistance Testing.)
Approach to Patients with Confirmed Virologic Failure
Once virologic failure is confirmed, every effort should be made to assess whether suboptimal adherence and
drug-drug or drug-food interactions may be contributing to the inadequate virologic response to ART. If
virologic failure persists after these issues have been adequately addressed, resistance testing should be
performed, and the regimen should be changed as soon as possible to avoid progressive accumulation of
resistance mutations.18 In addition, several studies have shown that virologic responses to new regimens are
greater in individuals with lower HIV RNA levels10,19 and/or higher CD4 cell counts at the time of regimen
changes.10,19 Discontinuing or briefly interrupting therapy in a patient with viremia may lead to a rapid increase
in HIV RNA and a decrease in CD4 cell count and increases the risk of clinical progression;20,21 therefore, this
strategy is not recommended (AI). See Discontinuation or Interruption of Antiretroviral Therapy.
Ideally, a new ARV regimen should contain at least two, and preferably three, fully active drugs whose
predicted activity is based on the patient’s drug treatment history, resistance testing, or the mechanistic action
of a new drug class (AI).10,22-31 Despite drug resistance, some ARV drugs (e.g., NRTIs) may contribute partial
ARV activity to a regimen,21 while other agents (e.g., enfuvirtide [T20], NNRTIs, the INSTI raltegravir
[RAL]) likely will not.32-34 Using a “new” drug that a patient has never used previously does not ensure that
the drug will be fully active; there is potential for cross-resistance, particularly among drugs from the same
class. In addition, archived drug-resistance mutations may not be detected by standard drug-resistance tests,
particularly if testing is performed when the patient is not taking the drug in question. Therefore, both
treatment history and prior and current drug-resistance test results must be considered when designing a new
regimen. When designing a new ART regimen, drug potency and viral susceptibility are more important
factors to consider than the number of component drugs.
In general, patients who receive at least three active drugs, selected based on a review of the patient’s
treatment history and past and most current drug-resistance test results, experience better and more sustained
virologic response than those receiving fewer active drugs in the regimen.23,24,26,27,35,36 However, there are
increasing data in treatment-naive and treatment-experienced patients showing that an active
pharmacokinetically enhanced PI plus one other active drug or several partially active drugs will effectively
reduce viral load in most patients.37-40 Active drugs are ARVs that, based on resistance test results and
treatment history, are expected to have antiviral activity equivalent to that seen when there is no resistance to
the specific drugs; ARVs with partial activity are those predicted to reduce HIV RNA but to a lesser extent
than when there is no underlying drug resistance. The activity of a given drug must be uniquely defined for
each patient. Active drugs may be newer members of existing drug classes that are active against HIV
isolates that are resistant to older drugs in the same classes (e.g., etravirine [ETR], darunavir [DRV] and
tipranavir, and dolutegravir [DTG]) An active drug may also be one with unique mechanisms of action (e.g.,
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the fusion inhibitor T20, the CCR5 antagonist maraviroc in patients with no detectable CXCR4-using virus).
In the presence of certain drug resistance mutations, some ARVs such as DTG, ritonavir-boosted DRV, and
ritonavir-boosted lopinavir (LPV/r) need to be given twice daily instead of once daily to achieve higher drug
concentrations necessary to be active against the less sensitive virus.41,42
Addressing Detectable Viral Load in Different Clinical Situations
•     HIV RNA above the LLOD and <200 copies/mL. Confirm that levels remain above the LLOD and
assess adherence, drug-drug interactions (including those with over-the-counter products and
supplements), and drug-food interactions. Patients with HIV RNA typically below the LLOD with
transient increases in HIV RNA (i.e., blips) do not require a change in treatment (AII).5 Although there is
no consensus on how to manage patients with persistent HIV RNA levels above the LLOD and <200
copies/mL, the risk of emerging resistance is believed to be relatively low. Therefore, these patients
should maintain on their current regimens and have HIV RNA levels monitored at least every 3 months
to assess the need for changes in ART in the future (AIII). 
•     HIV RNA ≥200 and <1,000 copies/mL. Confirm that HIV RNA levels remain in this range and assess
adherence and potential drug-drug interactions (including those with over-the-counter products and
supplements) and drug-food interactions. In contrast to patients with HIV RNA levels persistently <200
copies/mL, those with levels persistently ≥200 copies/mL often develop drug resistance, particularly with
HIV RNA levels >500 copies/mL.8,9 Persistent plasma HIV RNA levels in the 200 to 1,000 copies/mL
range should be considered as virologic failure, and resistance testing should be attempted, particularly if
HIV RNA >500 copies/mL. When resistance testing can successfully be performed and no resistance is
detected, manage the patient as outlined below in the section on HIV RNA >1,000 copies/mL and no
drug resistance identified. If drug resistance is detected, manage the patient as outlined below in the
section on HIV RNA >1,000 copies/mL and drug resistance identified. When resistance testing cannot
be performed because of low-level viremia, the decision whether to empirically change ARVs should be
made on a case-by-case basis.
•     HIV RNA >1,000 copies/mL and no drug resistance identified. This scenario is almost always
associated with suboptimal adherence. Conduct a thorough assessment to determine the level of
adherence and identify any drug-drug and drug-food interactions. Consider the timing of the drug-
resistance test (e.g., was the patient mostly or completely ART-non-adherent for more than 4 weeks
before testing). If the current regimen is well tolerated and there are no significant drug-drug or drug-
food interactions, it is reasonable to resume the same regimen. If the agents are poorly tolerated or there
are important drug-drug or drug-food interactions, consider changing the regimen. Two to four weeks
after treatment is resumed or started, repeat viral load testing; if viral load remains >500 copies/mL,
perform genotypic testing to determine whether a resistant viral strain emerges (CIII).
•     HIV RNA >1,000 copies/mL and drug resistance identified. The availability of newer ARVs,
including some with new mechanisms of action, makes it possible to suppress HIV RNA levels to below
the LLOD in most of these patients. The options in this setting depend on the extent of drug resistance
present and are addressed in the clinical scenarios outlined below.
Management of Virologic Failure in Different Clinical Scenarios
First Regimen Failure
•     Failing an NNRTI plus NRTI regimen. Patients failing an NNRTI-based regimen often have viral
resistance to the NNRTI, with or without lamivudine (3TC) and emtricitabine (FTC) resistance. Although
several options are available for these patients, several studies have explored the activity of a
pharmacokinetically boosted PI with NRTIs or an INSTI.43-45 Two of the studies found that regimens
containing a ritonavir-boosted PI (PI/r) combined with NRTIs were as active as regimens containing the PI/r
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combined with RAL.43,45 Two studies also demonstrated higher rates of virologic suppression with use of a
PI/r plus NRTIs than with a PI/r alone.44,45 On the basis of these studies, even patients with NRTI resistance
can often be treated with a pharmacokinetically boosted PI plus NRTIs or RAL (AI). Although LPV/r was
used in these studies, it is likely that other pharmacokinetically boosted PIs would behave similarly.
Although data are limited, the second-generation NNRTI ETR or the other INSTIs (i.e., elvitegravir [EVG]
or DTG) combined with a pharmacokinetically boosted PI may also be options in this setting.
•     Failing a pharmacokinetically boosted PI plus NRTI regimen. In this scenario, most patients will
have either no resistance or resistance limited to 3TC and FTC.46,47 Failure in this setting is often
attributed to poor adherence, drug-drug interactions, or drug-food interactions. A systematic review of
multiple randomized trials of PI/r first-line failure showed that maintaining the same regimen,
presumably with efforts to enhance adherence, is as effective as changing to new regimens with or
without drugs from new classes.48 In this setting, resistance testing should be performed along with an
assessment of overall adherence and tolerability of the regimen. If the regimen is well tolerated and there
are no concerns regarding drug-drug or drug-food interactions, the regimen can be continued with
adherence support and viral monitoring. Alternatively, if poor tolerability or interactions may be
contributing to virologic failure, the regimen can be modified to include a different pharmacokinetically
boosted PI plus NRTIs—even if not all of the NRTIs are fully active—or to a new non-PI-based regimen
that includes more than two fully active agents (AII). 
•     Failing an INSTI plus NRTI regimen. Virologic failure with a regimen consisting of RAL plus two
NRTIs or with EVG/cobicistat/tenofovir disoproxil fumarate/FTC may be associated with emergent
resistance to 3TC and FTC and possibly the INSTI.49 Viruses with INSTI resistance often have virus still
susceptible to DTG.19 In contrast, persons failing DTG plus two NRTI first-line therapy in clinical trials
have not yet been shown to develop phenotypic resistance to DTG.49 There are no clinical trial data to
guide therapy for first-line INSTI failures, although one can likely extrapolate from the data for NNRTI
failures. Thus, patients with first-line INSTI failure should respond to a pharmacokinetically boosted PI
plus NRTIs (AII). A pharmacokinetically boosted PI plus an INSTI may also be a viable option in
patients with no INSTI resistance (BII). In the setting the virus is found to have resistance to RAL and
EVG but remains susceptible to DTG, DTG can be used in combination with a pharmacokinetically
boosted PI. If no resistance is identified, the patient should be managed as outlined above in the section
on virologic failure without resistance.
Second-Line Regimen Failure and Beyond
•     Drug resistance with treatment options allowing for full virologic suppression. Depending on
treatment history and drug-resistance data, one can predict whether or not to have a fully active
pharmacokinetically boosted PI to include in future regimens. For example, those who have no
documented PI resistance and previously have never been treated with an unboosted PI are likely to
harbor virus that is fully susceptible to ARVs in the PI class. In this setting, viral suppression should be
achievable using a pharmacokinetically boosted PI combined with either NRTIs or an INSTI—provided
the virus is susceptible to the INSTI. If a fully susceptible pharmacokinetically boosted PI is not an
option, the new regimen should include at least two, and preferably three, fully active agents, if possible.
Drugs to be included in the regimen should be selected based on the likelihood that they will be active as
determined by the patient’s treatment history, past and present drug-resistance testing, and tropism testing
if a CCR5 antagonist is being considered.
•     Multidrug resistance without treatment options allowing for full virologic suppression. Use of
currently available ARVs has resulted in a dramatic decline in the number of patients who have few
treatment options because of multi-class drug resistance.50,51 Despite this progress, there remain patients
who have experienced toxicities and/or developed resistance to all or most currently available drugs. If
maximal virologic suppression cannot be achieved, the goals of ART will be to preserve immunologic
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function, prevent clinical progression, and minimize increasing resistance to drug classes that may
eventually include new drugs that may be important for future regimens. Consensus on the optimal
management of these patients is lacking. If resistance to NNRTIs, T20, EVG or RAL are identified, there
is rarely a reason to continue these drugs, as there is little evidence that keeping them in the regimen
helps delay disease progression (BII). Moreover, continuing these drugs, in particular INSTIs, may allow
for further increasing resistance and within-class cross resistance that may limit future treatment options.
It should be noted that even partial virologic suppression of HIV RNA to >0.5 log10 copies/mL from
baseline correlates with clinical benefits.50,52 Cohort studies provide evidence that continuing therapy,
even in the presence of viremia and the absence of CD4 count increases, reduces the risk of disease
progression.53 Other cohort studies suggest continued immunologic and clinical benefits with even
modest reductions in HIV RNA levels.54,55 However, all these potential benefits must be balanced with
the ongoing risk of accumulating additional resistance mutations. In general, adding a single fully active
ARV to the regimen is not recommended because of the risk of rapid development of resistance (BII). 
Patients with ongoing viremia who lack sufficient treatment options to construct a fully suppressive regimen
may be candidates for research studies or expanded access programs or may qualify for single-patient access of
an investigational new drug as specified in Food and Drug Administration regulations:
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm163982.htm.
Information about these programs may also be available from the sponsoring pharmaceutical manufacturer.
•     Previously treated patient with suspected drug resistance who need care but present with limited
information (i.e., incomplete or no self-reported history, medical records, or resistance-testing
results). Every effort should be made to obtain the patient’s medical records and prior drug-resistance
testing results; however, this may not always be possible. One strategy is to restart the most recent ARV
regimen and assess drug resistance in 2 to 4 weeks to guide selection of the next regimen. Another
strategy is to start two or three drugs predicted to be active on the basis of the patient’s treatment history.
Isolated Central Nervous System (CNS) Virologic Failure and New Onset Neurologic
Symptoms
Presentation with new-onset CNS signs and symptoms has been reported as a rare form of virologic failure.
These patients present with new, usually subacute, neurological symptoms associated with breakthrough of
HIV infection within the CNS compartment despite plasma HIV RNA suppression.56,57 Clinical evaluation
frequently shows abnormalities on MRI brain imaging and abnormal cerebrospinal fluid (CSF) findings with
characteristic lymphocytic pleocytosis. When available, measurement of CSF HIV RNA shows higher
concentrations in the CSF than in plasma, and in most patients, evidence of drug-resistant CSF virus. Drug-
resistance testing of HIV in CSF, if available, can be used to guide changes in the treatment regimen
according to principles outlined above for plasma HIV RNA resistance (CIII). In these patients it may be
useful to consider CNS pharmacokinetics in drug selection (CIII). If CSF HIV resistance testing is not
available, the regimen may be changed based on the patient’s treatment history or on predicted drug
penetration into the CNS58-60 (CIII). This “neurosymptomatic” CNS viral escape should be distinguished
from: (1) other CNS infections that can induce a transient increase in CSF HIV RNA (e.g., herpes zoster61),
(2) incidental detection of asymptomatic mild CSF HIV RNA elevation likely equivalent to plasma blips,62 or
(3) relatively common chronic, usually mild, neurocognitive impairment in HIV-infected patients without
evidence of CNS viral breakthrough.63 None of these latter conditions currently warrant a change in ART.64
Summary 
In summary, the management of treatment-experienced patients with virologic failure often requires expert
advice to construct virologically suppressive regimens. Before modifying a regimen, it is critical to carefully
evaluate the cause(s) of virologic failure, including incomplete adherence, poor tolerability, and drug and
food interactions, as well as review HIV RNA and CD4 cell count changes over time, treatment history, and
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drug-resistance test results. If HIV RNA suppression is not possible with currently approved agents, consider
use of investigational agents through participation in clinical trials or expanded/single-patient access
programs. If virologic suppression is still not achievable, the choice of regimens should focus on minimizing
toxicity and preserving treatment options while maintaining CD4 cell counts to delay clinical progression. 
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Poor CD4 Cell Recovery and Persistent Inflammation Despite Viral Suppression  (Last
updated April 8, 2015; last reviewed April 8, 2015)
Despite marked improvements in antiretroviral treatment (ART), morbidity and mortality in HIV-infected
individuals continues to be greater than in the general population, particularly when ART is delayed until
advanced disease stages. These morbidities include cardiovascular disease, many non-AIDS cancers, non-
AIDS infections, chronic obstructive pulmonary disease, osteoporosis, type II diabetes, thromboembolic
disease, liver disease, renal disease, neurocognitive dysfunction, and frailty.1 Although health-related
behaviors and toxicities of antiretroviral (ARV) drugs may also contribute to the increased risk of illness and
death, poor CD4 T lymphocyte (CD4) cell recovery, persistent immune activation, and inflammation likely
also contribute to the risk. 
Poor CD4 Cell Recovery
As long as ART-mediated viral suppression is maintained, peripheral blood CD4 cell counts in most HIV-
infected individuals will continue to increase for at least a decade. The rate of CD4 cell recovery is typically
most rapid in the first 3 months of suppressive ART, followed by more gradual increases over time.2-4 If ART-
mediated viral suppression is maintained, most individuals will eventually recover CD4 counts in the normal
range (>500 cells /mm3); however, approximately 15% to 20% of individuals who initiate ART at very low
CD4 counts (<200 cells/mm3) may plateau at abnormally low CD4 cell counts.3-5 Early initiation of ART in
recently HIV-infected individuals likely provides the best opportunity for maximal CD4 cell recovery.6
Persistently low CD4 cell counts despite ART-mediated viral suppression are associated with increased risk
of morbidity and mortality. For example, HIV-infected individuals with CD4  counts <200 cells/mm3 despite
at least 3 years of suppressive ART had a 2.6-fold greater risk of mortality than those with higher CD4 cell
counts.7 Lower CD4 cell counts during ART-mediated viral suppression are associated with an increased risk
• Morbidity and mortality from several AIDS and non-AIDS conditions are increased in HIV-infected individuals despite antiretroviral
therapy (ART)-mediated viral suppression, and are predicted by persistently low CD4 T lymphocyte (CD4) cell counts and/or
persistent immune activation.
• ART intensification by adding antiretroviral (ARV) drugs to a suppressive ART regimen does not consistently improve CD4 cell
recovery or reduce immune activation and is not recommended (AI).
• In individuals with viral suppression, switching ARV drug classes does not consistently improve CD4 cell recovery or reduce immune
activation and is not recommended (BIII).
• No interventions designed to increase CD4 cell counts and/or decrease immune activation are recommended at this time (in
particular, interleukin-2 is not recommended [AI]) because none has been proven to decrease morbidity or mortality during ART-
mediated viral suppression. 
• Monitoring markers of immune activation and inflammation is not recommended because no immunologically targeted intervention
has proven to improve the health of individuals with abnormally high biomarker levels, and many markers that predict morbidity and
mortality fluctuate widely in individuals (AII).
• Because there are no proven interventions to improve CD4 cell recovery and/or inflammation, efforts should focus on addressing
modifiable risk factors for chronic disease (e.g., encouraging smoking cessation, a healthy diet, and exercise; treating hypertension,
hyperlipidemia) (AII).
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
Panel’s Summary and Recommendations
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of non-AIDS morbidity and mortality,8-11 including cardiovascular disease,12 osteoporosis and fractures,13
liver disease,14 and infection-related cancers.15 The prognostic importance of higher CD4 cell counts likely
spans all ranges of CD4 cell counts, though incremental benefits are harder to discern once CD4 counts
increase to >500 cells/mm3.16 
Individuals with poor CD4 cell recovery should be evaluated for modifiable causes of CD4 cell lymphopenia.
Concomitant medications should be reviewed, with a focus on those known to decrease white blood cells or,
specifically, CD4 cells (e.g., cancer chemotherapy, interferon, zidovudine,17 or the combination of tenofovir
disoproxil fumarate (TDF) and didanosine (ddI).18,19 If possible, these drugs should be substituted for or
discontinued. Untreated coinfections (e.g., HCV, HIV-2) and serious medical conditions (e.g., malignancy)
should also be considered as possible causes of CD4 lymphopenia, particularly in individuals with consistently
declining CD4 cell counts (and percentages) and/or in those with CD4 counts consistently below 100
cells/mm3. In many cases, no obvious cause for suboptimal immunologic response can be identified.
Despite strong evidence linking low CD4 cell counts and increased morbidity during ART-mediated viral
suppression, no adjunctive therapies that increase CD4 cell count beyond levels achievable with ART alone
have been proven to decrease morbidity or mortality. Adding ARV drugs to an already suppressive ART
regimen does not improve CD4 cell recovery,20-25 and does not reduce morbidity or mortality. Therefore,
ART intensification is not recommended as a strategy to improve CD4 cell recovery (AI). In individuals
maintaining viral suppression, switching ARV drug classes in a suppressive regimen also does not
consistently improve CD4 cell recovery and is not recommended (BIII).26 Two large clinical trials, powered
to assess impact on clinical endpoints (AIDS and death), evaluated the role of interleukin-2, an immune-
based therapy, in improving CD4 cell recovery. Interleukin-2 adjunctive therapy resulted in CD4 cell count
increases but with no observable clinical benefit. Therefore, interleukin-2 is not recommended (AI).27 Other
immune-based therapies that increase CD4 cell counts (e.g., growth hormone, interleukin-7) are under
investigation. However, none of the therapies have been evaluated in clinical endpoint trials; therefore,
whether any of these approaches will offer clinical benefit is unclear. Currently, such immune-based
therapies should not be used except in the context of a clinical trial.
Persistent Immune Activation and Inflammation
Although poor CD4 cell recovery likely contributes to morbidity and mortality during ART-mediated viral
suppression, there is increasing focus on persistent immune activation and inflammation as potentially
independent mediators of risk. HIV infection results in heightened systemic immune activation and
inflammation, effects that are evident during acute infection, persist throughout chronic untreated infection,
and predict more rapid CD4 cell decline and progression to AIDS and death, independent of plasma HIV
RNA levels.28 Although immune activation declines with suppressive ART, it often persists at abnormal
levels in many HIV-infected individuals maintaining long-term ART-mediated viral suppression—even in
those with CD4 cell recovery to normal levels.29,30 Immune activation and inflammatory markers (e.g., IL-6,
D-dimer, hs-CRP) also predict mortality and non-AIDS morbidity during ART-mediated viral suppression,
including cardiovascular and thromboembolic events, cancer, neurocognitive dysfunction, and frailty.28
Although individuals with poor CD4 cell recovery (i.e., counts persistently <350 cells/mm3) tend to have
greater immune activation and inflammation than those with greater recovery,29 the relationship between
innate immune activation and inflammation and morbidity/mortality is largely independent of CD4 cell
count.31,32 Even in individuals with CD4 counts >500 cells/mm3, there is evidence that immune activation
and inflammation contribute to morbidity and mortality.33 Thus, innate immune activation and inflammation
are potentially important targets for future interventions. 
Although the drivers of persistent immune activation during ART are not completely understood, HIV
persistence, coinfections, and microbial translocation likely play important roles.28 Interventions to reduce each
of these presumed drivers are currently being investigated. Importantly, adding ARV drugs to an already
Downloaded from http://aidsinfo.nih.gov/guidelines on 9/16/2015
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents                                 H-14
suppressive ART regimen (ART intensification) does not consistently improve immune activation.20-23,25
Although some studies have suggested that switching an ART regimen to one with a more favorable lipid
profile may improve some markers of immune activation and inflammation,34,35 these studies have limitations
and results are not consistent across markers and among studies. Thus, at this time, ART modification cannot
be recommended as a strategy to reduce immune activation (BIII). Other commonly used medications with
anti-inflammatory properties (e.g., statins, aspirin) are being studied, and preliminary evidence suggests that
some may reduce immune activation in treated HIV infection.36,37 However, because no intervention
specifically targeting immune activation or inflammation has been studied in a clinical outcomes trial in treated
HIV infection, no interventions to reduce immune activation are recommended at this time. 
In the absence of proven interventions, there is currently no clear rationale to monitor levels of immune
activation and inflammation in treated HIV infection. Furthermore, many of the inflammatory markers that
predict morbidity and mortality fluctuate significantly in HIV-infected individuals. Thus, clinical monitoring
with immune activation or inflammatory markers is not currently recommended (AII). The focus of care to
reduce chronic non-AIDS morbidity and mortality should be on maintaining ART-mediated viral suppression
and addressing strategies to reduce risk factors (e.g., smoking cessation, healthy diet, and exercise) and
managing chronic comorbidities such as hypertension, hyperlipidemia, and diabetes (AII).
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Regimen Switching In the Setting of Virologic Suppression  (Last updated May 1, 2014; last
reviewed May 1, 2014)
With use of currently available antiretroviral therapy (ART), most HIV-infected patients are able to achieve
sustained HIV viral suppression. Furthermore, advances in treatment and better understanding about drug
resistance make it possible to consider switching an effective regimen to an alternative regimen in some
situations (see below). When contemplating such a switch, clinicians must consider several key principles to
maintain viral suppression while addressing concerns with the current treatment.
Reasons to Consider Regimen Switching in the Setting of Viral Suppression:
• To simplify the regimen by reducing pill burden and dosing frequency to improve adherence
• To enhance tolerability and decrease short- or long-term toxicity (see Adverse Effects section)
• To change food or fluid requirements
• To avoid parenteral administration
• To minimize or address drug interaction concerns (see Drug Interactions section)
• To allow for optimal use of ART during pregnancy or should pregnancy occur (see Perinatal Guidelines)1
• To reduce costs (see Cost section)
Principles and Strategies of Regimen Switching
The cardinal principle of regimen switching is to maintain viral suppression without jeopardizing future
treatment options. If a regimen switch results in virologic failure with emergence of new resistance
mutations, the patient may require more complex, difficult to follow, or expensive regimens. Principles for
successful regimen switching are highlighted below:
• It is critical to review a patient’s full antiretroviral (ARV) history (including virologic responses,
resistance test results, and past adverse events) before any treatment switch.
• Once a particular resistance mutation has been selected, it is generally archived in the HIV reservoir and
is likely to reappear under the appropriate selective drug pressure, even if not detected in the most recent
resistance test. If resistance data are unavailable, resistance may often be inferred from a patient’s
treatment history. For example, a clinician should assume that patients who have failed a cytosine
analogue (e.g., a lamivudine (3TC)- or emtricitabine (FTC)-containing regimen), likely have the M184V
substitution, even if the substitution is not documented. The same assumption of resistance may also
apply to patients with documented failure to an non-nucleoside reverse transcriptase inhibitor (NNRTI)-
or an integrase strand transfer inhibitors (INSTI)-based regimen because these drugs generally have a
lower barrier to resistance. If there is uncertainty about prior resistance, it is generally not advisable to
switch a suppressive ARV regimen unless the new regimen is likely to be as active against resistant virus
as the suppressive regimen.
• Consultation with an HIV specialist is recommended when considering a regimen switch for a patient
with a history of resistance to one or more drug classes.
• Switching from a ritonavir (RTV)-boosted protease inhibitor (PI) regimen to a regimen composed of
drugs with a lower barrier to resistance generally maintains viral suppression provided there is no
resistance to the other components of the regimen. However, such switches should be avoided if there is
any doubt about the activity of the other agents in the regimen.
• Within-class switches prompted by adverse events usually maintain viral suppression provided that there
is no drug resistance to the other ARV agents in the same drug class.
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• In the absence of any likely drug resistance, switching from complex regimens, parenteral drug (i.e.,
enfuvirtide), or drugs known now to be more toxic (e.g., zidovudine, stavudine, or didanosine) or with
higher pill burden or dosing frequency to simpler regimens (e.g., from a regimen including ritonavir-
boosted saquinavir [SQV/r] to one including ritonavir-boosted darunavir [DRV/r]) or to ARVs in a new
drug class (e.g., an INSTI) generally results in similar or improved adherence, continued viral
suppression and possibly improved quality of life.
• More intensive monitoring of tolerability, viral suppression, adherence, and laboratory changes is
recommended during the first 3 months after a regimen switch.
Alternative Switch Strategies for Patients with Virologic Suppression
RTV-Boosted PI Monotherapy
The strategy of switching virologically suppressed patients without PI resistance from one ART regimen to
RTV-boosted PI monotherapy has been studied. The rationale for this strategy is to avoid nucleoside reverse
transcriptase inhibitor (NRTI) toxicities and decrease costs, while taking advantage of the high barrier to
resistance of RTV-boosted PIs. RTV-boosted PI monotherapy maintains virologic suppression in most
patients, but at slightly lower rates than standard therapy that includes 2 NRTIs.2,3 Low-level viremia,
generally without the emergence of PI resistance, appears to be more common with monotherapy. In most
studies, resumption of NRTIs in patients experiencing low level viral rebound has led to re-suppression.
No clinical trials comparing available RTV-boosted PI monotherapy regimens have been conducted. Findings
from an observational study suggest that the rate of treatment failure is higher in patients on RTV-boosted
atazanavir (ATV/r) than in those on RTV-boosted lopinavir (LPV/r) or DRV/r.4 Another pilot study reported
early viral rebound with use of ATV/r monotherapy.5 There are rare reports of central nervous system
virologic escape, sometimes with clinical symptoms, in patients on RTV-boosted PI monotherapy.6,7
On the basis of the results from these studies, RTV-boosted PI monotherapy should generally be avoided.
Other strategies to avoid use of NRTIs (i.e., use of a RTV-boosted PI plus a NNRTI, an INSTI, or maraviroc
[MVC]) are also being studied, but data on these strategies are limited.
Switching from a Ritonavir-Boosted Protease Inhibitor to Unboosted Atazanavir
Several clinical studies have evaluated switching a RTV-boosted PI to unboosted atazanavir (ATV) in
virologically suppressed patients without NRTI resistance. Two comparative clinical trials reported that
ATV/r and ATV, both in combination with 2 NRTIs (mostly ABC/3TC), demonstrated comparable levels of
virologic suppression and a similar lack of treatment-emergent resistance. The benefits of the unboosted ATV
regimen included a slightly improved lipid profile and a lower incidence of hyperbilirubinemia.8,9 An
additional study of 296 patients with virologic suppression on tenofovir disoproxil fumarate (TDF)/FTC plus
ATV/r showed that patients switched to ABC/3TC plus ATV maintained viral suppression and showed
improvements in certain bone and renal biomarkers.10 The results of these and other non-comparative studies
suggest that a regimen of ABC/3TC plus ATV can be considered in virologically suppressed patients,
especially in those who have adverse effects from TDF or RTV.
Switching to Maraviroc
Co-receptor usage in virologically suppressed patients can be determined from proviral DNA obtained from
peripheral blood mononuclear cells. Individuals found to have R5-tropic virus by this technique could
potentially have a component of their regimens switched to MVC.11,12 However, although the use of MVC
after DNA tropism testing has potential, this strategy cannot be recommended until more data from larger
clinical studies are available (see Tropism Testing section).
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De-intensification
De-intensification of a standard RTV-boosted PI regimen from three to two active drugs (e.g., to a boosted PI
plus one NRTI,13 a boosted PI plus an INSTI,14,15 or an NNRTI such as etravirine15 or the CCR5 antagonist
MVC12) may be more effective virologically than RTV-boosted PI monotherapy, but, thus far, comparative
data on this approach are limited. In general, switching a regimen —even in a patient without known drug
resistance—from an effective three-drug regimen to a two-drug regimen has not been validated and is not
recommended.
Monitoring After Treatment Changes
Patients should be evaluated more closely for several months after a treatment switch (i.e., a clinic visit or
phone call 1 to 2 weeks after the change and a viral load test to check for rebound viremia 4 to 8 weeks after
the switch). The goal of the intensive monitoring is to assess medication tolerance and conduct targeted
laboratory testing if the patient had pre-existing laboratory abnormalities or there are potential concerns with
the new regimen. For example, if lipid abnormalities were present and/or were a reason for the ARV change
or are a concern with the new regimen, fasting cholesterol subsets and triglycerides should be assessed
within 3 months after the change in therapy. Absent any specific complaints, laboratory abnormalities, or
evidence of viral rebound at this 3-month visit, clinical and laboratory monitoring of the patient may resume
on a regularly scheduled basis (see Laboratory Testing section).
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Exposure-Response Relationship and Therapeutic Drug Monitoring (TDM) for Antiretroviral
Agents (Last updated April 8, 2015; last reviewed April 8, 2015)
Knowledge about the relationship between a drug’s systemic exposure (or concentration) and responses
(beneficial and/or adverse) is key in selecting the dose of a drug, in understanding why patients may respond
differently to the same drug and dose, and in designing strategies to optimize drug response and tolerability. 
Therapeutic drug monitoring (TDM) is a strategy used to guide dosing of certain antiarrhythmics,
anticonvulsants, antineoplastics, and antimicrobial agents by using measured drug concentrations to improve
the likelihood of the desired therapeutic and safety outcomes. Drugs suitable for TDM are characterized by a
known exposure-response relationship and a therapeutic range of concentrations. The therapeutic range is a
range of concentrations established through clinical investigations that are associated with a greater
likelihood of achieving the desired therapeutic response and/or reducing the frequency of drug-associated
adverse reactions. 
Several antiretroviral (ARV) agents meet most of the characteristics of agents suitable for a TDM strategy.1
Specifically, some ARVs have considerable interpatient variability in drug concentrations; other ARVs have
known drug concentrations associated with efficacy and/or toxicity; and in the case of other drugs, data from
small prospective studies have demonstrated that TDM improved virologic response and/or decreased the
incidence of concentration-related drug toxicities.2,3
TDM for ARV agents, however, is not recommended for routine use in the management of HIV-
infected adults (BII). This recommendation is based on multiple factors that limit the routine use of TDM in
HIV-infected patients. These limiting factors include lack of prospective studies that demonstrate routine use
of TDM improves clinical outcomes, uncertain therapeutic thresholds for most ARV agents, great intra- and
inter-patient variability in drug concentrations achieved, and a lack of commercial laboratories to perform
real time quantitation of ARV concentrations.2-5
Scenarios for Consideration of Therapeutic Drug Monitoring
Although routine use of TDM is not recommended, in some scenarios, ARV concentration data may be
useful in patient management. In these cases, assistance from a clinical pharmacologist or a clinical
pharmacist to interpret the concentration data may be advisable. These scenarios include the following:
•     Suspect clinically significant drug-drug or drug-food interactions that may result in reduced efficacy or
increased dose-related toxicities;
•     Changes in pathophysiologic states that may impair gastrointestinal, hepatic, or renal function, thereby
potentially altering drug absorption, distribution, metabolism, or elimination;
•     Among pregnant women who have risk factors for virologic failure (e.g., those not achieving viral
suppression during earlier stage of pregnancy)—during the later stages of pregnancy, physiologic
changes may result in reduced drug exposure and thus further increase the risk of virologic failure; 
Panel’s Recommendations
• Therapeutic drug monitoring for antiretroviral agents is not recommended for routine use in the management of HIV-infected patients
(BII).
• TDM may be considered in selected clinical scenarios, as discussed in the text below.
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
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•     Heavily pretreated patients experiencing virologic failure and who may have viral isolates with reduced
susceptibility to ARVs; 
•     Use of alternative dosing regimens and ARV combinations for which safety and efficacy have not been
established in clinical trials; 
•     Concentration-dependent, drug-associated toxicities; and
•     Lack of expected virologic response in medication-adherent patients.
Resources for Therapeutic Drug Monitoring Target Concentrations
Most TDM-proposed target concentrations for ARVs focus on a minimum concentration (Cmin) (i.e., the
plasma concentration at the end of a dosing interval before the next ARV dose). A summary of population
average ARV Cmin can be found in a review on the role of ARV-related TDM.2 Population average Cmin for
newer ARVs can be found in the Food and Drug Administration-approved product labels.
Guidelines for the collection of blood samples and other practical suggestions related to TDM can be found
in a position paper by the Adult AIDS Clinical Trials Group Pharmacology Committee.4
Challenges and Considerations in Using Drug Concentrations to Guide Therapy
There are several challenges and considerations for implementation of TDM in the clinical setting. Use of
TDM to monitor ARV concentrations in a patient requires the following:
•     quantification of the concentration of the drug, usually in plasma or serum; 
•     determination of the patient’s pharmacokinetic characteristics;
•     integration of information on patient adherence; 
•     interpretation of the drug concentrations; and 
•     adjustment of the drug dose to achieve concentrations within the therapeutic range, if necessary. 
A final caveat to the use of measured drug concentrations in patient management is a general one—drug
concentration information cannot be used alone; it must be integrated with other clinical information,
including the patient’s ARV history and adherence before the TDM result. In addition, as knowledge of
associations between ARV concentrations and virologic response evolves, clinicians who use a TDM strategy
for patient management should evaluate the most up-to-date information regarding the exposure-response
relationship of the tested ARV agent. 
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Discontinuation or Interruption of Antiretroviral Therapy  (Last updated April 8, 2015; last
reviewed April 8, 2015)
Discontinuation of antiretroviral therapy (ART) may result in viral rebound, immune decompensation, and
clinical progression.1-5 Thus, planned interruptions of ART are not generally recommended. However,
unplanned interruption of ART may occur under certain circumstances as discussed below. 
Short-Term Therapy Interruptions
Reasons for short-term interruption (days to weeks) of ART vary and may include drug toxicity; intercurrent
illnesses that preclude oral intake, such as gastroenteritis or pancreatitis; surgical procedures; or interrupted
access to drugs. Stopping ART for a short time (i.e., less than 1 to 2 days) because of a medical/surgical
procedure can usually be done by holding all drugs in the regimen. Recommendations for some other
scenarios are listed below:
Unanticipated Short-Term Therapy Interruption
When a Patient Experiences a Severe or Life-Threatening Toxicity or Unexpected Inability to Take Oral
Medications:
•     All components of the drug regimen should be stopped simultaneously, regardless of drug half-life.
Planned Short-Term Therapy Interruption (Up to 2 Weeks)
When All Regimen Components Have Similar Half-Lives and Do Not Require Food for Proper Absorption:
•     All drugs may be given with a sip of water, if allowed; otherwise, all drugs should be stopped
simultaneously. All discontinued regimen components should be restarted simultaneously.
When All Regimen Components have Similar Half-Lives and Require Food for Adequate Absorption, and the
Patient Cannot Take Anything by Mouth for a Short Time:
•     Temporary discontinuation of all drug components is indicated. The regimen should be restarted as soon
as the patient can resume oral intake.
When the ARV Regimen Contains Drugs with Different Half-Lives:
•     Stopping all drugs simultaneously may result in functional monotherapy with the drug with the longest
half-life (typically a non-nucleoside reverse transcriptase inhibitor [NNRTI]), which may increase the
risk of selection of NNRTI-resistant mutations. Some experts recommend stopping the NNRTI first and
the other ARV drugs 2 to 4 weeks later. Alternatively, the NNRTI may be replaced with a ritonavir (or
cobicistat)-boosted protease inhibitor (PI/r or PI/c) for 4 weeks. The optimal time sequence for staggered
discontinuation of regimen components, or replacement of the NNRTI with a PI/r (or PI/c), has not been
determined.
Planned Long-Term Therapy Interruptions
Planned long-term therapy interruptions are not recommended outside of controlled clinical trials (AI).
Several research studies are evaluating approaches to a functional (virological control in the absence of
therapy) or sterilizing (virus eradication) cure of HIV infection. Currently, the only way to reliably test the
effectiveness of these strategies may be to interrupt ART and closely monitor viral rebound over time in the
setting of a clinical trial. 
If therapy must be discontinued, patients should be aware of and understand the risks of viral rebound, acute
retroviral syndrome, increased risk of HIV transmission, decline of CD4 count, HIV disease progression,
development of minor HIV-associated manifestations such as oral thrush or serious non-AIDS complications
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(e.g., renal, cardiac, hepatic, or neurologic complications), development of drug resistance, and the need for
chemoprophylaxis against opportunistic infections as a result of CD4 decline. Patients should be counseled
about the need for close clinical and laboratory monitoring during therapy interruptions.
References 
1.    Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical
disease progression to AIDS or death. HIV Med. 2007;8(2):96-104. Available at
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17352766.
2.    Kousignian I, Abgrall S, Grabar S, et al. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in
patients with uncontrolled viral replication and profound immunodeficiency. Clin Infect Dis. 2008;46(2):296-304.
Available at
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18171266.
3.    Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected
adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006;367(9527):1981-1989. Available at
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=
16782488&itool=iconabstr&query_hl=147&itool=pubmed_docsum.
4.    DART Trial Team DTT. Fixed duration interruptions are inferior to continuous treatment in African adults starting
therapy with CD4 cell counts < 200 cells/microl. AIDS. 2008;22(2):237-247. Available at
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18097226.
5.    El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med.
2006;355(22):2283-2296. Available at
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17135583.
Downloaded from http://aidsinfo.nih.gov/guidelines on 9/16/2015
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents                                    I-1
Considerations for Antiretroviral Use in Special Patient Populations
Acute and Recent (Earlya) HIV Infection  (Last updated April 8, 2015; last reviewed April 8, 2015)
a Early infection represents either acute or recent infection.
Definitions: Acute HIV-1 infection is the phase of HIV-1 disease immediately after infection that is
characterized by an initial burst of viremia; although, anti-HIV-1 antibodies are undetectable, HIV-1 RNA or
p24 antigen are present. Recent infection generally is considered the phase up to 6 months after infection
during which anti-HIV-1 antibodies are detectable. Throughout this section, the term “early HIV-1 infection”
is used to refer to either acute or recent HIV-1 infection.
An estimated 40% to 90% of patients with acute HIV-1 infection will experience symptoms of acute
retroviral syndrome, such as fever, lymphadenopathy, pharyngitis, skin rash, myalgias/arthralgias, and other
symptoms.1-6 However, because the self-limiting symptoms are similar to those of many other viral
infections, such as influenza and infectious mononucleosis, primary care clinicians often do not recognize
acute HIV-1 infection. Acute infection can also be asymptomatic. Table 11 provides practitioners with
guidance to recognize, diagnose, and manage acute HIV-1 infection.
Diagnosing Acute HIV Infection
Health care providers should maintain a high level of suspicion of acute HIV-1 infection in patients who have
a compatible clinical syndrome—especially in those who report recent high-risk behavior (see Table 11).7
Patients may not always disclose or admit to high-risk behaviors or perceive that their behaviors put them at
risk for HIV-1 acquisition. Thus, even in the absence of reported high-risk behaviors, signs and symptoms
Panel’s Recommendations
• Antiretroviral therapy (ART) is recommended for all individuals with HIV-1 infection and should be offered to those with earlya HIV-1
infection (BII), although definitive data to confirm whether this approach will result in long-term virologic, immunologic, or clinical
benefits are lacking.
• All pregnant women with early HIV-1 infection should start ART as soon as possible to prevent perinatal transmission of HIV-1 (AI).
• If treatment is initiated in a patient with early HIV-1 infection, the goal is to suppress plasma HIV-1 RNA to undetectable levels (AIII).
• In patients with early HIV-1 infection in whom therapy is initiated, testing for plasma HIV-1 RNA levels, CD4 T lymphocyte counts,
and toxicity monitoring should be performed as described for patients with chronic HIV-1 infection (AII). 
• Genotypic drug resistance testing should be performed before initiation of ART to guide the selection of the regimen (AII). If therapy
is deferred, genotypic resistance testing should still be performed because the results will be useful in selecting a regimen with the
greatest potential for achieving optimal virologic response once therapy is initiated (AII).
• In patients without transmitted drug resistant virus, therapy should be initiated with one of the combination regimens that is
recommended for patients with chronic HIV-1 infection (see What to Start) (AIII).
• ART can be initiated before drug resistance test results are available. Because resistance to pharmacokinetically enhanced protease
inhibitors emerges slowly and clinically significant transmitted resistance to protease inhibitors is uncommon, these drugs and 2
nucleoside reverse transcriptase inhibitors should be used in this setting (AIII).
• Patients starting ART should be willing and able to commit to treatment and should understand the possible benefits and risks of
therapy and the importance of adherence (AIII). Patients may choose to postpone therapy, and providers, on a case-by-case basis,
may elect to defer therapy because of clinical and/or psychosocial factors.
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
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consistent with acute retroviral syndrome should motivate consideration of a diagnosis of acute HIV-1
infection.
Acute HIV-1 infection is usually defined as detectable HIV-1 RNA or p24 antigen in serum or plasma in the
setting of a negative or indeterminate HIV-1 antibody test result.7,8 Combination immunoassays that detect
HIV-1 and HIV-2 antibodies and HIV-1 p24 antigen are now approved by the Food and Drug Administration
(FDA), and the most recent Centers for Disease Control and Prevention testing algorithm recommends them
as the preferred assay to use for HIV screening, including for possible acute HIV-1 infection. Specimens that
are reactive on this initial assay should be tested with an immunoassay that differentiates HIV-1 and HIV-2
antibodies.9 Specimens that are reactive on the initial assay and have either negative or indeterminate
antibody differentiation test results should undergo testing using an FDA-approved quantitative or qualitative
HIV-1 RNA test; a negative HIV-1 RNA test result indicates that the original Ag/Ab test result was a false
positive. Detection of HIV-1 RNA indicates that acute HIV-1 infection is highly likely,9 and that
antiretroviral therapy (ART) may be warranted (see Treatment for Early HIV-1 Infection). HIV-1 infection
should be confirmed by subsequent testing to document HIV antibody seroconversion.
Some health care facilities may still be following HIV testing algorithms that recommend initial testing with
an assay that only tests for the presence of HIV antibody. In such settings, when acute HIV-1 infection is
suspected in a patient with a negative or indeterminate HIV antibody result, a quantitative or qualitative
FDA-approved HIV-1 RNA test should be performed (AII). A presumptive diagnosis of acute HIV-1
infection can be made on the basis of a negative or indeterminate HIV antibody test result and a positive
HIV-1 RNA test result, in which case, ART may be warranted (see Treatment for Early HIV-1 Infection).
Providers should be aware that a low-positive quantitative HIV-1 RNA level (e.g., <10,000 copies/mL) may
represent a false-positive result because HIV-1 RNA levels in acute infection are generally very high (e.g.,
>100,000 copies/mL).5,6 Therefore, when a low-positive quantitative HIV-1 RNA result is obtained, the HIV-
1 RNA test should be repeated using a different specimen from the same patient.6 In this setting, the
diagnosis of HIV-1 infection should be confirmed by subsequent documentation of HIV antibody
seroconversion (see Table 11).
Treating Early HIV-1 Infection
Clinical trial data regarding the treatment of early HIV-1 infection is limited. Many patients who enrolled in
studies to assess the role of ART in early HIV-1 infection (outlined below) were identified as trial
participants because they presented with signs or symptoms of acute infection. With the introduction of HIV
screening tests that include assays for HIV-1 RNA or p24 antigen and wider HIV screening in healthcare
systems, the number of asymptomatic patients identified with early infection may increase. The natural
history of HIV-1 disease in these patients may differ from that in individuals with symptomatic infections,
thus further studies on the impact of ART on the natural history of asymptomatic acute HIV-1 infection are
needed. The initial burst of high level viremia in infected individuals usually declines shortly after acute
infection (e.g., within 2 months); however, a rationale for treatment during recent infection (e.g., 2–6 months
after infection) remains, because during this transition period the immune system may not yet have
maximally contained viral replication in the lymphoid tissue.10 Several trials have addressed the question of
the long-term benefit of potent treatment regimens initiated during early HIV-1 infection. The potential
benefits and risks of treating HIV-1 during this stage of disease are discussed below.
Potential Benefits of Treatment During Early HIV-1 Infection
Preliminary data indicate that treatment of early HIV-1 infection with combination ART improves laboratory
markers of disease progression.11-15 The data, though limited, indicate that treatment of early HIV-1 infection
may also reduce the severity of acute disease; lower the viral set point,16-18 which can affect the rate of
disease progression if therapy is stopped; reduce the size of the viral reservoir;19 and decrease the rate of viral
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mutation by suppressing viral replication and preserving immune function.20 Because early HIV-1 infection
is often associated with high viral loads and increased infectiousness,21 and ART use by HIV-1-infected
individuals reduces transmission to serodiscordant sexual partners,22 treatment during early HIV-1 infection
is expected to substantially reduce the risk of HIV-1 transmission. In addition, although data are limited and
the clinical relevance unclear, the profound loss of gastrointestinal lymphoid tissue that occurs during the
first weeks of infection may be mitigated by initiating ART during early HIV-1 infection.23,24 Many of the
potential benefits described above may be more likely to occur with treatment of acute infection, but they
also may occur if treatment is initiated during recent HIV-1 infection. 
Potential Risks of Treatment During Early HIV-1 Infection
The potential disadvantages of initiating therapy during early HIV-1 infection include more prolonged
exposure to ART without a known long-term clinical benefit. This prolonged exposure to ART could result in
drug toxicities, development of drug resistance if the patient is non-adherent to the regimen, and adverse
effects on the patient’s quality of life due to earlier initiation of lifelong therapy that requires strict adherence.
Clinical Trial Data on Treatment During Early Infection
Several randomized controlled trials have studied the effect of ART during acute and recent infection to
assess whether initiating early therapy would allow patients to stop treatment and still maintain lower viral
loads and higher CD4 T lymphocyte (CD4) counts while off ART for prolonged periods of time. This
objective was of interest when these studies were initiated but is now less relevant because treatment is
recommended for virtually all HIV-1-infected patients and treatment interruptions are not recommended (see
Initiating Antiretroviral Therapy in Treatment-Naive Patients).
The Setpoint Study (ACTG A5217 Study) randomized patients with recent but not acute HIV-1 infection to
either defer therapy or immediately initiate ART for 36 weeks and then stop treatment.16 The primary study
end point was a composite of meeting criteria for ART or re-initiation of ART and viral load results at week
72 in both groups and at week 36 in the deferred treatment group. The study was stopped prematurely by the
Data and Safety Monitoring Board because of an apparent benefit associated with early therapy that was
driven mostly by the greater proportion of participants meeting the criteria for ART initiation in the deferred
treatment group (50%) than in the immediate treatment group (10%). Nearly half of the patients in the
deferred treatment group needed to start therapy during the first year of study enrollment. 
The Randomized Primo-SHM Trial randomized patients with acute (~70%) or recent (~30%) infection to
either defer ART or undergo treatment for 24 or 60 weeks and then stop.17 Significantly lower viral loads
were observed 36 weeks after treatment interruption in the patients who had been treated early. These
patients also took longer to reach a CD4 count threshold of <350 cells/mm3 for restarting ART. The median
time to starting treatment was 0.7 years for the deferred therapy group and 3.0 and 1.8 years for the 24- and
60-week treatment arms, respectively. The time to reaching a CD4 count of <500 cells/mm3 was only 0.5
years in the deferred group. 
The SPARTAC Trial included patients with acute and recent infection randomized to either defer therapy or
received ART for 12 or 48 weeks and then stop.18 In this trial, the time to reach CD4 <350 cells/mm3 or
initiate therapy was significantly longer in the group treated for 48 weeks than in the deferred treatment
group or the group treated for 12 weeks. However, no difference was observed between the participants who
received 12 weeks of ART and those who deferred treatment during early infection.
The strategies tested in these studies are of limited relevance today given that treatment interruption is not
recommended. The study results may not fully reflect the natural history of HIV-1 disease in persons with
asymptomatic acute infection because most patients in these trials were enrolled on the basis of identified early
symptomatic HIV-1 infections. Nevertheless, the results do demonstrate that some immunologic and virologic
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benefits may be associated with the treatment of early HIV-1 infection. Moreover, all the findings suggest, at
least in the population recruited for these studies, that the time to initiating ART after identification of early
infection is quite short when the threshold for ART initiation is 350 CD4 cells/mm3, and nonexistent when
therapy is advised for all individuals regardless of CD4 cell count as currently recommended in these
guidelines. These observations must be balanced with the risks of early treatment, risks that are largely the
same as those when therapy is initiated in chronically infected asymptomatic patients with high CD4 counts.
Consequently, the health care provider and the patient should be fully aware that the rationale for initiating
therapy during early HIV-1 infection is based on theoretical benefits and the extrapolation of data from the
strategy trials outlined above. These potential benefits must be weighed against the risks. For these reasons,
and because ART is currently recommended for all HIV-1-infected patients (see Initiating Antiretroviral
Therapy in Treatment Naive Patients), ART should be offered to all patients with early HIV-1 infection (BII).
However, patients must be willing and able to commit to treatment, and providers, on a case-by-case basis, may
elect to defer therapy for clinical and/or psychosocial reasons. Providers also should consider enrolling patients
with early HIV-1 infection in clinical studies to further evaluate the natural history of this stage of HIV-1
infection and to further define the role of ART in this setting. Providers can obtain information regarding such
trials at www.clinicaltrials.gov or from local HIV treatment experts.
Treating Early HIV-1 Infection During Pregnancy
Because early HIV-1 infection is associated with a high risk of perinatal transmission, all HIV-1-infected
pregnant women should start combination ART as soon as possible to prevent perinatal transmission of HIV-
1 (AI).25
Treatment Regimen for Early HIV-1 Infection
Data from the United States and Europe demonstrate that transmitted virus may be resistant to at least 1
antiretroviral drug in 6% to 16% of patients.26-28 In one study, 21% of isolates from patients with acute HIV-1
infection demonstrated resistance to at least 1 drug.29 Therefore, before initiating ART in a person with early
HIV-1 infection, genotypic antiretroviral (ARV) drug resistance testing should be performed to guide
selection of a regimen (AII). If the decision is made to initiate therapy during early infection, especially in
the setting of acute infection, treatment initiation should not be delayed pending resistance testing results.
Once results are available, the treatment regimen can be modified if warranted. If therapy is deferred,
resistance testing still should be performed because the results will help guide selection of a regimen that has
the greatest potential to optimize virologic response once therapy is initiated (AII).
The goal of therapy during early HIV-1 infection is to suppress plasma HIV-1 RNA to undetectable levels
(AIII). Because data are insufficient to draw firm conclusions regarding specific drug combinations to use in
this stage of HIV-1 infection, ART should be initiated with one of the combination regimens recommended for
patients with chronic infection (AIII) (see What to Start). If therapy is started before the results of drug
resistance testing are available, a pharmacologically boosted protease inhibitor (PI) should be used because
resistance to these agents emerges slowly and clinically significant transmitted resistance is uncommon (AIII).
If available, the results of ARV drug resistance testing or the ARV resistance pattern of the source person’s virus
should be used to guide selection of the ARV regimen. Given the increasing use of daily tenofovir disoproxil
fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in HIV-negative individuals,30-32 early
infection may be diagnosed in some patients while they are taking TDF/FTC as PrEP. In this setting, resistance
testing should be performed; however, because PI resistance is unlikely, use of a pharmacologically boosted PI
and TDF/FTC remains a reasonable option pending resistance testing results (see What to Start).
Patient Follow-Up
Testing for plasma HIV-1 RNA levels, CD4 cell counts, and toxicity monitoring should be performed as
described in Laboratory Testing for Initial Assessment and Monitoring While on Antiretroviral Therapy (i.e.,
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HIV-1 RNA at initiation of therapy, after 2 to 8 weeks, then every 4 to 8 weeks until viral suppression, and
thereafter, every 3 to 4 months) (AII).
Duration of Therapy for Early HIV-1 Infection
The optimal duration of therapy for patients with early HIV-1 infection is unknown. Recent studies of early
HIV-1 infection have evaluated starting and then stopping treatment as a potential strategy.16-18 Although
these studies showed some benefits associated with this strategy, a large randomized controlled trial of
patients with chronic HIV-1 infection found that treatment interruption was harmful in terms of increased
risk of AIDS and non-AIDS events,33 and that the strategy was associated with increased markers of
inflammation, immune activation, and coagulation.34 For these reasons and the potential benefit of ART in
reducing the risk of HIV-1 transmission, the Panel does not recommend discontinuation of ART in patients
treated for early HIV-1 infection (AIII).
Table 11. Identifying, Diagnosing, and Managing Acute and Recent HIV-1 Infection 
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HIV-Infected Adolescents and Young Adults  (Last updated May 1, 2014; last reviewed 
May 1, 2014)
Older children and adolescents now make up the largest percentage of HIV-infected children cared for at
pediatric HIV clinics in the United States. The Centers for Disease Control and Prevention (CDC) estimates
that 26% of the approximately 50,000 new HIV infections diagnosed in 2010 were among youth 13 to 24 years
of age. In this age group, 57% of the infections were among young black/African Americans and 75% among
young men who have sex with men (MSM).1 Among youth living with HIV infection in 2010, CDC estimates
that almost 60% had undiagnosed infections and were unaware they were HIV-infected.2 Recent trends in
HIV/AIDS prevalence reveal that the disproportionate burden of AIDS among racial minorities is even greater
among minority youth 13 to 24 years of age (64% to 66% of cases) than among those older than 24 years (48%
of cases).3 Furthermore, trends for all HIV diagnoses among adolescents and young adults in 46 states and 5
U.S. dependent areas from 2007 to 2010 decreased or remained stable for all transmission categories except
among young MSM. HIV-infected adolescents represent a heterogeneous group in terms of sociodemographics,
mode of HIV infection, sexual and substance abuse history, clinical and immunologic status, psychosocial
development, and readiness to adhere to medications. Many of these factors may influence decisions
concerning when to start antiretroviral therapy (ART) and what antiretroviral (ARV) medications to use.
Most adolescents who acquire HIV are infected through sexual risk behaviors. Many of them are recently
infected and unaware of their HIV infection status. Thus, many are in an early stage of HIV infection, which
makes them ideal candidates for early interventions, such as prevention counseling and linkage to and
engagement in care.4 High grade viremia was reported among a cohort of youth identified as HIV-infected by
adolescent HIV specialty clinics in 15 major metropolitan U.S. cities. The mean HIV viral load for the cohort
was 94,398 copies/ml; 30% of the youth were not successfully linked to care.5 A study among HIV-infected
adolescents and young adults presenting for care identified primary genotypic resistance mutations to ARV
medications in up to 18% of the evaluable sample of recently infected youth, as determined by the detuned
antibody testing assay strategy that defined recent infection as occurring within 180 days of testing.6
Recently, substantial multiclass resistance was noted in a cohort of behaviorally-infected, treatment-naive
youth who were screened for an ARV treatment trial.7 As these youth were naive to all ART, this reflects
transmission of resistant virus. This transmission dynamic reflects that a substantial proportion of youth’s
sexual partners are likely older and may be more ART experienced; thus, awareness of the importance of
baseline resistance testing among recently infected youth naive to ART is imperative.
A limited but increasing number of HIV-infected adolescents are long-term survivors of HIV infection acquired
perinatally or in infancy through blood products. Such adolescents are usually heavily ART experienced and may
have a unique clinical course that differs from that of adolescents infected later in life.8 Those adolescents infected
perinatally or in infancy were often started on ART early in life with mono or dual therapy regimens resulting in
incomplete viral suppression and emergence of resistance. If these heavily ART-experienced adolescents harbor
resistant virus, optimal ARV regimens should be selected on the basis of the same guiding principles used for
heavily ART-experienced adults (see Virologic Failure and Suboptimal Immunologic Response).
Adolescents are developmentally at a difficult crossroad. Their needs for autonomy and independence and
their evolving decisional capacity intersect and compete with their concrete thinking processes, risk-taking
behaviors, preoccupation with self-image, and need to fit in with their peers. This makes it challenging to
attract and sustain adolescents’ focus on maintaining their health, particularly for those with chronic
illnesses. These challenges are not specific to any particular transmission mode or stage of disease. Thus,
irrespective of disease duration or mode of HIV transmission, every effort must be made to engage and
maintain adolescents in care so they can improve and maintain their health for the long term. Adolescents
may seek care in several settings including pediatric-focused HIV clinics, adolescent/young adult clinics, and
adult-focused clinics.9 Regardless of the setting, expertise in caring for adolescents is critical to creating a
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supportive environment for engaging youth in care.9,10
Antiretroviral Therapy Considerations in Adolescents
Adult guidelines for ART are usually appropriate for postpubertal adolescents because the clinical course of
HIV infection in adolescents who were infected sexually or through injection drug use during adolescence is
more similar to that in adults than that in children. Adult guidelines can also be useful for postpubertal youth
who were perinatally infected. These patients often have treatment challenges associated with the long-term
use of ART that mirror those of ART-experienced adults, such as extensive resistance, complex regimens, and
adverse drug effects.
Dosage of medications for HIV infection and opportunistic infections should be prescribed according to Tanner
staging of puberty and not solely on the basis of age.11,12 Adolescents in early puberty (i.e., Tanner Stages I and
II) should be administered doses on pediatric schedules, whereas those in late puberty (i.e., Tanner Stage V)
should follow adult dosing schedules. However, Tanner stage and age are not necessarily directly predictive of
drug pharmacokinetics. Because puberty may be delayed in children who were infected with HIV perinatally,13
continued use of pediatric doses in puberty-delayed adolescents can result in medication doses that are higher
than the usual adult doses. Because data are not available to predict optimal medication doses for each ARV
medication for this group of children, issues such as toxicity, pill or liquid volume burden, adherence, and
virologic and immunologic parameters should be considered in determining when to transition from pediatric
to adult doses. Youth who are in their growth spurt period (i.e., Tanner Stage III in females and Tanner Stage IV
in males) and following adult or pediatric dosing guidelines and adolescents who have transitioned from
pediatric to adult doses should be closely monitored for medication efficacy and toxicity. Therapeutic drug
monitoring can be considered in each of these selected circumstances to help guide therapy decisions.
Pharmacokinetic studies of drugs in youth are needed to better define appropriate dosing. For a more detailed
discussion, see Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.14
Adherence Concerns in Adolescents
HIV-infected adolescents are especially vulnerable to specific adherence problems on the basis of their
psychosocial and cognitive developmental trajectory. Comprehensive systems of care are required to serve
both the medical and psychosocial needs of HIV-infected adolescents, who are frequently inexperienced with
health care systems and who lack health insurance. Recent studies in adolescents infected through risk
behaviors and in adolescents infected through perinatal transmission demonstrate that many adolescents in
both groups face numerous barriers to adherence.15-17 Compared with adults, these youth have lower rates of
viral suppression and higher rates of virologic rebound and loss to follow up.18 Many HIV-infected
adolescents face challenges in adhering to medical regimens for reasons that include:
• Denial and fear of their HIV infection;
• Misinformation;
• Distrust of the medical establishment;
• Fear and lack of belief in the effectiveness of medications;
• Low self-esteem;
• Unstructured and chaotic lifestyles;
• Mood disorders and other mental illness;
• Lack of familial and social support; 
• Absence of or inconsistent access to care or health insurance; and 
• Risk of inadvertent parental disclosure of the youth’s HIV infection status if parental health insurance is
used.
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In selecting treatment regimens for adolescents, clinicians must balance the goal of prescribing a maximally
potent ART regimen with realistic assessment of existing and potential support systems to facilitate
adherence. Adolescents benefit from reminder systems (e.g., beepers, timers, and pill boxes) that are stylish
and/or inconspicuous.19 In a recent randomized controlled study among non-adherent youth 15 to 24 years of
age, youth who received cell phone medication reminders demonstrated significantly higher adherence and
lower viral loads than youth who did not receive the reminder calls.20 It is important to make medication
adherence as user friendly and the least stigmatizing possible for the older child or adolescent. The concrete
thought processes of adolescents make it difficult for them to take medications when they are asymptomatic,
particularly if the medications have side effects. Adherence to complex regimens is particularly challenging
at a time of life when adolescents do not want to be different from their peers.21-23 Directly observed therapy
may be considered for selected HIV-infected adolescents such as those with mental illness.24-28
Difficult Adherence Problems
Because adolescence is characterized by rapid changes in physical maturation, cognitive processes, and life
style, predicting long-term adherence in an adolescent can be very challenging. The ability of youth to adhere
to therapy needs to be considered as part of therapeutic decision making concerning the risks and benefits of
starting treatment. Erratic adherence may result in the loss of future regimens because of the development of
resistance mutations. Clinicians who care for HIV-infected adolescents frequently manage youth who, while
needing therapy, pose significant concerns regarding their ability to adhere to therapy. In these cases,
alternative considerations to initiation of therapy can be the following: 
1. A short-term deferral of treatment until adherence is more likely or while adherence-related problems are
aggressively addressed; 
2. An adherence testing period in which a placebo (e.g., vitamin pill) is administered; and 
3. The avoidance of any regimens with low genetic resistance barriers. 
Such decisions are ideally individualized to each patient and should be made carefully in context with the
individual’s clinical status. For a more detailed discussion on specific therapy and adherence issues for HIV-
infected adolescents, see Guidelines for Use of Antiretroviral Agents in Pediatric HIV Infection.14
Special Considerations in Adolescents
Sexually transmitted infections (STIs), in particular human papilloma virus (HPV), should also be addressed
in all adolescents. In young MSM, screening for STIs may require sampling from several body sites because
oropharyngeal, rectal, and urethral infections may be present in this population.29 For a more detailed
discussion on STIs, see the most recent CDC guidelines30 and the adult and pediatric opportunistic infection
treatment guidelines on HPV among HIV-infected adolescents.31,32 Family planning counseling, including a
discussion of the risks of perinatal transmission of HIV and methods to reduce risks, should be provided to
all youth. Providing gynecologic care for HIV-infected female adolescents is especially important.
Contraception, including the interaction of specific ARV drugs with hormonal contraceptives, and the
potential for pregnancy also may alter choices of ART. As an example, efavirenz (EFV) should be used with
caution in females of childbearing age and should only be prescribed after intensive counseling and
education about the potential effects on the fetus, the need for close monitoring—including periodic
pregnancy testing—and a commitment on the part of the teen to use effective contraception. For a more
detailed discussion, see HIV-Infected Women and the Perinatal Guidelines.33
Transitioning Care
Given lifelong infection with HIV and the need for treatment through several stages of growth and
development, HIV care programs and providers need flexibility to appropriately transition care for HIV-
infected children, adolescents, and young adults. A successful transition requires an awareness of some
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fundamental differences between many adolescent and adult HIV care models. In most adolescent HIV
clinics, care is more teen-centered and multidisciplinary, with primary care highly integrated into HIV care.
Teen services, such as sexual and reproductive health, substance abuse treatment, mental health, treatment
education, and adherence counseling are all found in one clinic setting. In contrast, some adult HIV clinics
may rely more on referral of the patient to separate subspecialty care settings, such as gynecology.
Transitioning the care of an emerging young adult includes considerations of areas such as medical
insurance; the adolescent’s degree of independence/autonomy and decisional capacity; patient
confidentiality; and informed consent. Also, adult clinic settings tend to be larger and can easily intimidate
younger, less motivated patients. As an additional complication to this transition, HIV-infected adolescents
belong to two epidemiologically distinct subgroups: 
1. Those perinatally infected—who would likely have more disease burden history, complications, and
chronicity; less functional autonomy; greater need for ART; and higher mortality risk—and 
2. Those more recently infected because of high-risk behaviors. 
Thus, these subgroups have unique biomedical and psychosocial considerations and needs.
To maximize the likelihood of a successful transition, interventions to facilitate transition are best
implemented early on.34 These include the following: 
• Developing an individualized transition plan to address comprehensive care needs including medical,
psychosocial and financial aspects of transitioning; 
• Optimizing provider communication between adolescent and adult clinics; 
• Identifying adult care providers willing to care for adolescents and young adults; 
• Addressing patient/family resistance caused by lack of information, stigma or disclosure concerns, and
differences in practice styles; 
• Preparing youth for life skills development, including counseling them on the appropriate use of a
primary care provider and appointment management, the importance of prompt symptom recognition and
reporting, and the importance of self-efficacy in managing medications, insurance, and entitlements; 
• Identifying an optimal clinic model for a given setting (i.e., simultaneous transition of mental health
and/or case management versus a gradual phase-in); 
• Implementing ongoing evaluation to measure the success of a selected model; 
• Engaging in regular multidisciplinary case conferences between adult and adolescent care providers;
• Implementing interventions that may be associated with improved outcomes, such as support groups and
mental health consultation; 
• Incorporating a family planning component into clinical care; and 
• Educating HIV care teams and staff about transitioning. 
Discussions regarding transition should begin early and before the actual transition process.35 Attention to these
key areas will likely improve adherence to appointments and avert the potential for a youth to fall through the
cracks, as it is commonly referred to in adolescent medicine. For a more detailed discussion on specific topics
on transitioning care for adolescents and young adults, see http://www.hivguidelines.org/clinical-
guidelines/adolescents/transitioning-hiv-infected-adolescents-into-adult-care/.
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HIV and Illicit Drug Users  (Last updated March 27, 2012; last reviewed March 27, 2012)
Treatment Challenges of HIV-Infected Illicit Drug Users
Injection drug use is the second most common mode of HIV transmission in the United States. In addition,
noninjection illicit drug use may facilitate sexual transmission of HIV. Injection and noninjection illicit drugs
include the following: heroin, cocaine, marijuana, and club drugs (i.e., methamphetamine, ketamine, gamma-
hydroxybutyrate [GHB], and amyl nitrate [i.e., poppers]). The most commonly used illicit drugs associated
with HIV infection are heroin and stimulants (e.g., cocaine and amphetamines); however, the use of club
drugs has increased substantially in the past several years and is common among individuals who have HIV
infection or who are at risk of HIV infection. The association between club drugs and high-risk sexual
behavior in men who have sex with men (MSM) is strongest for methamphetamine and amyl nitrate; this
association is less consistent with the other club drugs.1
Illicit drug use has been associated with depression and anxiety, either as part of the withdrawal process or as
a consequence of repeated use. This is particularly relevant in the treatment of HIV infection because
depression is one of the strongest predictors of poor adherence and poor treatment outcomes.2 Treatment of
HIV disease in illicit drug users can be successful but HIV-infected illicit drug users present special treatment
challenges. These challenges may include the following: (1) an array of complicating comorbid medical and
mental health conditions; (2) limited access to HIV care; (3) inadequate adherence to therapy; (4) medication
side effects and toxicities; (5) the need for substance abuse treatment; and (6) drug interactions that can
complicate HIV treatment.3
Underlying health problems in injection and noninjection drug users result in increased morbidity and
mortality, either independent of or accentuated by HIV disease. Many of these problems are the consequence
of prior exposures to infectious pathogens from nonsterile needle and syringe use. Such problems can include
hepatitis B or C virus infection, tuberculosis (TB), skin and soft tissue infections, recurrent bacterial
pneumonia, and endocarditis. Other morbidities such as alteration in levels of consciousness and neurologic
and renal disease are not uncommon. Furthermore, these comorbidities are associated with a higher risk of
drug overdoses in illicit drug users with HIV disease than in HIV-uninfected illicit drug users, due in part to
respiratory, hepatic, and neurological impairments associated with HIV infection.4 Successful HIV therapy
for illicit drug users often depends on clinicians becoming familiar with and managing these comorbid
conditions and providing overdose prevention support.
Illicit drug users have less access to HIV care and are less likely to receive antiretroviral therapy (ART) than
other populations.5-6 Factors associated with low rates of ART use among illicit drug users include active
drug use, younger age, female gender, suboptimal health care, recent incarceration, lack of access to
rehabilitation programs, and health care providers’ lack of expertise in HIV treatment.5-6 The typically
unstable, chaotic life patterns of many illicit drug users; the powerful pull of addictive substances; and
common misperceptions about the dangers, impact, and benefits of ART all contribute to decreased
adherence.7 The chronic and relapsing nature of substance abuse as a biologic and medical disease,
compounded by the high rate of mental illness that antedates and/or is exacerbated by illicit substance use,
additionally complicate the relationship between health care workers and illicit drug users.8-9 The first step in
provision of care and treatment for these individuals is to recognize the existence of a substance abuse
problem. It is often obvious that the problem exists, but some patients may hide these problem behaviors
from clinicians. Assessment of a patient for substance abuse should be part of routine medical history taking
and should be done in a professional, straightforward, and nonjudgmental manner.
Treatment Efficacy in HIV-Infected Illicit Drug Use Populations 
Although illicit drug users are underrepresented in HIV therapy clinical trials, available data indicate that
efficacy of ART in illicit drug users—when they are not actively using drugs—is similar to that seen in other
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populations.10 Furthermore, therapeutic failure in this population generally correlates with the degree that
drug use disrupts daily activities rather than with drug use per se.11 Providers need to remain attentive to the
possible impact of disruptions caused by drug use on the patient both before and while receiving ART.
Although many illicit drug users can sufficiently control their drug use for long enough time to benefit from
care, substance abuse treatment is often necessary for successful HIV management.
Close collaboration with substance abuse treatment programs and proper support and attention to this
population’s special multidisciplinary needs are critical components of successful HIV treatment. Essential to
this end are accommodating, flexible, community-based HIV care sites that are characterized by familiarity
with and nonjudgmental expertise in management of drug users’ wide array of needs and in development of
effective strategies to promote medication adherence.9 These strategies should include, if available, the use of
adherence support mechanisms such as modified directly observed therapy (mDOT), which has shown
promise in this population.12
Antiretroviral Agents and Opioid Substitution Therapy
Compared with noninjection drug users receiving ART, injection drug users (IDUs) receiving ART are more
likely to experience an increased frequency of side effects and toxicities of ART. Although not systematically
studied, this is likely because underlying hepatic, renal, neurologic, psychiatric, gastrointestinal (GI), and
hematologic disorders are highly prevalent among IDUs. These comorbid conditions should be considered
when selecting antiretroviral (ARV) agents in this population. Opioid substitution therapies such as
methadone and buprenorphine/naloxone and extended-release naltrexone are commonly used for
management of opioid dependence in HIV-infected patients.
Methadone and Antiretroviral Therapy. Methadone, an orally administered, long-acting opioid agonist, is
the most common pharmacologic treatment for opioid addiction. Its use is associated with decreased heroin
use, decreased needle sharing, and improved quality of life. Because of its opioid-induced effects on gastric
emptying and the metabolism of cytochrome P (CYP) 450 isoenzymes 2B6, 3A4, and 2D6, pharmacologic
effects and interactions with ARV agents may commonly occur.13 These may diminish the effectiveness of
either or both therapies by causing opioid withdrawal or overdose, increased methadone toxicity, and/or
decreased ARV efficacy. Efavirenz (EFV), nevirapine (NVP), and lopinavir/ritonavir (LPV/r) have been
associated with significant decreases in methadone levels. Patients and substance abuse treatment facilities
should be informed of the likelihood of this interaction. The clinical effect is usually seen after 7 days of
coadministration and may be managed by increasing the methadone dosage, usually in 5-mg to 10-mg
increments daily until the desired effect is achieved.
Buprenorphine and Antiretroviral Therapy. Buprenorphine, a partial µ-opioid agonist, is administrated
sublingually and is often coformulated with naloxone. It is increasingly used for opioid dependence
treatment. Compared with methadone, buprenorphine has a lower risk of respiratory depression and
overdose. This allows physicians in primary care to prescribe buprenorphine for the treatment of opioid
dependency. The flexibility of the primary care setting can be of significant value to opioid-addicted HIV-
infected patients who require ART because it enables one physician or program to provide both medical and
substance abuse services. Limited information is currently available about interactions between
buprenorphine and ARV agents.13-14 Findings from available studies show that the drug interaction profile of
buprenorphine is more favorable than that of methadone.
Naltrexone and Antiretroviral Therapy. A once-monthly extended-release intramuscular formulation of
naltrexone was recently approved for prevention of relapse in patients who have undergone an opioid
detoxification program. Naltrexone is also indicated for treatment of alcohol dependency. Naltrexone is not
metabolized via the CYP450 enzyme system and is not expected to interact with protease inhibitors (PIs) or
non-nucleoside reverse transcriptase inhibitors (NNRTIs).15
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Currently available pharmacokinetic (PK) interaction data that clinicians can use as a guide for managing
patients receiving ART and methadone or buprenorphine can be found in Tables 19a-d. Particular attention is
needed concerning communication between HIV care providers and drug treatment programs regarding
additive drug toxicities and drug interactions resulting in opiate withdrawal or excess.
Methylenedioxymethamphetamine (MDMA), GHB, ketamine, and methamphetamine all have the potential
to interact with ARV agents because all are metabolized, at least in part, by the CYP450 system. Overdoses
secondary to interactions between the party drugs (i.e., MDMA or GHB) and PI-based ART have been
reported.16
Summary
It is usually possible over time to support most active drug users such that acceptable adherence levels with
ARV agents can be achieved.17-18 Providers must work to combine all available resources to stabilize an
active drug user in preparation for ART. This should include identification of concurrent medical and
psychiatric illnesses, drug treatment and needle and syringe exchange programs, strategies to reduce high-
risk sexual behavior, and harm-reduction strategies. A history of drug use alone is insufficient reason to
withhold ART because individuals with a history of prior drug use have adherence rates similar to those who
do not abuse drugs.
Important considerations in the selection of successful regimens and the provision of appropriate patient
monitoring in this population include need for supportive clinical sites; linkage to substance abuse treatment;
and awareness of the interactions between illicit drugs and ARV agents, including the increased risk of side
effects and toxicities. Simple regimens should be considered to enhance medication adherence. Preference
should be given to ARV agents that have a lower risk of hepatic and neuropsychiatric side effects, simple
dosing schedules, and minimal interaction with methadone.
References 
1.    Colfax G, Guzman R. Club drugs and HIV infection: a review. Clin Infect Dis. May 15 2006;42(10):1463-1469.
2.    Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of
nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J
Med. May 2003;114(7):573-580.
3.    Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy
and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr. Apr 15
2006;41(5):563-572.
4.    Wang C, Vlahov D, Galai N, et al. The effect of HIV infection on overdose mortality. AIDS. Jun 10 2005;19(9):935-942.
5.    Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA.
Aug 12 1998;280(6):547-549.
6.    Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection
drug users. JAMA. Aug 12 1998;280(6):544-546.
7.    Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir
Immune Defic Syndr. Sep 1 2001;28(1):47-58.
8.    Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-
use comorbidities in people infected with HIV who use drugs. Lancet. Jul 31 2010;376(9738):367-387.
9.    Bruce RD, Altice FL, Friedland GH, Volberding P. HIV Disease Among Substance Misusers: Treatment Issues. Global
AIDS/HIV Medicine. San Diego, CA: Elsevier Inc; 2007:513-526.
10.  Morris JD, Golub ET, Mehta SH, Jacobson LP, Gange SJ. Injection drug use and patterns of highly active antiretroviral
therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS Res Ther. 2007;4:12.
Downloaded from http://aidsinfo.nih.gov/guidelines on 9/16/2015
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents                                  I-17
11.  Bouhnik AD, Chesney M, Carrieri P, et al. Nonadherence among HIV-infected injecting drug users: the impact of social
instability. J Acquir Immune Defic Syndr. Dec 15 2002;31(Suppl 3):S149-153.
12.  Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy
over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect
Dis. Sep 15 2007;45(6):770-778.
13.  Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications.
Curr HIV/AIDS Rep. Aug 2010;7(3):152-160.
14.  Bruce RD, McCance-Katz E, Kharasch ED, Moody DE, Morse GD. Pharmacokinetic interactions between
buprenorphine and antiretroviral medications. Clin Infect Dis. Dec 15 2006;43(Suppl 4):S216-223.
15.  Food and Drug Administration (FDA). Vivitrol (package insert). October 2010.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021897s015lbl.pdf.
16.  Bruce RD, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacokinetic drug interactions between drugs of
abuse and antiretroviral medications: Implications and management for clinical practice. Exp Rev of Clin Pharmacol.
2008;1(1):115-127.
17.  Hicks PL, Mulvey KP, Chander G, et al. The impact of illicit drug use and substance abuse treatment on adherence to
HAART. AIDS Care. Oct 2007;19(9):1134-1140.
18.  Cofrancesco J, Jr., Scherzer R, Tien PC, et al. Illicit drug use and HIV treatment outcomes in a US cohort. AIDS. Jan 30
2008;22(3):357-365.
Downloaded from http://aidsinfo.nih.gov/guidelines on 9/16/2015
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents                                  I-18
HIV-Infected Women  (Last updated February 12, 2013; last reviewed February 12, 2013)
This section provides discussion of some basic principles and unique considerations to follow when caring
for HIV-infected women, including during pregnancy. Clinicians who provide care for pregnant women
should consult the current Perinatal Guidelines1 for more in-depth discussion and management assistance.
Additional guidance on the management of HIV-infected women can be found at
http://hab.hrsa.gov/deliverhivaidscare/clinicalguide11.
Gender Considerations in Antiretroviral Therapy
In general, studies to date have not shown gender differences in virologic responses to antritretroviral therapy
(ART),2-4 but a number of studies have suggested that gender may influence the frequency, presentation, and
severity of selected antiretroviral (ARV)-related adverse events.5 Although data are limited, evidence also
exists that pharmacokinetics for some ARV drugs may differ between men and women, possibly because of
variations between men and women in factors such as body weight, plasma volume, gastric emptying time,
plasma protein levels, cytochrome P (CYP) 450 activity, drug transporter function, and excretion activity.6-8
Adverse Effects:
•     Nevirapine (NVP)-associated hepatotoxicity: NVP has been associated with an increased risk of
symptomatic, potentially fatal, and often rash-associated liver toxicity in ARV-naive individuals; women
with higher CD4 counts (>250 cells/mm3) or elevated baseline transaminase levels appear to be at
greatest risk.9-12 It is generally recommended that NVP not be prescribed to ARV-naive women who have
CD4 counts >250 cells/mm3 unless there is no other alternative and the benefit from NVP outweighs the
risk of hepatotoxicity (AI).
Panel’s Recommendations
• The indications for initiation of antiretroviral therapy (ART) and the goals of treatment are the same for HIV-infected women as for
other HIV-infected adults and adolescents (AI).
• Women taking antiretroviral (ARV) drugs that have significant pharmacokinetic interactions with oral contraceptives should use an
additional or alternative contraceptive method to prevent unintended pregnancy (AIII).
• In pregnant women, an additional goal of therapy is prevention of perinatal transmission of HIV, with a goal of maximal viral
suppression to reduce the risk of transmission of HIV to the fetus and newborn (AI).
• When selecting an ARV combination regimen for a pregnant woman, clinicians should consider the known safety, efficacy, and
pharmacokinetic data on use during pregnancy for each agent (AIII). 
• Women of childbearing potential should undergo pregnancy testing before initiation of efavirenz (EFV) and receive counseling about
the potential risk to the fetus and desirability of avoiding pregnancy while on EFV-based regimens (AIII). 
• Alternative regimens that do not include EFV should be strongly considered in women who are planning to become pregnant or
sexually active and not using effective contraception, assuming these alternative regimens are acceptable to the provider and are not
thought to compromise the woman’s health (BIII). 
• Because the risk of neural tube defects is restricted to the first 5 to 6 weeks of pregnancy and pregnancy is rarely recognized before
4 to 6 weeks of pregnancy, EFV can be continued in pregnant women receiving an EFV-based regimen who present for antenatal
care in the first trimester, provided the regimen produces virologic suppression (CIII). 
• When designing a regimen for a pregnant woman, clinicians should consult the most current Health and Human Services (HHS)
Perinatal Guidelines (AIII).
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
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•     Lactic acidosis: There is a female predominance in the increased incidence of symptomatic and even
fatal lactic acidosis associated with prolonged exposure to nucleoside reverse transcriptase inhibitors
(NRTIs). Lactic acidosis is most common with stavudine (d4T), didanosine (ddI), and zidovudine (ZDV)
but it can occur with other NRTIs.13
•     Metabolic complications: A few studies have compared women and men in terms of metabolic
complications associated with ARV use. Compared with HIV-infected men, HIV-infected women are
more likely to experience increases in central fat with ART and are less likely to have triglyceride
elevations on treatment.14, 15 Women have an increased risk of osteopenia/osteoporosis, particularly after
menopause, and this risk is exacerbated by HIV and ART.16, 17 At the present time, none of these
differences requires women-specific recommendations regarding treatment or monitoring.
Women of Childbearing Potential
All women of childbearing potential should be offered pre-conception counseling and care as a component of
routine primary medical care. Counseling should include discussion of special considerations pertaining to
ARV use when trying to conceive and during pregnancy (see Perinatal Guidelines1). Safe sexual practices,
reproductive desires and options for conception, HIV status of sexual partner(s), and use of effective
contraception to prevent unintended pregnancy should be discussed. An HIV-infected woman who wishes to
conceive with an HIV-uninfected male partner should be informed of options to prevent sexual transmission
of HIV while attempting conception. Interventions include initiation of maximally suppressive ART, which
significantly decreases the risk of sexual transmission (see Preventing Secondary Transmission of HIV), and
artificial insemination, including the option to self-inseminate with the partner’s sperm during the
periovulatory period18 (for more extensive discussion on this topic, see the Reproductive Options for HIV-
Concordant and Serodiscordant Couples section of the Perinatal Guidelines.1
Efavirenz (EFV) is teratogenic in non-human primates. Women of childbearing potential should undergo
pregnancy testing before initiation of EFV and receive counseling about the potential risk to the fetus and
desirability of avoiding pregnancy while on EFV-based regimens (AIII). Alternative regimens that do not
include EFV should be strongly considered in women who are planning to become pregnant or who are
sexually active and not using effective contraception, assuming these alternative regimens are acceptable to
the provider and are not thought to compromise the woman’s health (BIII). The most vulnerable period in
fetal organogenesis is early in gestation, before pregnancy is recognized. 
Hormonal Contraception
Safe and effective reproductive health and family planning services to reduce unintended pregnancy and
perinatal transmission of HIV are an essential component of care for HIV-infected women of childbearing
age. Counseling about reproductive issues should be provided on an ongoing basis.
Providers should be aware of potential interactions between ARV drugs and hormonal contraceptives that
could lower contraceptive efficacy. Several protease inhibitors (PIs) and non-nucleoside reverse transcriptase
inhibitors (NNRTIs) have drug interactions with combined oral contraceptives (COCs). Interactions include
either a decrease or an increase in blood levels of ethinyl estradiol, norethindrone, or norgestimate (see
Tables 20a and 20b), which potentially decreases contraceptive efficacy or increases estrogen- or progestin-
related adverse effects (e.g., thromboembolism). Small studies of HIV-infected women receiving injectable
depot-medroxyprogesterone acetate (DMPA) while on ART showed no significant interactions between
DMPA and EFV, NVP, nelfinavir (NFV), or NRTI drugs.19-21 Contraceptive failure of the etonogestrel
implant in two patients on EFV-based therapy has been reported and a study has shown EFV may decrease
plasma progestin concentrations of COCs containing ethinyl estradiol and norgestimate.22, 23 Several RTV-
boosted PIs decrease oral contraceptive estradiol levels.24, 25 A small study from Malawi showed that NVP
use did not significantly affect estradiol or progestin levels in HIV-infected women.26 Overall, data are
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relatively limited and the clinical implications of these findings are unclear. The magnitudes of change in
drug levels that may reduce contraceptive efficacy or increase adverse effects are unknown. Concerns about
pharmacokinetic interactions between oral and implant hormonal contraceptives and ARVs should not
prevent clinicians from prescribing hormonal contraceptives for women on ART if that is their preferred
contraceptive method. However, when women wish to use hormonal contraceptives and drug interactions
with ARVs are known, additional or alternative contraceptive methods may be recommended (see drug
interaction Tables 19a, 19b, and 19d and Perinatal Guidelines1). Consistent use of male or female condoms
to prevent transmission of HIV and protect against other sexually transmitted diseases (STDs) is
recommended for all HIV-infected women and their partners, regardless of contraceptive use.
The data on the association between hormonal contraception and the risk of acquisition of HIV are
conflicting.27 A retrospective secondary analysis of two studies of serodiscordant couples in Africa in which
the HIV-infected partner was not receiving ART found that women using hormonal contraception (the vast
majority using injectable DMPA) had a twofold increased risk of acquiring HIV (for HIV-infected male/HIV-
uninfected female couples) or transmitting HIV (HIV-infected female/HIV-uninfected male couples).
HIV-infected women using hormonal contraception had higher genital HIV RNA concentrations than did
women not using hormonal contraceptives.28 Oral contraceptive use was not significantly associated with
transmission of HIV; however, the number of women using oral contraceptives in this study was insufficient
to adequately assess risk. It is important to note that not all studies have supported a link between hormonal
contraception and transmission or acquisition of HIV and that the individuals in this study were not receiving
ART. Further research is needed to definitively determine if hormonal contraceptive use is an independent
risk factor for acquisition and transmission of HIV, particularly in the setting of ART.27, 29
Intrauterine devices (IUDs) appear to be a safe and effective contraceptive option for HIV-infected women.30-33
Although studies have focused primarily on non-hormone-containing IUDs (e.g., copper IUD), several small
studies have also found levonorgestrel-releasing IUDs to be safe and not associated with increased genital tract
shedding of HIV.31, 34, 35
Pregnant Women
Clinicians should review the Perinatal Guidelines1 for a detailed discussion of the management of HIV-
infected pregnant women. The use of combination ARV regimens is recommended for all HIV-infected
pregnant women, regardless of virologic, immunologic, or clinical parameters (AI). Pregnant HIV-infected
women should be counseled regarding the known benefits and risks of ARV use during pregnancy to the
woman, fetus, and newborn. A woman’s decision regarding ARV use should be respected. Coercive and
punitive approaches undermine provider-patient trust and could discourage women from seeking prenatal
care and adopting health care behaviors that optimize maternal, fetal, and neonatal well-being.
Prevention of Perinatal Transmission of HIV. The use of ARVs and the resultant reduction of HIV RNA
levels decrease perinatal transmission of HIV.36-38 The goal of ARV use is to achieve maximal and sustained
suppression of HIV RNA levels during pregnancy.
As in non-pregnant individuals, genotypic resistance testing is recommended for all pregnant women before
ARV initiation (AIII) and for pregnant women with detectable HIV RNA levels while on therapy (AI).
Optimal prevention of perinatal transmission may require initiation of ARV drugs before results of resistance
testing are available. If results demonstrate the presence of significant mutation(s) that may confer resistance
to the prescribed ARV regimen, the regimen should be modified.
Long-term follow-up is recommended for all infants born to women who have received ARVs during
pregnancy, regardless of the infant’s HIV status (see the Perinatal Guidelines1).
Regimen Considerations. Pregnancy should not preclude the use of optimal drug regimens. Because
recommendations on ARVs to use for treatment of HIV-infected pregnant women are subject to unique
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considerations, recommendations specific to the timing of therapy initiation and the choice of ARVs for pregnant
women may differ from those for non-pregnant individuals. These considerations include the following:
•     Potential changes in pharmacokinetics and, thus, dosing requirements, which result from physiologic
changes associated with pregnancy; 
•     potential ARV-associated adverse effects in pregnant women and the woman’s ability to adhere to a
particular regimen during pregnancy; and
•     potential short- and long-term effects of the ARV on the fetus and newborn, which are unknown for
many drugs.
Combination drug regimens are considered the standard of care in pregnancy, both for the treatment of HIV
infection and for the prevention of perinatal transmission of HIV. Because the risk of neural tube defects is
restricted to the first 5 to 6 weeks of pregnancy and pregnancy is rarely recognized before 4 to 6 weeks of
pregnancy, and unnecessary changes in ARV drugs during pregnancy may be associated with loss of viral
control and increased risk of perinatal transmission, EFV can be continued in pregnant women receiving an
EFV-based regimen who present for antenatal care in the first trimester, provided the regimen produces
virologic suppression (CIII). Detailed recommendations on ARV choice in pregnancy are discussed in detail
in the Perinatal Guidelines (see Perinatal Guidelines1).
Intravenous (IV) zidovudine (ZDV) infusion to the mother during labor is recommended if maternal HIV
RNA is ≥400 copies/mL (or with unknown HIV RNA levels) near delivery, regardless of antepartum regimen
or mode of delivery (AI). Consideration can be given to omitting IV ZDV infusion during labor for HIV-
infected women receiving combination ART regimens who have HIV RNA <400 copies/mL near delivery
(BII); however, the combination ART should continue to be administered during labor. 
Clinicians who are treating HIV-infected pregnant women are strongly encouraged to report cases of prenatal
exposure to ARVs (either administered alone or in combinations) to the Antiretroviral Pregnancy Registry
(http://www.apregistry.com). The registry collects observational data regarding exposure to Food and Drug
Administration-approved ARV drugs during pregnancy for the purpose of assessing potential teratogenicity.
For more information regarding selection and use of ART during pregnancy, refer to the Perinatal
Guidelines.1
Postpartum Management
Following delivery, clinical, immunologic, and virologic follow-up should continue as recommended for
non-pregnant adults and adolescents. Because maternal ART reduces but does not eliminate the risk of
transmission of HIV in breast milk and postnatal transmission can occur despite maternal ART, women
should also be counseled to avoid breastfeeding.1 HIV-infected women should avoid pre-mastication of food
fed to their infants because the practice has been associated with transmission of HIV from mother to child.39
Considerations regarding continuation of ART for maternal therapeutic indications are the same as those for
ART use in other non-pregnant individuals. For more information regarding postpartum discontinuation of
ART, refer to the Perinatal Guidelines.1
Several studies have demonstrated that adherence to ART may worsen in the postpartum period.40-44
Clinicians caring for women postpartum who are receiving ART should specifically address adherence,
including an evaluation of specific facilitators and barriers to adherence. Clinicians may consider an
intervention to improve adherence (see Adherence to Antiretroviral Therapy).
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HIV-2 Infection  (Last updated April 8, 2015; last reviewed April 8, 2015)
HIV-2 infection is endemic in West Africa. Although HIV-2 has had only limited spread outside this area, it
should be considered in persons of West African origin or in those who have had sexual contact or shared
needles with persons of West African origin. The prevalence of HIV-2 infection is also disproportionately
high in countries with strong socioeconomic ties to West Africa (e.g., France; Spain; Portugal; and former
Portuguese colonies such as Brazil, Angola, Mozambique, and parts of India).
Clinical Course of HIV-2 Infection
Compared to HIV-1 infection, the clinical course of HIV-2 infection is generally characterized by a longer
asymptomatic stage, lower plasma HIV-2 viral loads, and lower mortality rate.1,2 However, HIV-2 infection
can also progress to AIDS over time. Concomitant HIV-1 and HIV-2 infection may occur and should be
considered in patients from areas with a high prevalence of HIV-2. 
Diagnosis of HIV-2 Infection
In the appropriate epidemiologic setting, HIV-2 infection should be suspected in patients with clinical
conditions suggestive of HIV infection but with atypical serologic results (e.g., a positive screening assay
with an indeterminate HIV-1 Western blotf3 The possibility of HIV-2 infection should also be considered in
the appropriate epidemiologic setting in patients with serologically confirmed HIV infection but low or
undetectable HIV-1 RNA levels or in those with declining CD4 T lymphocyte (CD4) cell counts despite
apparent virologic suppression on antiretroviral therapy (ART). 
The 2014 Centers for Disease Control and Prevention guidelines for HIV diagnostic testing4 recommend initial
HIV testing using an HIV-1/HIV-2 antigen/antibody combination immunoassay and subsequent testing using
an HIV-1/HIV-2 antibody differentiation immunoassay. The Multispot HIV-1/HIV-2 Rapid Test (Bio-Rad
Laboratories) is Food and Drug Administration approved for differentiating HIV-1 from HIV-2 infection.
Commercially available HIV-1 viral load assays do not reliably detect or quantify HIV-2.5,6 Quantitative HIV-2
plasma RNA viral load testing has recently become available for clinical care at the University of Washington
Summary of HIV-2 Infection
• Compared to HIV-1 infection, the clinical course of HIV-2 infection is generally characterized by a longer asymptomatic stage, lower
plasma HIV-2 RNA levels, and lower mortality; however, progression to AIDS does occur.
• There have been no randomized trials addressing the question of when to start antiretroviral therapy or the choice of initial or
second-line therapy for HIV-2 infection; thus, the optimal treatment strategy has not been defined. 
• Although the optimal CD4 T lymphocyte (CD4) cell count threshold for initiating antiretroviral therapy in HIV-2 infection is unknown,
therapy should be started before there is clinical progression.
• HIV-2 is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and to enfuvirtide; thus, these drugs should not be
included in an antiretroviral regimen for an HIV-2 infected patient.
• Pending more definitive data on outcomes in an antiretroviral therapy -naive patient who has HIV-2 mono-infection or HIV-1/HIV-2
dual infection and requires treatment, an initial antiretroviral therapy regimen for these patients should include two nucleoside
reverse transcriptase inhibitors plus an HIV-2 active boosted protease inhibitor or integrase strand transfer inhibitors.
• A few laboratories now offer quantitative plasma HIV-2 RNA testing for clinical care (see section text).
• Monitoring of HIV-2 RNA levels, CD4 cell counts, and clinical improvements can be used to assess treatment response, as is
recommended for HIV-1 infection.
• Resistance-associated viral mutations to nucleoside reverse transcriptase inhibitors, protease inhibitors, and/or integrase strand
transfer inhibitors may develop in HIV-2 infected patients while on therapy. However, no validated HIV-2 genotypic or phenotypic
antiretroviral resistance assays are available for clinical use.
• In the event of virologic, immunologic, or clinical failure, second-line treatment should be instituted in consultation with an expert in
HIV-2 management.  
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(http://depts.washington.edu/labweb/AboutLM/Contact.htm)7 and the New York State Department of Health
(http://www.wadsworth.org/divisions/infdis/hiv/Diagnostic_HIV_Testing_Services.html).8 However, it is
important to note that approximately one-quarter to one-third of HIV-2-infected patients without ART will have
HIV-2 RNA levels below the limits of detection; some of these patients will have clinical progression and CD4
cell count decline. No validated HIV-2 genotypic or phenotypic antiretroviral (ARV) resistance assays are
available for clinical use. 
Treatment of HIV-2 Infection
To date, no randomized trials addressing the question of when to start ART or the choice of initial or second-
line therapy for HIV-2 infection have been completed;9 thus, the optimal treatment strategy has not been
defined. Three clinical trials to assess first-line ART for HIV-2 infection are currently underway; 2 are enrolling
patients with CD4 counts <500 cells/mm3 (NCT016058090 and NCT02180438) and 1 is enrolling patients with
CD4 count >200 and ≤600 cells/mm3 (NCT02150993). Although the optimal CD4 cell count threshold for
initiating ART in HIV-2 infection is unknown, therapy should be started before there is clinical progression.
HIV-2 is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors (NNRTI)10 and to
enfuvirtide (T20).11 Data from in vitro studies suggest that HIV-2 is sensitive to the currently available
nucleoside reverse transcriptase inhibitors (NRTIs), although with a lower barrier to resistance than HIV-
1.12,13 Darunavir (DRV), lopinavir (LPV), and saquinavir (SQV) are more active against HIV-2 than other
approved protease inhibitors (PIs);14-17 one of these boosted PIs should be used if a PI-based regimen is used.
Other PIs should be avoided because of their lack of ARV activity and high failure rates. The integrase strand
transfer inhibitors (INSTIs) raltegravir (RAL), elvitegravir (EVG), and dolutegravir (DTG) have potent
activity against HIV-2.18-21 The CCR5 antagonist maraviroc (MVC) appears active against some HIV-2
isolates;22 however, no approved assays to determine HIV-2 co-receptor tropism exist and HIV-2 is known to
use many other minor co-receptors in addition to CCR5 and CXCR4.23
Several small studies suggest poor responses in HIV-2 infected individuals treated with some ARV regimens
including dual-NRTI regimens; regimens containing NNRTI plus 2NRTIs; and some unboosted PI-based
regimens including nelfinavir (NFV) or indinavir (IDV) plus zidovudine (ZDV) and lamivudine (3TC); and
atazanavir (ATV)-based regimens.9,24-27 Clinical data on the effectiveness of triple-NRTI regimens are
conflicting.28,29 In general, HIV-2 active, boosted PI-containing regimens have resulted in more favorable
virologic and immunologic responses than 2 or 3-NRTI-based regimens.29-31 However, CD4 cell recovery on
therapy are generally poorer than that observed for HIV-1.31-33 INSTI-based regimens may also have favorable
treatment responses.34,35 A recent large systematic review of ART for HIV-2-infected patients (n = 17 studies,
976 HIV-2 infected patients) was unable to conclude which specific regimens are preferred.36
Resistance-associated viral mutations to NRTIs, PIs and/or INSTIs commonly develop in HIV-2 infected patients
while on therapy.24,29,37-40,41 Currently, HIV-2 transmitted drug resistance appears rare.42 In one small study, DTG
was found to have activity as a second-line INSTI in some HIV-2 patients with extensive ARV experience and
RAL resistance.43 Genotypic algorithms used to predict drug resistance in HIV-1 may not be applicable to HIV-2,
because pathways and mutational patterns leading to resistance may differ between the HIV types.13,29,44
Some groups have recommended specific preferred and alternative regimens for initial therapy of HIV-2
infection;45-48 however, currently, there are no controlled trial data to support the effectiveness of the
recommended regimens. Pending more definitive data on outcomes in an ART-naive patient who has HIV-2
mono-infection or HIV-1/HIV-2 dual infection and requires treatment, a regimen containing two NRTIs plus
an HIV-2 active boosted PI or INSTI should be initiated in HIV-2 infected individuals. 
HIV-2 plasma RNA levels, CD4 cell counts, and clinical improvements can be monitored to assess treatment
response, as is recommended for HIV-1. Patients who have HIV-2 RNA levels below the limits of detection
before therapy should still have HIV-2 plasma RNA monitoring, in addition to CD4 cell count and clinical
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monitoring. In the event of virologic, immunologic, or clinical failure, second-line treatment should be
instituted in consultation with an expert in HIV-2 management.  
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HIV and the Older Patient (Last updated March 27, 2012; last reviewed March 27, 2012)
Effective antiretroviral therapy (ART) has increased survival in HIV-infected individuals, resulting in an
increasing number of older individuals living with HIV infection. In the United States, approximately 30% of
people currently living with HIV/AIDS are age 50 years or older and trends suggest that the proportion of
older persons living with HIV/AIDS will increase steadily.1 Care of HIV-infected patients increasingly will
involve adults 60 to 80 years of age, a population for which data from clinical trials or pharmacokinetic
studies are very limited.
There are several distinct areas of concern regarding the association between age and HIV disease.2 First,
older HIV-infected patients may suffer from aging-related comorbid illnesses that can complicate the
management of HIV infection, as outlined in detail below. Second, HIV disease may affect the biology of
aging, possibly resulting in early manifestations of many clinical syndromes generally associated with
advanced age. Third, reduced mucosal and immunologic defenses (such as post-menopausal atrophic
vaginitis) and changes in risk behaviors (for example, decrease in condom use because of less concern about
pregnancy and increased use of erectile dysfunction drugs) in older adults could lead to increased risk of
acquisition and transmission of HIV.3-4 Finally, because older adults generally are perceived to be at low risk
of HIV infection, screening for HIV in this population remains low. For these reasons, HIV infection in many
older adults may not be diagnosed until late in the disease process. This section focuses on HIV diagnosis
and treatment considerations in the older HIV-infected patient.
HIV Diagnosis and Prevention
Even though many older individuals are engaged in risk behaviors associated with acquisition of HIV, they
may be perceived to be at low risk of infection and, as a result, they are less likely to be tested for HIV than
younger persons.5 According to one U.S. survey, 71% of men and 51% of women age 60 years and older
continue to be sexually active,6 with less concern about the possibility of pregnancy contributing to less
condom use. Another national survey reported that among individuals age 50 years or older, condoms were
not used during most recent intercourse with 91% of casual partners or 70% of new partners.7 In addition,
results from a CDC survey8 show that in 2008 only 35% of adults age 45 to 64 years had ever been tested for
HIV infection despite the 2006 CDC recommendation that individuals age 13 to 64 years be tested at least
once and more often if sexually active.9 Clinicians must be attuned to the possibility of HIV infection in
older patients, including those older than 64 years of age who, based on CDC recommendations, would not
Key Considerations When Caring for Older HIV-Infected Patients
• Antiretroviral therapy (ART) is recommended in patients >50 years of age, regardless of CD4 cell count (BIII), because the risk of
non-AIDS related complications may increase and the immunologic response to ART may be reduced in older HIV-infected patients.
• ART-associated adverse events may occur more frequently in older HIV-infected adults than in younger HIV-infected individuals.
Therefore, the bone, kidney, metabolic, cardiovascular, and liver health of older HIV-infected adults should be monitored closely.
• The increased risk of drug-drug interactions between antiretroviral (ARV) drugs and other medications commonly used in older HIV-
infected patients should be assessed regularly, especially when starting or switching ART and concomitant medications.
• HIV experts and primary care providers should work together to optimize the medical care of older HIV-infected patients with
complex comorbidities.
• Counseling to prevent secondary transmission of HIV remains an important aspect of the care of the older HIV-infected patient.
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
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be screened for HIV. Furthermore, sexual history taking, risk-reduction counseling, and screening for
sexually transmitted diseases (STDs) (if indicated), are important components of general health care for HIV-
infected and -uninfected older patients.
Failure to consider a diagnosis of HIV in older persons likely contributes to later disease presentation and
initiation of ART.10 One surveillance report showed that the proportion of patients who progressed to AIDS
within 1 year of diagnosis was greater among patients >60 years of age (52%) than among patients younger
than 25 years (16%).1 When individuals >50 years of age present with severe illnesses, AIDS-related
opportunistic infections (OIs) need to be considered in the differential diagnosis of the illness.
Initiating Antiretroviral Therapy
Concerns about decreased immune recovery and increased risk of serious non-AIDS events are factors that
favor initiating ART in patients >50 years of age regardless of CD4 cell count (BIII). (See Initiating
Antiretroviral Therapy in Treatment-Naive Patients.) Data that would favor use of any one of the Panel’s
recommended initial ART regimens (see What to Start) on the basis of age are not available. The choice of
regimen should be informed by a comprehensive review of the patient’s other medical conditions and
medications. A noteworthy limitation of currently available information is lack of data on the long-term safety
of specific antiretroviral (ARV) drugs in older patients, such as use of tenofovir disoproxil fumarate (TDF) in
older patients with declining renal function. The recommendations on how frequently to monitor parameters of
ART effectiveness and safety for adults age >50 years are similar to those for the general HIV-infected
population; however, the recommendations for older adults focus particularly on the adverse events of ART
pertaining to renal, liver, cardiovascular, metabolic, and bone health (see Table 15). 
HIV, Aging, and Antiretroviral Therapy
The efficacy, pharmacokinetics, adverse effects, and drug interaction potentials of ART in the older adult
have not been studied systematically. There is no evidence that the virologic response to ART is different in
older patients than in younger patients. However, CD4 T-cell recovery after starting ART generally is less
robust in older patients than in younger patients.11-14 This observation suggests that starting ART at a younger
age will result in better immunologic and possibly clinical outcomes.
Hepatic metabolism and renal elimination are the major routes of drug clearance, including the clearance of
ARV drugs. Both liver and kidney function may decrease with age, which may result in impaired drug
elimination and drug accumulation.15 Current ARV drug doses are based on pharmacokinetic and
pharmacodynamic data derived from studies conducted in subjects with normal organ function. Most clinical
trials include only a small proportion of study participants >50 years of age. Whether drug accumulation in the
older patient may lead to greater incidence and severity of adverse effects than seen in younger patients is
unknown. 
HIV-infected patients with aging-associated comorbidities may require additional pharmacologic
intervention, making therapeutic management increasingly complex. In addition to taking medications to
manage HIV infection and comorbid conditions, many older HIV-infected patients also are taking
medications to ameliorate discomfort (e.g., pain medications, sedatives) or to manage adverse effects of
medications (e.g., anti-emetics). They also may self-medicate with over-the-counter medicines or
supplements. In the HIV-negative population, polypharmacy is a major cause of iatrogenic problems in
geriatric patients.16 This may be the result of medication errors (by prescribers or patients), nonadherence,
additive drug toxicities, and drug-drug interactions. Older HIV-infected patients probably are at an even
greater risk of polypharmacy and its attendant adverse consequences than younger HIV-infected or similarly
aged HIV-uninfected patients.
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Drug-drug interactions are common with ART and easily can be overlooked by prescribers.17 The available
drug interaction information on ARV agents is derived primarily from pharmacokinetic studies performed in
a small number of relatively young, HIV-uninfected subjects with normal organ function (see Tables 18-19b).
Data from these studies provide clinicians with a basis to assess whether a significant interaction may exist.
However, the magnitude of the interaction may be different in older HIV-infected patients than in younger
HIV-infected patients. 
Nonadherence is the most common cause of treatment failure. Complex dosing requirements, high pill
burden, inability to access medications because of cost or availability, limited health literacy including lack
of numeracy skills, misunderstanding of instructions, depression, and neurocognitive impairment are among
the key reasons for nonadherence.18 Although many of these factors likely will be more prevalent in an aging
HIV-infected population, some data suggest that older HIV-infected patients may be more adherent to ART
than younger HIV-infected patients.19-21 Clinicians should assess adherence regularly to identify any factors,
such as neurocognitive deficits, that may make adherence a challenge. One or more interventions such as
discontinuation of unnecessary medications; regimen simplification; or use of adherence tools, including
pillboxes, daily calendars, and evidence-based behavioral approaches may be necessary to facilitate
medication adherence (see Adherence to Antiretroviral Therapy).
Non-AIDS HIV-Related Complications and other Comorbidities
With the reduction in AIDS-related morbidity and mortality observed with effective use of ART, non-AIDS
conditions constitute an increasing proportion of serious illnesses in ART-treated HIV-infected populations.22-24
Heart disease and cancer are the leading causes of death in older Americans.25 Similarly, for HIV-infected
patients on ART, non-AIDS events such as heart disease, liver disease, and cancer have emerged as major
causes of morbidity and mortality. Neurocognitive impairment, already a major health problem in aging
patients, may be exacerbated by the effect of HIV infection on the brain.26 That the presence of multiple non-
AIDS comorbidities coupled with the immunologic effects of HIV infection could add to the disease burden of
an aging HIV-infected person is a concern.27-29 At present, primary care recommendations are the same for
HIV-infected and HIV-uninfected adults and focus on identifying and managing risks of conditions such as
heart, liver, and renal disease; cancer; and bone demineralization.30-32
Discontinuing Antiretroviral Therapy in Older Patients
Important issues to discuss with aging HIV-infected patients are living wills, advance directives, and long-
term care planning including financial concerns. Health care cost sharing (e.g., co-pays, out-of-pocket costs),
loss of employment, and other financial-related factors can cause interruptions in treatment. Clinic systems
can minimize loss of treatment by helping patients maintain access to insurance.
For the severely debilitated or terminally ill HIV-infected patient, adding palliative care medications, while
perhaps beneficial, further increases the complexity and risk of negative drug interactions. For such patients,
a balanced consideration of both the expected benefits of ART and the toxicities and negative quality-of-life
effects of ART is needed. 
Few data exist on the use of ART in severely debilitated patients with chronic, severe, or non-AIDS terminal
conditions.33-34 Withdrawal of ART usually results in rebound viremia and a decline in CD4 cell count. Acute
retroviral syndrome after abrupt discontinuation of ART has been reported. In very debilitated patients, if
there are no significant adverse reactions to ART, most clinicians would continue therapy. In cases where
ART negatively affects quality of life, the decision to continue therapy should be made together with the
patient and/or family members after a discussion on the risks and benefits of continuing or withdrawing ART. 
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Conclusion
HIV infection may increase the risk of many major health conditions experienced by aging adults and
possibly accelerate the aging process.35 As HIV-infected adults age, their health problems become
increasingly complex, placing additional demands on the health care system. This adds to the concern that
outpatient clinics providing HIV care in the United States share the same financial problems as other chronic
disease and primary care clinics and that reimbursement for care is not sufficient to maintain care at a
sustainable level.36 Continued involvement of HIV experts in the care of older HIV-infected patients is
warranted. However, given that the current shortage of primary care providers and geriatricians is projected
to continue, current HIV providers will need to adapt to the shifting need for expertise in geriatrics through
continuing education and ongoing assessment of the evolving health needs of aging HIV-infected patients.37
The aging of the HIV-infected population also signals a need for more information on long-term safety and
efficacy of ARV drugs in older patients.
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Considerations for Antiretroviral Use in Patients with Coinfections
HIV/Hepatitis B Virus (HBV) Coinfection  (Last updated January 10, 2011; last reviewed 
January 10, 2011)
Approximately 5%–10% of HIV-infected persons also have chronic HBV infection, defined as testing
positive for HBsAg for more than 6 months.1 The progression of chronic HBV to cirrhosis, end-stage liver
disease, and/or hepatocellular carcinoma is more rapid in HIV-infected persons than in persons with chronic
HBV alone.2 Conversely, chronic HBV does not substantially alter the progression of HIV infection and does
not influence HIV suppression or CD4 cell responses following ART initiation.3-4 However, several liver-
associated complications that are ascribed to flares in HBV activity, discontinuation of dually active ARVs,
or toxicity of ARVs can affect the treatment of HIV in patients with HBV coinfection.5-7 These include the
following:
•     FTC, 3TC, and TDF are approved ARVs that also have antiviral activity against HBV. Discontinuation of
these drugs may potentially cause serious hepatocellular damage resulting from reactivation of HBV.8
•     Entecavir has activity against HIV; its use for HBV treatment without ART in patients with dual infection
may result in the selection of the M184V mutation that confers HIV resistance to 3TC and FTC.
Therefore, entecavir must be used in addition to a fully suppressive ARV regimen when used in
HIV/HBV-coinfected patients (AII).9
•     3TC-resistant HBV is observed in approximately 40% of patients after 2 years on 3TC for chronic HBV
and in approximately 90% of patients after 4 years when 3TC is used as the only active drug for HBV in
coinfected patients. Therefore, 3TC or FTC should be used in combination with other anti-HBV drugs
(AII).10
Panel’s Recommendations
• Prior to initiation of antiretroviral therapy (ART), all patients who test positive for hepatitis B surface antigen (HBsAg) should be
tested for hepatitis B virus (HBV) DNA using a quantitative assay to determine the level of HBV replication (AIII).
• Because emtricitabine (FTC), lamivudine (3TC), and tenofovir (TDF) have activity against both HIV and HBV, if HBV or HIV
treatment is needed, ART should be initiated with the combination of TDF + FTC or TDF + 3TC as the nucleoside reverse
transcriptase inhibitor (NRTI) backbone of a fully suppressive antiretroviral (ARV) regimen (AI).
• If HBV treatment is needed and TDF cannot safely be used, the alternative recommended HBV therapy is entecavir in addition to
a fully suppressive ARV regimen (BI). Other HBV treatment regimens include peginterferon alfa monotherapy or adefovir in
combination with 3TC or FTC or telbivudine in addition to a fully suppressive ARV regimen (BII).
• Entecavir has activity against HIV; its use for HBV treatment without ART in patients with dual infection may result in the
selection of the M184V mutation that confers HIV resistance to 3TC and FTC. Therefore, entecavir must be used in addition to
a fully suppressive ARV regimen when used in HIV/HBV-coinfected patients (AII).
• Discontinuation of agents with anti-HBV activity may cause serious hepatocellular damage resulting from reactivation of HBV;
patients should be advised against self-discontinuation and carefully monitored during interruptions in HBV treatment (AII).
• If ART needs to be modified due to HIV virologic failure and the patient has adequate HBV suppression, the ARV drugs active
against HBV should be continued for HBV treatment in combination with other suitable ARV agents to achieve HIV
suppression (AIII).
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
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•     Immune reconstitution after initiation of treatment for HIV and/or HBV can be associated with elevation
in transaminases, possibly because HBV is primarily an immune-mediated disease.11
•     Some ARV agents can cause increases in transaminase levels. The rate and magnitude of these increases
are higher with HBV coinfection.12-13 The etiology and consequences of these changes in liver function
tests are unclear because continuation of ART may be accompanied by resolution of the changes.
Nevertheless, some experts suspend the implicated agent(s) when the serum alanine transferase (ALT)
level is increased to 5–10 times the upper limit of normal. However, in HIV/HBV-coinfected persons,
increases in transaminase levels can herald hepatitis B e antigen (HBeAg) seroconversion due to immune
reconstitution, so the cause of the elevations should be investigated prior to the decision to discontinue
medications. In persons with transaminase increases, HBeAg seroconversion should be evaluated by
testing for HBeAg and anti-HBe as well as HBV DNA levels.
Recommendations for HBV/HIV-Coinfected Patients
•     All patients with chronic HBV should be advised to abstain from alcohol, assessed for immunity to
hepatitis A virus (HAV) infection (anti-HAV antibody total) and vaccinated if nonimmune, advised on
methods to prevent HBV transmission (methods that do not differ from those to prevent HIV
transmission), and evaluated for the severity of HBV infection as outlined in the Guidelines for
Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents.14
•     Prior to intiation of ART, all persons who test positive for HBsAg should be tested for HBV DNA using a
quantitative assay to determine the level of HBV replication (AIII). Persons with chronic HBV infection
already receiving ART active against HBV should undergo quantitative HBV DNA testing every 6–12
months to determine the effectiveness of therapy in suppressing HBV replication. The goal of HBV
therapy with NRTIs is to prevent liver disease complications by sustained suppression of HBV
replication to the lowest achievable level.
•     If not yet on therapy and HBV or HIV treatment is needed: In persons without HIV infection, the
recommended anti-HBV drugs for the treatment of persons naive to HBV therapy are TDF and
entecavir.15-16 In HIV-infected patients, however, only TDF can be considered part of the ARV regimen;
entecavir has weak anti-HIV activity and must not be considered part of an ARV regimen. In addition,
only TDF is fully active for the treatment of persons with known or suspected 3TC-resistant HBV
infection. To avoid selection of HBV-resistant variants, when possible, these agents should not be used as
the only agent with anti-HBV activity in an ARV regimen (AIII).
Preferred regimen. The combination of TDF + FTC or TDF + 3TC should be used as the NRTI backbone of
a fully suppressive ARV regimen and for the treatment of HBV infection (AII).17-19
Alternative regimens. If TDF cannot safely be used, entecavir should be used in addition to a fully
suppressive ARV regimen (AII); importantly, entecavir should not be considered to be a part of the ARV
regimen20 (BII). Due to a partially overlapping HBV-resistance pathway, it is not known if the combination
of entectavir + 3TC or FTC will provide additional virologic or clinical benefit compared with entecavir
alone. In persons with known or suspected 3TC-resistant HBV infection, the entecavir dose should be
increased from 0.5 mg/day to 1 mg/day. However, entecavir resistance may emerge rapidly in patients with
3TC-resistant HBV infection. Therefore, entecavir should be used with caution in such patients with frequent
monitoring (~ every 3 months) of the HBV DNA level to detect viral breakthrough. Other HBV treatment
regimens include peginterferon alfa monotherapy or adefovir in combination with 3TC or FTC or telbivudine
in addition to a fully suppressive ARV regimen;17, 21-22 however, data on these regimens in persons with
HIV/HBV coinfection are limited (BII). Due to safety concerns, peginterferon alfa should not be used in
HIV/HBV-coinfected persons with cirrhosis.
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•     Need to discontinue medications active against HBV: The patient’s clinical course should be
monitored with frequent liver function tests. The use of adefovir dipivoxil, entecavir, or telbivudine to
prevent flares, especially in patients with marginal hepatic reserve such as persons with compensated or
decompensated cirrhosis, can be considered.8 These alternative HBV regimens should only be used in
addition to a fully suppressive ARV regimen.
•     Need to change ART because of HIV resistance: If the patient has adequate HBV suppression, the
ARV drugs active against HBV should be continued for HBV treatment in combination with other
suitable ARV agents to achieve HIV suppression (AIII).
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HIV/Hepatitis C Virus Coinfection   (Last updated April 8, 2015; last reviewed April 8, 2015)
The management of hepatitis C virus (HCV)-infected patients is rapidly evolving. Data suggest that
HIV/HCV-coinfected patients treated with all-oral HCV regimens have sustained virologic response rates
comparable to those of HCV-monoinfected patients. The purpose of this section is to discuss hepatic safety
and drug-drug interaction issues related to HIV/HCV coinfection and the concomitant use of antiretroviral
(ARV) agents and HCV drugs. For specific guidance on HCV treatment, please refer to
http://www.hcvguidelines.org/.
Among patients with chronic HCV infection, approximately one-third progress to cirrhosis, at a median time
of less than 20 years.1,2 The rate of progression increases with older age, alcoholism, male sex, and HIV
infection.3-6 A meta-analysis found that HIV/HCV-coinfected patients had a three fold greater risk of
progression to cirrhosis or decompensated liver disease than HCV-monoinfected patients.5 The risk of
progression is even greater in HIV/HCV-coinfected patients with low CD4 T lymphocyte (CD4) cell counts.
Although antiretroviral therapy (ART) appears to slow the rate of HCV disease progression in HIV/HCV-
coinfected patients, several studies have demonstrated that the rate continues to exceed that observed in those
without HIV infection.7,8 Whether HCV infection accelerates HIV progression, as measured by AIDS-related
opportunistic infections (OIs) or death,9 is unclear. Although some older ARV drugs that are no longer
commonly used have been associated with higher rates of hepatotoxicity in patients with chronic HCV
infection,10,11 newer ARV agents currently in use appear to be less hepatotoxic.
For more than a decade, the mainstay of treatment for HCV infection was a combination regimen of
peginterferon and ribavirin (PegIFN/RBV), but this regimen was associated with a poor rate of sustained
virologic response (SVR), especially in HIV/HCV-coinfected patients. Rapid advances in HCV drug
development led to the discovery of new classes of direct acting antiviral (DAA) agents that target the HCV
replication cycle. These new agents, when used with or without PegIFN and RBV, have been shown to
achieve high SVR rates. The first DAA agents approved for the treatment of HCV infection in combination
with PegIFN/RBV were the HCV protease inhibitors (PI), boceprevir and telaprevir. In HCV genotype 1
Panel Recommendations
• All HIV-infected patients should be screened for hepatitis C virus infection (HCV). Patients at high risk of HCV infection should be
screened annually and whenever HCV infection is suspected.
• Antiretroviral therapy may slow the progression of liver disease by preserving or restoring immune function and reducing HIV-related
immune activation and inflammation. For most HIV/HCV-coinfected patients, including those with cirrhosis, the benefits of
antiretroviral therapy outweigh concerns regarding drug-induced liver injury. Therefore, antiretroviral therapy should be initiated in
most HIV/HCV-coinfected patients, regardless of CD4 T lymphocyte (CD4) cell count (BII).
• Initial antiretroviral therapy combination regimens recommended for most HIV/HCV-coinfected patients are the same as those
recommended for individuals without HCV infection. However, when treatment for both HIV and HCV is indicated, the antiretroviral
regimen should be selected with special considerations of potential drug-drug interactions and overlapping toxicities with the HCV
treatment regimen (see discussion in the text below and in Table 12).
• Combined treatment of HIV and HCV can be complicated by drug-drug interactions, increased pill burden, and toxicities. Although
antiretroviral therapy should be initiated for most HIV/HCV-coinfected patients regardless of CD4 cell count, in antiretroviral therapy -
naive patients with CD4 counts >500 cells/mm3 some clinicians may choose to defer antiretroviral therapy until HCV treatment is
completed (CIII).
• In patients with lower CD4 counts (e.g., <200 cells/mm3), antiretroviral therapy should be initiated promptly (AI) and HCV therapy
may be delayed until the patient is stable on HIV treatment (CIII).
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
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infected patients, the combined use of either boceprevir or telaprevir with PegIFN/RBV was associated with
higher rates of SVR than use of PegIFN/RBV alone.12-15 However, combined use of these drugs was
associated with a large pill burden, increased dosing frequency, and adverse effects. Subsequently approved
DAA agents in the same class and in newer classes that are used with or without RBV have higher SVR
rates, reduced pill burden, less frequent dosing, fewer side effects, and shorter durations of therapy.14,16-19
Therefore, the combination of boceprevir or telaprevir and PegIFN/RBV is no longer recommended, and
has been replaced by newer combination regimens. Additional guidance on the treatment and management of
HCV in HIV-infected and uninfected adults can be found at http://www.hcvguidelines.org/.20
Assessment of HIV/Hepatitis C Virus Coinfection
•     All HIV-infected patients should be screened for HCV infection using sensitive immunoassays licensed
for detection of antibody to HCV in blood.21 At risk HCV-seronegative patients should undergo repeat
testing annually. HCV-seropositive patients should be tested for HCV RNA using a sensitive quantitative
assay to confirm the presence of active infection.22,23 Patients who test HCV RNA-positive should
undergo HCV genotyping and liver disease staging as recommended by the most updated HCV
guidelines (see http://www.hcvguidelines.org/).
•     Patients with HIV/HCV coinfection should be counseled to avoid consuming alcohol and to use
appropriate precautions to prevent transmission of HIV and/or HCV to others. HIV/HCV-coinfected
patients who are susceptible to hepatitis A virus (HAV) or hepatitis B virus (HBV) infection should be
vaccinated against these viruses.
•     All patients with HIV/HCV coinfection should be evaluated for HCV therapy. 
Antiretroviral Therapy in HIV/Hepatitis C Virus Coinfection
When to Start Antiretroviral Therapy
The rate of liver disease (liver fibrosis) progression is accelerated in HIV/HCV-coinfected patients,
particularly in individuals with low CD4 counts (≤350 cells/mm3). Data largely from retrospective cohort
studies are inconsistent regarding the effect of ART on the natural history of HCV disease;6,24,25 however,
some studies suggest that ART may slow the progression of liver disease by preserving or restoring immune
function and by reducing HIV-related immune activation and inflammation.26-28 Therefore, ART should be
initiated in most HIV/HCV-coinfected patients, regardless of CD4 count (BII). However, in HIV treatment-
naive patients with CD4 counts >500 cells/mm3, some clinicians may choose to defer ART until HCV
treatment is completed to avoid drug-drug interactions (CIII). Compared to patients with CD4 counts >350
cells/mm3, those with CD4 counts <200 had lower HCV treatment response rates and higher rates of toxicity
due to PegIFN/RBV.29 Data regarding HCV treatment response to combination therapy with DAA agents in
those with advanced immunosuppression is lacking. For patients with lower CD4 counts (e.g., <200
cells/mm3), ART should be initiated promptly (AI) and HCV therapy may be delayed until the patient is
stable on HIV treatment (CIII).23,30-32
Antiretroviral Drugs to Start and Avoid
Initial ARV combination regimens recommended for most HIV treatment-naive patients with HCV are the
same as those recommended for patients without HCV infection. Special considerations for ARV selection in
HIV/HCV-coinfected patients include the folllowing:
•     When both HIV and HCV treatments are indicated, the ARV regimen should be selected with special
considerations of potential drug-drug interactions (see Table 12) and overlapping toxicities with the HCV
treatment regimen.
•     Cirrhotic patients should be carefully evaluated by an expert in advanced liver disease for signs of liver
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decompensation according to the Child-Turcotte-Pugh classification system. This assessment is
necessary because hepatically metabolized ARV and HCV DAA drugs may be contraindicated or require
dose modification in patients with Child-Pugh class B and C disease (see Appendix B, Table 7).
Hepatotoxicity
Drug-induced liver injury (DILI) following the initiation of ART is more common in HIV/HCV-coinfected
patients than in those with HIV monoinfection. The greatest risk of DILI may be observed in coinfected
individuals with advanced liver disease (e.g., cirrhosis, end-stage liver disease).33 Eradication of HCV
infection with treatment may decrease the likelihood of ARV-associated DILI.34
•     Given the substantial heterogeneity in patient populations and drug regimens, comparison of DILI
incidence rates for individual ARV agents across clinical trials is difficult. The incidence of significant
elevations in liver enzyme levels (more than 5 times the upper limit of the normal laboratory reference
range) is low with currently recommended ART regimens. Hypersensitivity (or allergic) reactions
associated with rash and elevations in liver enzymes can occur with certain ARVs. Alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be monitored 2 to 8 weeks
after initiation of ART and every 3 to 6 months thereafter. Mild to moderate fluctuations in ALT and/or
AST are typical in individuals with chronic HCV infection. In the absence of signs and/or symptoms of
liver disease or increases in bilirubin, these fluctuations do not warrant interruption of ART. Patients with
significant ALT and/or AST elevation should be careful evaluated for signs and symptoms of liver
insufficiency and for alternative causes of liver injury (e.g., acute HAV or HBV infection, hepatobiliary
disease, or alcoholic hepatitis). Short-term interruption of the ART regimen or of the specific drug
suspected of causing the DILI may be required.35
Concurrent Treatment of HIV and Hepatitis C Virus Infection
Concurrent treatment of HIV and HCV is feasible but may be complicated by pill burden, drug-drug
interactions, and toxicities. In this context, the stage of HCV disease should be assessed to determine the
medical need for HCV treatment and inform decision making on when to start HCV. Additional guidance on
the treatment and management of HCV in HIV-infected and uninfected adults can be found at
http://www.hcvguidelines.org/. If the decision is to treat HCV, the ART regimen may need to be modified
before HCV treatment is initiated to reduce the potential for drug-drug interactions and/or toxicities that may
develop during the period of concurrent HIV and HCV treatment. (See Table 12 for recommendations on the
concomitant use of selected drugs for treatment of HCV and HIV infection.) In patients with suppressed
plasma HIV RNA and modified ART, HIV RNA should be measured within 4 to 8 weeks after changing HIV
therapy to confirm the effectiveness of the new regimen. After completion of HCV treatment, the modified
ART regimen should be continued for at least 2 weeks before reinitiating the original regimen. Continued use
of the modified regimen is necessary because of the prolonged half-life of some HCV drugs and the potential
risk of drug-drug interactions if a prior HIV regimen is resumed soon after HCV treatment is completed.
Drug-Drug Interaction
Considerations for the concurrent use of ART and recommended HCV agents (per http://hcvguidelines.org/)
are discussed below. Table 12 provides recommendations on the concomitant use of selected drugs for
treatment of HCV and HIV infection.
•     Sofosbuvir is an HCV NS5B nucleotide polymerase inhibitors that is not metabolized by the cytochrome
P450 enzyme system and, therefore, can be used in combination with most ARV drugs. Sofosbuvir is a
substrate of p-glycoprotein (P-gp). P-gp inducers, such as tipranavir (TPV), may decrease sofosbuvir
plasma concentrations and should not be co-administered with sofosbuvir. No other clinicially significant
pharmocokinetic intractions between sofosbuvir and ARVs have been identified. Drug-drug interaction
studies in healthy volunteers did not find any significant interaction between sofosbuvir and
Downloaded from http://aidsinfo.nih.gov/guidelines on 9/16/2015
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents                                   J-8
darunavir/ritonavir (DRV/r), efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), tenofovir disoproxil
fumarate (TDF), or emtricitabine (FTC).36 See Table 12 for recommendations on the concomitant use of
selected drugs for treatment of HCV and HIV infection.
•     Ledipasvir is an HCV NS5A inhibitor and is part of a fixed-dose drug combination of sofosbuvir and
ledipasvir.37 Similar to sofosbuvir, ledipasvir is not metabolized by the cytochrome P450 system (CYP)
of enzymes and is a substrate for P-gp. Ledipasvir is an inhibitor of the drug transporters P-gp and breast
cancer resistance protein (BCRP) and may increase intestinal absorption of coadministered substrates for
these transporters. The use of P-gp inducers is not recommended with ledipasivir/sofosbuvir. The
coadministration of ledipasvir/sofosbuvir and ARV regimens containing TDF is associated with increased
exposure to TDF, especially when TDF is taken with an HIV PI boosted with either RTV or cobicistat
(COBI) (see Table 12 for recommendations on the concomitant use of selected drugs for treatment of
HCV and HIV infection). In some patients, alternative HCV or ARV drugs should be considered to avoid
increases in TDF exposures. If the drugs are co-administered, the patient should be monitored for
potential TDF-associated renal injury by assessing measurements of renal function (i.e., estimated
creatinine clearance, serum phosphorus, urine glucose, and urine protein) before HCV treatment
initiation and periodically during treatment. 
•     The fixed-dose drug combination of ombitasvir (a NS5A inhibitor), paritaprevir (an HCV PI), and RTV
(a pharmacokinetic enhancer) is co-packaged and used in combination with dasabuvir, an NS5B
inhibitor.38 Paritaprevir is a substrate and inhibitor of the CYP3A4 enzymes and therefore may have
significant interactions with certain ARVs that are metabolized by, or may induce or inhibit the same
pathways. Dasabuvir is primarily metabolized by the CYP2C8 enzymes. Furthermore, ombitasvir,
paritaprevir, and dasabuvir are inhibitors of UGT1A1 and also substrates of P-gp and BCRP. Paritaprevir
is also a substrate and inhibitor of OATP1B1/3. Coadministration with drugs that are substrates or
inhibitors of these enzymes and drug transporters may result in increased plasma concentrations of either
the coadministered drug or the HCV drugs. Given that several CYP enzymes and drug transporters are
involved in the metabolism of dasabuvir, ombitasvir, paritaprevir, and RTV, complex drug-drug
interactions are likely. Therefore clinicians need to consider all coadministered drugs for potential drug-
drug interactions. No significant drug-drug interactions have been found when dasabuvir, ombitasvir,
paritaprevir, and RTV are used in conjunction with ATV or RAL. When either RTV or COBI is used in
conjunction with ATV, the boosting agent should be discontinued during HCV therapy and ATV should
be taken in the morning at the same time as ombitasvir, paritaprevir/r, and dasabuvir. RTV or COBI
should be restarted after completion of HCV treatment. See Table 12 for other recommendations for
concomitmant use of HCV drugs with ARVs. HIV-infected patients not on ART should be placed on an
alternative HCV regimen because RTV has activity against HIV.
•     Simeprevir is a HCV NS3/4A PI that has been studied in HIV/HCV-coinfected patients.39 Simeprevir is a
substrate and inhibitor of CYP3A4 and P gp enzymes, and therefore may have significant interactions
with certain ARVs that are metabolized by the same pathways. Simeprevir is also an inhibitor of the drug
transporter OATP1B1/3. On the basis of drug-drug interaction studies in healthy volunteers, simeprevir
can be coadministered with RAL, DTG, RPV, and TDF.40 However, coadministration of simeprevir with
EFV, ETR, HIV PIs, COBI, or EVG/c/TDF/FTC is not recommended. (See Table 12 for
recommendations on the concomitant use of selected drugs for treatment of HCV and HIV infection.)
Given that the treatment of HCV is rapidly evolving, this section will be updated when new HCV drugs are
approved that may have an impact on the treatment of HIV. For guidance on the treatment of HCV infection,
refer to http://www.hcvguidelines.org/. 
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Table 12. Concomitant Use of Selected HIV Drugs and FDA-Approved HCV Drugs for Treatment of
HCV in HIV-Infected Adults  (page 1 of 3)
Recommendations in this table are based on available pharmacokinetics interaction data or predictions based
on the known metabolic pathways of the HIV and HCV drugs. Whenever HIV and HCV drugs are used
concomitantly, patients should be closely monitored for HIV and HCV virologic efficacy and potential
toxicities. Given that the field of HCV therapy is rapidly evolving, clinicians should also refer to the latest
drug product labels and HCV guidelines (www.hcvguidelines.org/) for updated information.  
HCV DAA drugs
HCV Non-DAA Drugs
Selected
HIV Drugs
NS5B
Inhibitor
Coformulated
NS5A/NS5B
Inhibitor
HCV
Protease
Inhibitora
Sofosbuvir Ledipasvir/Sofosbuvir Simeprevir Ribavirin
Pegylated
Interferon
alpha 
NRTIs
3TC ü ü ü ü ü ü
ABC ü ü ü ü ü ü
FTC ü ü ü ü ü ü
TDF ü !ü!
Monitor for TDF toxicity
ü ü ü ü
ZDV ü ü ü ü ûc ûd
PIs
ATV
(Unboosted)
ü ü ü
Reduce ATV dose to 300 mg
and take in AM at same time as
(ombitasvir/paritaprevir/r plus
dasabuvir).
If RTV cannot be used, choose an
alternative HCV regimen.
û ü ü
ATV/r
or
ATV/c
ü
ü
If PI/r [or ATV/c, DRV/c]
is used with TDF, ↑
TDF concentrations
are expected. If
coadministration
necessary, monitor for
TDF-associated
toxicities (see
footnotee)
ü
Take ATV 300 mg in AM at same
time as (ombitasvir/paritaprevir
/r plus dasabuvir); discontinue
RTV or COBI in HIV regimen
until HCV therapy completed.
û ü ü
DRV/r
or
DRV/c
ü û û ü ü
FPV
or
FPV/r
ü û û ü ü
LPV/r ü û û ü ü
SQV/r ü û û ü ü
Coformulated NS5A/HCV
PI Plus NS5B Inhibitor
Ombitasvir/Paritaprevir/
Ritonavir Plus Dasabuvirb
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Table 12. Concomitant Use of Selected HIV Drugs and FDA-Approved HCV Drugs for Treatment of
HCV in HIV-Infected Adults  (page 2 of 3)
HCV DAA drugs
HCV Non-DAA Drugs
Selected
HIV Drugs
NS5B
Inhibitor
Coformulated
NS5A/NS5B
Inhibitor
HCV
Protease
Inhibitora
Sofosbuvir Ledipasvir/Sofosbuvir Simeprevir Ribavirin
Pegylated
Interferon
alpha 
PIs, continued
TPV/r û û û û ü ü
EFV ü ü
If EFV used with
TDF/FTC, monitor for
TDF toxicity due to ↑
TDF concentrations
û û ü ü
ETR ü ü û û ü ü
NVP ü ü û û ü ü
RPV ü ü û ü ü ü
INSTIs
DTG ü ü ? ü ü ü
EVG/c/
TDF/FTC
ü û û û ü ü
EVG (plus
PI/r Without
COBI)
Refer to recommendations specific to each PI/r.
RAL ü ü ü ü ü ü
CCR5 Antagonist
MVC ü ü û ü ü ü
ü = ARV agents that can be used concomitantly
û = ARV agents not recommended
? = Data on PK interactions with the ARV drug are unavailable or insufficient to make a recommendation. 
a Boceprevir is no longer recommended for HCV treatment and telaprevir is no longer available in the United States; therefore, these
products have been removed from this table.
b Dasabuvir must be prescribed with ombitasvir/paritaprevir/ritonavir.
c Concomitant use of ZDV with ribavirin is not recommended given the potential for worsening anemia. 
d Concomitant use of ZDV with pegylated interferon is not recommended given the potential for worsening neutropenia
e Consider alternative HCV or ARV therapy to avoid increases in TDF exposures. If coadministration is necessary, monitor for TDF-
associated adverse reactions
NNRTIs
Coformulated NS5A/HCV
PI Plus NS5B Inhibitor
Ombitasvir/Paritaprevir/
Ritonavir Plus Dasabuvirb
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Mycobacterium Tuberculosis Disease with HIV Coinfection  (Last updated March 27, 2012;
last reviewed March 27, 2012)
Treatment of Active Tuberculosis in HIV-Infected Patients
HIV infection significantly increases the risk of progression from latent to active TB disease. The CD4 cell
count influences both the frequency and severity of active TB disease.1-2 Active TB also negatively affects
HIV disease. It may be associated with a higher HIV viral load and more rapid progression of HIV disease.3
Active pulmonary or extrapulmonary TB disease requires prompt initiation of TB treatment. The treatment of
active TB disease in HIV-infected patients should follow the general principles guiding treatment for
Panel’s Recommendations
• The principles for treatment of active tuberculosis (TB) disease in HIV-infected patients are the same as those for HIV-uninfected
patients (AI).
• All HIV-infected patients with diagnosed active TB should be started on TB treatment immediately (AI).
• All HIV-infected patients with diagnosed active TB should be treated with antiretroviral therapy (ART) (AI).
• In patients with CD4 counts <50 cells/mm3, ART should be initiated within 2 weeks of starting TB treatment (AI).
• In patients with CD4 counts ≥50 cells/mm3 who present with clinical disease of major severity as indicated by clinical evaluation
(including low Karnofsky score, low body mass index [BMI], low hemoglobin, low albumin, organ system dysfunction, or extent of
disease), ART should be initiated within 2 to 4 weeks of starting TB treatment. The strength of this recommendation varies on the
basis of CD4 cell count:
• CD4 count 50 to 200 cells/mm3 (BI)
• CD4 count >200 cells/mm3 (BIII)
• In patients with CD4 counts ≥50 cells/mm3 who do not have severe clinical disease, ART can be delayed beyond 2 to 4 weeks of
starting TB therapy but should be started within 8 to 12 weeks of TB therapy initiation. The strength of this recommendation also
varies on the basis of CD4 cell count:
• CD4 count 50 to 500 cells/mm3 (AI)
• CD4 count >500 cells/mm3 (BIII)
• In all HIV-infected pregnant women with active TB, ART should be started as early as feasible, both for maternal health and for
prevention of mother-to-child transmission (PMTCT) of HIV (AIII).
• In HIV-infected patients with documented multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, ART should be initiated within
2 to 4 weeks of confirmation of TB drug resistance and initiation of second-line TB therapy (BIII).
• Despite pharmacokinetic drug interactions, a rifamycin (rifampin or rifabutin) should be included in TB regimens for patients receiving
ART, with dosage adjustment if necessary (AII).
• Rifabutin is the preferred rifamycin to use in HIV-infected patients with active TB disease on a protease inhibitor (PI)-based regimen
because the risk of substantial drug interactions with PIs is lower with rifabutin than with rifampin (AII).
• Coadministration of rifampin and PIs (with or without ritonavir [RTV] boosting) is not recommended (AII).
• Rifapentine (RPT) is NOT recommended in HIV-infected patients receiving ART for treatment of latent TB infection (LTBI) or active
TB, unless in the context of a clinical trial (AIII). 
• Immune reconstitution inflammatory syndrome (IRIS) may occur after initiation of ART. Both ART and TB treatment should be
continued while managing IRIS (AIII).
• Treatment support, which can include directly observed therapy (DOT) of TB treatment, is strongly recommended for HIV-infected
patients with active TB disease (AII).
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = Expert opinion
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individuals without HIV (AI). Treatment of drug-susceptible TB disease should include a standard regimen
that consists of isoniazid (INH) + a rifamycin (rifampin or rifabutin) + pyrazinamide + ethambutol given for
2 months, followed by INH + a rifamycin for 4 to 7 months.4 The Guidelines for Prevention and Treatment of
Opportunistic Infections in HIV-Infected Adults and Adolescents4 include a more complete discussion of the
diagnosis and treatment of TB disease in HIV-infected patients.
All patients with HIV/TB disease should be treated with ART (AI). Important issues related to the use of
ART in patients with active TB disease include: (1) when to start ART, (2) significant pharmacokinetic drug-
drug interactions between rifamycins and some antiretroviral (ARV) agents, (3) the additive toxicities
associated with concomitant ARV and TB drug use, (4) the development of TB-associated IRIS after ART
initiation, and (5) the need for treatment support including DOT and the integration of HIV and TB care and
treatment.
Antiretroviral Therapy in Patients with Active Tuberculosis
Patients Diagnosed with Tuberculosis While Receiving Antiretroviral Therapy
When TB is diagnosed in a patient receiving ART, the patient’s ARV regimen should be assessed with
particular attention to potential pharmacokinetic interactions with rifamycins (discussed below). The
patient’s regimen may need to be modified to permit use of the optimal TB treatment regimen (see Tables
17–19 for dosing recommendations).
Patients Not Yet Receiving Antiretroviral Therapy
Until recently, when to start ART in patients with active TB has been a subject of debate. Survival is
improved when ART is started early following initiation of TB therapy, but a delay in initiating ART often
was favored because of the potential complications of high pill burden, additive toxicities, drug interactions,
adherence, and the potential for development of IRIS.Recent studies primarily conducted in resource-limited
settings, including three randomized controlled trials, have helped clarify the question of when to start ART
in patients with active TB.5-8
The SAPiT study conducted in South Africa convincingly demonstrated that starting ART during rather than
after concluding treatment for TB can significantly reduce mortality. In this study, ambulatory HIV-infected
patients with smear-positive TB and CD4 counts <500 cells/mm3 were randomized to one of three treatment
arms: integrated therapy with ART initiated either during the first 4 weeks of TB therapy or after the first 8
weeks of TB treatment (i.e., during the continuation phase of TB therapy) or sequential therapy with ART
initiated after the conclusion of standard TB therapy. The median CD4 cell count of participants at study
entry was 150 cells/mm3. The sequential therapy arm was stopped when an early analysis demonstrated that
the mortality rate in the combined two integrated arms was 56% lower than the rate in the sequential therapy
arm. Treatment was continued in the two integrated arms until study completion.5
With the completion of SAPiT and 2 other randomized controlled trials, CAMELIA and STRIDE, the question
on the optimal time to initiate ART during TB therapy has been addressed. Findings from these trials now serve
as the basis for the Panel’s recommendations on when to start ART in patients with active TB. 
In the final analysis of the SAPiT trial, there were no differences in rates of AIDS or death between the 2
integrated arms of the study (patients who started ART within 4 weeks after initiating TB treatment vs. those
who started ART at 8–12 weeks [i.e., within 4 weeks after completing the intensive phase of TB treatment]).
However, in patients with baseline CD4 counts <50 cells/mm3 (17% of the study population), the rate of AIDS
or death was lower in the earlier therapy group than in the later therapy group (8.5 vs. 26.3 cases per 100
person-years, a strong trend favoring the earlier treatment arm, P = 0.06). For all patients, regardless of CD4
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cell count, earlier therapy was associated with a higher incidence of IRIS and of adverse events that required a
switch in ARV drugs than later therapy. Two deaths were attributed to IRIS.6
In the CAMELIA study, which was conducted in Cambodia7, patients who had CD4 counts <200 cells/mm3
were randomized to initiate ART at 2 weeks or 8 weeks after initiation of TB treatment. Study participants had
advanced HIV disease, with a median entry CD4 count of 25 cells/mm3; low BMIs (median = 16.8 kg/m2),
Karnofsky scores (87% <70), and hemoglobin levels (median = 8.7 g/dl); and high rates of disseminated TB
disease. Compared with therapy initiated at 8 weeks, ART initiated at 2 weeks resulted in a 38% reduction in
mortality (P = 0.006). A significant reduction in mortality was seen in patients with CD4 counts ≤50 cells/mm3
and in patients with CD4 counts 51 to 200 cells/mm3. Overall, 6 deaths associated with TB-IRIS were reported. 
The ACTG 5221 (STRIDE) trial, a multinational study conducted at 28 sites, randomized ART-naive patients
with confirmed or probable TB and CD4 counts <250 cells/mm3 to earlier (<2 weeks) or later (8–12 weeks)
ART.8 At study entry, the participants’ median CD4 count was 77 cells/mm3. The rates of mortality and AIDS
diagnoses were not different between the earlier and later arms, although higher rates of IRIS were seen in the
earlier arm. However, a significant reduction in AIDS or death was seen in the subset of patients with CD4
counts <50 cells/mm3 who were randomized to the earlier ART arm (P = 0.02). 
In each of these 3 studies, IRIS was more common in patients initiating ART earlier than in patients starting
ART later, but the syndrome was infrequently associated with mortality. Collectively these 3 trials demonstrate
that in patients with active TB and with very low CD4 cell counts (i.e., <50 cells/mm3), early initiation of ART
can reduce mortality and AIDS progression, albeit at the risk of increased IRIS. These findings strongly favor
initiation of ART within the first 2 weeks of TB treatment in patients with CD4 cell counts <50 cells/mm3 (AI).
The question of when to start ART in patients with CD4 counts ≥50 cells/mm3 is also informed by these
studies. The STRIDE and SAPiT studies—in which the patients with CD4 cell counts ≥50 cells/mm3 were
relatively healthy and with reasonable Karnofsky scores (note the SAPiT study excluded patients with
Karnofsky scores <70) and BMIs—demonstrated that ART initiation in these patients can be delayed until 8
to 12 weeks after initiation of TB therapy (AI for CD4 counts 51–500 cells/mm3 and BIII for CD4 counts
>500 cells/mm3).
However, the CAMELIA study, which included more patients who were severely ill than the STRIDE and
SAPiT studies, showed that early initiation of ART improved survival both in patients with CD4 counts ≤50
cells/mm3 and in patients with CD4 counts from 51 to 200 cells/mm3. In a multivariate analysis, age >40
years, low BMI (<16), low Karnofsky score (<40), elevated aspartate aminotransferase (AST) level (>1.25 x
the upper limit of normal [ULN]), disseminated and MDR TB were independently associated with poor
survival; whereas in a univariate analysis, hemoglobin <10g/dl also was associated with poor survival. 
Thus, recently published results from the three clinical trials are complementary in defining the need for ART
and use of CD4 count and clinical status to inform decisions on the optimal time to initiate ART in patients
with HIV and TB disease. Earlier initiation of ART within 2 to 4 weeks of TB treatment should be strongly
considered for patients with CD4 cell counts from 50 to 200 cells/mm3 who have evidence of clinical disease
of major severity as indicated by clinical evaluation, low Karnofsky score, low BMI, low hemoglobin, low
albumin, or organ system dysfunction (BI). Initiation of ART within 2 to 4 weeks also should be considered
for patients with CD4 counts >200 cells/mm3 who present with evidence of severe disease (BIII).
Of additional importance, each of the above studies demonstrated excellent responses to ART, with 90% and
>95% of participants achieving suppressed viremia (HIV RNA <400 copies/mL) at 12 months in the SAPiT
and CAMELIA studies, respectively, and 74% of participants at 2 years in the STRIDE study. 
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Mortality rates in patients with MDR or XDR TB and HIV coinfection are very high.9 Retrospective case control
studies and case series provide growing evidence of better outcomes associated with receipt of ART in such
coinfected patients,10 but the optimal timing for initiation of ART is unknown. However, given the high rates and
rapid mortality, most experts recommend that ART be initiated within 2 to 4 weeks after confirmation of the
diagnosis of drug resistance and initiation of second-line TB therapy (BIII).
All HIV-infected pregnant women with active TB should be started on ART as early as feasible, both for
maternal health and to prevent perinatal transmission of HIV (AIII). The choice of ART should be based on
efficacy and safety in pregnancy and take into account potential drug-drug interactions between ARVs and
rifamycins (see Perinatal Guidelines for more detailed discussions).11
TB meningitis often is associated with severe complications and high mortality rate. In a randomized study
conducted in Vietnam, patients were randomized to immediate ART or to therapy deferred until 2 months
after initiation of TB treatment. A higher rate of severe (Grade 4) adverse events was seen in patients who
received immediate ART than in those who deferred therapy (80.3% vs. 69.1%, respectively; P = 0.04).12 In
this study 59.8% of the immediate ART patients and 55.5% of the delayed ART patients died within 9
months. However, in the United States, where patients may be more closely monitored and treated for severe
adverse events such as central nervous system (CNS) IRIS, many experts feel that ART should be initiated as
for other HIV/TB-coinfected patients (CIII).
Drug Interaction Considerations
A rifamycin is a crucial component in treatment of drug-sensitive TB. However, both rifampin and rifabutin
are inducers of the hepatic cytochrome P (CYP) 450 and uridine diphosphate gluconyltransferase (UGT) 1A1
enzymes and are associated with significant interactions with most ARV agents including all PIs, non-
nucleoside reverse transcriptase inhibitors (NNRTIs), maraviroc (MVC), and raltegravir (RAL). Rifampin is
a potent enzyme inducer, leading to accelerated drug clearance and significant reduction in ARV drug
exposure. Despite these interactions, some observational studies suggest that good virologic, immunologic,
and clinical outcomes may be achieved with standard doses of efavirenz (EFV)13-14 and, to a lesser extent,
nevirapine (NVP)15-16 when combined with rifampin. However, rifampin is not recommended in combination
with all PIs and the NNRTIs etravirine (ETR) and rilpivirine (RPV). When rifampin is used with MVC or
RAL, increased dosage of the ARV is generally recommended. Rifabutin, a weaker enzyme inducer, is an
alternative to rifampin. Because rifabutin is a substrate of the CYP 450 enzyme system, its metabolism may
be affected by the NNRTI or PI. Tables 18, 19a, 19b, 19d, and 19e outline the magnitude of these interactions
and provide dosing recommendations when rifamycins and selected ARV drugs are used concomitantly. After
determining the drugs and doses to use, clinicians should monitor patients closely to assure good control of
both TB and HIV infections. Suboptimal HIV suppression or suboptimal response to TB treatment should
prompt assessment of drug adherence, subtherapeutic drug levels (consider therapeutic drug monitoring
[TDM]), and acquired drug resistance.
Rifapentine is a long-acting rifamycin that can be given once weekly with INH for the treatment of active or
latent TB infection. Similar to rifampin and rifabutin, rifapentine is also a CYP3A4 inducer. No systematic
study has been performed to assess the magnitude of the enzyme induction effect of rifapentine on the
metabolism of ARV drugs and other concomitant drugs. Significant enzyme induction can result in reduced
ARV drug exposure, which may compromise virologic efficacy. Rifapentine is not recommended for
treatment of latent or active TB infection in patients receiving ART, unless given in the context of a clinical
trial (AIII).  
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Anti-Tuberculosis/Antiretroviral Drug Toxicities
ARV agents and TB drugs, particularly INH, rifamycin, and pyrazinamide, can cause drug-induced hepatitis.
These first-line TB drugs should be used for treatment of active TB disease, even with coadministration of
other potentially hepatotoxic drugs or when baseline liver disease is present (AIII). Patients receiving
potentially hepatotoxic drugs should be monitored frequently for clinical symptoms and signs of hepatitis and
have laboratory monitoring for hepatotoxicity. Peripheral neuropathy can occur with administration of INH,
didanosine (ddI), or stavudine (d4T) or may be a manifestation of HIV infection. All patients receiving INH
also should receive supplemental pyridoxine to reduce peripheral neuropathy. Patients should be monitored
closely for signs of drug-related toxicities and receive alternative ARVs to ddI or d4T.
Immune Reconstitution Inflammatory Syndrome with Tuberculosis and Antiretroviral
Agents
IRIS occurs in two forms: unmasking and paradoxical. The mechanism of the syndrome is the same for both
forms: restoration of immune competence by administration of ART, resulting in an exuberant host response to
TB bacilli and/or antigens. Unmasking IRIS refers to the initial clinical manifestations of active TB that occurs
soon after ART is started. Paradoxical IRIS refers to the worsening of TB clinical symptoms after ART is started
in patients who are receiving TB treatment. Severity of IRIS ranges from mild to severe to life threatening. IRIS
has been reported in 8% to more than 40% of patients starting ART after TB is diagnosed, although the
incidence depends on the definition of IRIS and the intensity of monitoring.17-18
Predictors of IRIS include CD4 count <50 cells/mm3; higher on-ART CD4 counts; high pre-ART and lower
on-ART HIV viral loads; severity of TB disease, especially high pathogen burden; and less than 30-day
interval between initiation of TB and HIV treatments.19-22 Most IRIS in HIV/TB disease occurs within 3
months of the start of TB treatment. Delaying initiation of ART for 2 to 8 weeks may reduce the incidence
and severity of IRIS. However, this possible advantage of delayed ART must be weighed against the
potential benefit of earlier ART in improving immune function and preventing progression of HIV disease
and mortality.
Patients with mild or moderately severe IRIS can be managed symptomatically or treated with nonsteroidal
anti-inflammatory agents. Patients with more severe IRIS can be treated successfully with corticosteroids. A
recent randomized, placebo-controlled trial demonstrated benefit of corticosteroids in the management of
IRIS symptoms (as measured by decreasing days of hospitalization and Karnofsky performance score)
without adverse consequences.23 In the presence of IRIS, neither TB therapy nor ART should be stopped
because both therapies are necessary for the long-term health of the patient (AIII).
Immune Reconstitution with Antiretroviral Therapy: Conversion to Positive Tuberculin
Skin Test and Interferon-Gamma Release Assay
Immune reconstitution with ART may result in unmasking LTBI (i.e., conversion of a previously negative
tuberculin skin test [TST] to a positive TST or a positive interferon-gamma [IFN-γ] release assay [IGRA] for
Mycobacterium tuberculosis-specific proteins). A positive IGRA, similar to a positive TST, is indicative of
LTBI in the absence of evidence of active TB disease.24 Because treatment for LTBI is indicated in the absence
of evidence of active TB disease, clinicians should be aware of this phenomenon. Patients with a negative TST
or IGRA and advanced HIV disease (i.e., CD4 count <200 cells/mm3) should have a repeat TST or IGRA after
initiation of ART and CD4 count increase to >200 cells/mm3 (BII).25
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Caring for Patients with HIV and Tuberculosis
Close collaboration among clinicians, health care institutions, and public health programs involved in the
diagnosis and treatment of HIV-infected patients with active TB disease is necessary in order to integrate
care and improve medication adherence and TB treatment completion rates, reduce drug toxicities, and
maximize HIV outcomes. HIV-infected patients with active TB disease should receive treatment support,
including adherence counseling and DOT, corresponding to their needs (AII). ART simplification or use of
coformulated fixed-dose combinations also may help to improve drug adherence.
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Limitations to Treatment Safety and Efficacy
Adherence to Antiretroviral Therapy  (Last updated May 1, 2014; last reviewed May 1, 2014)
Strict adherence to antiretroviral therapy (ART) is key to sustained HIV suppression, reduced risk of drug
resistance, improved overall health, quality of life, and survival,1,2 as well as decreased risk of HIV
transmission.3 Conversely, poor adherence is the major cause of therapeutic failure. Achieving adherence to ART
is a critical determinant of long-term outcome in HIV infected patients. For many chronic diseases, such as
diabetes or hypertension, drug regimens remain effective even after treatment is resumed following a period of
interruption. In the case of HIV infection, however, loss of virologic control as a consequence of non-adherence
to ART may lead to emergence of drug resistance and loss of future treatment options. Many patients initiating
ART or already on therapy are able to maintain consistent levels of adherence with resultant viral suppression,
CD4+ T-lymphocyte (CD4) count recovery, and improved clinical outcomes. Others, however, have poor
adherence from the outset of ART and/or experience periodic lapses in adherence over the lifelong course of
treatment. Identifying those with adherence-related challenges that require attention and implementing
appropriate strategies to enhance adherence are essential roles for all members of the treatment team.
Recent data underscore the importance of conceptualizing treatment adherence broadly to include early
engagement in care and sustained retention in care. The concept of an HIV “treatment cascade” has been
used to describe the process of HIV testing, linkage to care, initiation of effective ART, adherence to
treatment, and retention in care. The U.S. Centers for Disease Control and Prevention estimates that only
36% of the people living with HIV in the United States are prescribed ART and that among these individuals,
only 76% have suppressed viral loads.4 Thus, to achieve optimal clinical outcomes and to realize the
potential public health benefit of treatment as prevention, attention to each step in the treatment cascade is
critical.5 Therefore, provider skill and involvement to retain patients in care and help them achieve high
levels of medication adherence are crucial. 
This section provides updated guidance on assessing and monitoring adherence and outlines strategies to
help patients maintain high levels of adherence. 
Factors Associated with Adherence Success and Failure
Adherence to ART can be influenced by a number of factors, including the patient’s social situation and
clinical condition; the prescribed regimen; and the patient-provider relationship.6 It is critical that each
patient receives and understands information about HIV disease including the goals of therapy (achieving
and maintaining viral suppression, decreasing HIV-associated morbidity and mortality, and preventing sexual
transmission of HIV), the prescribed regimen (including dosing schedule and potential side effects), the
importance of strict adherence to ART, and the potential for the development of drug resistance as a
consequence of suboptimal adherence. However, information alone is not sufficent to assure high levels of
adherence; patients must also be positively motivated to initiate and maintain therapy.
From a patient perspective, nonadherence is often a consequence of one or more behavioral, structural, and
psychosocial barriers (e.g., depression and other mental illnesses, neurocognitive impairment, low health
literacy, low levels of social support, stressful life events, high levels of alcohol consumption and active
substance use, homelessness, poverty, nondisclosure of HIV serostatus, denial, stigma, and inconsistent
access to medications).7-9 Furthermore, patient age may affect adherence. For example, some adolescent and
young adult HIV patients, in particular, have substantial challenges in achieving levels of adherence
necessary for successful therapeutic outcomes (see HIV-Infected Adolescents section).10,11 In additon, failure
to adopt practices that facilitate adherence, such as linking medication taking to daily activities or using a
medication reminder system or a pill organizer, is also associated with treatment failure.12
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Characteristics of one or more components of the prescribed regimen can affect adherence. Simple, once-
daily regimens,13 including those with low pill burden, without a food requirement, and few side effects or
toxicities, are associated with higher levels of adherence.14,15 Many currently available ARV regimens are
much easier to take and better tolerated than older regimens. Studies have shown that patients taking once-
daily regimens have higher rates of adherence than those taking twice-daily dosing regimens.15 However,
data to support or refute the superiority of fixed-dose combination product of 1-pill versus 3-pills (of
individual drug products), once-daily regimens—as might be required for the use of some soon-to-be-
available generic-based ARV regimens—are limited.
Characteristics of the clinical setting can also have important structural influences on the success or failure of
medication adherence. Settings that provide comprehensive multidisciplinary care (e.g., with case managers,
pharmacists, social workers, psychiatric care providers) are often more successful in supporting patients’
complex needs, including their medication adherence-related needs. Further, specific settings, such as prisons
and other institutional settings, may thwart or support medication adherence. Drug abuse treatment programs
are often best suited to address substance use that may confound adherence and may offer services, such as
directly observed therapy, that promote adherence.
Finally, a patient-provider relationship that enhances patient trust through non-judgmental and supportive
care and use of motivational strategies can positively influence medication adherence. 
Routine Monitoring of Adherence and Retention in Care
Although there is no gold standard for assessing adherence,1 properly implemented validated tools and
assessment strategies can prove valuable in most clinical settings. Viral load suppression is one of the most
reliable indicators of adherence and can be used as positive reinforcement to encourage continuous adherence.
When patients initiating ART fail to achieve viral suppression by 24 weeks of treatment, the possibility of
suboptimal adherence and other factors must be assessed. Similarly, treatment failure as measured by
detectable viral load during chronic care is most likely the result of non-adherence. Patient self-report, the most
frequently used method for evaluating medication adherence, remains a useful tool for assessing adherence
over time. However, self-reports must be properly and carefully assessed as patients may overestimate
adherence. While carefully assessed patient self report of high-level adherence to ART has been associated with
favorable viral load responses,16,17 patient admission of suboptimal adherence is highly correlated with poor
therapeutic response. The reliability of self report often depends on how the clinican elicits the information. It
is most reliable when ascertained in a simple, nonjudgmental, routine, and structured format that normalizes
less-than-perfect adherence and minimizes socially desirable or “white coat adherence” responses. Some
patients may selectively adhere to components of a regimen believed to have the fewest side effects or the
lowest dosing frequency or pill burden. To allow patients to more accurately disclose lapses in adherence, some
experts suggest that providers inquire about the number of missed doses during a defined time period rather
than directly asking “Are you taking your medicines?” Others advocate simply asking patients to rate their
adherence during the last 4 weeks on a 5- or 6-point Likert scale.18,19 Regardless of how obtained, patient self-
report, in contrast to other measures of adherence, allows for immediate patient-provider discussion to identify
reasons for missed doses and to explore corrective strategies. 
Other measures of adherence include pharmacy records and pill counts. Pharmacy records can be valuable
when medications are obtained exclusively from a single source so that refills can be traced. Pill counts are
commonly used but can be altered by patients. Other methods of assessing adherence include the use of
therapeutic drug monitoring and electronic measurement devices (e.g., MEMS bottle caps and dispensing
systems). However, these methods are costly and are usually done primarily in research settings. 
Interventions to Improve Adherence and Retention in Care
A continuum of ART adherence support services is necessary to meet individual patient needs. All health care
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team members, including physicians, physician assistants, nurse practitioners, nurse midwives, nurses,
pharmacists, medication managers, and social workers play integral roles in successful adherence
programs.17,20-22
Effective adherence interventions vary in modality and duration, and by clinical setting, provider, and
patient. There are many options that can be customized to suit a range of needs and settings (see Table 13).
An increasing number of interventions have proven effective in improving adherence to ART. For
descriptions of the interventions, see: http://www.cdc.gov/hiv/topics/research/prs/ma-good-evidence-
interventions.htm.23
Clinicians should provide all patients with a basic level of adherence-related information and support. Before
writing the first prescription(s) for patients initiating or reinitiating ART, clinicians should assess the patient’s
adherence readiness. Clinicians should evaluate patients’ knowledge about HIV disease, treatment, and
prevention and provide basic information about ART, viral load and CD4 count and the expected outcome of
ART based on these parameters, the importance of strict adherence to ART, and the consequences of non-
adherence. In addition, clinicians should assess patients’ motivation to successfully adhere to ART and
identify and support facilitating factors and address potential barriers to adherence. Finally, clinicians should
be assured that patients have the necessary medication taking skills to follow the regimen as prescribed.
Given the wide array of treatment options, individualizing treatment with patient involvement in decision
making is the cornerstone of treatment planning and therapeutic success. The first principle of successful
treatment is to design an understandable plan to which the patient can commit.24,25 It is important to consider
the patient’s daily schedule; patient tolerance of pill number, size and frequency; and any issues affecting
absorption (e.g., use of acid reducing therapy and food requirements). With the patient’s input, a medication
choice and administration schedule should be tailored to his/her routine daily activities. If necessary,
soliciting help from family members may also improve adherence. Patients who are naive to ART should
understand that their first regimen usually offers the best chance for taking a simple regimen that affords
long-term treatment success and prevention of drug resistance. Establishing a trusting patient-provider
relationship over time and maintaining good communication will help to improve adherence and long-term
outcomes. Medication taking can also be enhanced by the use of pill organizers and medication reminder
aids (e.g., alarm clock, pager, calendar). 
Positive reinforcement can greatly help patients maintain high levels of adherence. This technique to foster
adherence includes informing patients of their low or suppressed HIV viral load levels and increases in CD4
cell counts. Motivational interviewing has also been used with some successes. Recognizing high levels of
adherence with incentives and rewards can facilitate treatment success in some patients. Adherence-contingent
reward incentives such as meal tickets, grocery bags, lotto tickets, and cash have been used in the treatment of
HIV and other chronic diseases. The effectiveness of using cash incentives to promote HIV testing, entry to
care, and adherence to ART is currently being studied in the multi-site HPTN 065 trial. Other effective
interventions include nurse home visits, a five-session group intervention, pager messaging, and couples or
family-based interventions. To maintain high levels of adherence in some patients, it is critically important to
provide substance abuse therapy and to strengthen social support. Directly observed therapy (DOT) has been
effective in providing ART to active drug users26 but not to patients in a general clinic population.27
To determine whether additional adherence or retention interventions are warranted, assessments should be
done at each clinical encounter and should be the responsibility of the entire health care team. Routine
monitoring of HIV viral load, pharmacy records, and indicators that measure retention in care are useful to
determine if more intense efforts are needed to improve adherence. Patients with a history of non-adherence
to ART are at risk for poor adherence when re-starting therapy with the same or new drugs. Special attention
should be given to identify and address any reason for previous poor adherence. Preferential use of ritonavir-
boosted protease inhibitor-(PI/r)-based ART, which has a higher barrier to the development of resistance than
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other treatment options, should be considered if poor adherence is predicted.
The critical elements of adherence go hand in hand with linkage-to-care and retention in care. A recently
released guideline provides a number of strategies to improve entry and retention in care and adherence to
therapy for HIV infected patients.5 As with adherence monitoring, research advances offer many options for
systematic monitoring of retention in care that may be used in accordance with local resources and standards.
The options include surveillance of visit adherence, gaps in care, and the number of visits during a specified
period of time.28
Conclusion
Adherence to ART is central to therapeutic success. Given the many available assessment strategies and
interventions, the challenge for the treatment team is to select the techniques that best fit each patient and
patient population, and, according to available resources, the treatment setting. In addition to maintaining high
levels of medication adherence, attention to effective linkage to care, engagement in care, and retention in care
is critical for successful treatment outcomes. To foster treatment success, there are interventions to support each
step in the cascade of care, as well as guidance on systematic monitoring of each step in the cascade.5
Table 13. Strategies to Improve Adherence to Antiretroviral Therapy and Retention in Care  
(page 1 of 3)
Strategies Examples
Use a multidisciplinary team approach.
Provide an accessible, trustworthy health care
team.
• Nonjudgmental providers, nurses, social workers, pharmacists, and medication
managers
Strengthen early linkage to care and retention in
care.
• Encourage healthcare team participation in linkage to and retention in care.
Assess patient readiness to start ART.
Evaluate patient’s knowledge about HIV disease,
prevention and treatment and, on the basis of the
assessment, provide HIV-related information. 
• Considering the patient’s current knowledge base, provide information about
HIV, including the natural history of the disease, HIV viral load and CD4 count
and expected clinical outcomes according to these parameters, and therapeutic
and prevention consequences of non-adherence.
Identify facilitators, potential barriers to adherence,
and necessary medication management skills
before starting ART medication. 
• Assess patient’s cognitive competence and impairment. 
• Assess behavioral and psychosocial challenges including depression, mental
illnesses, levels of social support, high levels of alcohol consumption and active
substance use, non-disclosure of HIV serostatus and stigma.
• Identify and address language and literacy barriers.
• Assess beliefs, perceptions, and expectations about taking ART (e.g., impact on
health, side effects, disclosure issues, consequences of non-adherence).
• Ask about medication taking skills and foreseeable challenges with adherence
(e.g., past difficulty keeping appointments, adverse effects from previous
medications, issues managing other chronic medications, need for medication
reminders and organizers). 
• Assess structural issues including unstable housing, lack of income,
unpredictable daily schedule, lack of prescription drug coverage, lack of
continuous access to medications.
Provide needed resources. • Provide or refer for mental health and/or substance abuse treatment.
• Provide resources to obtain prescription drug coverage, stable housing, social
support, and income and food security.
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Table 13. Strategies to Improve Adherence to Antiretroviral Therapy and Retention in Care  
(page 2 of 3)
Strategies Examples
Involve the patient in ARV regimen selection. • Review regimen potency, potential side effects, dosing frequency, pill burden,
storage requirements, food requirements, and consequences of nonadherence. 
• Assess daily activities and tailor regimen to predictable and routine daily events.
• Consider preferential use of PI/r-based ART if poor adherence is predicted.
• Consider use of fixed-dose combination formulation.
• Assess if cost/co-payment for drugs can affect access to medications and
adherence.
Assess adherence at every clinic visit. • Monitor viral load as a strong biologic measure of adherence.
• Use a simple behavioral rating scale. 
• Employ a structured format that normalizes or assumes less-than-perfect
adherence and minimizes socially desirable or “white coat adherence”
responses. 
• Ensure that other members of the health care team also assess adherence. 
Use positive reinforcement to foster adherence
success.
• Inform patients of low or non-detectable levels of HIV viral load and increases in
CD4 cell counts. 
• When needed, consider providing incentives and rewards for achieving high
levels of adherence and treatment success.
Identify the type of and reasons for nonadherence. • Failure to fill the prescription(s)
• Failure to understand dosing instructions
• Complexity of regimen (e.g., pill burden, size, dosing schedule, food
requirements)
• Pill aversion
• Pill fatigue
• Adverse effects
• Inadequate understanding of drug resistance and its relationship to adherence
• Cost-related issues 
• Depression, drug and alcohol use, homelessness, poverty
• Stigma
• Non-disclosure
• Other potential barriers
Select from among available effective treatment
adherence interventions. 
• See http://www.cdc.gov/hiv/topics/research/prs/ma-good-evidence-
interventions.htm.
• Use adherence-related tools to complement education and counseling
interventions (e.g., pill boxes, dose planners, reminder devices).
• Use community resources to support adherence (e.g., visiting nurses, community
workers, family, peer advocates).
• Use patient prescription assistance programs.
• Use motivational interviews.
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Table 13. Strategies to Improve Adherence to Antiretroviral Therapy and Retention in Care  
(page 3 of 3)
Strategies Examples
Systematically monitor retention in care. • Record and follow up on missed visits.
On the basis of any problems identified through
systematic monitoring, consider options to enhance
retention in care given resources available.
• Provide outreach for those patients who drop out of care.
• Use peer or paraprofessional treatment navigators.
• Employ incentives to encourage clinic attendance or recognize positive clinical
outcomes resulting from good adherence.
• Arrange for directly observed therapy (if feasible).
Key to Acronyms: ART = antiretroviral therapy; CD4 = CD4 T lymphocyte; PI = protease inhibitor; PI/r = ritonavir-boosted protease
inhibitor
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Adverse Effects of Antiretroviral Agents  (Last updated April 8, 2015; last reviewed April 8,
2015)
Adverse effects have been reported with the use of all antiretroviral (ARV) drugs and are among the most
common reasons cited for switching or discontinuing therapy and for medication non-adherence.1
Fortunately, newer ARV regimens are less toxic than regimens used in the past. Generally less than 10% of
antiretroviral therapy (ART)-naive patients enrolled in randomized trials have treatment-limiting adverse
events. However, because most clinical trials have a relatively short follow-up duration, the longer term
complications of ART can be underestimated. In the Swiss Cohort study during a median of 6 years of
follow-up, the presence of laboratory adverse events probably or certainly related to ART was associated
with higher rates of mortality, which highlights the importance of monitoring for adverse events in overall
patient management.2
Several factors may predispose individuals to adverse effects of ARV medications. For example, compared
with men, women (especially ART-naive women with CD4 T lymphocyte cell counts >250 cells/mm3) seem
to have a higher propensity to develop Stevens-Johnson syndrome, rashes, and hepatotoxicity from
nevirapine (NVP)3-5 and have higher rates of lactic acidosis due to nucleoside reverse transcriptase
inhibitors.6-8 Other factors may also contribute to the development of adverse events: 
•     Concomitant use of medications with overlapping and additive toxicities; 
•     Comorbid conditions that increase the risk of or exacerbate adverse effects (e.g., alcoholism9 or
coinfection with viral hepatitis10-12 increases the risk of hepatotoxicity); 
•     Drug-drug interactions that may lead to an increase in drug toxicities (e.g., interactions that result from
concomitant use of statins with protease inhibitors); or
•     Genetic factors that predispose patients to abacavir (ABC) hypersensitivity reaction.13,14
The therapeutic goals of ART are to safely achieve and maintain viral suppression and improve immune
function. To accomplish these goals, the clinician must consider the toxicity potential of an ARV regimen, as
well as the individual patient’s underlying conditions, concomitant medications, and prior history of drug
intolerances. In addition, it should be appreciated that, in general, the overall benefits of ART outweigh its
risks and that some non-AIDS related conditions (e.g., anemia, cardiovascular disease, renal impairment)
may be more likely in the absence of ART.15,16
Information on the adverse events of ARVs is outlined in several tables in the guidelines. Table 14 provides
clinicians with a list of the most common and/or severe known ARV-associated adverse events for each drug
class. The most common adverse effects of individual ARV agents are summarized in Appendix B, Tables 1–6. 
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Table 14. Antiretroviral Therapy-Associated Common and/or Severe Adverse Effects  (page 1 of 5)
N/A indicates either that there are no reported cases for the particular side effect or that data for the specific ARV drug class are not available. See Appendix B for
additional information listed by drug.
Adverse Effect NRTIs NNRTIs PIs INSTI EI
Bleeding Events N/A N/A Spontaneous bleeding, hematuria in hemophilia. 
TPV: Intracranial hemorrhage associated with CNS
lesions, trauma, alcohol abuse, hypertension,
coagulopathy, anti-coagulant or anti-platelet agents,
vitamin E
N/A N/A
Bone Density
Effects
TDF: Associated with greater
loss of BMD than other
NRTIs. 
Osteomalacia has been
reported in association with
proximal renal tubulopathy.
Decreases in BMD observed after the initiation of any ART regimen. N/A
Bone Marrow
Suppression
ZDV: Anemia, neutropenia N/A N/A N/A N/A
Cardiovascular
Disease
ABC and ddI: Associated
with an increased risk of MI
in some cohort studies.
Absolute risk greatest in
patients with traditional CVD
risk factors.
N/A Associated with MI and stroke in some cohorts.
SQV/r, ATV/r, and LPV/r: PR prolongation. Risks
include pre-existing heart disease, other
medications.
SQV/r: QT prolongation. Obtain ECG before
administering SQV.
N/A N/A
Cholelithiasis N/A N/A ATV: Cholelithiasis and kidney stones may present
concurrently.
Median onset is 42 months.
N/A N/A
Diabetes Mellitus/
Insulin
Resistance
ZDV, d4T, and ddI N/A Reported for some (IDV, LPV/r), but not all PIs N/A N/A
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Table 14. Antiretroviral Therapy-Associated Common and/or Severe Adverse Effects  (page 2 of 5)
Adverse Effect NRTIs NNRTIs PIs INSTI EI
Dyslipidemia d4T > ZDV > ABC: hLDL
and TG
EFV: hTG, hLDL,
hHDL 
All RTV-boosted PIs: hLDL, hTG, hHDL 
LPV/r = FPV/r and LPV/r > DRV/r and ATV/r: hTG
EVG/c/TDF/FTC:
hTG, hLDL, hHDL
N/A
Gastrointestinal
Effects
Nausea and vomiting: ddI
and ZDV > other NRTIs
Pancreatitis: ddI
N/A GI intolerance (e.g., diarrhea, nausea, vomiting)
Diarrhea: Common with LPV/r, more frequent than
DRV/r and ATV/r
Nausea and
diarrhea: EVG/c/
TDF/FTC
N/A
Hepatic Effects Reported with most NRTIs.
Steatosis most common with
ZDV, d4T, or ddI.
ddI: Prolonged exposure
linked to non-cirrhotic portal
hypertension, esophageal
varices.
Flares: HIV/HBV-co-infected
patients may develop severe
hepatic flares when TDF,
3TC, and FTC are withdrawn
or when HBV resistance
develops.
NVP > other NNRTIs
NVP: Severe
hepatotoxicity
associated with skin
rash or hypersensitivity.
2-week NVP dose
escalation may reduce
risk. Risk is greater for
women with pre-NVP
CD4 count >250
cells/mm3 and men with
pre-NVP CD4 count
>400 cells/mm3. NVP
should never be used
for post-exposure
prophylaxis, or in
patients with hepatic
insufficiency (Child-
Pugh B or C).
All PIs: Drug-induced hepatitis and hepatic
decompensation have been reported; greatest
frequency with TPV/r.
IDV, ATV: Jaundice due to indirect
hyperbilirubinemia
TPV/r: Contraindicated in patients with hepatic
insufficiency (Child-Pugh B or C)
N/A MVC: Hepatotoxicity with or
without rash or HSRs
reported
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Table 14. Antiretroviral Therapy-Associated Common and/or Severe Adverse Effects  (page 3 of 5)
Adverse Effect NRTIs NNRTIs PIs INSTI EI
Hypersensitivity
Reaction
Excluding rash
alone or Stevens-
Johnson syndrome 
ABC: Contraindicated if
HLA-B*5701 positive.
Median onset 9 days; 90%
of reactions occur within first
6 weeks of treatment. 
HSR symptoms (in order of
descending frequency):
fever, rash, malaise, nausea,
headache, myalgia, chills,
diarrhea, vomiting,
abdominal pain, dyspnea,
arthralgia, and respiratory
symptoms.
Symptoms worsen with
continuation of ABC.
Patients, regardless of HLA-
B*5701 status, should not be
re-challenged with ABC if
HSR is suspected.
NVP: Hypersensitivity
syndrome of hepatotoxicity
and rash that may be
accompanied by fever,
general malaise, fatigue,
myalgias, arthralgias, blisters,
oral lesions, conjunctivitis,
facial edema, eosinophilia,
renal dysfunction,
granulocytopenia, or
lymphadenopathy.
Risk is greater for ARV-naive
women with pre-NVP CD4
count >250 cells/mm3 and
men with pre-NVP CD4 count
>400 cells/mm3. Overall, risk
is higher for women than men.
2-week dose escalation of
NVP reduces risk.
N/A RAL: HSR reported
when RAL given in
combination with
other drugs known
to cause HSR. All
ARVs should be
stopped if HSR
occurs.
DTG: Reported in
<1% of patients in
clinical development
program 
MVC: Reported as part of a
syndrome related to
hepatotoxicity
Lactic Acidosis Reported with NRTIs,
especially d4T, ZDV, and
ddI: Insidious onset with GI
prodrome, weight loss, and
fatigue. May rapidly
progress with tachycardia,
tachypnea, jaundice,
weakness, mental status
changes, pancreatitis, and
organ failure. Mortality high
if serum lactate >10 mmol/L. 
Women and obese patients
at increased risk.
N/A N/A N/A N/A
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Table 14. Antiretroviral Therapy-Associated Common and/or Severe Adverse Effects  (page 4 of 5)
Adverse Effect NRTIs NNRTIs PIs INSTI EI
Lipodystrophy Lipoatrophy: d4T > ZDV. May
be more likely when NRTIs
combined with EFV than with
an RTV-boosted PI.
Lipohypertophy: Trunk fat increase observed with EFV-, PI-, and RAL-containing regimens; however,
causal relationship has not been established.
N/A
Myopathy/
Elevated Creatine
Phosphokinase
ZDV: Myopathy N/A N/A RAL: CPK,
weakness and
rhabdomyolysis
N/A
Nervous System/
Psychiatric
Effects
Peripheral neuropathy: d4T
> ddI and ddC (can be
irreversible).
d4T: Associated with rapidly
progressive, ascending
neuromuscular weakness
resembling Guillain-Barré
syndrome (rare)
EFV: Somnolence, insomnia,
abnormal dreams, dizziness,
impaired concentration,
depression, psychosis, and
suicidal ideation. Symptoms
usually subside or diminish
after 2–4 weeks. Bedtime
dosing may reduce
symptoms. Risks include
psychiatric illness,
concomitant use of agents
with neuropsychiatric effects,
and increased EFV
concentrations because of
genetic factors or increased
absorption with food. An
association between EFV and
suicidal ideation, suicide, and
attempted suicide (especially
among younger patients and
those with history of mental
illness or substance abuse)
was found in a retrospective
analysis of comparative trials.
N/A All INSTIs: Insomnia
RAL: Depression
and suicidal ideation
(uncommon)
N/A
Rash FTC: Hyperpigmentation All NNRTIs ATV, DRV, FPV, LPV/r, TPV RAL, EVG/c/TDF/
FTC
MVC
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Table 14. Antiretroviral Therapy-Associated Common and/or Severe Adverse Effects  (page 5 of 5)
Adverse Effect NRTIs NNRTIs PIs INSTI EI
Renal Effects/
Urolithiasis
TDF: SCr, proteinuria,
hypophosphatemia, urinary
phosphate wasting,
glycosuria, hypokalemia,
non-anion gap metabolic
acidosis
Concurrent use with PI
appears to increase risk.
N/A ATV and LPV/r: Increased chronic kidney
disease risk in a large cohort study.
IDV: SCr, pyuria, renal atrophy or
hydronephrosis
IDV, ATV: Stone, crystal formation; adequate
hydration may reduce risk.
COBI (in EVG/c/
TDF/FTC) and
DTG: Inhibits Cr
secretion without
reducing renal
glomerular function. 
N/A
Stevens-Johnson
Syndrome/Toxic
Epidermal
Necrosis
ddI, ZDV: Reported cases NVP > DLV, EFV, ETR, RPV FPV, DRV, IDV, LPV/r, ATV: Reported cases RAL N/A
Key to Abbreviations: 3TC = lamivudine; ABC = abacavir; ALT = alanine aminotransferase; ARV = antiretroviral; ATV = atazanavir; ATV/r = atazanavir/ritonavir; BMD = bone mineral
density; Cr = creatinine; CrCl = creatinine clearance; CNS = central nervous system; COBI or c = cobicistat; CPK = creatine phosphokinase; CVD = cardiovascular disease; d4T =
stavudine; ddC = zalcitabine; ddI = didanosine; DLV = delavirdine; DRV = darunavir; DRV/r = darunavir/ritonavir; DTG = dolutegravir; ECG = electrocardiogram; EFV = efavirenz; EI = entry
inhibitor; ETR = etravirine; EVG = elvitegravir; FPV = fosamprenavir; FPV/r = fosamprenavir/ritonavir; FTC = emtricitabine; GI = gastrointestinal; HBV = hepatitis B virus; HDL = high-density
lipoprotein; HSR = hypersensitivity reaction; IDV = indinavir; INSTI = integrase strand transfer inhibitor; LDL = low-density lipoprotein; LPV/r = lopinavir/ritonavir; MI = myocardial infarction;
MVC = maraviroc; NFV = nelfinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PT
= prothrombin time; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SCr = serum creatinine; SQV = saquinavir; SQV/r = saquinavir/ritonavir; TDF = tenofovir disoproxil fumarate; TG =
triglyceride; TPV = tipranavir; TPV/r = tipranavir/ritonavir; ZDV = zidovudine
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Switching Antiretroviral Therapy Because of Adverse Effects
Most patients do not experience treatment-limiting ART-associated toxicities; however, some patients do, and
in these cases, ART must be modified. ART-associated adverse events can range from acute and potentially
life threatening to chronic and insidious. Acute life-threatening events (e.g., acute hypersensitivity reaction
due to ABC, lactic acidosis due to stavudine [d4T] and didanosine [ddI], liver and/or severe cutaneous
toxicities due to NVP) usually require the immediate discontinuation of all ARV drugs and re-initiation of an
alternative regimen without overlapping toxicity. Non-life threatening toxicities (e.g., urolithiasis with
atazanavir [ATV], renal tubulopathy with tenofovir [TDF]) can usually be managed by substituting another
ARV agent for the presumed causative agent without interruption of ART. Other, chronic, non-life
threatening adverse events (e.g., dyslipidemia) can be addressed either by switching the potentially causative
agent for another agent or by managing the adverse event with additional pharmacological or non-
pharmacological interventions. Management strategies must be individualized for each patient. 
Switching from an effective ARV regimen to a new regimen must be done carefully and only when the
potential benefits of the change outweigh the potential complications of altering treatment. The fundamental
principle of regimen switching is to maintain viral suppression. When selecting a new agent or regimen,
providers should be aware that resistance mutations selected for, regardless of whether previously or
currently identified by genotypic resistance testing, are archived in HIV reservoirs, and even if absent from
subsequent resistance test results, may reappear under selective pressure. It is critical that providers review
the following before implementing any treatment switch: 
•     the patient’s medical and complete ARV history including prior virologic responses to ART; 
•     resistance test results; 
•     viral tropism (when maraviroc [MVC] is being considered); 
•     HLA B*5701 status (when ABC is being considered); 
•     co-morbidities; 
•     adherence history; 
•     prior intolerances to any medications; and 
•     concomitant medications and supplements and their potential for drug interactions with ARVs. 
Patient acceptance of new food or dosing requirements must also be assessed. In some cases, medication
costs may also be a factor to consider before switching treatment. Signs and symptoms of ART-associated
adverse events may mimic those of comorbidities, adverse effects of concomitant medications, or HIV
infection itself. Therefore, concurrent with ascribing a particular clinical event to ART, alternative causes for
the event should be investigated. In the case of a severe adverse event, it may be necessary to discontinue or
switch ARVs pending the outcome of such an investigation. For the first few months after an ART switch, the
patient should be closely monitored for any new adverse events. The patient’s viral load should also be
monitored to assure continued viral suppression.
Table 15 lists several major ART-associated adverse events and potential options to appropriately switch
agents in an ARV regimen. The table focuses on the ARVs most commonly used in the United States and lists
substitutions that are supported by ARV switch studies, findings of comparative ARV trials and observational
cohort studies, or expert opinion. Switching a successful ARV regimen should be done carefully and only
when the potential benefits of the change outweigh the potential complications of altering treatment. 
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Table 15. Antiretroviral Therapy-Associated Adverse Events That Can Be Managed with Substitution
of Alternative Antiretroviral Agent  (page 1 of 2)
Bone Density Effects TDFa ABCb Declines in BMD have been observed with the start of most
ART regimens. Switching from TDF to alternative ARV
agents has been shown to increase bone density, but the
clinical significance of this increase remains uncertain.
Bone Marrow
Suppression
ZDV TDF or ABCb ZDV has been associated with neutropenia and macrocytic
anemia
Central Nervous
System/
Neuropsychiatric Side
Effects 
Dizziness, suicidal
ideation, abnormal
dreams, depression
EFV Alternative NNRTI
(RPV, ETR, NVP), a
PI/c or PI/r, or an
INSTI
In most patients, EFV-related CNS effects subside within 4
weeks after initiation of the drug. Persistent or intolerable
effects should prompt substitution of EFV.
Dyslipidemia
Hypertriglyceridemia
(with or without elevated
low-density LDL level)
RTV- or COBI-boosted
regimens or EFV
RAL, DTG, RPV,
NVP, or unboosted
ATVc
Elevated TG and LDL levels are more common with LPV/r
and FPV/r than with other RTV-boosted PIs. Improvements
in TG and LDL levels observed with switch from LPV/r to
ATV or ATV/r.c
Gastrointestinal
Effects
Nausea, diarrhea
LPV/r ATV/c, ATV/r, DRV/c,
DRV/r, RAL, DTG,
EVG/c/TDF/FTC
GI intolerance is common with boosted PIs and is linked to
the total dose of RTV. More GI toxicity is seen with LPV/r
than with ATV/r or DRV/r. GI effects are often transient, and
do not warrant substitution unless persistent and intolerable.
Other RTV- or COBI-
boosted regimens 
RAL, DTG,
unboosted ATV,c
NNRTIs
In a trial of treatment-naive patients, rates of diarrhea and
nausea were similar for EVG/c/TDF/FTC and ATV/r plus
TDF/FTC.
Hypersensitivity
Reaction
ABC TDF Never re-challenge with ABC following a suspected HSR,
regardless of the patient’s HLA B*5701 status.
NVP, EFV, ETR, RPV Non-NNRTI ART Risk of HSR with NVP is higher for women and those with
high CD4 cell counts.
DTG, RAL
MVC
Non-INSTI ART
Suitable alternative
ART
Reactions to NVP, ETR, RAL, DTG and MVC may be
accompanied by elevated liver transaminases.
Insulin Resistance LPV/r, FPV/r NNRTI (NVP or
RPV), INSTI,
unboosted ATVc
Results of switch studies have been inconsistent. Studies in
HIV-negative patients suggest a direct causal effect of
LPV/r (and IDV) on insulin resistance. However, traditional
risk factors may be stronger risk factors for insulin
resistance than use of any PI.
Jaundice and Icterus ATV, ATV/c, ATV/r DRV/c, DRV/r,
INSTI, or NNRTI
Increases in unconjugated bilirubin are common with ATV
and generally do not require modification of therapy unless
resultant symptoms are distressing to the patient.
Adverse Event
ARV Agent(s)/Drug Class
Switch from Switch to
Comments
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Table 15. Antiretroviral Therapy-Associated Adverse Events That Can Be Managed with Substitution
of Alternative Antiretroviral Agent  (page 2 of 2)
Lipoatrophy
Subcutaneous fat
wasting of limbs, face,
buttocks
d4T, ZDV TDF or ABCb Peripheral lipoatrophy is a legacy of prior thymidine analog
(d4T and ZDV) use. Switching from these ARVs prevents
worsening lipoatrophy, but fat recovery is typically slow
(may take years) and incomplete.
Lipohypertrophy Accumulation of visceral, truncal, dorso-cervical, and breast fat has been observed during ART, particularly
during use of older PI-based regimens (e.g., IDV), but whether ART directly causes increased fat deposits
remains unclear. There is no clinical evidence that switching to another first line regimen will reverse weight
or visceral fat gain.
Rash
NNRTIs (especially
NVP and EFV)
PI- or INSTI-based
regimen
Mild rashes developing after initiation of NNRTIs other than
NVP rarely require treatment switch. When serious rash
develops due to any NNRTI, switch to another drug class.
DRV/c, DRV/r ATV/c, ATV/r or
another drug class
(e.g., INSTI)
Mild rashes following DRV/r may resolve with close follow-
up only. For more severe reactions, change to an
alternative boosted PI or an agent from another drug class.
Renal Effects
Including proximal renal
tubulopathy, elevated
creatinine
TDFa ABCb TDF may cause tubulopathy.
ATV/c, ATV/r, LPV/r DTG, RAL, or NNRTI COBI and DTG, and to a lesser extent RPV can increase
SCr through inhibition of creatinine secretion. This effect
does not affect glomerular filtration. However, assess for
renal dysfunction if SCr increases by >0.4 mg/dL.
Stones
Nephrolithiasis and
cholelithiasis
ATV, ATV/c, ATV/r DRV/c, DRV/r,
INSTI, or NNRTI
Assuming that ATV/r is believed to cause the stones
Adverse Event
ARV Agent(s)/Drug Class
Switch from Switch to
Comments
a In patients with chronic active HBV infection, another agent active against HBV should be substituted for TDF.
b ABC should be used only in patients known to be HLA-B*5701 negative.
c TDF reduces ATV levels; therefore, unboosted ATV should not be coadministered with TDF. Long term data for unboosted ATV are
unavailable.
Key to Abbreviations: ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; ATV = atazanavir; ATV/c = atazanavir/cobicistat;
ATV/r = atazanavir/ritonavir; BMD = bone mineral density; CD4 = CD4 T lymphocyte; CNS = central nervous system; COBI or c =
cobicistat; d4T = stavudine; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; ETR =
etravirine; EVG = elvitegravir; FPV/r = fosamprenavir/ritonavir; FTC = emtricitabine; GI = gastrointestinal; HBV = hepatitis B virus; HSR =
hypersensitivity reaction; IDV = indinavir; INSTI = integrase strand transfer inhibitor; LDL = low-density lipoprotein; LPV/r =
lopinavir/ritonavir; MVC = maraviroc; NNRTI = non-nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor;
PI/c = protease inhibitor/cobicistat; PI/r = protease inhibitor/ritonavir; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SCr = serum
creatinine; TDF = tenofovir disoproxil fumarate; TG = triglycerides; ZDV = zidovudine
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Cost Considerations and Antiretroviral Therapy  (Last updated May 1, 2014; last reviewed 
May 1, 2014)
Although antiretroviral therapy (ART) is expensive (see Table 16 below), the cost-effectiveness of ART has
been demonstrated in analyses of older1 and newer regimens,2,3 as well as for treatment-experienced patients
with drug-resistant HIV.4 Given the recommendations for immediate initiation of lifelong treatment and the
increasing number of patients taking ART, the Panel now introduces cost-related issues pertaining to
medication adherence and cost-containment strategies, as discussed below.
Costs as They Relate to Adherence from a Patient Perspective
Cost sharing: Cost sharing is where the patient is responsible for some of the medication cost burden
(usually accomplished via co-payments, co-insurance, or deductibles); these costs are often higher for
branded medications than for generic medications. In one comprehensive review, increased patient cost
sharing resulted in decreased medical adherence and more frequent drug discontinuation; for patients with
chronic diseases, increased cost sharing was also associated with increased use of the medical system.5
Conversely, co-payment reductions, such as those that might be used to incentivize prescribing of generic
drugs, have been associated with improved adherence in patients with chronic diseases.6 Whereas cost-
sharing disproportionately affects low income patients, resources (e.g., the Ryan White AIDS Drug
Assistance Program [ADAP]) are available to assist eligible patients with co-pays and deductibles. Given the
clear association between out-of-pocket costs for patients with chronic diseases and the ability of those
patients to pay for and adhere to medications, clinicians should minimize patients’ out-of-pocket drug-related
expenses whenever possible.
Prior authorizations: As a cost-containment strategy, some programs require that clinicians obtain prior
authorizations or permission before prescribing newer or more costly treatments rather than older or less
expensive drugs. Although there are data demonstrating that prior authorizations do reduce spending, several
studies have also shown that prior authorizations result in fewer prescriptions filled and increased non-
adherence.7-9 Prior authorizations in HIV care specifically have been reported to cost over $40 each in
provider personnel time (a hidden cost) and have substantially reduced timely access to medications.10
Generic ART: The impact of the availability of generic antiretroviral (ARV) drugs on selection of ART in
the United States is unknown. Because U.S. patent laws currently limit the co-formulation of some generic
alternatives to branded drugs, generic options may result in increased pill burden. To the extent that pill
burden, rather than drug frequency, results in reduced adherence, generic ART could lead to decreased costs
but at the potential expense of worsening virologic suppression rates and poorer clinical outcomes.11,12
Furthermore, prescribing the individual, less-expensive generic components of a branded co-formulated
product rather than the branded product itself could, under some insurance plans, lead to higher copays—an
out-of-pocket cost increase that may reduce medication adherence.
Potential Cost Containment Strategies from a Societal Perspective
Given resource constraints, it is important to maximize the use of resources without sacrificing clinical
outcomes. Evidence-based revisions to these guidelines recommend tailored laboratory monitoring for
patients with long-term virologic suppression on ART as one possible way to provide overall cost savings.
Data suggest that continued CD4 monitoring yields no clinical benefit for patients whose viral loads are
suppressed and CD4 counts exceed 200 cells/mm3 after 48 weeks of therapy.13 A reduction in laboratory use
from biannual to annual CD4 monitoring could save ~$10 million per year in the United States14 (see the
Laboratory Monitoring section). Although this is a small proportion of the overall costs associated with HIV
care, such a strategy could reduce patients’ personal expenses if they have deductibles for laboratory tests.
The present and future availability of generic formulations of certain ARV drugs, despite the potential
caveats of increased pill burden and reduced adherence, offers other money-saving possibilities on a much
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greater scale. One analysis suggests the possibility of saving approximately $900 million nationally in the
first year of switching from a branded fixed-dose combination product to a three-pill regimen containing
generic efavirenz.3
In summary, understanding HIV and ART-related costs in the United States is complicated because of the
wide variability in medical coverage, accessibility, and expenses across regions, insurance plans, and
pharmacies. In an effort to retain excellent clinical outcomes in an environment of cost-containment
strategies, providers should remain informed of current insurance and payment structures, ART costs (see
Table 16 below for estimates of drugs’ average wholesale prices), discounts among preferred pharmacies,
and available generic ART options. Providers should work with patients and their case managers and social
workers to understand their patients’ particular pharmacy benefit plans and potential financial barriers to
filling their prescriptions. Additionally, providers should familiarize themselves with ARV affordability
resources (such as ADAP and pharmaceutical company patient assistance programs for patients who qualify)
and refer patients to such assistance if needed.
Table 16. Monthly Average Wholesale Pricea of Antiretroviral Drugs  (Last updated April 8, 2015; last
reviewed April 8, 2015)  (page 1 of 4)
ARV Drug
(Generic and Brand Names) Strength Dosing
Tablets/Capsules/
mLs per Month AWP
a (Monthly)
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Abacavir
• Generic 300 mg tab 2 tabs daily 60 tabs $602.66
• Ziagen 300 mg tab 2 tabs daily 60 tabs $670.37
• Ziagen 20 mg/mL soln 30 mL daily 900 mL $660.86
Didanosine Delayed-Release
• Generic 400 mg cap 1 cap daily 30 caps $368.72
• Videx EC 400 mg cap 1 cap daily 30 caps $515.84
Emtricitabine
• Emtriva 200 mg cap 1 cap daily 30 caps $602.27
• Emtriva 10 mg/mL soln 24 mL daily 680 mL (28-day supply) $568.88
Lamivudine
• Generic 300 mg tab 1 tab daily 30 tabs $429.66
• Epivir 300 mg tab 1 tab daily 30 tabs $498.89
• Epivir 10 mg/mL soln 30 mL daily 900 mL $498.90
Stavudine
• Generic 40 mg cap 1 cap twice daily 60 caps $410.70
• Zerit 40 mg cap 1 cap twice daily 60 caps $553.12
Tenofovir
• Viread 300 mg tab 1 tab daily 30 tabs $1,120.04
Zidovudine
• Generic 300 mg tab 1 tab twice daily 60 tabs $360.97
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Table 16. Monthly Average Wholesale Pricea of Antiretroviral Drugs  (Last updated April 8, 2015; last
reviewed April 8, 2015)  (page 2 of 4)
ARV Drug
(Generic and Brand Names) Strength Dosing
Tablets/Capsules/
mLs per Month AWP
a (Monthly)
NRTI Combination Products
Abacavir/Lamivudine
• Epzicom 600/300 mg tab 1 tab daily 30 tabs $1,416.35
Tenofovir Disoproxil Fumarate/
Emtricitabine
• Truvada 300/200 mg tab 1 tab daily 30 tabs $1,539.90
Zidovudine/Lamivudine
• Generic 300/150 mg tab 1 tab twice daily 60 tabs $931.61
• Combivir 300/150 mg tab 1 tab twice daily 60 tabs $1,081.70
Abacavir Sulfate/Zidovudine/
Lamivudine
• Generic 300/300/150 mg tab 1 tab twice daily 60 tabs $1,738.46
• Trizivir 300/300/150 mg tab 1 tab twice daily 60 tabs $1,931.64
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Efavirenz
• Sustiva 600 mg tab 1 tab daily 30 tabs $1,011.97
Etravirine
• Intelence 200 mg tab 1 tab twice daily 60 tabs $1,212.29
Nevirapine
• Generic 200 mg tab 1 tab twice daily 60 tabs $650.05
• Viramune 200 mg tab 1 tab twice daily 60 tabs $861.19
• Viramune XR (nevirapine
extended release)
400 mg tab 1 tab daily 30 tabs $798.73
Rilpivirine
• Edurant 25 mg tab 1 tab daily 30 tabs $996.43
Protease Inhibitors (PIs)
Atazanavir
• Reyataz 200 mg cap 2 caps daily 60 caps $1,535.23
• Reyataz 300 mg capc 1 cap daily 30 caps $1,520.72
Atazanavir/Cobicistat
• Evotaz 300 mg/150 mg tab 1 tab daily 30 tabs $1,684.44
Darunavir
• Prezista 600 mg tabb 1 tab twice daily 60 tabs $1,509.79
• Prezista 800 mg tabc 1 tab daily 30 tabs $1,509.79
• Prezista 100 mg/mL suspb 8 mL daily
6 mL twice daily
240 mL
360 mL
$1,006.54
$1,509.80
Darunavir/Cobicistat
• Prezcobix 800 mg/150 mg tab 1 tab daily 30 tabs $1,725.29
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Table 16. Monthly Average Wholesale Pricea of Antiretroviral Drugs  (Last updated April 8, 2015; last
reviewed April 8, 2015)  (page 3 of 4)
ARV Drug
(Generic and Brand Names) Strength Dosing
Tablets/Capsules/
mLs per Month AWP
a (Monthly)
Protease Inhibitors (PIs), continued
Fosamprenavir
• Lexiva 700 mg tab 2 tabs twice daily 120 tabs $2,408.86
• Lexiva 700 mg tab 1 tab twice dailyb or 
2 tabs once dailyb
60 tabs $1,204.43
Lopinavir/Ritonavir
• Kaletra
200 mg/50 mg tab 2 tabs twice daily or
4 tabs once daily
120 tabs $977.22
• Kaletra 80 mg/20 mg per mL
soln
5 mL twice daily 300 mL $916.13
Nelfinavir
• Viracept 625 mg tab 2 tabs twice daily 120 tabs $1,169.22
Saquinavir
• Invirase 500 mg tabb 2 tabs twice daily 120 tabs $1,260.01
Tipranavir
• Aptivus 250 mg capb 2 caps twice daily 120 caps $1,590.18
Integrase Strand Transfer Inhibitors (INSTIs)
Dolutegravir
• Tivicay 50 mg tab 1 tab once daily 30 tabs $1,581.68
• Tivicay 50 mg tab 1 tab twice daily 60 tabs $3,163.36
Elvitegravir
• Vitekta 85 mg tab 1 tab daily 30 tabs $1,352.05
• Vitekta 150 mg tab 1 tab daily 30 tabs $1,352.05
Raltegravir
• Isentress 400 mg tab 1 tab twice daily 60 tabs $1,445.34
Fusion Inhibitor
Enfuviritide
• Fuzeon 90 mg injection kit 1 injection twice daily 60 doses (1 kit) $3,759.43
CCR5 Antagonist
Maraviroc
• Selzentry 150 mg tab 1 tab twice daily 60 tabs $1,455.13
• Selzentry 300 mg tab 1 tab twice daily 60 tabs $1,455.13
• Selzentry 300 mg tab 2 tabs twice daily 120 tabs $2,910.26
Co-Formulated Combination Products as Single Tablet Regimens
Dolutegravir/Abacavir/Lamivudine
• Triumeq 50/600/300 mg tab 1 tab daily 30 tabs $2,648.84
Efavirenz/Tenofovir Disoproxil
Fumarate/Emtricitabine
• Atripla 600/300/200 mg tab 1 tab daily 30 tabs $2,551.99
Elvitegravir/Cobicistat/Tenofovir
Disoproxil Fumarate/ Emtricitabine
• Stribild 150/150/300/200 mg tab 1 tab daily 30 tabs $2,948.70
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a AWP = Average Wholesale Price. Note that this price may not represent the pharmacy acquisition price or the price paid by consumers.
Source: http://micromedexsolutions.com. Accessed February 2015.
b Should be used in combination with ritonavir. Please refer to Appendix B, Table 3 for ritonavir doses.
c Should be used in combination with ritonavir or cobicistat. Please refer to Appendix B, Table 3 for ritonavir doses.
Key to Abbreviations: AWP = average wholesale price; cap = capsule; EC = enteric coated; soln = solution; susp = suspension; tab =
tablet; XR = extended release
Table 16. Monthly Average Wholesale Pricea of Antiretroviral Drugs  (Last updated April 8, 2015; last
reviewed April 8, 2015)  (page 4 of 4)
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Drug-Drug Interactions  (Last updated April 8, 2015; last reviewed April 8, 2015)
Pharmacokinetic (PK) drug-drug interactions between antiretroviral (ARV) drugs and concomitant medications
are common, and may lead to increased or decreased drug exposure. In some instances, changes in drug
exposure may increase toxicities or affect therapeutic responses. When prescribing or switching one or more
drugs in an ARV regimen, clinicians must consider the potential for drug-drug interactions—both those that
affect ARVs and those that ARVs affect on other drugs a patient is taking. A thorough review of concomitant
medications in consultation with a clinician with expertise in ARV pharmacology can help in designing a
regimen that minimizes undesirable interactions. Recommendations for managing a particular drug interaction
may differ depending on whether a new ARV is being initiated in a patient on a stable concomitant medication
or a new concomitant medication is being initiated in a patient on a stable ARV regimen. The magnitude and
significance of interactions are difficult to predict when several drugs with competing metabolic pathways are
prescribed concomitantly. When prescribing interacting drugs is necessary, clinicians should be vigilant in
monitoring for therapeutic efficacy and/or concentration-related toxicities.
Mechanisms of Pharmacokinetic Interactions
PK interactions may occur during absorption, metabolism, or elimination of the ARV and/or the interacting drugs.
The most common mechanisms of interactions are described below and listed for each ARV drug in Table 17.
Pharmacokinetic Interactions Affecting Drug Absorption
The extent of oral absorption of drugs can be affected by the following mechanisms: 
•     Acid reducing agents, such as proton pump inhibitors, H2 antagonists, or antacids, can reduce the absorption
of ARVs that require gastric acidity for optimal absorption (i.e., atazanavir [ATV] and rilpivirine [RPV]).  
•     Products that contain polyvalent cations, such as aluminum, calcium, magnesium-containing antacids,
supplements, or iron products, can bind to integrase inhibitors (INSTI) and reduce absorption of these
ARV agents.
•     Drugs that induce or inhibit the enzyme CYP3A4 or efflux transporter p-glycoprotein in the intestines
may reduce or promote the absorption of other drugs.
Pharmacokinetic Interactions Affecting Hepatic Metabolism
Two major enzyme systems are most frequently responsible for clinically significant drug interactions. 
1.   The cytochrome P450 enzyme system is responsible for the metabolism of many drugs, including the
non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), CCR5 antagonist
maraviroc (MVC), and the INSTI elvitegravir (EVG). Cytochrome P450 3A4 (CYP3A4) is the most
common enzyme responsible for drug metabolism, though multiple enzymes may be involved in the
metabolism of a drug. ARVs and concomitant medications may be inducers, inhibitors, and/or substrates
of these enzymes. 
2.   The uridine diphosphate (UDP)-glucuronosyltransferase (UGT) 1A1 enzyme is the primary enzyme
responsible for the metabolism of the INSTIs dolutegravir (DTG) and raltegravir (RAL). Drugs that
induce or inhibit the UGT enzyme can affect the PKs of these INSTIs.
Pharmacokinetic Enhancers (Boosters)
PK enhancing is a strategy used to increase exposure of an ARV by concomitantly administering a drug that
inhibits the enzymes that metabolize the ARV. Currently in clinical practice, two agents are used as PK
enhancers: ritonavir (RTV) and cobicistat (COBI). Both of these agents are potent inhibitors of the CYP3A4
enzyme, resulting in higher drug exposures of the coadministered ARV metabolized by this pathway.
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Importantly, RTV and COBI may have different effects on other CYP or UGT metabolizing enzymes and
drug transporters. Complex or unknown mechanisms of PK-based interactions preclude extrapolation of
RTV drug interactions to certain COBI interactions, such as interactions with warfarin, phenytoin,
voriconazole, oral contraceptives, certain HMG-CoA reductase inhibitors (or statins), and other drugs.
Other Mechanisms of Pharmacokinetic Interactions
Knowledge of drug transporters is evolving, elucidating additional drug interaction mechanisms. For
example, DTG decreases the renal clearance of metformin by inhibiting organic anion transporters in renal
tubular cells. Similar transporters aid hepatic, renal, and biliary clearance of drugs and may be susceptible to
drug interactions. ARVs and concomitant medications may be inducers, inhibitors, and/or substrates of these
drug transporters.
Tables 18–20b provide information on known or suspected drug interactions between ARV agents and
commonly prescribed medications based on published PK data or information from product labels. The
tables provide general guidance on drugs that should not be coadministered and recommendations for dose
modifications or alternative therapy.  
Table 17. Mechanisms of Antiretroviral-Associated Drug Interactions  (page 1 of 2)
Pharmacokinetic interactions may occur during absorption, metabolism, or elimination of the ARV and/or the
interacting drugs. This table does not include a comprehensive list of all possible mechanisms of interactions
for individual ARV drugs (e.g., transporters); however, the table lists the most common mechanisms of
interactions and focuses on absorption and CYP and UGT1A1 mediated interactions.
Note: Ellipses ( … ) indicate that there are no clinically relevant interactions by these mechanisms.
ARV Drugs
by Drug
Class
Mechanisms That May Affect or Be
Affected by Oral Absorption of ARV Drugs
Enzymes That Metabolize or Are Induced or
Inhibited by ARV Drugs
Other
Mechanisms
of Drug
Interactions
Increasing
Gastric pH
Cationic
Chelation P-glycoprotein
CYP
Substrate
CYP
Inhibitor
CYP
Inducer UGT1A1
Integrase Strand Transfer Inhibitors (INSTIs)
Dolutegravir
(DTG) …
Concentration
decreased by
products
containing
polyvalent
cations (e.g.,
Ca, Mg, Al,
Fe, Zn)
Substrate 3A4 (small
contribution) … …
Substrate Inhibitor of renal
transporters
OCT2 and
MATE
Elvitegravir
(EVG)
… … 3A4 … … Substrate …
Raltegravir
(RAL)
… … … … … Substrate …
Pharmacokinetic (PK) Enhancers (Boosters)
Cobicistat
(COBI)
… … Inhibitor 3A4 3A4, 2D6 … … …
Ritonavir
(RTV)
… … Substrate,
inhibitor
3A4, 2D6 3A4, 2D6
(lesser extent)
1A2, 2C8,
2C9, 2C19
Inducer …
Protease Inhibitors (PIs) 
Note: When PIs are coadministered with PK enhancers (boosters), the pharmacologic properties of both agents should be considered
when assessing potential drug interactions.
Atazanavir
(ATV)
Concentration
decreased
… Substrate,
inducer, inhibitor
3A4 3A4, 2C8
(weak)
… Inhibitor …
Darunavir
(DRV)
… … Substrate 3A4 3A4 2C9 … …
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Table 17. Mechanisms of Antiretroviral-Associated Drug Interactions  (page 2 of 2)
ARV Drugs
by Drug
Class
Mechanisms That May Affect or be
Affected by Oral Absorption of ARV Drugs
Enzymes That Metabolize or are Induced or
Inhibited by ARV Drugs
Other
Mechanisms
of Drug
Interactions
Increasing
Gastric pH
Cationic
Chelation P-glycoprotein
CYP
Substrate
CYP
Inhibitor
CYP
Inducer UGT1A1
Protease Inhibitors (PIs), continued 
Note: When PIs are coadministered with PK enhancers (boosters), the pharmacologic properties of both agents should be considered
when assessing potential drug interactions.
Fosampren-
avir
(FPV)
Concentration
decreased by
H2 antagonist
… Substrate,
inhibitor
3A4 3A4 3A4
(weak)
… …
Lopinavir
(LPV)
… … Substrate 3A4 3A4 … … …
Saquinavir
(SQV)
… … Substrate,
inhibitor
3A4 3A4 … … …
Tipranavir
(TPV)
… … Substrate,
inducer 
3A4 2D6 3A4, 1A2,
2C19
… …
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Efavirenz
(EFV)
… … … 2B6
(primary),
2A6, 3A4
2C9, 2C19,
3A4
3A4, 2B6 … …
Etravirine
(ETR)
… … Inducer 3A4, 2C9,
2C19
2C9, 2C19 3A4 … …
Nevirapine
(NVP)
… … … 3A4, 2B6 … 3A4, 2B6 … …
Rilpivirine
(RPV)
Concentration
decreased
… … 3A4 … … … …
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Abacavir
(ABC)
… … … … … … Substrate Alcohol
dehydrogenase
substrate
Emtricitabine
(FTC)
… … … … … … … …
Lamivudine
(3TC)
… … … … … … … …
Tenofovir
(TDF)
… … Substrate … … … … Competition of
active renal
tubular secretion
Zidovudine
(ZDV)
… … … … … … … Glucuronidation 
CCR5 Antagonist
Maraviroc
(MVC)
… … Substrate 3A4 … … … …
Fusion Inhibitor
Enfuvirtide
(T20)
… … … … … … … …
Key to Abbreviations: Al = aluminium; ARV = antiretroviral; Ca = calcium; CYP = cytochrome P; Fe = iron; MATE = multidrug and toxin
extrusion transporter; Mg = magnesium; OCT2 = organic cation transporter 2; UGT1A1 = uridine diphosphate glucuronosyltransferase; 
Zn = zinc
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Table 18. Drugs That Should Not Be Used With Antiretroviral Agents  (Last updated April 8, 2015; last
reviewed April 8, 2015)  (page 1 of 2)
This table only lists drugs that should not be coadministered at any dose, regardless of RTV or COBI enhancing. See Tables
19 and 20 for more detailed PK interaction data.
ARV
Agentsa,b
Cardiac
Agents
Lipid-
Lowering
Agents
Antimyco-
bacterial
Agents
Herbs Other Agents
ATV 
+/−
RTV or COBI
Dronedarone 
Ranolazine
Lovastatin 
Simvastatin 
Rifampin 
Rifapentined
None Lurasidone 
Midazolame
Pimozide 
Triazolam
St. John’s
wort
Boceprevir 
Simeprevir
Alfuzosin 
Cisapridef
Ergot derivatives
Irinotecan
Salmeterol 
Sildenafil for PAH
DRV/c 
or
DRV/r
Dronedarone 
Ranolazine
Lovastatin 
Simvastatin
Rifampin 
Rifapentined
None Lurasidone 
Midazolame
Pimozide 
Triazolam
St. John’s
wort
Boceprevir 
Dasabuvir 
Ombitasvir 
Paritaprevir 
Simeprevir
Alfuzosin 
Cisapridef
Ergot derivatives 
Salmeterol 
Sildenafil for PAH
FPV
+/−
RTV
Dronedarone 
Flecainide 
Propafenone 
Ranolazine
Lovastatin 
Simvastatin
Rifampin 
Rifapentined
None Lurasidone 
Midazolame
Pimozide 
Triazolam
St. John’s
wort
Boceprevir 
Dasabuvir 
Ombitasvir  
Paritaprevir 
Simeprevir
Alfuzosin 
Cisapridef
Ergot derivatives 
Salmeterol
Sildenafil for PAH
LPV/r Dronedarone
Ranolazine
Lovastatin
Simvastatin
Rifamping
Rifapentined
None Lurasidone
Midazolame
Pimozide
Triazolam
St. John’s
wort
Boceprevir
Dasabuvir
Ombitasvir 
Paritaprevir 
Simeprevir
Alfuzosin
Cisapridef
Ergot derivatives
Salmeterol
Sildenafil for PAH
SQV/r Amiodarone
Dofetilide
Dronedarone
Flecainide
Lidocaine
Propafenone
Quinidine
Ranolazine 
Lovastatin
Simvastatin
Rifamping
Rifapentined
None Lurasidone
Midazolame
Pimozide
Trazodone
Triazolam
Garlic
supple-
ments 
St. John’s
wort
Boceprevir
Dasabuvir
Ombitasvir
Paritaprevir 
Simeprevir
Alfuzosin
Cisapridef
Ergot derivatives
Salmeterol
Sildenafil for PAH
TPV/r Amiodarone
Dronedarone
Flecainide
Propafenone
Quinidine
Ranolazine
Lovastatin
Simvastatin
Rifampin
Rifapentined
None Lurasidone
Midazolame
Pimozide
Triazolam
St. John’s
wort
Boceprevir
Dasabuvir 
Ledipasvir
Ombitasvir
Paritaprevir
Simeprevir
Sofosbuvir
Alfuzosin
Cisapridef
Ergot derivatives
Salmeterol
Sildenafil for PAH
EFV None None Rifapentined None None St. John’s
wort
Boceprevir
Dasabuvir
Ombitasvir
Paritaprevir
Simeprevir
None
ETR None None Rifampin
Rifapentined
Carbamazepine
Phenobarbital
Phenytoin
None St John’s
wort
Dasabuvir
Ombitasvir
Paritaprevir
Simeprevir
Clopidogrel
NVP None None Rifapentined None None St. John’s
wort
Dasabuvir
Ombitasvir
Paritaprevir 
Simeprevir
Ketoconazole
Antiepileptic
Agents
Neurologic
Agents
HCV
Agentsc
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a DLV, IDV, NFV, and RTV (as sole PI) are not included in this table. Refer to the appropriate FDA package insert for information regarding DLV-, IDV-,
NFV-, and RTV (as sole PI)-related drug interactions.
b Certain listed drugs are contraindicated on the basis of theoretical considerations. Thus, drugs with narrow therapeutic indices and suspected metabolic
involvement with CYP450 3A, 2D6, or unknown pathways are included in this table. Actual interactions may or may not occur in patients.
c HCV agents listed include only those that are commercially available at the publication of these guidelines.
d HIV-infected patients who received rifapentine as part of a treatment regimen for TB had a higher rate of TB relapse and acquired rifamycin resistance
than those treated with other rifamycin-based regimens. Therefore an alternative agent to rifapentine is recommended for TB treatment.
e Use of oral midazolam is contraindicated. Single-dose parenteral midazolam can be used with caution and can be given in a monitored situation for
procedural sedation.
f The manufacturer of cisapride has a limited-access protocol for patients who meet specific clinical eligibility criteria.
g A high rate of Grade 4 serum transaminase elevation was seen when a higher dose of RTV was added to LPV/r or SQV or when double-dose LPV/r was
used with rifampin to compensate for rifampin’s induction effect; therefore, these dosing strategies should not be used.
Suggested alternatives to: 
• Lovastatin, simvastatin: Fluvastatin, pitavastatin, and pravastatin (except for pravastatin with DRV/r) have the least potential for drug-drug interactions
(see Table 19a). Use atorvastatin and rosuvastatin with caution; start with the lowest possible dose and titrate based on tolerance and lipid-lowering
efficacy. 
• Rifampin: Rifabutin (with dosage adjustment, see Tables 19a and 19b) 
• Midazolam, triazolam: temazepam, lorazepam, oxazepam
Key to Acronyms: ARV = antiretroviral; ATV = atazanavir; COBI = cobicistat; CYP = cytochrome P; DLV = delavirdine; DRV/c = darunavir/cobicistat;
DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; ETR = etravirine; EVG = elvitegravir; EVG/c/TDF/FTC = elvitegravir/cobicistat/tenofovir/
emtricitabine; FDA = Food and Drug Administration; FPV = fosamprenavir; FTC = emtricitabine; HCV = hepatitis C virus; IDV = indinavir; LPV/r =
lopinavir/ritonavir; MVC = maraviroc; NFV = nelfinavir; NVP = nevirapine; PAH = pulmonary arterial hypertension; PI = protease inhibitor; PI/r = ritonavir-
boosted protease inhibitor; PK = pharmacokinetic; RPV = rilpivirine; RTV = ritonavir; SQV = saquinavir; SQV/r = saquinavir/ritonavir; TB = tuberculosis;
TDF = tenofovir disoproxil fumarate; TPV/r = tipranavir/ritonavir
Table 18. Drugs That Should Not Be Used With Antiretroviral Agents  (Last updated April 8, 2015; last
reviewed April 8, 2015)  (page 2 of 2)
This table only lists drugs that should not be coadministered at any dose, regardless of RTV or COBI enhancing. See Tables
19 and 20 for more detailed PK interaction data.
ARV
Agentsa,b
Cardiac
Agents
Lipid-
Lowering
Agents
Antimyco-
bacterial
Agents
Anti-epileptic
Agents
Neurologic
Agents Herbs HCV Agents
c Other Agents
RPV None None Rifampin
Rifapentined
Carbamazepine
Oxcarbazepine
Phenobarbital
Phenytoin
None St. John’s
wort
Dasabuvir
Ombitasvir
Paritaprevir 
Proton pump
inhibitors
MVC None None Rifapentined None None St. John’s
wort
Dasabuvir
Ombitasvir
Paritaprevir 
None
EVG/c/TDF/
FTC
or 
EVG + PI/r
Ranolazine Lovastatin
Simvastatin
Rifampin
Rifapentined
None Lurasidone
Pimozide
Midazolame
Triazolam
St. John’s
wort
EVG/c/TDF/
FTC:
• Boceprevir
• Dasabuvir 
• Ledipasvir
• Ombitasvir
• Paritaprevir 
• Simeprevir
EVG + PI/r:
• Refer to agents
listed for the
selected PI
Alfuzosin
Cisapridef
Ergot derivatives
Salmeterol
Sildenafil for PAH
DTG Dofetilide None Rifapentined None None St. John’s
wort
None None
ti il ti  t c
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Table 19a. Drug Interactions Between Protease Inhibitors and Other Drugs  (Last updated April 8,
2015; last reviewed April 8, 2015)  (page 1 of 14)
This table provides known or predicted information regarding PK interactions between PIs and non-ARV drugs. When
information is available, interactions for specific pharmacologically-boosted (with either RTV or COBI) and unboosted PIs
are listed separately. The term “All PIs” refers to both unboosted and pharmacologically-boosted PI products. For interactions
between ARV agents and for dosing recommendations, refer to Tables 19c, 20a, and 20b.
Note: NFV and IDV are not included in this table. Please refer to the FDA product labels for NFV and IDV for information
regarding drug interactions with these PIs.
Concomitant
Drug PI
Effect on PI and/or Concomitant
Drug Concentrations Dosing Recommendations and Clinical Comments
Acid Reducers
Antacids
ATV, ATV/c,
ATV/r
When given simultaneously, ↓
ATV expected 
Give ATV at least 2 hours before or 1 to 2 hours after antacids or
buffered medications.
FPV APV AUC ↓ 18%; n in APV Cmin Give FPV simultaneously with (or at least 2 hours before or 1 hour
after) antacids.
TPV/r TPV AUC ↓ 27% Give TPV at least 2 hours before or 1 hour after antacids.
H2 Receptor
Antagonists
ATV
(unboosted)
↓ ATV H2 receptor antagonist single dose should not exceed a dose
equivalent to famotidine 20 mg and the total daily dose should not
exceed a dose equivalent to famotidine 20 mg BID in ART-naive
patients.
Give ATV at least 2 hours before and at least 10 hours after the H2
receptor antagonist.
ATV/c, ATV/r ↓ ATV H2 receptor antagonist dose should not exceed a dose equivalent to
famotidine 40 mg BID in ART-naive patients or 20 mg BID in ART-
experienced patients.
Give ATV 300 mg plus COBI 150 mg or RTV 100 mg simultaneously
with and/or ≥10 hours after the dose of H2 receptor antagonist.
If using TDF and H2 receptor antagonist in ART-experienced
patients, use ATV 400 mg plus COBI 150 mg or RTV 100 mg.
DRV/c, DRV/r,
LPV/r
No significant effect shown or
expected
No dosage adjustment necessary.
FPV
(unboosted)
APV AUC ↓ 30%; no significant
change in APV Cmin
If concomitant use is necessary, give FPV at least 2 hours before
H2 receptor antagonist. Consider boosting FPV with RTV.
PPIs
ATV
(unboosted)
↓ ATV PPIs are not recommended in patients receiving unboosted
ATV. In these patients, consider alternative acid-reducing agents,
RTV or COBI boosting, or alternative PIs.
ATV/c, ATV/r ↓ ATV PPIs should not exceed a dose equivalent to omeprazole 20 mg
daily in PI-naive patients. PPIs should be administered at least 12
hours before ATV/c or ATV/r.
PPIs are not recommended in PI-experienced patients.
DRV/r omeprazole AUC ↓ 42% No dosage adjustment necessary.
DRV/c No significant effect expected No dosage adjustment necessary.
FPV, FPV/r,
LPV/r
No significant effect No dosage adjustment necessary.
SQV/r SQV AUC ↑ 82% Monitor for SQV toxicities.
TPV/r ↓ omeprazole May need to increase omeprazole dose.
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Table 19a. Drug Interactions between Protease Inhibitors and Other Drugs  (Last updated April 8,
2015; last reviewed April 8, 2015)  (page 2 of 14)
Concomitant
Drug PI
Effect on PI and/or Concomitant
Drug Concentrations Dosing Recommendations and Clinical Comments
Anticoagulants
Apixaban All PIs ↑ apixaban expected Avoid concomitant use.
Dabigatran All RTV-
boosted PIs,
ATV/c, DRV/c
↑ dabigatran possible No dosage adjustment if CrCl > 50 mL/min. 
Avoid coadministration if CrCl < 50 mL/min.
Rivaroxaban All PIs ↑ rivaroxaban Avoid concomitant use.
Ticagrelor All PIs ↑ ticagrelor expected Avoid concomitant use.
Vorapaxar All PIs ↑ vorapaxar expected Avoid concomitant use.
Warfarin
PI/r ↓ warfarin possible Monitor INR closely when stopping or starting PI/r and adjust
warfarin dose accordingly.
ATV/c, DRV/c No data Monitor INR closely when stopping or starting PI/c and adjust
warfarin dose accordingly.
If switching between RTV and COBI, the effect of COBI on
warfarin is not expected to be equivalent to RTV’s effect on
warfarin.
Anticonvulsants
Carbamazepine
ATV, FPV
(unboosted)
May ↓ PI levels substantially Do not coadminister. Consider alternative anticonvulsant or
ATV/r, ATV/c, or FPV/r.
ATV/c, ATV/r,
DRV/c, FPV/r,
LPV/r, SQV/r,
TPV/r 
↑ carbamazepine possible
TPV/r ↑ carbamazepine AUC 26%
May ↓ PI levels substantially
Consider alternative anticonvulsant or monitor levels of both
drugs and assess virologic response. Do not coadminister
with LPV/r or FPV/r once daily.
DRV/r carbamazepine AUC ↑ 45%
DRV: no significant change
Monitor anticonvulsant level and adjust dose accordingly.
Ethosuximide All PIs ↑ ethosuximide possible Clinically monitor for ethosuxamide toxicities.
Lamotrigine
ATV
(unboosted)
lamotrigine: no effect No dose adjustment necessary.
ATV/r lamotrigine AUC ↓ 32%
A dose increase of lamotrigine may be needed; consider
monitoring lamotrigine concentration or consider alternative
anticonvulsant. 
LPV/r lamotrigine AUC ↓ 50%
LPV: no significant change
PI/r (other
than ATV/r or
LPV/r)
↓ lamotrigine possible 
ATV/c, DRV/c No data Monitor lamotrigine concentration or consider alternative
anticonvulsant.
and Antiplatelets
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Table 19a. Drug Interactions between Protease Inhibitors and Other Drugs  (Last updated April 8,
2015; last reviewed April 8, 2015)  (page 3 of 14)
Concomitant
Drug PI
Effect on PI and/or Concomitant
Drug Concentrations Dosing Recommendations and Clinical Comments
Anticonvulsants, continued
Phenobarbital All PIs May ↓ PI levels substantially Consider alternative anticonvulsant or monitor levels of both
drugs and assess virologic response. 
Do not coadminister with LPV/r or FPV/r once daily, or
unboosted ATV or FPV.
Phenytoin
ATV, FPV
(unboosted)
May ↓ PI levels substantially Do not coadminister. Consider alternative anticonvulsant or
boosting either ATV or FPV.
ATV/r, DRV/r,
SQV/r, TPV/r
↓ phenytoin possible 
↓ PI possible Consider alternative anticonvulsant or monitor levels of both
drugs and assess virologic response. ATV/c, DRV/c Effect on phenytoin unknown
↓ PI possible
FPV/r phenytoin AUC ↓ 22%
APV AUC ↑ 20%
Monitor phenytoin level and adjust dose accordingly. No change
in FPV/r dose recommended.
LPV/r phenytoin AUC ↓ 31%
LPV/r AUC ↓ 33%
Consider alternative anticonvulsant or monitor levels of both
drugs and assess virologic response. 
Do not coadminister with LPV/r once daily.
Valproic Acid LPV/r ↓ or n VPA possible
LPV AUC ↑ 75%
Monitor VPA levels and virologic response. Monitor for LPV-
related toxicities.
Antidepressants, 
Bupropion
LPV/r bupropion AUC ↓ 57%
Titrate bupropion dose based on clinical response.
TPV/r bupropion AUC ↓ 46%
Buspirone All PIs ↑ buspirone expected Use a low dose of buspirone with caution and titrate buspirone
dose based on clinical response.
Fluvoxamine All PIs ↑ or ↓ PI possible Consider alternative therapeutic agent.
Other Selective
Serotonin
Reuptake
Inhibitors
(SSRIs) (e.g.,
citalopram,
escitalopram,
fluoxetine,
paroxetine,
sertraline)
RTV escitalopram n
Titrate SSRI dose based on clinical response.
DRV/r paroxetine AUC ↓ 39%
sertraline AUC ↓ 49%
FPV/r paroxetine AUC ↓ 55%
ATV/r, LPV/r,
SQV/r, TPV/r
No data
ATV/c, DRV/c Effects unknown Titrate SSRI dose using the lowest available initial or
maintenance dose.
Anxiolytics, and Antipsychotics (Also see Sedative/Hypnotics section below.)
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Table 19a. Drug Interactions between Protease Inhibitors and Other Drugs  (Last updated April 8,
2015; last reviewed April 8, 2015)  (page 4 of 14)
Concomitant
Drug PI
Effect on PI and/or Concomitant
Drug Concentrations Dosing Recommendations and Clinical Comments
Antidepressants,
Quetiapine All PIs ↑ quetiapine expected Starting quetiapine in a patient receiving a PI:
• Start quetiapine at the lowest dose and titrate up as needed.
Monitor for quetiapine effectiveness and adverse effects. 
Starting a PI in a patient receiving a stable dose of quetiapine: 
• Reduce quetiapine dose to 1/6 of the original dose. Closely
monitor for quetiapine effectiveness and adverse effects.
Trazodone
All PIs except
SQV/r
RTV 200 mg BID (for 2 days) ↑
trazodone AUC 240% 
Use lowest dose of trazodone and monitor for CNS and
cardiovascular adverse effects.
SQV/r ↑ trazodone expected Contraindicated. Do not coadminister.
Tricyclic
Antidepressants
Amitriptyline,
Desipramine,
Doxepin,
Imipramine,
Nortriptyline
All RTV-
boosted PIs,
ATV/c, DRV/c
↑ TCA expected Use lowest possible TCA dose and titrate based on clinical
assessment and/or drug levels.
Antifungals
Fluconazole
ATV/c, ATV/r No significant effect observed or
expected
No dosage adjustment necessary.
SQV/r No data with RTV boosting No dosage adjustment necessary.
TPV/r TPV AUC ↑ 50% Fluconazole >200 mg daily is not recommended. If high-dose
fluconazole is indicated, consider alternative ARV.
Itraconazole All PIs ↑ itraconazole possible
↑ PI possible
Consider monitoring itraconazole level to guide dosage
adjustments. Doses >200 mg/day are not recommended with
RTV-boosted PIs, ATV/c, or DRV/c unless dosing is guided by
itraconazole levels.
Posaconazole
ATV/c ↑ ATV possible
Monitor for adverse effects of ATV. ATV/r ATV AUC ↑ 146%
ATV ATV AUC ↑ 268%
FPV With FPV 700 mg BID (without
RTV): posaconazole AUC ↓ 23%,
APV AUC similar to that with FPV
1400 mg BID
With FPV 1400 mg BID: ↑ APV
expected
If coadministered, monitor posaconazole concentrations. 
DRV/c, DRV/r,
FPV/r, LPV/r,
SQV/r, TPV/r
↑ PI possible
↑ posaconazole possible
If coadministered, consider monitoring posaconazole
concentrations. Monitor for PI adverse effects.
Anxiolytics, and Antipsychotics (Also see Sedative/Hypnotics section below.), continued
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Table 19a. Drug Interactions between Protease Inhibitors and Other Drugs  (Last updated April 8,
2015; last reviewed April 8, 2015)  (page 5 of 14)
Concomitant
Drug PI
Effect on PI and/or Concomitant
Drug Concentrations Dosing Recommendations and Clinical Comments
Antifungals, continued
Voriconazole
ATV, FPV
(unboosted)
↑ voriconazole possible
↑ PI possible
Monitor for toxicities.
All RTV-
boosted PIs
RTV 400 mg BID ↓ voriconazole AUC
82% 
RTV 100 mg BID ↓ voriconazole AUC
39% 
Do not coadminister voriconazole and RTV or COBI unless
benefit outweighs risk. If coadministered, consider monitoring
voriconazole concentration and adjust dose accordingly.
ATV/c, DRV/c Effects unknown 
Antimalarials
Artemether/
Lumefantrine
DRV/r artemether AUC ↓ 16%
DHAa AUC ↓ 18% 
lumefantrine AUC ↑ 2.5-fold
Clinical significance unknown. If used, monitor closely for anti-
malarial efficacy and lumefantrine toxicity.
DRV/c ↑ lumefantrine expected
effect on artemether unknown
LPV/r artemether AUC ↓ 40%
DHA AUC ↓ 17%
lumefantrine AUC ↑ 470%
Atovaquone/
Proguanil
ATV/r, LPV/r ATV/r ↓ atovaquone AUC 46% and ↓
proguanil AUC 41%
LPV/r ↓ atovaquone AUC 74% and ↓
proguanil AUC 38%
No dosage recommendation. Consider alternative drug for
malaria prophylaxis, if possible.
Mefloquine RTV With RTV 200 mg BID: RTV AUC ↓
31%, Cmin ↓ 43%; n mefloquine
Use with caution. Effect on exposure of RTV-boosted PIs is
unknown.
Antimycobacterials 
Bedaquiline All RTV-
boosted PIs,
ATV/c, DRV/c 
With LPV/r: bedaquiline AUC ↑ 22%,
Cmaxn
With other PI/r, ATV/c, or DRV/c: ↑
bedaquiline possible
Clinical significance unknown. Use with caution if benefit
outweighs the risk and monitor for QTc prolongation and liver
function tests.
Clarithromycin
ATV/r, ATV clarithromycin AUC ↑ 94% May cause QTc prolongation. Reduce clarithromycin dose by
50%. Consider alternative therapy (e.g., azithromycin).
ATV/c, DRV/c ↑ clarithromycin expected Consider alternative macrolide (e.g., azithromycin)
DRV/r, FPV/r,
LPV/r, SQV/r,
TPV/r
DRV/r ↑ clarithromycin AUC 57%
FPV/r ↑ clarithromycin possible
LPV/r ↑ clarithromycin expected
RTV 500 mg BID ↑ clarithromycin 77%
SQV unboosted ↑ clarithromycin 45%
TPV/r ↑ clarithromycin 19% 
clarithromycin ↑ unboosted SQV 177%
clarithromycin ↑ TPV 66%
Monitor for clarithromycin-related toxicities or consider
alternative macrolide (e.g., azithromycin).
Reduce clarithromycin dose by 50% in patients with CrCl 30–
60 mL/min.
Reduce clarithromycin dose by 75% in patients with CrCl <30
mL/min. 
FPV APV AUC ↑ 18% No dosage adjustment necessary.
(for treatment of Mycobacterium tuberculosis and non-tuberculosis mycobacterial infections)
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Table 19a. Drug Interactions between Protease Inhibitors and Other Drugs  (Last updated April 8,
2015; last reviewed April 8, 2015)  (page 6 of 14)
Concomitant
Drug PI
Effect on PI and/or Concomitant
Drug Concentrations Dosing Recommendations and Clinical Comments
Antimycobacterials 
Rifabutin
ATV
(unboosted)
↑ rifabutin AUC expected Rifabutin 150 mg daily or 300 mg three times a week 
FPV
(unboosted)
No data Consider alternative ARV.
ATV/c, DRV/c ↑ rifabutin expected
Rifabutin 150 mg once daily or 300 mg three times a week.
Monitor for antimycobacterial activity and consider therapeutic
drug monitoring. 
PK data reported in this table are results from healthy volunteer
studies. Lower rifabutin exposure has been reported in HIV-
infected patients than in the healthy study participants.
ATV/r Compared with rifabutin (300 mg once
daily) alone, rifabutin (150 mg once
daily) with ATV/r, rifabutin AUC ↑
110% and metabolite AUC ↑ 2101%
DRV/r Compared with rifabutin (300 mg once
daily) alone, rifabutin (150 mg every
other day) with DRV/r, rifabutin AUC
n and metabolite AUC ↑ 881%
FPV/r Compared with rifabutin (300 mg once
daily) alone, rifabutin (150 mg every
other day) with FPV/r, rifabutin and
metabolite AUC ↑ 64%.
LPV/r Compared with rifabutin (300 mg
daily) alone, rifabutin (150 mg once
daily) with LPV/r, rifabutin and
metabolite AUC ↑ 473%.
SQV/r ↑ rifabutin with unboosted SQV
TPV/r rifabutin and metabolite AUC ↑ 333%
Rifampin All PIs ↓ PI concentration by >75% Do not coadminister rifampin and PIs. Additional RTV does
not overcome this interaction and increases hepatotoxicity.
Additional COBI is not recommended. Consider rifabutin if a
rifamycin is indicated.
Rifapentine All PIs ↓ PI expected Do not coadminister.
Cardiac Medications
Amiodarone
SQV/r, TPV/r ↑ both amiodarone and PI possible Do not coadminister.
All PIs
(except
SQV/r, TPV/r)
↑ both amiodarone and PI possible Use with caution. Monitor for amiodarone toxicity and consider
ECG and amiodarone drug level monitoring.
Antiarrhythmics
(e.g., dofetilide,
dronedarone,
flecainide,
lidocaine,
propafenone,
quinidine)
SQV/r ↑ antiarrhythmic possible Do not coadminister.
All PIs ↑ antiarrhythmic possible Use with caution. Refer to Table 18 for contraindicated
combinations.
(for treatment of Mycobacterium tuberculosis and non-tuberculosis mycobacterial infections), continued
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Table 19a. Drug Interactions between Protease Inhibitors and Other Drugs  (Last updated April 8,
2015; last reviewed April 8, 2015)  (page 7 of 14)
Concomitant
Drug PI
Effect on PI and/or Concomitant
Drug Concentrations Dosing Recommendations and Clinical Comments
Cardiac Medications, continued 
Beta-blockers
(e.g., metoprolol,
timolol)
All PIs ↑ beta-blockers possible May need to decrease beta-blocker dose; adjust dose based on
clinical response.
Consider using beta-blockers that are not metabolized by
CYP450 enzymes (e.g., atenolol, labetalol, nadolol, sotalol).
Bosentan All PIs LPV/r ↑ bosentan 48-fold (day 4)
and 5-fold (day 10)
↓ ATV expected
Do not coadminister bosentan and unboosted ATV. 
In Patients on a PI (Other than Unboosted ATV) >10 Days: 
• Start bosentan at 62.5 mg once daily or every other day. 
In Patients on Bosentan who Require a PI (Other than
Unboosted ATV): 
• Stop bosentan ≥36 hours before PI initiation and 10 days after
PI initiation restart bosentan at 62.5 mg once daily or every
other day.
When switching between COBI and RTV: 
• Maintain same bosentan dose.
Calcium
Channel
Blockers
(CCBs) (except
diltiazem)
All PIs ↑ dihydropyridine possible
↑ verapamil possible
Use with caution. Titrate CCB dose and monitor closely. ECG
monitoring is recommended when CCB used with ATV and SQV. 
Digoxin PI/r, ATV/c, or
DRV/c
RTV (200 mg BID) ↑ digoxin AUC
29% and ↑ half-life 43%
SQV/r ↑ digoxin AUC 49%
DRV/r ↑ digoxin AUC 36%
COBI ↑ digoxin Cmax 41%, AUC n
Use with caution. Monitor digoxin levels. Digoxin dose may need
to be decreased. Titrate initial digoxin dose.
Diltiazem
ATV/c, ATV/r,
ATV
Unboosted ATV ↑ diltiazem AUC
125%
Greater ↑ likely with ATV/c or ATV/r
Decrease diltiazem dose by 50%. ECG monitoring is
recommended.
DRV/c, DRV/r,
FPV/r, FPV,
LPV/r, SQV/r,
TPV/r
↑ diltiazem possible Use with caution. Adjust diltiazem according to clinical response
and toxicities.
Corticosteroids
Beclomethasone
Inhaled
DRV/r RTV 100 mg BID ↑ 17-BMP AUC 2-
fold and ↑ Cmax 1.6-fold 
(DRV 600 mg + RTV 100 mg) BID ↓
17-BMP AUC 11% and ↓ Cmax 19%
No dosage adjustment necessary. 
Significant interaction between beclomethasone (inhaled or
intranasal) and other RTV-boosted PIs, ATV/c, or DRV/c is not
expected.
Budesonide
Systemic
All PIs ↓ PI levels possible
↑ glucocorticoids
Coadministration can result in adrenal insufficiency and
Cushing’s syndrome. Do not coadminister unless potential
benefits of systemic budesonide outweigh the risks of
systemic corticosteroid adverse effects.
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Concomitant Drug PI Effect on PI and/or ConcomitantDrug Concentrations Dosing Recommendations and Clinical Comments
Corticosteroids, continued 
Budesonide,
Fluticasone,
Mometasone
Inhaled or
Intranasal
All RTV- or
COBI-boosted
PIs
↑ glucocorticoids possible
RTV 100 mg BID ↑ fluticasone AUC
350-fold and ↑ Cmax 25-fold
Coadministration can result in adrenal insufficiency and
Cushing’s syndrome. Do not coadminister unless potential
benefits of inhaled or intranasal corticosteroid outweigh
the risks of systemic corticosteroid adverse effects.
Consider alternative corticosteroid (e.g., beclomethasone).
Dexamethasone
Systemic
All PIs ↓ PI levels possible Use systemic dexamethasone with caution. Consider
alternative corticosteroid for long-term use.
Prednisone
LPV/r ↑ prednisolone AUC 31% Use with caution. Coadministration can result in adrenal
insufficiency and Cushing’s syndrome. Do not coadminister
unless potential benefits of prednisone outweigh the
risks of systemic corticosteroid adverse effects.
All PIs ↑ prednisolone possible
Methyl-
prednisolone,
Prednisolone,
Triamcinolone
(local injections,
including intra-
articular, epidural,
intra-orbital)
All RTV- or
COBI-
boosted PIs 
↑ glucocorticoids expected Do not coadminister. Coadministration can result in adrenal
insufficiency and Cushing’s syndrome. 
Hepatitis C 
Boceprevir
ATV/r ATV AUC ↓ 35%, Cmin ↓ 49%
boceprevir AUC n
Do not coadminister.
ATV/c, DRV/c Effects unknown Do not coadminister.
DRV/r DRV AUC ↓ 44%, Cmin ↓ 59%
boceprevir AUC ↓ 32%, Cmin ↓ 35%
Do not coadminister.
LPV/r LPV AUC ↓ 34%, Cmin ↓ 43%
boceprevir AUC ↓ 45%, Cmin ↓
57%
Do not coadminister. 
Dasabuvir +
Paritaprevir/
Ombitasvir/RTV
ATV ATV n ATV 300 mg alone, without COBI or additional RTV, should
be given in the morning with dasabuvir + paritaprevir/
ombitasvir/RTV.
DRV DRV Cmin ↓ 43% to 48% Do not coadminister.
LPV/r paritaprevir AUC ↑ 117% Do not coadminister.
ATV/c, DRV/c,
FPV, SQV,
TPV
No data Do not coadminister.
Direct-Acting Antiviral Agents
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Concomitant
Drug PI
Effect on PI and/or Concomitant
Drug Concentrations Dosing Recommendations and Clinical Comments
Hepatitis C 
Ledipasvir/
Sofosbuvir
ATV/r ATV AUC ↑ 33%
ledipasvir AUC ↑ 113%
sofosbuvir: no significant effect
No dosage adjustment necessary.
Coadministration of ledipasvir/sofosbuvir with TDF and a PI/r
results in increased exposure to TDF. The safety of the increased
TDF exposure has not been established. Consider alternative HCV
or ARV drugs to avoid increased TDF toxicities. If coadministration
is necessary, monitor for TDF-associated adverse reactions.
DRV/r DRV: no significant effect expected
ledipasvir/sofosbuvir: no significant
effect
ATV/c, DRV/c,
FPV, FPV/r,
LPV/r, SQV/r
No significant effect expected
TPV/r ↓ ledipasvir and sofosbuvir expected Do not coadminister.
Simeprevir All PIs Compared with simeprevir 150 mg
alone, simeprevir 50 mg plus DRV/r
800/100 mg daily, simeprevir AUC
↑ 159% 
RTV 100 mg BID ↑ simeprevir AUC
618%
Do not coadminister.
Herbal Products
St. John’s Wort All PIs ↓ PI expected Do not coadminister.
Hormonal Contraceptives
Hormonal
Contraceptives
(oral)
ATV
(unboosted)
ethinyl estradiol AUC ↑ 48%
norethindrone AUC ↑ 110%
Prescribe oral contraceptive that contains no more than 30 mcg of
ethinyl estradiol or recommend alternative contraceptive method. 
Oral contraceptives containing less than 25 mcg of ethinyl
estradiol or progestins other than norethindrone or norgestimate
have not been studied.c
ATV/r ethinyl estradiol AUC ↓ 19% and
Cmin ↓ 37%
norgestimate ↑ 85% 
Oral contraceptive should contain at least 35 mcg of ethinyl estradiol. 
Oral contraceptives containing progestins other than norethindrone
or norgestimate have not been studied.b
ATV/c, DRV/c Effects unknown Recommend alternative or additional contraceptive method or
alternative ARV drug.
DRV/r, FPV/r,
LPV/r, SQV/r,
TPV/r
ethinyl estradiol AUC ↓ 37% to 48%
norethindrone AUC ↓ 14% to 34%
With TPV/r: norethindrone AUC n
Recommend alternative or additional contraceptive method or
alternative ARV drug.
FPV With APV: ↑ ethinyl estradiol and 
↑ norethindrone Cmin; APV Cmin↓ 20% 
Recommend alternative contraceptive method or alternative ARV
drug.
Etonogestrel-
releasing
subdermal
implant
LPV/r etonogestrel AUC ↑ 52% and Cmin↑ 34%
Use standard dose.
All other PIs No data Recommend alternative or additional contraceptive method or
alternative ARV drug.
Direct-Acting Antiviral Agents, continued
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Concomitant
Drug PI
Effect on PI and/or Concomitant
Drug Concentrations Dosing Recommendations and Clinical Comments
Hormonal Contraceptives, continued
Transdermal
ethinyl
estradiol/
norelgestromin
LPV/r LPV n
ethinyl estradiol AUC ↓ 45%,
norelgestromin AUC ↑ 83%
Use standard dose.
All other PIs No data Recommend alternative or additional contraceptive method or
alternative ARV drug.
HMG-CoA Reductase Inhibitors
Atorvastatin
ATV, ATV/c,
ATV/r, DRV/c
↑ atorvastatin possible Titrate atorvastatin dose carefully and use lowest dose necessary.
DRV/r 
FPV, FPV/r, 
SQV/r
DRV/r plus atorvastatin 10 mg
similar to atorvastatin 40 mg
administered alone
FPV +/– RTV ↑ atorvastatin AUC
130% to 153%
SQV/r ↑ atorvastatin AUC 79%
Titrate atorvastatin dose carefully and use the lowest necessary
dose. Do not exceed 20 mg atorvastatin daily. 
LPV/r LPV/r ↑ atorvastatin AUC 488% Use with caution and use the lowest atorvastatin dose necessary.
TPV/r ↑ atorvastatin AUC 836% Do not coadminister.
Lovastatin All PIs Significant ↑ lovastatin expected Contraindicated. Do not coadminister.
Pitavastatin All PIs ATV ↑ pitavastatin AUC 31%, Cmax↑ 60%
ATV: no significant effect 
DRV/r: no significant effect 
LPV/r ↓ pitavastatin AUC 20%
LPV: no significant effect
No dose adjustment necessary.
Pravastatin
ATV/c, ATV/r No data Use lowest starting dose of pravastatin and monitor for efficacy
and adverse effects. 
DRV/c, DRV/r With DRV/r, pravastatin AUC 
• ↑ 81% following single dose of
pravastatin
• ↑ 23% at steady state
Use lowest possible starting dose of pravastatin with careful
monitoring. 
LPV/r pravastatin AUC ↑ 33% No dose adjustment necessary.
SQV/r pravastatin AUC ↓ 47% to 50% No dose adjustment necessary.
Downloaded from http://aidsinfo.nih.gov/guidelines on 9/16/2015
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents                                 L-16
Table 19a. Drug Interactions between Protease Inhibitors and Other Drugs  (Last updated April 8,
2015; last reviewed April 8, 2015)  (page 11 of 14)
Concomitant
Drug PI
Effect on PI and/or Concomitant
Drug Concentrations Dosing Recommendations and Clinical Comments
HMG-CoA Reductase Inhibitors, continued
Rosuvastatin
ATV/c, DRV/c ↑ rosuvastatin possible Titrate rosuvastatin dose carefully and use the lowest necessary
dose while monitoring for toxicities.
ATV/r, LPV/r ATV/r ↑ rosuvastatin AUC 3-fold
and Cmax ↑ 7-fold 
LPV/r ↑ rosuvastatin AUC 108%
and Cmax ↑ 366%
Titrate rosuvastatin dose carefully and use the lowest necessary
dose. Do not exceed 10 mg rosuvastatin daily.
DRV/r rosuvastatin AUC ↑ 48% and Cmax↑ 139%
Titrate rosuvastatin dose carefully and use the lowest necessary
dose while monitoring for toxicities.
FPV +/- RTV No significant effect on rosuvastatin No dosage adjustment necessary.
SQV/r No data available Titrate rosuvastatin dose carefully and use the lowest necessary
dose while monitoring for toxicities.
TPV/r rosuvastatin AUC ↑ 26% and Cmax↑ 123%
No dosage adjustment necessary.
Simvastatin All PIs Significant ↑ simvastatin level:
SQV/r 400 mg/400 mg BID ↑
simvastatin AUC 3059%
Contraindicated. Do not coadminister.
Immunosuppressants
Cyclosporine
Everolimus
Sirolimus
Tacrolimus
All PIs ↑ immunosuppressant expected Initiate with an adjusted dose of immunosuppressant to account
for potential increased concentrations of the immunosuppressant
and monitor for toxicities. Therapeutic drug monitoring of
immunosuppressant is recommended. Consult with specialist as
necessary.
Narcotics and Treatment for Opioid Dependence
Buprenorphine
ATV
(unboosted)
buprenorphine AUC ↑ 93%
norbuprenorphined AUC ↑ 76%
↓ ATV possible
Do not coadminister buprenorphine with unboosted ATV.
ATV/r buprenorphine AUC ↑ 66%
norbuprenorphined AUC ↑ 105%
Monitor for sedation. Buprenorphine dose reduction may be
necessary.
ATV/c, DRV/c Effects unknown Titrate buprenorphine dose using the lowest initial dose. Dose
adjustment of buprenorphine may be needed. Clinical monitoring
is recommended. 
DRV/r buprenorphine: no significant effect
norbuprenorphined AUC ↑ 46% and
Cmin ↑ 71%
No dosage adjustment necessary. Clinical monitoring is
recommended.
FPV/r buprenorphine: no significant effect
norbuprenorphined AUC ↓ 15%
No dosage adjustment necessary. Clinical monitoring is
recommended. 
LPV/r No significant effect No dosage adjustment necessary.
TPV/r buprenorphine: no significant effect
norbuprenorphined AUC, Cmax, and
Cmin ↓ 80%
TPV Cmin ↓ 19% to 40%
Consider monitoring TPV level.
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Concomitant
Drug PI
Effect on PI and/or Concomitant
Drug Concentrations Dosing Recommendations and Clinical Comments
Narcotics and Treatment for Opioid Dependence, continued
Fentanyl All PIs ↑ fentanyl possible Clinical monitoring is recommended, including for potentially fatal
respiratory depression.
Methadone
ATV
(unboosted)
No significant effect No dosage adjustment necessary.
ATV/c, DRV/c Effects unknown Titrate methadone dose using the lowest feasible initial dose.
Dose adjustment of methadone may be needed. Clinical
monitoring is recommended.
FPV
(unboosted)
No data with unboosted FPV
APV ↓ R-methadonee Cmin 21%,
AUC no significant change
Monitor and titrate methadone as clinically indicated. The
interaction with FPV is presumed to be similar to that with APV.
RTV-boosted
PIs
ATV/r, DRV/r, and FPV/r  
↓ R-methadonee AUC 16% to 18%
LPV/r ↓ methadone AUC 26% to
53%
SQV/r 1000/100 mg BID 
↓ R-methadonee AUC 19%
TPV/r ↓ R-methadonee AUC 48%
Opioid withdrawal unlikely but may occur. Dosage adjustment of
methadone is not usually required, but monitor for opioid
withdrawal and increase methadone dose as clinically indicated.
Oxycodone LPV/r oxycodone AUC ↑ 2.6-fold Monitor for opioid-related adverse effects. Oxycodone dose
reduction may be necessary.
Phosphodiesterase Type 5 (PDE5) Inhibitors
Avanafil
All PIs except
unboosted
FPV
RTV (600 mg BID for 5 days) ↑
avanafil AUC 13-fold, Cmax 2.4-fold
Coadministration is not recommended.
ATV, FPV
(unboosted)
No data Avanafil dose should not exceed 50 mg once every 24 hours. 
Sildenafil All PIs DRV/r plus sildenafil 25 mg similar
to sildenafil 100 mg alone
RTV 500 mg BID ↑ sildenafil AUC
1,000%
SQV unboosted ↑ sildenafil AUC
210%
For Treatment of Erectile Dysfunction:
• Start with sildenafil 25 mg every 48 hours and monitor for
adverse effects of sildenafil.
For Treatment of PAH:
• Contraindicated
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Drug PI
Effect on PI and/or Concomitant
Drug Concentrations Dosing Recommendations and Clinical Comments
Phosphodiesterase Type 5 (PDE5) Inhibitors, continued
Tadalafil All PIs RTV 200 mg BID ↑ tadalafil AUC
124%
TPV/r (1st dose) ↑ tadalafil AUC
133%
TPV/r steady state: no significant
effect 
For Treatment of Erectile Dysfunction:
• Start with tadalafil 5-mg dose and do not exceed a single dose of
10 mg every 72 hours. Monitor for adverse effects of tadalafil.
For Treatment of PAH
In patients on a PI >7 days:
• Start with tadalafil 20 mg once daily and increase to 40 mg once
daily based on tolerability.
In patients on tadalafil who require a PI:
• Stop tadalafil ≥24 hours before PI initiation. 7 days after PI
initiation restart tadalafil at 20 mg once daily, and increase to 40
mg once daily based on tolerability.
In patients switching between COBI and RTV:
• Maintain tadalafil dose.
For Treatment of Benign Prostatic Hyperplasia:
• Maximum recommended daily dose is 2.5 mg per day.
Vardenafil All PIs RTV 600 mg BID ↑ vardenafil AUC
49-fold
Start with vardenafil 2.5 mg every 72 hours and monitor for
adverse effects of vardenafil.
Sedative/Hypnotics
Alprazolam 
Diazepam
All PIs ↑ benzodiazepine possible
RTV (200 mg BID for 2 days) ↑
alprazolam half-life 222% and AUC
248% 
Consider alternative benzodiazepines such as lorazepam,
oxazepam, or temazepam.
Lorazepam
Oxazepam
Temazepam
All PIs No data These benzodiazepines are metabolized via non-CYP450
pathways; thus, there is less interaction potential than with other
benzodiazepines.
Midazolam All PIs ↑ midazolam expected
SQV/r ↑ midazolam (oral) AUC
1144% and Cmax 327%
Do not coadminister oral midazolam and PIs.
Parenteral midazolam can be used with caution when given as a
single dose in a monitored situation for procedural sedation.
Suvorexant All PIs ↑ suvorexant expected Coadministration is not recommended.
Triazolam All PIs ↑ triazolam expected
RTV (200 mg BID) ↑ triazolam half-
life 1200% and AUC 2000%
Do not coadminister. 
Zolpidem PI/r or ATV/c
or DRV/c
↑ zolpidem possible Initiate zolpidem at a low dose. Dose reduction may be necessary.
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Drug PI
Effect on PI and/or Concomitant
Drug Concentrations Dosing Recommendations and Clinical Comments
Miscellaneous Drugs
Colchicine All PIs RTV 100 mg BID ↑ colchicine AUC
296%, Cmax 184%
With all PIs with or without COBI or
RTV: significant ↑ colchicine
expected
For Treatment of Gout Flares:
• Colchicine 0.6 mg x 1 dose, followed by 0.3 mg 1 hour later. Do
not repeat dose for at least 3 days.
With FPV without RTV: 
• 1.2 mg x 1 dose and no repeat dose for at least 3 days
For Prophylaxis of Gout Flares:
• Colchicine 0.3 mg once daily or every other day
With FPV without RTV: 
• Colchicine 0.3 mg BID or 0.6 mg once daily or 0.3 mg once daily
For Treatment of Familial Mediterranean Fever:
• Do not exceed colchicine 0.6 mg once daily or 0.3 mg BID. 
With FPV without RTV: 
• Do not exceed 1.2 mg once daily or 0.6 mg BID.
Do not coadminister in patients with hepatic or renal
impairment.
Salmeterol All PIs ↑ salmeterol possible Do not coadminister because of potential increased risk of
salmeterol-associated cardiovascular events. 
a DHA is an active metabolite of artemether.
b The following products contain at least 35 mcg of ethinyl estradiol combined with norethindrone or norgestimate (generic formulation may
also be available): Brevicon; Femcon Fe; Modicon; Norinyl 1/35; Ortho-Cyclen; Ortho-Novum 1/35, 7/7/7; Ortho Tri-Cyclen; Ovcon 35; Tri-
Norinyl.
c The following products contain no more than 30 mcg of ethinyl estradiol combined with norethindrone or norgestimate (generic
formulation may also be available): Lo Minastrin Fe; Lo Loestrin Fe; Loestrin 1/20, 1.5/30; Loestrin Fe 1/20, 1.5/30; Loestrin 24 Fe;
Minastrin 24 Fe; Ortho Tri-Cyclen Lo.
d Norbuprenorphine is an active metabolite of buprenorphine.
e R-methadone is the active form of methadone.
Key to Symbols: ↑ = increase, ↓ = decrease, n = no change
Key to Acronyms: 17-BMP = beclomethasone 17-monopropionate; APV = amprenavir; ART = antiretroviral therapy; ARV = antiretroviral;
ATV = atazanavir; ATV/c = cobicistat-boosted atazanavir; ATV/r = ritonavir-boosted atazanavir; AUC = area under the curve; BID = twice
daily; Cmax = maximum plasma concentration; Cmin = minimum plasma concentration; CNS = central nervous system; COBI = cobicistat;
CrCl = creatinine clearance; CYP = cytochrome P; DHA = dihydroartemisinin; DRV = darunavir; DRV/c = cobicistat-boosted darunavir;
DRV/r = ritonavir-boosted darunavir; ECG = electrocardiogram; FPV = fosamprenavir; FPV/r = ritonavir-boosted fosamprenavir; HCV =
hepatitis C virus; INR = international normalized ratio; LPV = lopinavir; LPV/r = ritonavir-boosted lopinavir; PAH = pulmonary arterial
hypertension; PI = protease inhibitor; PI/c = cobicistat-boosted protease inhibitor; PI/r = ritonavir-boosted protease inhibitor; PK =
pharmacokinetic; PPI = proton pump inhibitor; QTc = QT corrected for heart rate; RTV = ritonavir; SQV = saquinavir; SQV/r = ritonavir-
boosted saquinavir; TCA = tricyclic antidepressant; TDF = tenofovir disoproxil fumarate; TPV = tipranavir; TPV/r = ritonavir-boosted
tipranavir; VPA = valproic acid
Note: FPV is a pro-drug of APV.
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Table 19b. Drug Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors and Other
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This table provides information relating to PK interactions between NNRTIs and non-ARV drugs. For interactions between
ARV agents and for dosing recommendations, refer to Tables 19c, 20a and 20b.
Note: DLV is not included in this table. Please refer to the DLV FDA package insert for information regarding drug
interactions.
Concomitant Drug
Class/Name NNRTI
a Effect on NNRTI and/or
Concomitant Drug Concentrations Dosing Recommendations and Clinical Comments
Acid Reducers
Antacids RPV ↓ RPV expected when given
simultaneously
Give antacids at least 2 hours before or at least 4 hours
after RPV.
H2 Receptor
Antagonists
RPV ↓ RPV Give H2-receptor antagonists at least 12 hours before or
at least 4 hours after RPV.
PPIs RPV With omeprazole 20 mg daily:
• RPV AUC ↓ 40%, Cmin ↓ 33%
Contraindicated. Do not coadminister.
Anticoagulants/Antiplatelets
Warfarin
EFV, NVP ↑ or ↓ warfarin possible Monitor INR and adjust warfarin dose accordingly.
ETR ↑ warfarin possible Monitor INR and adjust warfarin dose accordingly.
Clopidogrel ETR ↓ activation of clopidogrel possible ETR may prevent metabolism of clopidogrel (inactive) to
its active metabolite. Avoid coadministration, if possible.
Anticonvulsants
Carbamazepine
Phenobarbital
Phenytoin
EFV Carbamazepine plus EFV: 
• Carbamazepine AUC ↓ 27% 
• EFV AUC ↓ 36%
Phenytoin plus EFV:
• ↓ EFV 
• ↓ phenytoin possible
Monitor anticonvulsant and EFV levels or, if possible, use
alternative anticonvulsant to those listed.
ETR ↓ anticonvulsant and ETR possible Do not coadminister. Consider alternative
anticonvulsant. 
NVP ↓ anticonvulsant and NVP possible Monitor anticonvulsant and NVP levels and virologic
responses or consider alternative anticonvulsant.
RPV ↓ RPV possible Contraindicated. Do not coadminister. Consider
alternative anticonvulsant.
Antidepressants
Bupropion EFV Bupropion AUC ↓ 55% Titrate bupropion dose based on clinical response.
Paroxetine EFV, ETR No significant effect No dosage adjustment necessary.
Sertraline EFV Sertraline AUC ↓ 39% Titrate sertraline dose based on clinical response.
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Concomitant Drug
Class/Name NNRTI
a Effect on NNRTI and/or
Concomitant Drug Concentrations Dosing Recommendations and Clinical Comments
Antifungals
Fluconazole
EFV No significant effect No dosage adjustment necessary.
ETR ETR AUC ↑ 86% No dosage adjustment necessary. Use with caution. 
NVP NVP AUC ↑ 110% Increased risk of hepatotoxicity possible with this
combination. Monitor NVP toxicity or use alternative ARV
agent.
RPV ↑ RPV possible No dosage adjustment necessary. Clinically monitor for
breakthrough fungal infection. (RPV 150 mg/day reduces
ketoconazole exposure; no data on interaction with
fluconazole.)
Itraconazole
EFV Itraconazole and OH-itraconazole
AUC, Cmax, and Cmin ↓ 35% to 44%
Failure to achieve therapeutic itraconazole concentrations
has been reported. Avoid this combination if possible. If
coadministered, closely monitor itraconazole
concentration and adjust dose accordingly.
ETR ↓ itraconazole possible
↑ ETR possible
Dose adjustments for itraconazole may be necessary.
Monitor itraconazole level and antifungal response.
NVP ↓ itraconazole possible
↑ NVP possible
Avoid combination if possible. If coadministered, monitor
itraconazole concentration and adjust dose accordingly.
RPV ↑ RPV possible No dosage adjustment necessary. Clinically monitor for
breakthrough fungal infection. (RPV 150 mg/day reduces
ketoconazole exposure; no data on interaction with
itraconazole.)
Posaconazole
EFV Posaconazole AUC ↓ 50%
n EFV
Avoid concomitant use unless the benefit outweighs the
risk. If coadministered, monitor posaconazole
concentration and adjust dose accordingly.
ETR ↑ ETR possible No dosage adjustment necessary.
RPV ↑ RPV possible No dosage adjustment necessary. Clinically monitor for
breakthrough fungal infection. (RPV 150 mg/day reduces
ketoconazole exposure; no data on interaction with
posaconazole.)
Voriconazole
EFV Voriconazole AUC ↓ 77%
EFV AUC ↑ 44%
Contraindicated at standard doses.
Dose adjustment: 
• Voriconazole 400 mg BID, EFV 300 mg daily
ETR Voriconazole AUC ↑ 14%
ETR AUC ↑ 36%
No dosage adjustment necessary; use with caution.
Consider monitoring voriconazole level.
NVP ↓ voriconazole possible
↑ NVP possible
Monitor for toxicity and antifungal response and/or
voriconazole level. 
RPV ↑ RPV possible No dosage adjustment necessary. Clinically monitor for
breakthrough fungal infection. (RPV 150 mg/day reduces
ketoconazole exposure; no data on interaction with
voriconazole.)
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Concomitant Drug
Class/Name NNRTI
a Effect on NNRTI and/or
Concomitant Drug Concentrations Dosing Recommendations and Clinical Comments
Antimalarials
Artemether/
Lumefantrine
EFV Artemether AUC ↓ 79%
DHA AUC ↓ 75%
Lumefantrine AUC ↓ 56%
Clinical significance of the reduced antimalarial drug
concentrations unknown. If used in combination with EFV,
monitor closely for anti-malarial efficacy.
ETR Artemether AUC ↓ 38%
DHA AUC ↓ 15%
Lumefantrine AUC ↓ 13%
ETR AUC ↑ 10%
Clinical significance of the reduced antimalarial drug
concentrations unknown. If used in combination with ETR,
monitor closely for anti-malarial efficacy.
NVP Artemether AUC ↓ 72%
DHA AUC ↓ 37%
Lumefantrine: 
• Study results are conflicting:
lumefantrine AUC ↓ 25% in one
study but ↑ 55.6% in another.
Clinical significance unknown. If used, monitor closely for
anti-malarial efficacy and lumefantrine toxicity.
Atovaquone/
Proguanil
EFV Atovaquone AUC ↓ 75%
Proguanil AUC ↓ 43%
No dosage recommendation. Consider alternative drug for
malaria prophylaxis, if possible.
Antimycobacterials
Bedaquiline EFV, NVP n bedaquiline AUC No dosage adjustment necessary.
Clarithromycin
EFV Clarithromycin AUC ↓ 39% Monitor for effectiveness or consider alternative agent,
such as azithromycin, for MAC prophylaxis and treatment. 
ETR Clarithromycin AUC ↓ 39%
ETR AUC ↑ 42%
Consider alternative agent, such as azithromycin, for MAC
prophylaxis and treatment. 
NVP Clarithromycin AUC ↓ 31% Monitor for effectiveness or use alternative agent, such as
azithromycin, for MAC prophylaxis and treatment.
RPV n clarithromycin expected
↑ RPV possible
Consider alternative macrolide, such as azithromycin, for
MAC prophylaxis and treatment.
Rifabutin
EFV Rifabutin ↓ 38% Dose:
• Rifabutin 450–600 mg/day; or 
• Rifabutin 600 mg 3 times/week if EFV is not
coadministered with a PI.
ETR Rifabutin and metabolite AUC ↓ 17%
ETR AUC ↓ 37%
If ETR is used with an RTV-boosted PI, rifabutin
should not be coadministered.
Dose: 
• Rifabutin 300 mg once daily if ETR is not
coadministered with an RTV-boosted PI. 
NVP Rifabutin AUC ↑ 17% and metabolite
AUC ↑ 24%
NVP Cmin ↓ 16%
No dosage adjustment necessary. Use with caution.
RPV RPV AUC ↓ 46% Increase RPV to 50 mg once daily.
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Table 19b. Drug Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors and Other
Drugs  (Last updated April 8, 2015; last reviewed April 8, 2015)  (page 4 of 7)
Concomitant Drug
Class/Name NNRTI
a Effect on NNRTI and/or
Concomitant Drug Concentrations Dosing Recommendations and Clinical Comments
Antimycobacterials, continued
Rifampin
EFV EFV AUC ↓ 26% Maintain EFV dose at 600 mg once daily and monitor for
virologic response. Consider therapeutic drug monitoring.
Some clinicians suggest EFV 800 mg dose in patients
who weigh more than 60 kg.
ETR Significant ↓ ETR possible Do not coadminister.
NVP NVP ↓ 20% to 58% Do not coadminister.
RPV RPV AUC ↓ 80% Contraindicated. Do not coadminister.
Rifapentine EFV, ETR,
NVP, RPV
↓ NNRTI expected Do not coadminister.
Benzodiazepines
Alprazolam EFV, ETR,
NVP, RPV
No data Monitor for therapeutic effectiveness of alprazolam.
Diazepam ETR ↑ diazepam possible Decreased dose of diazepam may be necessary.
Lorazepam EFV Lorazepam Cmax ↑ 16%, AUC ↔ No dosage adjustment necessary.
Midazolam EFV Significant ↑ midazolam expected Do not coadminister with oral midazolam.
Parenteral midazolam can be used with caution as a
single dose and can be given in a monitored situation for
procedural sedation.
Triazolam EFV Significant ↑ triazolam expected Do not coadminister.
Cardiac Medications
Dihydropyridine
CCBs
EFV, NVP ↓ CCBs possible Titrate CCB dose based on clinical response.
Diltiazem
Verapamil
EFV Diltiazem AUC ↓ 69%
↓ verapamil possible Titrate diltiazem or verapamil dose based on clinical
response.
NVP ↓ diltiazem or verapamil possible
Corticosteroids
Dexamethasone
EFV, ETR,
NVP
↓ EFV, ETR, NVP possible Consider alternative corticosteroid for long-term use. If
dexamethasone is used with NNRTI, monitor virologic
response.
RPV Significant ↓ RPV possible Contraindicated with more than a single dose of
dexamethasone.
Hepatitis C 
Boceprevir
EFV EFV AUC ↑ 20%
Boceprevir AUC ↓ 19%, Cmin ↓ 44%
Coadministration is not recommended.
ETR ETR AUC ↓ 23% 
Boceprevir AUC, Cmax ↑ 10% 
No dosage adjustment necessary.
Direct-Acting Antiviral Agents 
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Table 19b. Drug Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors and Other
Drugs  (Last updated April 8, 2015; last reviewed April 8, 2015)  (page 5 of 7)
Concomitant Drug
Class/Name NNRTI
a Effect on NNRTI and/or
Concomitant Drug Concentrations Dosing Recommendations and Clinical Comments
Hepatitis C 
Dasabuvir 
plus 
Parataprevir/
Ombitasivir/RTV
EFV No data Contraindicated. Do not coadminister.
ETR, NVP ↓ DAAs possible Do not coadminister.
RPV RPV AUC ↑ 150% to 225% Do not coadminister because of potential for QT
interval prolongation with higher concentrations of
RPV.
Ledipasvir/
Sofosbuvir
EFV Ledipasvir AUC, Cmin, Cmax – all ↓
34%
Sofosbuvir: no significant effect No dosage adjustment necessary.
ETR, NVP,
RPV
No significant effect expected
Simeprevir
EFV Simeprevir AUC ↓ 71%, Cmin ↓ 91%
n EFV 
Coadministration is not recommended.
ETR, NVP ↓ simeprevir expected Coadministration is not recommended.
RPV n simeprevir and RPV No dosage adjustment necessary.
Herbal Products
St. John’s Wort EFV, ETR,
NVP, RPV
↓ NNRTI Do not coadminister.
Hormonal Contraceptives
Hormonal
Contraceptives
EFV Ethinyl estradiol n
Levonorgestrel AUC ↓ 83%
Norelgestromin AUC ↓ 64%
Etonogestrel (implant) AUC ↓ 63%
Use alternative or additional contraceptive methods.
Norelgestromin and levonorgestrel are active metabolites
of norgestimate.
ETR Ethinyl estradiol AUC ↑ 22%
Norethindrone: no significant effect
No dosage adjustment necessary.
NVP
Ethinyl estradiol AUC ↓ 20%
Norethindrone AUC ↓ 19% 
Use alternative or additional contraceptive methods.
DMPA: no significant change No dosage adjustment necessary.
RPV Ethinyl estradiol AUC ↑ 14%
Norethindrone: no significant change
No dosage adjustment necessary.
Levonorgestrel
For emergency
contraception
EFV Levonorgestrel AUC ↓ 58% Effectiveness of emergency post-coital contraception may
be diminished.
Direct-Acting Antiviral Agents, continued
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Concomitant Drug
Class/Name NNRTI
a Effect on NNRTI and/or
Concomitant Drug Concentrations Dosing Recommendations and Clinical Comments
HMG-CoA Reductase Inhibitors
Atorvastatin
EFV, ETR Atorvastatin AUC ↓ 32% to 43% Adjust atorvastatin according to lipid responses, not to
exceed the maximum recommended dose. 
RPV Atorvastatin AUC n
Atorvastatin metabolites ↑
No dosage adjustment necessary.
Fluvastatin ETR ↑ fluvastatin possible Dose adjustments for fluvastatin may be necessary.
Lovastatin
Simvastatin
EFV Simvastatin AUC ↓ 68% Adjust simvastatin dose according to lipid responses, not
to exceed the maximum recommended dose. If EFV is
used with a RTV-boosted PI, simvastatin and lovastatin
should be avoided.
ETR, NVP ↓ lovastatin possible
↓ simvastatin possible
Adjust lovastatin or simvastatin dose according to lipid
responses, not to exceed the maximum recommended
dose. If ETR or NVP is used with a RTV-boosted PI,
simvastatin and lovastatin should be avoided. 
Pitavastatin
EFV Pitavastatin AUC ↓ 11%, Cmax↑ 20%
No dosage adjustment necessary.
ETR, NVP,
RPV
No data No significant effect expected. No dosage adjustment
necessary.
Pravastatin
Rosuvastatin
EFV Pravastatin AUC ↓ 44%
Rosuvastatin: no data
Adjust statin dose according to lipid responses, not to
exceed the maximum recommended dose.
ETR No significant effect expected No dosage adjustment necessary.
Immunosuppressants
Cyclosporine
Sirolimus
Tacrolimus
EFV, ETR,
NVP
↓ immunosuppressant possible Increase in immunosuppressant dose may be necessary.
Therapeutic drug monitoring of immunosuppressant is
recommended. Consult with specialist as necessary.
Narcotics/Treatments for Opioid Dependence
Buprenorphine
EFV Buprenorphine AUC ↓ 50%
Norbuprenorphineb AUC ↓ 71%
No dosage adjustment recommended; monitor for
withdrawal symptoms.
ETR Buprenorphine AUC ↓ 25% No dosage adjustment necessary.
NVP No significant effect No dosage adjustment necessary.
Methadone
EFV Methadone AUC ↓ 52% Opioid withdrawal common; increased methadone dose
often necessary.
ETR No significant effect No dosage adjustment necessary.
NVP Methadone AUC ↓ 37% to 51%
NVP: no significant effect
Opioid withdrawal common; increased methadone dose
often necessary. 
RPV R-methadonec AUC ↓ 16% No dosage adjustment necessary, but monitor for
withdrawal symptoms.
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Concomitant Drug
Class/Name NNRTI
a Effect on NNRTI and/or
Concomitant Drug Concentrations Dosing Recommendations and Clinical Comments
PDE5 Inhibitors
Avanafil EFV, ETR,
NVP, RPV
No data Coadministration is not recommended.
Sildenafil
ETR Sildenafil AUC ↓ 57% May need to increase sildenafil dose based on clinical
effect.
RPV n sildenafil No dosage adjustment necessary.
Tadalafil ETR ↓ tadalafil possible May need to increase tadalafil dose based on clinical
effect.
Vardenafil ETR ↓ vardenafil possible May need to increase vardenafil dose based on clinical
effect.
a Approved dose for RPV is 25 mg once daily. Most PK interaction studies were performed using 75 to 150 mg per dose.
b Norbuprenorphine is an active metabolite of buprenorphine.
c R-methadone is the active form of methadone.
Key to Symbols: ↑ = increase, ↓ = decrease, n = no change
Key to Acronyms: ARV = antiretroviral; AUC = area under the curve; BID = twice daily; CCB = calcium channel blockers; Cmax =
maximum plasma concentration; Cmin = minimum plasma concentration; DAAs = direct-acting antivirals; DHA = dihydroartemisinin; DLV =
delavirdine; DMPA = depot medroxyprogesterone acetate; EFV = efavirenz; ETR = etravirine; FDA = Food and Drug Administration; HMG-
CoA = hydroxy-methylglutaryl-coenzyme A; INR = international normalized ratio; MAC = Mycobacterium avium complex; NNRTI =
non-nucleoside reverse transcriptase inhibitor; NVP = nevirapine; OH-itraconazole  = active metabolite of itraconazole; PDE5 =
phosphodiesterase type 5; PI = protease inhibitor; PK = pharmacokinetic; PPI = proton pump inhibitor; RPV = rilpivirine; RTV = ritonavir
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Table 19c. Drug Interactions Between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs
(Including Antiretroviral Agents)  (Last updated April 8, 2015; last reviewed April 8, 2015)  (page 1 of
2)
Concomitant Drug
Class/Name NRTI
Effect on NRTI and/or
Concomitant Drug Concentrations
Dosage Recommendations and Clinical
Comments
Non-ARV Antivirals
Adefovir TDF No data Do not coadminister. Serum concentrations of TDF
and/or other renally eliminated drugs may be increased. 
Ganciclovir
Valganciclovir
TDF No data Serum concentrations of these drugs and/or TDF may be
increased. Monitor for dose-related toxicities. 
ZDV No significant effect Potential increase in hematologic toxicities
Ledipasvir/
Sofosbuvir
TDF • Ledipasvir ↑ TDF AUC 40% to 98%
when TDF given with RPV and EFV
• Further ↑ TDF possible if TDF given
with PIs
No dose adjustment necessary. Monitor for TDF toxicity.
The safety of increased TDF exposure when
ledipasvir/sofosbuvir is coadministered with TDF and a
PI/r, ATV/c, or DRV/c has not been established. Consider
alternative HCV or ARV drugs to avoid increased TDF
toxicities. If coadministration is necessary, monitor for
TDF-associated adverse reactions.
Coadministration of ledipasvir/sofosbuvir with
EVG/c/TDF/FTC is not recommended.
Ribavirin
ddI ↑ intracellular ddI Contraindicated. Do not coadminister. Fatal hepatic
failure and other ddI-related toxicities have been reported
with coadministration.
ZDV Ribavirin inhibits phosphorylation of ZDV. Avoid coadministration if possible, or closely monitor HIV
virologic response and possible hematologic toxicities.
INSTIs
DTG TDF • TDF AUC ↑ 12% and Cmin ↑ 19% 
• DTG n
No dosage adjustment necessary.
RAL TDF RAL AUC ↑ 49% No dosage adjustment necessary.
Narcotics/Treatment for Opioid Dependence
Buprenorphine 3TC, ddI,
TDF, ZDV
No significant effect No dosage adjustment necessary.
Methadone
ABC Methadone clearance ↑ 22% No dosage adjustment necessary.
d4T d4T AUC ↓ 23% No dosage adjustment necessary.
ZDV ZDV AUC ↑ 29% to 43% Monitor for ZDV-related adverse effects.
NRTIs
ddI
d4T No significant PK interaction Do not coadminister. Additive toxicities of peripheral
neuropathy, lactic acidosis, and pancreatitis seen with
this combination.
TDF ddI-EC AUC and Cmax ↑ 48% to 60% Avoid coadministration.
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(Including Antiretroviral Agents)  (Last updated April 8, 2015; last reviewed April 8, 2015)  (page 2 of 2)
Concomitant Drug
Class/Name NRTI
Effect on NRTI and/or
Concomitant Drug Concentrations
Dosage Recommendations and Clinical
Comments
Other
Allopurinol ddI ddI AUC ↑ 113%
In patients with renal impairment:
• ddI AUC ↑ 312% 
Contraindicated. Potential for increased ddI-associated
toxicities.
Atovaquone ZDV ZDV AUC ↑ 31% Monitor for ZDV-related adverse effects.
PIs
ATV
+/-
RTV or COBI
ddI With ddI-EC plus ATV (with food): 
• ddI AUC ↓ 34%
• ATV no change
Administer ATV with food 2 hours before or 1 hour after
ddI. 
TDF With ATV (unboosted):
• ATV AUC ↓ 25% and Cmin ↓ 23% to
40% (higher Cmin with RTV than
without RTV)
• TDF AUC ↑ 24% to 37%
Avoid concomitant use without RTV or COBI. 
Dose:
• ATV 300 mg daily plus (RTV 100 mg or COBI 150 mg)
daily when coadministered with TDF 300 mg daily. 
• If using TDF and H2 receptor antagonist in ART-
experienced patients, use ATV 400 mg daily plus (RTV
100 mg or COBI 150 mg) daily.
Monitor for TDF-associated toxicity. 
ZDV With ATV (unboosted):
• ZDV Cmin ↓ 30% and AUC n
Clinical significance unknown.
DRV/c TDF Increased TDF possible Monitor for TDF-associated toxicity.
DRV/r TDF TDF AUC ↑ 22% and Cmin ↑ 37% Clinical significance unknown. Monitor for TDF toxicity. 
LPV/r TDF • LPV/r AUC ↓ 15%
• TDF AUC ↑ 34%
Clinical significance unknown. Monitor for TDF toxicity.
TPV/r 
ABC ABC AUC ↓ 35% to 44% Appropriate doses for this combination have not been
established. 
ddI • ddI-EC AUC n and Cmin ↓ 34%
• TPV/r n
Separate doses by at least 2 hours. 
TDF • TDF AUC n
• TPV/r AUC ↓ 9% to 18% and Cmin ↓
12% to 21%
No dosage adjustment necessary.
ZDV • ZDV AUC ↓ 35%
• TPV/r AUC ↓ 31% to 43% 
Appropriate doses for this combination have not been
established. 
Key to Symbols: ↑ = increase, ↓ = decrease, n = no change
Key to Abbreviations: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; ATV = atazanavir; ATV/c =
atazanavir/cobicistat; AUC = area under the curve; Cmax = maximum plasma concentration; Cmin = minimum plasma concentration; COBI =
cobicistat; d4T = stavudine; ddI = didanosine; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; DTG = douletegravir; EC = enteric
coated; EFV = efavirenz; EFV/c/TDF/FTC = efavirenz/cobicistat/tenofovir disoproxil fumarate/emtricitabine; HCV = hepatitis C virus; INSTI =
integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PI/r =
ritonavir-boosted protease inhibitor; PK = pharmacokinetic; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; TDF = tenofovir disoproxil
fumarate; TPV/r = tipranavir/ritonavir; ZDV = zidovudine
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Table 19d. Drug Interactions Between Integrase Strand Transfer Inhibitors and Other Drugs  (Last
updated April 8, 2015; last reviewed April 8, 2015)  (page 1 of 11)
This table provides information on known or predicted PK interactions between INSTIs and non-ARV drugs. The
table includes information on interactions with EVG, an INSTI that is available in two formulations: 
1. A fixed-dose combination tablet of EVG/c/TDF/FTC indicated for use as a single-tablet regimen 
2. A stand-alone tablet indicated for use with a RTV-boosted PI (PI/r) and other ARVs in ARV treatment-
experienced patients. 
In the table, the drug interactions with EVG/c/TDF/FTC and those with EVG plus (PI/r) are presented separately.
For several interactions, no dose adjustment is necessary for EVG when given with a concomitant drug; however,
since EVG should always be given with a PI/r, clinicians should refer to Table 19a for recommendations on the
management of drug interactions resulting from the PI/r used with EVG.
Concomitant Drug
Class/Name INSTI
Effect on INSTI or Concomitant
Drug Concentrations
Dosing Recommendations and
Clinical Comments
Acid Reducers
Aluminium, Magnesium 
+/- 
Calcium Containing Antacids
Please refer to the Miscellaneous
Drugs section of this table for
recommendations on use with
other polyvalent cation products
(e.g., iron, calcium supplements,
multivitamins).
DTG DTG AUC ↓ 74% if given
simultaneously with antacid; DTG
AUC ↓ 26% if given 2 hours before
antacid
Give DTG at least 2 hours before or
at least 6 hours after antacids
containing polyvalent cations.
EVG/c/TDF/FTC EVG AUC ↓ 40% to 50% if given
simultaneously with antacid; EVG
AUC ↓ 15% to 20% if given 2 hours
before or after antacid; n with 4-hour
interval
Separate EVG/c/TDF/FTC and
antacid administration by more than
2 hours.
EVG plus (PI/r) • EVG AUC ↓ 40% to 50% if given
simultaneously with antacid;
• EVG AUC ↓ 15% to 20% if antacid
given 2 hours before or after EVG;
n with 4-hour interval
Separate EVG and antacid
administration by more than 2 hours.
RAL Al-Mg Hydroxide Antacid: 
• RAL Cmin ↓ 54% to 63%
CaCO3 Antacid: 
• RAL Cmin ↓ 32%
Do not coadminister RAL and Al-
Mg hydroxide antacids. Use
alternative acid reducing agent.
No dosing separation necessary
when coadministering RAL and
CaCO3 antacids.
H2-Receptor Antagonists
EVG/c/TDF/FTC No significant effect No dosage adjustment necessary.
EVG plus (PI/r) n EVG No dosage adjustment necessary for
EVG. Refer to Table 19a for
information on PI/r interactions.
PPIs
DTG No significant effect No dosage adjustment necessary.
EVG/c/TDF/FTC No significant effect No dosage adjustment necessary.
EVG plus (PI/r) n EVG No dosage adjustment necessary for
EVG. Refer to Table 19a for
information on PI/r interactions.
RAL RAL AUC ↑ 212% and Cmin ↑ 46% No dosage adjustment necessary.
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Concomitant Drug
Class/Name INSTI
Effect on INSTI or Concomitant
Drug Concentrations
Dosing Recommendations and
Clinical Comments
Anticoagulants
Apixaban • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ apixaban expected Avoid concomitant use.
Dabigatran • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ dabigatran possible No dosage adjustment for dabigatran
if CrCl >50 mL/min. Avoid coadmin-
istration if CrCl <50 mL/min.
Rivaroxaban • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ rivaroxaban expected Avoid concomitant use.
Ticagrelor • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ ticagrelor expected Avoid concomitant use.
Vorapaxar • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ vorapaxar expected Avoid concomitant use.
Warfarin • EVG/c/TDF/FTC
• EVG plus (PI/r)
No data, but warfarin levels may be
affected
Monitor INR and adjust warfarin dose
accordingly.
Anticonvulsants
Carbamazepine
Oxcarbazepine
Phenobarbital
Phenytoin
DTG ↓ DTG possible Consider alternative anticonvulsant.
EVG/c/TDF/FTC • ↑ carbamazepine possible
• ↓ EVG possible
• ↓ COBI possible
Consider alternative anticonvulsant.
EVG plus (PI/r) ↓ EVG Consider alternative anticonvulsant.
Ethosuximide • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ ethosuximide possible Clinically monitor for ethosuxamide
toxicities.
Antidepressants 
Bupropion
EVG/c/TDF/FTC ↑ or ↓ bupropion possible Titrate bupropion dose based on
clinical response.
EVG plus (PI/r) ↓ bupropion possible Titrate bupropion dose based on
clinical response.
Buspirone • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ buspirone possible Initiate buspirone at a low dose.
Dose reduction may be necessary.
Fluvoxamine • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ or ↓ EVG possible Consider alternative antidepressant
or ARV.
and Antiplatelets
/Anxiolytics/Antipsychotics
Also see Sedative/Hypnotics section below.
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Concomitant Drug
Class/Name INSTI
Effect on INSTI or Concomitant
Drug Concentrations
Dosing Recommendations and
Clinical Comments
Antidepressants 
Quetiapine • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ quetiapine AUC expected. Initiation of quetiapine in a patient
receiving EVG/c/TDF/FTC:
• Start quetiapine at the lowest dose
and titrate up as needed. Monitor for
quetiapine efficacy and adverse
effects. 
Initiation of EVG/c/TDF/FTC in a
patient receiving a stable dose of
quetiapine:
• Reduce quetiapine dose to 1/6 of
the original dose, and closely
monitor for quetiapine efficacy and
adverse effects.
SSRIs
Citalopram
Escitalopram
Fluoxetine
Paroxetine
Sertraline
EVG/c/TDF/FTC ↑ SSRI possible Initiate with lowest dose of SSRI and
titrate dose carefully based on
antidepressant response.
EVG plus (PI/r) ↑ or ↓ SSRI possible Titrate SSRI dose based on clinical
response.
TCAs
Amitriptyline
Desipramine
Doxepin
Imipramine
Nortriptyline
EVG/c/TDF/FTC Desipramine AUC ↑ 65% Initiate with lowest dose of TCA and
titrate dose carefully.
EVG plus (PI/r) ↑ TCA expected Initiate with lowest dose of TCA and
titrate dose carefully based on
antidepressant response and/or drug
levels.
Trazodone • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ trazodone possible Initiate with lowest dose of trazodone
and titrate dose carefully.
Antifungals
Itraconazole
EVG/c/TDF/FTC • ↑ itraconazole expected
• ↑ EVG and COBI possible
Consider monitoring itraconazole level
to guide dosage adjustments. High
itraconazole doses (>200 mg/day) are
not recommended unless dose is
guided by itraconazole levels.
EVG plus (PI/r) ↑ EVG possible Refer to Table 19a for PI
recommendations.
Posaconazole
EVG/c/TDF/FTC • ↑ EVG and COBI possible
• ↑ posaconazole possible
If coadministered, monitor
posaconazole concentrations. 
EVG plus (PI/r) ↑ EVG possible Refer to Table 19a for PI
recommendations.
/Anxiolytics/Antipsychotics, continued
Also see Sedative/Hypnotics section below.
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Concomitant Drug
Class/Name INSTI
Effect on INSTI or Concomitant
Drug Concentrations
Dosing Recommendations and
Clinical Comments
Antifungals, continued 
Voriconazole EVG/c/TDF/FTC • ↑ voriconazole expected
• ↑ EVG and COBI possible
Risk/benefit ratio should be
assessed to justify use of
voriconazole. If administered,
consider monitoring voriconazole
level. Adjust dose accordingly.
EVG plus (PI/r) Changes in voriconazole and EVG
possible
Refer to Table 19a for PI
recommendations.
Antimycobacterials
Clarithromycin EVG/c/TDF/FTC • ↑ clarithromycin possible
• ↑ COBI possible
CrCl 50−60 mL/min:
• Reduce clarithromycin dose by 50%.
CrCl <50 mL/min:
• EVG/c/TDF/FTC is not
recommended.
Rifabutin
DTG Rifabutin (300 mg once daily):
• DTG AUC n and Cmin ↓ 30%
No dosage adjustment necessary.
EVG/c/TDF/FTC Rifabutin 150 mg every other day with
EVG/c/TDF/FTC once daily compared
to Rifabutin 300 mg once daily alone: 
• No significant change in rifabutin
AUC 
• 25-O-desacetyl-rifabutin AUC ↑
625% 
• EVG AUC ↓ 21% and Cmin ↓ 67%
Do not coadminister.
EVG plus (PI/r) • n EVG
• n rifabutin AUC
• 25-O-desacetyl-rifabutin AUC ↑ 951%
Refer to Table 19a for dosing
recommendations for rifabutin with
PI. 
RAL RAL AUC ↑ 19% and Cmin ↓ 20% No dosage adjustment necessary.
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Table 19d. Drug Interactions Between Integrase Strand Transfer Inhibitors and Other Drugs  (Last
updated April 8, 2015; last reviewed April 8, 2015)  (page 5 of 11)
Concomitant Drug
Class/Name INSTI
Effect on INSTI or Concomitant
Drug Concentrations
Dosing Recommendations and
Clinical Comments
Antimycobacterials, continued 
Rifampin
DTG Rifampin with DTG 50 mg BID
compared to DTG 50 mg BID alone: 
• DTG AUC ↓ 54% and Cmin ↓ 72%
Rifampin with DTG 50 mg BID
compared to DTG 50 mg once daily
alone: 
• DTG AUC ↑ 33% and Cmin ↑ 22%
Dose: 
• DTG 50 mg BID (instead of 50 mg
once daily) for patients without
suspected or documented INSTI
mutation. 
Alternative to rifampin should be
used in patients with certain
suspected or documented INSTI-
associated resistance substitutions.
Consider using rifabutin.
• EVG/c/TDF/FTC
• EVG plus (PI/r)
Significant ↓ EVG and COBI
expected
Do not coadminister.
RAL RAL 400 mg: 
• RAL AUC ↓ 40% and Cmin ↓ 61% 
Compared with RAL 400 mg BID
alone, Rifampin with RAL 800 mg BID: 
• RAL AUC ↑ 27% and Cmin ↓ 53% 
Dose: 
• RAL 800 mg BID
Monitor closely for virologic response
or consider using rifabutin as an
alternative rifamycin.
Rifapentine
DTG Significant ↓ DTG expected Do not coadminister.
• EVG/c/TDF/FTC
• EVG plus (PI/r)
Significant ↓ EVG and COBI
expected
Do not coadminister.
RAL RAL Cmin ↓ 41% Do not coadminister.
Cardiac Medications
Anti-Arrhythmics
Amiodarone
Bepridil
Digoxin
Disopyramide
Dronedarone
Flecainide
Systemic lidocaine
Mexilitine
Propafenone
Quinidine
EVG/c/TDF/FTC • ↑ anti-arrhythmics possible
• digoxin Cmax ↑ 41% and AUC no
significant change
Use anti-arrhythmics with caution.
Therapeutic drug monitoring, if
available, is recommended for anti-
arrhythmics. 
EVG plus (PI/r) ↑ anti-arrhythmics possible Refer to Table 18 and 19a for use of
anti-arrhythmics and PI/r
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Table 19d. Drug Interactions Between Integrase Strand Transfer Inhibitors and Other Drugs  (Last
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Concomitant Drug
Class/Name INSTI
Effect on INSTI or Concomitant
Drug Concentrations
Dosing Recommendations and
Clinical Comments
Cardiac Medications, continued 
Bosentan
EVG/c/TDF/FTC ↑ bosentan possible In patients on EVG/c/TDF/FTC ≥10 days: 
• Start bosentan at 62.5 mg once daily or
every other day based on individual
tolerability. 
In patients on bosentan who require
EVG/c/TDF/FTC: 
• Stop bosentan ≥36 hours before EVG/
c/TDF/FTC initiation. At least 10 days
after initiation of EVG/c/TDF/FTC,
resume bosentan at 62.5 mg once daily
or every other day based on individual
tolerability.
EVG plus (PI/r) ↑ bosentan possible Refer to Table 19a for recommendations
on bosentan dosing when used with PI/r.
Beta-blockers
(e.g., metoprolol, timolol)
• EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ beta-blockers possible Beta-blocker dose may need to be
decreased; adjust dose based on clinical
response.
Consider using beta-blockers that are not
metabolized by CYP450 enzymes (e.g.,
atenolol, labetalol, nadolol, sotalol).
Dofetilide DTG ↑ dofetilide expected Do not coadminister.
CCBs • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ CCBs possible Coadminister with caution. Titrate CCB
dose and monitor for CCB efficacy and
toxicities. 
Refer to Table 19a for diltiazem plus
ATV/r and SQV/r recommendations.
Corticosteroids
Dexamethasone (systemic)
EVG/c/TDF/FTC ↓ EVG and COBI possible Use systemic dexamethasone with
caution. Monitor virologic response to
ART. Consider alternative corticosteroid.EVG plus (PI/r) ↓ EVG possible
Fluticasone
Inhaled/Intranasal
• EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ fluticasone possible Coadministration may result in adrenal
insufficiency and Cushing’s syndrome.
Consider alternative therapy (e.g.,
beclomethasone), particularly for long-
term use.
Methylprednisolone,
Prednisolone, Triamcinolone
Local injections, including intra-
articular, epidural, intra-orbital
• EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ glucocorticoids expected Coadministration may result in adrenal
insufficiency and Cushing’s syndrome.
Do not coadminister.
Downloaded from http://aidsinfo.nih.gov/guidelines on 9/16/2015
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents                                 L-35
Table 19d. Drug Interactions Between Integrase Strand Transfer Inhibitors and Other Drugs  (Last
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Concomitant Drug
Class/Name INSTI
Effect on INSTI or Concomitant
Drug Concentrations
Dosing Recommendations and
Clinical Comments
Hepatitis C
Boceprevir
DTG DTG AUC n No dosage adjustment necessary.
EVG/c/TDF/FTC No data Do not coadminister.
EVG plus (PI/r) ↓ boceprevir Do not coadminister.
RAL No significant effect No dosage adjustment necessary.
Dasabuvir 
plus 
Ombitasvir/Paritaprevir/r
RAL RAL AUC ↑ 134% No dosage adjustment necessary.
DTG No data No dosing recommendations at this
time.
• EVG plus (PI/r)
• EVG/c/TDF/FTC
No data Do not coadminister.
Ledipasvir/
Sofosbuvir
EVG/c/TDF/FTC ↑ TDF and ↑ ledipasvir expected Do not coadminister.
EVG plus (PI/r) n EVG expected Refer to Table 19a for PI dosing
recommendations.
Simeprevir
EVG/c/TDF/FTC ↑ simeprevir expected Coadministration is not
recommended.
EVG plus (PI/r) n EVG expected Coadministration is not
recommended.
RAL No significant effect No dosage adjustment necessary.
Sofosbuvir All INSTIs No significant effect expected No dosage adjustment necessary.
Herbal Products
St. John’s Wort
DTG ↓ DTG possible Do not coadminister.
• EVG/c/TDF/FTC
• EVG plus (PI/r)
↓ EVG and COBI possible Do not coadminister.
Hormonal Contraceptives
Hormonal Contraceptives RAL No clinically significant effect No dosage adjustment necessary.
Norgestimate/Ethinyl
Estradiol
DTG No significant effect No dosage adjustment necessary.
EVG/c/TDF/FTC • Norgestimate AUC, Cmax, and
Cmin ↑ >2-fold
• Ethinyl estradiol AUC ↓ 25% and
Cmin ↓ 44%
The effects of increases in progestin
(norgestimate) are not fully known and can
include insulin resistance, dyslipidemia,
acne, and venous thrombosis. Weigh the
risks and benefits of the drug, and
consider alternative contraceptive method.
EVG plus (PI/r) n EVG Refer to Table 19a for recommendations
when used with PI/r.
HMG-CoA Reductase Inhibitors
Atorvastatin
EVG/c/TDF/FTC ↑ atorvastatin possible Titrate statin dose slowly and use the
lowest dose possible.
EVG plus (PI/r) n EVG expected Refer to Table 19a for dosing
recommendations when used with PI/r.
Direct Acting Antivirals
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Concomitant Drug
Class/Name INSTI
Effect on INSTI or Concomitant
Drug Concentrations
Dosing Recommendations and
Clinical Comments
HMG-CoA Reductase Inhibitors, continued
Lovastatin • EVG/c/TDF/FTC
• EVG plus (PI/r)
Significant ↑ lovastatin expected Contraindicated. Do not coadminister.
Pitavastatin
Pravastatin
EVG/c/TDF/FTC No data No dosage recommendation
EVG plus (PI/r) n EVG expected Refer to Table 19a for dosing
recommendations when used with PI/r.
Rosuvastatin
EVG/c/TDF/FTC Rosuvastatin AUC ↑ 38% and Cmax↑ 89%
Titrate statin dose slowly and use the
lowest dose possible.
EVG plus (PI/r) n EVG expected Refer to Table 19a for dosing
recommendations when used with PI/r.
Simvastatin
• EVG/c/TDF/FTC
• EVG plus (PI/r)
Significant ↑ simvastatin expected Contraindicated. Do not coadminister.
Immunosuppressants
Cyclosporine
Everolimus
Sirolimus
Tacrolimus
• EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ immunosuppressant possible Initiate with an adjusted immuno-
suppressant dose to account for potential
increased concentration and monitor for
toxicities. Therapeutic drug monitoring of
immunosuppressant is recommended.
Consult with specialist as necessary.
Narcotics/Treatment for Opioid Dependence
Buprenorphine
EVG/c/TDF/FTC • Buprenorphine AUC ↑ 35%, Cmax↑ 12%, and Cmin ↑ 66%
• Norbuprenorphine AUC ↑ 42%,
Cmax ↑ 24%, and Cmin ↑ 57%
No dosage adjustment necessary.
Clinical monitoring is recommended. 
EVG plus (PI/r) n EVG expected Refer to Table 19a for dosing
recommendations when used with PI/r.
RAL No significant effect No dosage adjustment necessary.
Methadone
DTG No significant effect No dosage adjustment necessary.
EVG/c/TDF/FTC No significant effect No dosage adjustment necessary.
EVG plus (PI/r) ↓ methadone Opioid withdrawal unlikely but may occur.
Dosage adjustment of methadone is not
usually required. Monitor for opioid
withdrawal and increase methadone
dose as clinically indicated.
RAL No significant effect No dosage adjustment necessary.
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Concomitant Drug
Class/Name INSTI
Effect on INSTI or Concomitant
Drug Concentrations
Dosing Recommendations and
Clinical Comments
Neuroleptics
Perphenazine
Risperidone
Thioridazine
EVG/c/TDF/FTC ↑ neuroleptic possible Initiate neuroleptic at a low dose.
Decrease in neuroleptic dose may be
necessary.
PDE5 Inhibitors
Avanafil • EVG/c/TDF/FTC
• EVG plus (PI/r)
No data Coadministration is not
recommended.
Sildenafil • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ sildenafil expected For treatment of erectile dysfunction:
• Start with sildenafil 25 mg every 48 hours
and monitor for adverse effects of
sildenafil.
For treatment of PAH:
• Contraindicated
Tadalafil • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ tadalafil expected For treatment of erectile dysfunction:
• Start with tadalafil 5-mg dose and do
not exceed a single dose of 10 mg
every 72 hours. Monitor for adverse
effects of tadalafil.
For treatment of PAH
In patients on EVG/c/TDF/FTC >7 days:
• Start with tadalafil 20 mg once daily and
increase to 40 mg once daily based on
tolerability.
In patients on tadalafil who require
EVG/c/TDF/FTC:
• Stop tadalafil ≥24 hours before
EVG/c/TDF/FTC initiation. Seven days
after EVG/c/TDF/FTC initiation restart
tadalafil at 20 mg once daily, and
increase to 40 mg once daily based on
tolerability.
Vardenafil • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ vardenafil expected Start with vardenafil 2.5 mg every 72
hours and monitor for adverse effects of
vardenafil.
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Concomitant Drug
Class/Name INSTI
Effect on INSTI or Concomitant
Drug Concentrations
Dosing Recommendations and
Clinical Comments
Clonazepam
Clorazepate
Diazepam
Estazolam
Flurazepam
• EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ benzodiazepines possible Dose reduction of benzodiazepine may
be necessary. Initiate with low dose and
clinically monitor.
Consider alternative benzodiazepines to
diazepam, such as lorazepam,
oxazepam, or temazepam.
Midazolam
Triazolam
DTG With DTG 25 mg: 
• midazolam AUC n
No dosage adjustment necessary.
• EVG/c/TDF/FTC
• EVG plus (PI/r)
• ↑ midazolam expected
• ↑ triazolam expected
Do not coadminister triazolam or oral
midazolam and EVG/c/TDF/FTC or
(EVG plus PI).
Parenteral midazolam can be used with
caution in a closely monitored setting.
Consider dose reduction, especially if
more than one dose is administered.
Suvorexant • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ suvorexant expected Coadministration is not
recommended.
Zolpidem • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ zolpidem expected Initiate zolpidem at a low dose. Dose
reduction may be necessary.
Miscellaneous Drugs
Colchicine • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ colchicine expected Do not coadminister in patients with
hepatic or renal impairment.
For treatment of gout flares:
• Colchicine 0.6 mg for 1 dose, followed
by 0.3 mg 1 hour later. Do not repeat
dose for at least 3 days.
For prophylaxis of gout flares:
• If original dose was colchicine 0.6 mg
BID, decrease to colchicine 0.3 mg once
daily. If regimen was 0.6 mg once daily,
decrease to 0.3 mg every other day.
For treatment of Familial Mediterranean
Fever:
• Do not exceed colchicine 0.6 mg once
daily or 0.3 mg BID.
Sedative/Hypnotics
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Concomitant Drug
Class/Name INSTI
Effect on INSTI or Concomitant
Drug Concentrations
Dosing Recommendations and
Clinical Comments
Miscellaneous Drugs, continued
Metformin DTG DTG 50 mg once daily plus
metformin: 
• Metformin AUC ↑ 79%, Cmax ↑
66%, and Cmin ↑ 9% 
DTG 50 mg BID plus metformin: 
• Metformin AUC ↑ 2.4 fold, Cmax ↑
2 fold, and Cmin ↑ 14%
When starting metformin in patient on
DTG, start at low metformin dose and
titrate dose to achieve glycemic control
and minimize GI symptoms.
When starting/stopping DTG in patient on
metformin, dose adjustment of metformin
may be necessary to maintain optimal
glycemic control and/or minimize GI
symptoms.
Polyvalent Cation
Supplements
Mg, Al, Fe, Ca, Zn, including
multivitamins with minerals
Note: Please refer to the Acid
Reducers section in this table
for recommendations on use
with Al-, Mg-, and Ca-containing
antacids.
All INSTIs • ↓ INSTI possible 
• DTG n when administered with
Ca or Fe supplement
simultaneously with food 
If coadministration is necessary, give
INSTI at least 2 hours before or at least 6
hours after supplements containing
polyvalent cations, including but not
limited to the following products: cation-
containing laxatives; Fe, Ca, or Mg
supplements; and sucralfate. Monitor for
virologic efficacy.
DTG and supplements containing Ca or
Fe can be taken simultaneously with
food.
Many oral multivitamins also contain
varying amounts of polyvalent cations;
the extent and significance of chelation is
unknown. 
Salmeterol • EVG/c/TDF/FTC
• EVG plus (PI/r)
↑ salmeterol possible Do not coadminister because of
potential increased risk of salmeterol-
associated cardiovascular events.
Key to Acronyms: Al = aluminum; ART = antiretroviral therapy; ARV = antiretroviral; ATV/r = atazanavir/ritonavir; AUC = area under the
curve; BID = twice daily; Ca = calcium; CaCO3 = calcium carbonate; CCB = calcium channel blocker; Cmax = maximum plasma
concentration; Cmin = minimum plasma concentration; COBI = cobicistat; CrCl = creatinine clearance; CYP = cytochrome P; DTG =
dolutegravir; EVG = elvitegravir; EVG/c/TDF/FTC = elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine; Fe = iron; GI =
gastrointestinal; INR = international normalized ratio; INSTI = integrase strand transfer inhibitor; Mg = magnesium; PAH = pulmonary
arterial hypertension; PI = protease inhibitor; PI/r = ritonavir-boosted protease inhibitor; PPI = proton pump inhibitor; RAL = raltegravir;
SQV/r = saquanavir/ritonavir; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic anti-depressant; TDF = tenofovir disoproxil
fumarate; Zn = zinc
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Table 19e. Drug Interactions Between CCR5 Antagonist (Maraviroc) and Other Drugs (Including
Antiretroviral Agents)  (Last updated April 8, 2015; last reviewed April 8, 2015)  (page 1 of 3)
Concomitant
Drug Class/Name
CCR5
Antagonist
Effect on CCR5 Antagonist and/or
Concomitant Drug Concentrations
Dosing Recommendations and
Clinical Comments
Anticonvulsants
Carbamazepine
Phenobarbital
Phenytoin
MVC ↓ MVC possible If used without a strong CYP3A inhibitor,
use MVC 600 mg BID or an alternative
antiepileptic agent.
Antifungals
Itraconazole MVC ↑ MVC possible Dose: 
• MVC 150 mg BID
Voriconazole MVC ↑ MVC possible Consider dose reduction to MVC 150 mg
BID.
Antimycobacterials
Clarithromycin MVC ↑ MVC possible Dose: 
• MVC 150 mg BID
Rifabutin MVC ↓ MVC possible If used without a strong CYP3A inducer or
inhibitor, use MVC 300 mg BID.
If used with a strong CYP3A inhibitor, use
MVC 150 mg BID.
Rifampin MVC MVC AUC ↓ 64% Coadministration is not recommended.
If coadministration is necessary, use MVC
600 mg BID.
If coadministered with a strong CYP3A
inhibitor, use MVC 300 mg BID.
Rifapentine MVC ↓ MVC expected Do not coadminister.
Hepatitis C 
Boceprevir MVC MVC AUC ↑ 202% Dose: 
• MVC 150 mg BID
Dasabuvir plus
Ombitasvir/
Paritaprevir/RTV
MVC ↑ MVC expected Do not coadminister.
Ledipasvir/
Sofosbuvir
MVC n MVC expected Dose: 
• MVC 300 mg BID
Simeprevir MVC n MVC expected Dose: 
• MVC 300 mg BID
Herbal Products
St. John’s Wort MVC ↓ MVC possible Coadministration is not recommended.
Hormonal Contraceptives
Hormonal
Contraceptives
MVC No significant effect on ethinyl estradiol or
levonorgestrel
Safe to use in combination
Direct Acting Antivirals
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Concomitant
Drug Class/Name
CCR5
Antagonist
Effect on CCR5 Antagonist and/or
Concomitant Drug Concentrations
Dosing Recommendations and
Clinical Comments
ARV Drugs
INSTIs
EVG/c/TDF/FTC MVC ↑ MVC possible Do not coadminister.
EVG + PI/r MVC No data Refer to PIs listed below for dosing
recommendations when MVC is used with a
PI/r.
RAL MVC MVC AUC ↓ 21%
RAL AUC ↓ 37%
Dose: 
• Standard
NNRTIs
EFV MVC MVC AUC ↓ 45% Dose: 
• MVC 600 mg BID
ETR MVC MVC AUC ↓ 53% Dose: 
• MVC 600 mg BID in the absence of a
potent CYP3A inhibitor
NVP MVC MVC AUC n Without HIV PI: 
• MVC 300 mg BID
With HIV PI (except TPV/r): 
• MVC 150 mg BID
PIs
ATV
+/-
RTV or COBI
MVC With Unboosted ATV: 
• MVC AUC ↑ 257%
With (ATV 300 mg Plus  RTV 100 mg) Once Daily: 
• MVC AUC ↑ 388%
Dose: 
• MVC 150 mg BID
DRV/r
or 
DRV/c
MVC With (DRV 600 mg Plus  RTV 100 mg) BID: 
• MVC AUC ↑ 305%
With (DRV 600 mg Plus RTV 100 mg) BID and ETR: 
• MVC AUC ↑ 210%
Dose: 
• MVC 150 mg BID
FPV
+/-
RTV
MVC With (FPV 700 mg Plus RTV 100 mg) BID and
MVC 300 mg BID:
• MVC AUC ↑ 149%, Cmin ↑ 374%
With (FPV 1400 mg Plus RTV 200 mg) Once Daily
and MVC 300 mg Once Daily: 
• MVC AUC ↑ 126%, Cmin ↑ 80%
Dose: 
• MVC 150 mg BID
LPV/r MVC MVC AUC ↑ 295%
With LPV/r and EFV: 
• MVC AUC ↑ 153%
Dose: 
• MVC 150 mg BID
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Concomitant
Drug Class/Name
CCR5
Antagonist
Effect on CCR5 Antagonist and/or
Concomitant Drug Concentrations
Dosing Recommendations and
Clinical Comments
PIs, continued
RTV MVC With RTV 100 mg BID: 
• MVC AUC ↑ 161%
Dose: 
• MVC 150 mg BID
SQV/r MVC With (SQV 1000 mg Plus RTV 100 mg) BID: 
• MVC AUC ↑ 877%
With (SQV 1000 mg Plus RTV 100 mg) BID and
EFV: 
• MVC AUC ↑ 400%
Dose: 
• MVC 150 mg BID
TPV/r MVC With (TPV 500 mg Plus RTV 200 mg) BID: 
• MVC AUC n
Dose: 
• MVC 300 mg BID
Note: FPV is a pro-drug of APV.
Key to Symbols: ↑ = increase, ↓ = decrease, n = no change
Key to Acronyms: ARV = antiretroviral; ATV = atazanavir; ATV/r = atazanavir/ritonavir; AUC = area under the curve; BID = twice daily;
COBI = cobicistat; CYP = cytochrome P; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; EFV = efavirenz; ETR = etravirine; EVG
= elvitegravir; FPV = fosamprenavir; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; MVC =
maraviroc; NVP = nevirapine; PI = protease inhibitor; PK = pharmacokinetic; RAL = raltegravir; RTV = ritonavir; SQV/r =
saquinavir/ritonavir; TDF = tenofovir disoproxil fumarate; TPV/r = tipranavir/ritonavir
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Table 20a. Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors and Protease
Inhibitorsa (Last updated April 8, 2015; last reviewed April 8, 2015)  (Page 1 of 3)
Note: DLV, IDV, and NFV are not included in this table. Refer to the DLV, IDV, and NFV Food and Drug Administration
package inserts for information regarding drug interactions.
PIs
NNRTIs
EFV ETR NVP RPVa
ATV
Unboosted
PK Data EFV: no significant
change
ATV AUC ↓ 74%
ETR AUC ↑ 50% and
Cmin ↑ 58%
ATV AUC ↓ 17% and
Cmin ↓ 47%
↓ ATV possible ↑ RPV possible
Dose Do not coadminister. Do not coadminister. Do not coadminister. Standard doses
ATV/c
PK Data ↓ ATV
↓ COBI
↓ ATV
↓ COBI
↓ COBI ↑ RPV possible
n ATV expected
Dose EFV standard dose
In ART-Naive Patients:
• ATV 400 mg plus COBI
150 mg Once Daily 
Do not coadminister in
ART-experienced
patients.
Do not coadminister. Do not coadminister. Standard doses
ATV/r
PK Data (ATV 300 mg plus RTV
100 mg) Once Daily:
• ATV concentrations are
similar to those with
unboosted ATV without
EFV.
(ATV 300 mg plus RTV
100 mg) Once Daily:
• ETR AUC and Cmin
both ↑ ~30%
• ATV AUC n and Cmin↓ 18%
(ATV 300 mg plus RTV
100 mg) Once Daily:
• ATV AUC ↓ 42% and
Cmin ↓ 72%
• NVP AUC ↑ 25%
↑ RPV possible
Dose EFV standard dose
In ART-Naive Patients:
• (ATV 400 mg plus RTV
100 mg) Once Daily 
Do not coadminister in
ART-experienced
patients.
ETR standard dose
(ATV 300 mg plus RTV
100 mg) Once Daily 
Do not coadminister. Standard doses
DRV/c
PK Data ↓ DRV possible
↓ COBI possible
Effect on DRV unknown
↓ COBI possible
Effect on DRV unknown
↓ COBI possible
n DRV expected
↑ RPV possible
Dose Do not coadminister. Do not coadminister. Do not coadminister. Standard doses
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Table 20a. Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors, and Protease
Inhibitorsa (Last updated April 8, 2015; last reviewed April 8, 2015)  (Page 2 of 3)
PIs
NNRTIs
EFV ETR NVP RPVa
DRV/r
PK Data With (DRV 300 mg plus
RTV 100 mg) BID:
• EFV AUC ↑ 21%
• DRV AUC ↓ 13% and
Cmin ↓ 31%
ETR 100 mg BID with
(DRV 600 mg plus RTV
100 mg) BID:
• ETR AUC ↓ 37% and
Cmin ↓ 49%
• DRV: no significant
change
With (DRV 400 mg plus
RTV 100 mg) BID:
• NVP AUC ↑ 27% and
Cmin ↑ 47%
• DRV AUC ↑ 24%b
RPV 150 mg Once Daily
with (DRV 800 mg plus
RTV 100 mg) Once Daily:
• RPV AUC ↑ 130% and
Cmin ↑ 178%
• DRV: no significant
change
Dose Clinical significance
unknown. Use standard
doses and monitor
patient closely. Consider
monitoring drug levels.
Standard doses 
Safety and efficacy of this
combination, despite
reduced ETR
concentration, have been
established in a clinical
trial.
Standard doses Standard doses
FPV
+/- 
RTV
PK Data With (FPV 1400 mg plus
RTV 200 mg) Once Daily:
• APV Cmin ↓ 36%
With (FPV 700 mg plus
RTV 100 mg) BID:
• APV AUC ↑ 69% and
Cmin ↑ 77%
With Unboosted FPV
1400 mg BID:
• NVP AUC ↑ 29%
• APV AUC ↓ 33%
With (FPV 700 mg plus
RTV 100 mg) BID:
• NVP Cmin ↑ 22% 
With Boosted and
Unboosted FPV:
• ↑ RPV possible
Dose (FPV 1400 mg plus RTV
300 mg) Once Daily or
(FPV 700 mg plus RTV
100 mg) BID
EFV standard dose
Do not coadminister
with FPV +/− RTV.
(FPV 700 mg plus RTV
100 mg) BID
NVP standard dose
Standard doses
LPV/r
PK Data With LPV/r Tablets
500/125 mgc BID:
• LPV concentration
similar to that with LPV/r
400/100 mg BID without
EFV
With LPV/r Tablets:
• ETR AUC ↓ 35%
(comparable to the
decrease with DRV/r)
• LPV AUC ↓ 13%
With LPV/r Capsules:
• LPV AUC ↓ 27% and
Cmin ↓ 51% 
RPV 150 mg Once Daily
with LPV/r Capsules:
• RPV AUC ↑ 52% and
Cmin ↑ 74%
• LPV no significant
change
Dose LPV/r tablets 500/125
mgc BID; LPV/r oral
solution 533/133 mg BID
EFV standard dose
Standard doses LPV/r tablets 500/125
mgc BID; LPV/r oral
solution 533/133 mg BID
NVP standard dose
Standard doses
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a Approved dose for RPV is 25 mg once daily. Most PK studies were performed using 75 mg to 150 mg RPV per dose.
b Based on between-study comparison.
c Use a combination of two LPV/r 200 mg/50 mg tablets plus one LPV/r 100 mg/25 mg tablet to make a total dose of LPV/r 500 mg/125 mg.
Key to Symbols: ↑ = increase, ↓ = decrease, n = no change
Key to Acronyms: APV = amprenavir; ART = antiretroviral therapy; ATV = atazanavir; ATV/c = atazanavir/cobicistat; AUC = area under the
curve; BID = twice daily; Cmax = maximum plasma concentration; Cmin = minimum plasma concentration; CYP = cytochrome P; DLV =
delavirdine; DRV = darunavir; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; EFV = efavirenz; ETR = etravirine; FDA = Food
and Drug Administration; FPV = fosamprenavir; IDV = indinavir; LPV = lopinavir; LPV/r = lopinavir/ritonavir; NFV = nelfinavir; NVP =
nevirapine; PK = pharmacokinetic; RPV = rilpivirine; RTV = ritonavir; SQV = saquinavir; SQV/r = saquinavir/ritonavir; TID = three times a
day; TPV = tipranavir
Table 20a. Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors, and Protease
Inhibitorsa (Last updated April 8, 2015; last reviewed April 8, 2015)  (Page 3 of 3)
PIs
NNRTIs
EFV ETR NVP RPVa
SQV
Always
use with
RTV
PK Data With SQV 1200 mg TID:
• EFV AUC ↓ 12%
• SQV AUC ↓ 62%
With (SQV 1000 mg plus
RTV 100 mg) BID:
• ETR AUC ↓ 33% and
Cmin ↓ 29%
• SQV AUC n
↓ ETR levels similar to
reduction with DRV/r
With SQV 600 mg TID:
• NVP: no significant
change 
• SQV AUC ↓ 24%
↑ RPV possible
Dose (SQV 1000 mg plus RTV
100 mg) BID
(SQV 1000 mg plus RTV
100 mg) BID
Dose with SQV/r not
established
Standard doses
TPV
Always
use with
RTV
PK Data With (TPV 500 mg plus
RTV 100 mg) BID: 
• EFV no significant
change
• TPV AUC ↓ 31% and
Cmin ↓ 42%
With (TPV 750 mg plus
RTV 200 mg) BID:
• EFV: no significant
change 
• TPV: no significant
change
With (TPV 500 mg plus
RTV 200 mg) BID:
• ETR AUC ↓ 76% and
Cmin ↓ 82%
• TPV AUC ↑ 18% and
Cmin ↑ 24%
With (TPV 250 mg plus
RTV 200 mg) BID or with
(TPV 750 mg plus RTV
100 mg) BID:
• NVP: no significant
change
• TPV: no data
↑ RPV possible
Dose Standard doses Do not coadminister. Standard doses Standard doses
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Table 20b. Interactions Between Integrase Strand Transfer Inhibitors and Non-Nucleoside Reverse
Transcriptase Inhibitors or Protease Inhibitors  (Last updated April 8, 2015; last reviewed April 8,
2015)  (page 1 of 4)
ARV Drugs by
Drug Class
INSTIs
DTG EVG/c/TDF/FTC RAL
NNRTIs
EFV
PK Data With DTG 50 mg once daily:
• DTG AUC ↓ 57% and Cmin ↓ 75%
↑ or ↓ EVG, COBI, EFV
possible
↓ EVG expected RAL: 
• AUC ↓ 36%
Dose In patients without INSTI resistance: 
• DTG 50 mg BID 
In patients with certain INSTI-
associated resistancea or clinically
suspected INSTI resistance:
• Consider alternative combination.
Do not coadminister. Do not coadminister. Standard doses
ETR
PK Data ETR 200 mg BID plus DTG 50 mg
once daily:
• DTG AUC ↓ 71% and Cmin ↓ 88%
ETR 200 mg BID with (DRV 600 mg
plus RTV 100 mg) BID and DTG 50
mg once daily:
• DTG AUC ↓ 25% and Cmin ↓ 37%
ETR 200 mg BID with (LPV 400 mg
plus RTV 100 mg) BID and DTG 50
mg once daily:
• DTG AUC ↑ 11% and Cmin ↑ 28%
↑ or ↓ EVG, COBI, ETR
possible
No significant
interaction between
EVG/r and ETR
• ETR Cmin ↓ 17%
• RAL Cmin ↓ 34%
Dose Do not coadminister ETR and DTG
without concurrently
administering ATV/r, DRV/r, or
LPV/r.
In patients without INSTI resistance: 
• DTG 50 mg once daily with ETR
(concurrently with ATV/r, DRV/r, or
LPV/r) 
In patients with certain INSTI-
associated resistancea or clinically
suspected INSTI resistance:
• DTG 50 mg BID with ETR
(concurrently with ATV/r, DRV/r, or
LPV/r)
Do not coadminister. May coadminister EVG
with ETR plus (ATV/r,
DRV/r, or LPV/r)
EVG: 
• Standard dose
depending on the
concomitant PI (see
below)
Standard doses
EVG
(EVG must be given
with a PI/r.)
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Table 20b. Interactions Between Integrase Strand Transfer Inhibitors and Non-Nucleoside Reverse
Transcriptase Inhibitors or Protease Inhibitors  (Last updated April 8, 2015; last reviewed April 8,
2015)  (page 2 of 4)
ARV Drugs by
Drug Class
INSTIs
DTG EVG/c/TDF/FTC RAL
NNRTIs, continued
NVP
PK Data ↓ DTG possible ↑ or ↓ EVG, COBI, NVP
possible
↓ EVG possible No data
Dose Do not coadminister. Do not coadminister. Do not coadminister. Standard doses
RPV
PK Data With DTG 50 mg once daily:
• DTG AUC n and Cmin ↑ 22%
• RPV AUC n and Cmin ↑ 21%
↑ or ↓ EVG, COBI, RPV
possible
↑ RPV expected • RPV n
• RAL Cmin ↑ 27% 
Dose Standard doses Do not coadminister. EVG: 
• Standard dose
depending on the
concomitant PI (see
below)
RPV: 
• Standard dose
Standard doses
ATV/c
PK Data No data ATV/c plus EVG/c: 
• No data
No data No data
Dose Standard doses Do not coadminister. Do not coadminister. Standard doses
ATV
+/-
RTV
PK Data Unboosted ATV plus DTG 30 mg
once daily: 
• DTG AUC ↑ 91% and Cmin ↑ 180%
(ATV 300 mg plus RTV 100 mg) once
daily plus DTG 30 mg once daily:
• DTG AUC ↑ 62% and Cmin ↑ 121%
↑ or ↓ EVG, COBI, ATV
possible
EVG 85 mg with (ATV
300 mg plus RTV 100
mg) once daily:
• EVG AUC n and
Cmin ↑ 38%
• ATV AUC and Cmin
n
With unboosted ATV:
• RAL AUC ↑ 72%
With (ATV 300 mg
plus RTV 100 mg)
once daily:
• RAL AUC ↑ 41%
Dose Standard doses Do not coadminister. • EVG 85 mg once daily
• (ATV 300 mg plus
RTV 100 mg) once
daily
Standard doses
DRV/c
PK Data No data. DRV/c plus EVG/c: 
• ↓ EVG possible
No data. No data
Dose Standard doses Do not coadminister. Do not coadminister. Standard doses
EVG
(EVG must be given
with a PI/r.)
PIs
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Table 20b. Interactions Between Integrase Strand Transfer Inhibitors and Non-Nucleoside Reverse
Transcriptase Inhibitors or Protease Inhibitors  (Last updated April 8, 2015; last reviewed April 8,
2015)  (page 3 of 4)
ARV Drugs by
Drug Class
INSTIs
DTG EVG/c/TDF/FTC RAL
DRV/r
PK Data (DRV 600 mg plus RTV 100 mg) BID
with DTG 30 mg once daily:
• DTG AUC ↓ 22% and Cmin ↓ 38%
↑ or ↓ EVG, COBI, DRV
possible
EVG 125 mg once
daily with (DRV 600 mg
plus RTV 100 mg) BID:
• EVG AUC and Cminn
• DRV AUC and Cminn
With (DRV 600 mg
plus RTV 100 mg)
BID:
• RAL AUC ↓ 29%
and Cmin ↑ 38%
Dose Standard doses: 
• Once or twice daily dosing of DRV/r
Do not coadminister. • EVG 150 mg once
daily
• (DRV 600 mg plus
RTV 100 mg) BID
Standard doses
FPV
+/-
RTV
PK Data With (FPV 700 mg plus RTV 100 mg)
BID and DTG 50 mg once daily:
• DTG AUC ↓ 35% and Cmin ↓ 49%
↑ or ↓ EVG, COBI, FPV
possible
No significant
interaction with FPV
and EVG
FPV: No significant
effect
Dose In patients without INSTI resistance: 
• DTG 50 mg BID 
In patients with certain INSTI-
associated resistancea or clinically
suspected INSTI resistance:
• Consider alternative combination.
Do not coadminister. • EVG 150 mg once
daily
• (FPV 700 mg plus
RTV 100 mg) BID
Standard doses
LPV/r
PK Data With (LPV 400 mg plus RTV 100 mg)
BID and DTG 30 mg once daily:
• DTG: no significant effect
↑ or ↓ EVG, COBI, LPV
possible
RTV and COBI have
similar effects on CYP3A.
EVG 125 mg once daily
with (LPV 400 mg plus
RTV 100 mg) BID:
• EVG AUC ↑ 75% and
Cmin ↑ 138%
• LPV AUC and Cminn
• ↓ RAL
• n LPV/r
Dose Standard doses: 
• Once or twice daily dosing of LPV/r
Do not coadminister. • EVG 85 mg once daily
• (LPV 400 mg plus
RTV 100 mg) BID
Standard doses
SQV/r
PK Data No data ↑ or ↓ EVG, COBI, SQV
possible
RTV and COBI have
similar effects on CYP3A.
No data No data
Dose Standard doses Do not coadminister. No dosage
recommendation
Standard doses
EVG
(EVG must be given
with a PI/r.)
PIs, continued
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Table 20b. Interactions Between Integrase Strand Transfer Inhibitors and Non-Nucleoside Reverse
Transcriptase Inhibitors or Protease Inhibitors  (Last updated April 8, 2015; last reviewed April 8,
2015)  (page 4 of 4)
ARV Drugs by
Drug Class
INSTIs
DTG EVG/c/TDF/FTC RAL
TPV/r
PK Data With (TPV 500 mg plus RTV 200 mg)
BID and DTG 50 mg once daily:
• DTG AUC ↓ 59% and Cmin ↓ 76%
↑ or ↓ EVG, COBI, TPV
possible
RTV and COBI have
similar effects on CYP3A.
EVG 200 mg once
daily with (TPV 500 mg
plus RTV 200 mg) BID:
• EVG AUC and Cminn
• TPV AUC and Cminn
With (TPV 500 mg plus
RTV 200 mg) BID:
• RAL AUC ↓ 24%
Dose In patients without INSTI resistance: 
• DTG 50 mg BID 
In patients with certain INSTI-
associated resistancea or clinically
suspected INSTI resistance:
• Consider alternative combination.
Do not coadminister. • EVG 150 mg once
daily
• (TPV 500 mg plus
RTV 200 mg) BID
Standard doses
EVG
(EVG must be given
with a PI/r.)
PIs, continued
a Refer to dolutegravir product labeling for details.
Key to Symbols: ↑ = increase; ↓ = decrease; n = no change
Key to Abbreviations: ARV = antiretroviral; ATV = atazanavir; ATV/c = atazanavir/cobicistat; ATV/r = atazanavir/ritonavir; AUC = area
under the curve; BID = twice daily; Cmin = minimum plasma concentration; COBI, c = cobicistat; CYP = cytochrome P; DRV = darunavir;
DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; ETR = etravirine; EVG = elvitegravir;
EVG/c = elvitegravir/cobicistat; EVG/c/TDF/FTC = elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine; EVG/r = elvitegravir/
ritonavir; FPV = fosamprenavir; INSTI = integrase strand transfer inhibitor; LPV = lopinavir; LPV/r = lopinavir/ritonavir; NNRTI = non-
nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PI/r = ritonavir-boosted protease inhibitor; PK =
pharmacokinetic; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SQV = saquinavir; SQV/r = saquinavir/ritonavir; TPV = tipranavir;
TPV/r = tipranavir/ritonavir
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Preventing Secondary Transmission of HIV  (Last updated March 27,
2012; last reviewed March 27, 2012)
Despite substantial advances in prevention and treatment of HIV infection in the United States, the rate of
new infections has remained stable.1-2 Although earlier prevention interventions mainly were behavioral,
recent data demonstrate the strong impact of antiretroviral therapy (ART) on secondary HIV transmission.
The most effective strategy to stem the spread of HIV will probably be a combination of behavioral,
biological, and pharmacological interventions.3
Prevention Counseling
Counseling and related behavioral interventions for those living with HIV infection can reduce behaviors
associated with secondary transmission of HIV. Each patient encounter offers the clinician an opportunity to
reinforce HIV prevention messages, but multiple studies show that prevention counseling is frequently
neglected in clinical practice.4-5 Although delivering effective prevention interventions in a busy practice
setting may be challenging, clinicians should be aware that patients often look to their providers for
messages about HIV prevention. Multiple approaches to prevention counseling are available, including
formal guidance from the Centers for Disease Control and Prevention (CDC) for incorporating HIV
prevention into medical care settings. Such interventions have been demonstrated to be effective in changing
sexual risk behavior6-8 and can reinforce self-directed behavior change early after diagnosis.9
CDC has identified several prevention interventions for individuals infected with HIV that meet stringent
criteria for efficacy and scientific rigor (http://www.cdc.gov/hiv/topics/research/prs/index.htm). The
following three interventions have proven effective in treatment settings and can be delivered by providers as
brief messages during clinic visits:
•     Partnership for Health (http://effectiveinterventions.org/en/Interventions/PfH.aspx), 
•     Options (http://www.cdc.gov/hiv/topics/research/prs/resources/factsheets/options.htm), 
•     Positive Choice (http://www.cdc.gov/hiv/topics/research/prs/resources/factsheets/positive-choice.htm). 
In addition, CDC’s “Prevention Is Care” campaign (http://www.actagainstaids.org/provider/pic/index.html)
helps providers (and members of a multidisciplinary care team) integrate simple methods to prevent
transmission by HIV-infected individuals into routine care. These prevention interventions are designed to
reduce the risk of secondary HIV transmission through sexual contact. The interventions are designed generally
for implementation at the community or group level, but some can be adapted and administered in clinical
settings by a multidisciplinary care team.
Need for Screening for High-Risk Behaviors
The primary care visit provides an opportunity to screen patients for ongoing high-risk drug and sexual
behaviors for transmitting HIV infection. Routine screening and symptom-directed testing for and treatment
of sexually transmitted diseases (STDs), as recommended by CDC,10 remain essential adjuncts to prevention
counseling. Genital ulcers may facilitate HIV transmission and STDs may increase HIV viral load in plasma
and genital secretions.7, 11-13 They also provide objective evidence of unprotected sexual activity, which
should prompt prevention counseling. 
The contribution of substance and alcohol use to HIV risk behaviors and transmission has been well
established in multiple populations;14-18 therefore, effective counseling for injection and noninjection drug
users is essential to prevent HIV transmission. Identifying the substance(s) of use is important because HIV
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prevalence, transmission risk, risk behaviors, transmission rates, and potential for pharmacologic
intervention all vary according to the type of substance used.19-21 Risk-reduction strategies for injection drug
users (IDUs), in addition to condom use, include needle exchange and instructions on cleaning drug
paraphernalia. Evidence supporting the efficacy of interventions to reduce injection drug use risk behavior
also exists. Interventions include both behavioral strategies14-15, 22 and opiate substitution treatment with
methadone or buprenorphine.23-24 No successful pharmacologic interventions have been found for cocaine
and methamphetamine users; cognitive and behavioral interventions demonstrate the greatest effect on
reducing the risk behaviors of these users.25-27 Given the significant impact of cocaine and methamphetamine
on sexual risk behavior, reinforcement of sexual risk-reduction strategies is important.14-18, 28
Antiretroviral Therapy as Prevention
ART can play an important role in preventing HIV transmission. Lower levels of plasma HIV RNA have
been associated with decreases in the concentration of virus in genital secretions.29-32 Observational studies
have demonstrated the association between low serum or genital HIV RNA and a decreased rate of HIV
transmission among serodiscordant heterosexual couples.29, 33-34 Ecological studies of communities with
relatively high concentrations of men who have sex with men (MSM) and IDUs suggest increased use of
ART is associated with decreased community viral load and reduced rates of new HIV diagnoses.35-37 These
data suggest that the risk of HIV transmission is low when an individual’s viral load is below 400
copies/mL,35, 38 but the threshold below which transmission of the virus becomes impossible is unknown.
Furthermore, to be effective at preventing transmission it is assumed that: (1) ART is capable of durably and
continuously suppressing viremia; (2) adherence to an effective ARV regimen is high; and (3) there is an
absence of a concomitant STD. Importantly, detection of HIV RNA in genital secretions has been
documented in individuals with controlled plasma HIV RNA and data describing a differential in
concentration of most ARV drugs in the blood and genital compartments exist.30, 39 At least one case of HIV
transmission from a patient with suppressed plasma viral load to a monogamous uninfected sexual partner
has been reported.40
In the HPTN 052 trial in HIV-discordant couples, the HIV-infected partners who were ART naive and had
CD4 counts between 350 and 550 cells/mm3 were randomized to initiate or delay ART. In this study, those
who initiated ART had a 96% reduction in HIV transmission to the uninfected partners.3 Almost all of the
participants were in heterosexual relationships, all participants received risk-reduction counseling, and the
absolute number of transmission events was low: 1 among ART initiators and 27 among ART delayers. Over
the course of the study virologic failure rates were less than 5%, a value much lower than generally seen in
individuals taking ART for their own health. These low virologic failure rates suggest high levels of
adherence to ART in the study, which may have been facilitated by the frequency of study follow-up (study
visits were monthly) and by participants’ sense of obligation to protect their uninfected partners. Therefore,
caution is indicated when interpreting the extent to which ART for the HIV-infected partner protects
seronegative partners in contexts where adherence and, thus, rates of continuous viral suppression, may be
lower. Furthermore, for HIV-infected MSM and IDUs, biological and observational data suggest suppressive
ART also should protect against transmission, but the actual extent of protection has not been established.
Rates of HIV risk behaviors can increase coincidently with the availability of potent combination ART, in
some cases almost doubling compared with rates in the era prior to highly effective therapy.9 A meta-analysis
demonstrated that the prevalence of unprotected sex acts was increased in HIV-infected individuals who
believed that receiving ART or having a suppressed viral load protected against transmitting HIV.41
Attitudinal shifts away from safer sexual practices since the availability of potent ART underscore the role of
provider-initiated HIV prevention counseling. With wider recognition that effective treatment decreases the
risk of HIV transmission, it is particularly important for providers to help patients understand that a sustained
viral load below the limits of detection will dramatically reduce but does not absolutely assure the absence of
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HIV in the genital and blood compartments and, hence, the inability to transmit HIV to others.41-42
Maximal suppression of viremia not only depends on the potency of the ARV regimen used but also on the
patient’s adherence to prescribed therapy. Suboptimal adherence can lead to viremia that not only harms the
patient but also increases his/her risk of transmitting HIV (including drug-resistant strains) via sex or needle
sharing. Screening for and treating behavioral conditions that can impact adherence, such as depression and
alcohol and substance use, improve overall health and reduce the risk of secondary transmission.
Summary
Consistent and effective use of ART resulting in a sustained reduction in viral load in conjunction with
consistent condom usage, safer sex and drug use practices, and detection and treatment of STDs are essential
tools for prevention of sexual and blood-borne transmission of HIV. Given these important considerations,
medical visits provide a vital opportunity to reinforce HIV prevention messages, discuss sex- and drug-
related risk behaviors, diagnose and treat intercurrent STDs, review the importance of medication adherence,
and foster open communication between provider and patient. 
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Conclusion  (Last updated January 10, 2011; last reviewed January 10, 2011)
The Panel has carefully reviewed recent results from clinical trials in HIV therapy and considered how they
inform appropriate care guidelines. The Panel appreciates that HIV care is highly complex and rapidly
evolving. Guidelines are never fixed and must always be individualized. Where possible, the Panel has based
recommendations on the best evidence from prospective trials with defined endpoints. When such evidence
does not yet exist, the Panel attempted to reflect reasonable options in its conclusions.
HIV care requires, as always, partnerships and open communication. The provider can make
recommendations most likely to lead to positive outcomes only if the patient's own point of view and social
context are well known. Guidelines are only a starting point for medical decision making. They can identify
some of the boundaries of high-quality care but cannot substitute for sound judgment.
As further research is conducted and reported, guidelines will be modified. The Panel anticipates continued
progress in the simplicity of regimens, improved potency and barrier to resistance, and reduced toxicity. The
Panel hopes the guidelines are useful and is committed to their continued adjustment and improvement.
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Appendix A: Key to Acronyms  (Last updated April 8, 2015; last reviewed April 8, 2015)
Drug Name Abbreviations
Abbreviation Full Name
3TC lamivudine 
ABC abacavir 
APV amprenavir
ATV atazanavir 
ATV/c atazanavir/cobicistat 
ATV/r atazanavir/ritonavir 
COBI or c cobicistat 
d4T stavudine 
ddC zalcitabine 
ddI didanosine 
DLV delavirdine 
DRV darunavir 
DRV/c darunavir/cobicistat 
DRV/r darunavir/ritonavir 
DTG dolutegravir 
EFV efavirenz 
EFV/c/TDF/FTC efavirenz/cobicistat/tenofovir disoproxil fumarate/emtricitabine 
ETR etravirine 
EVG elvitegravir 
EVG/c elvitegravir/cobicistat 
EVG/c/TDF/FTC elvitegravir/cobicistat/tenofovir 
disoproxil 
fumarate/emtricitabine 
EVG/r elvitegravir/ritonavir 
FPV fosamprenavir 
FPV/r fosamprenavir/ritonavir 
FTC emtricitabine 
IDV indinavir 
LPV lopinavir 
LPV/r lopinavir/ritonavir 
MVC maraviroc 
NFV nelfinavir 
NVP nevirapine 
PI/c cobicistat-boosted protease inhibitor 
PI/r ritonavir-boosted protease inhibitor 
RAL raltegravir 
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RPV rilpivirine 
RTV ritonavir 
SQV saquinavir 
SQV/r saquinavir/ritonavir 
TDF tenofovir disoproxil fumarate 
TPV tipranavir 
TPV/r tipranavir/ritonavir 
ZDV zidovudine
General Terms
Abbreviation Definition
17-BMP beclomethasone 17-monopropionate 
Al aluminum 
ART antiretroviral therapy 
ARV antiretroviral 
AUC area under the curve 
AWP average wholesale price 
BID twice daily 
BMD bone mineral density 
Ca calcium 
CaCO3 calcium carbonate 
cap capsule 
CCB calcium channel blockers 
CD4 CD4 T lymphocyte 
Cmax maximum plasma concentration 
Cmin minimum plasma concentration 
CNS central nervous system 
CPK creatine phosphokinase 
Cr creatinine 
CrCl creatinine clearance 
CVD cardiovascular disease 
CYP cytochrome P 
DAAs direct-acting antivirals 
DHA dihydroartemisinin 
DMPA depot medroxyprogesterone acetate 
DSMB Data Safety Monitoring Board 
EC enteric coated 
ECG electrocardiogram 
EI entry inhibitor 
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FDA Food and Drug Administration 
Fe iron 
GAZT azidothymidine glucuronide 
GI gastrointestinal 
HBV hepatitis B virus 
HCV hepatitis C virus 
HDL high-density lipoprotein 
HLA human leukocyte antigen 
HMG-CoA hydroxy-methylglutaryl-coenzyme A 
HSR hypersensitivity reaction 
INR international normalized ratio 
INSTI integrase strand transfer inhibitor 
LDL low-density lipoprotein 
MAC Mycobacterium avium complex 
MATE multidrug and toxin extrusion transporter 
Mg magnesium 
MI myocardial infarction 
N/A Not Applicable
NNRTI non-nucleoside reverse transcriptase inhibitor 
NRTI nucleoside reverse transcriptase inhibitor 
OCT2 organic cation transporter 2 
OH-itraconazole  active metabolite of itraconazole 
PAH pulmonary arterial hypertension 
PDE5 phosphodiesterase type 5 
PI protease inhibitor 
PPI proton pump inhibitor 
PK pharmacokinetic 
QTc QT corrected for heart rate 
SCr serum creatinine 
soln solution 
SSRI selective serotonin reuptake inhibitor 
susp suspension 
tab tablet 
TB tuberculosis 
TCA tricyclic anti-depressant 
TG triglyceride 
TID three times a day 
UGT1A1 uridine diphosphate glucuronosyltransferase 
VPA valproic acid
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WHO World Health Organization 
XR extended release
Zn zinc
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Generic Name
(Abbreviation)
Trade Name
Formulations DosingRecommendationsa Elimination
Serum/
Intracellular
Half-Lives
Adverse Eventsb
Abacavir
(ABC)
Ziagen
Note: Generic
available in tablet
formulation
Also available as
a component of
fixed-dose
combinations.
Ziagen:
• 300 mg tablet
• 20 mg/mL oral
solution
Ziagen:
• 300 mg BID, or
• 600 mg once daily
• Take without regard to
meals.
Metabolized by
alcohol
dehydrogenase and
glucuronyl transferase
Renal excretion of
metabolites: 82%
Dosage adjustment
for ABC is
recommended in
patients with hepatic
insufficiency (see
Appendix B, Table 7).
1.5 hours/ 
12–26 hours
• HSRs: Patients who test positive
for HLA-B*5701 are at highest
risk. HLA screening should be
done before initiation of ABC. 
• For patients with history of HSR,
re-challenge is not recommended.
• Symptoms of HSR may include
fever, rash, nausea, vomiting,
diarrhea, abdominal pain,
malaise, fatigue, or respiratory
symptoms such as sore throat,
cough, or shortness of breath.
• Some cohort studies suggest
increased risk of MI with recent or
current use of ABC, but this risk is
not substantiated in other studies.
Trizivir
(ABC/ZDV/3TC)
Note: Generic
available
Trizivir:
• (ABC 300 mg
plus ZDV 300
mg plus 3TC
150 mg) tablet
Trizivir:
• 1 tablet BID
Epzicom
(ABC/3TC)
Epzicom:
• (ABC 600 mg
plus 3TC 300
mg) tablet
Epzicom:
• 1 tablet once daily
Triumeq
(ABC/3TC/DTG)
Triumeq:
• (ABC 600 mg
plus 3TC 300
mg plus DTG 50
mg) tablet
Triumeq:
• 1 tablet once daily
Didanosine
(ddI)
Videx
Videx EC
Note: Generic
available; dose
same as Videx or
Videx EC
Videx EC:
• 125, 200, 250,
and 400 mg
capsules
Videx:
• 10 mg/mL oral
solution
Body Weight ≥60 kg:
• 400 mg once daily
With TDF:
• 250 mg once daily
Body Weight <60 kg:
• 250 mg once daily
With TDF:
• 200 mg once daily
Take 1/2 hour before or 2
hours after a meal.
Note: Preferred dosing
with oral solution is BID
(total daily dose divided
into 2 doses).
Renal excretion: 50%
Dosage adjustment in
patients with renal
insufficiency is
recommended (see
Appendix B, Table 7).
1.5 hours/
>20 hours
• Pancreatitis
• Peripheral neuropathy
• Retinal changes, optic neuritis
• Lactic acidosis with hepatic
steatosis with or without
pancreatitis (rare but potentially
life-threatening toxicity)
• Nausea, vomiting
• Potential association with non-
cirrhotic portal hypertension; in
some cases, patients presented
with esophageal varices
• One cohort study suggested
increased risk of MI with recent or
current use of ddI, but this risk is
not substantiated in other studies.
• Insulin resistance/diabetes
mellitus
Appendix B, Table 1. Characteristics of Nucleoside Reverse Transcriptase Inhibitors  (Last updated
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Appendix B, Table 1. Characteristics of Nucleoside Reverse Transcriptase Inhibitors  (Last updated
April 8, 2015; last reviewed April 8, 2015)  (page 2 of 5)
Generic Name
(Abbreviation)
Trade Name
Formulations DosingRecommendationsa Elimination
Serum/
Intracellular
Half-Lives
Adverse Eventsb
Emtricitabine
(FTC)
Emtriva
Also available as
a component of
fixed-dose
combinations.
Emtriva:
• 200 mg hard
gelatin capsule
• 10 mg/mL oral
solution
Emtriva
Capsule:
• 200 mg once daily
Oral Solution:
• 240 mg (24 mL) once
daily
Take without regard to
meals.
Renal excretion: 86%
Dosage adjustment in
patients with renal
insufficiency is
recommended (see
Appendix B, Table 7).
10 hours/
>20 hours
• Minimal toxicity
• Hyperpigmentation/skin
discoloration
• Severe acute exacerbation of
hepatitis may occur in HBV-
coinfected patients who
discontinue FTC.
Atripla
(FTC/EFV/TDF)
Atripla:
• (FTC 200 mg
plus EFV 600
mg plus TDF
300 mg) tablet
Atripla:
• 1 tablet at or before
bedtime
• Take on an empty
stomach to reduce side
effects.
Complera
(FTC/RPV/TDF)
Complera:
• (FTC 200 mg
plus RPV 25 mg
plus TDF 300
mg) tablet
Complera:
• 1 tablet once daily with
a meal
Stribild
(FTC/EVG/c/
TDF)
Stribild:
• (FTC 200 mg
plus EVG 150
mg plus COBI
150 mg plus
TDF 300 mg)
tablet
Stribild:
• 1 tablet once daily with
food
Truvada
(FTC/TDF)
Truvada:
• (FTC 200 mg
plus TDF 300
mg) tablet
Truvada:
• 1 tablet once daily
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Appendix B, Table 1. Characteristics of Nucleoside Reverse Transcriptase Inhibitors  (Last updated
April 8, 2015; last reviewed April 8, 2015)  (page 3 of 5)
Generic Name
(Abbreviation)
Trade Name
Formulations DosingRecommendationsa Elimination
Serum/
Intracellular
Half-Lives
Adverse Eventsb
Lamivudine
(3TC)
Epivir
Note: Generic
available 
Also available as
a component of
fixed-dose
combinations.
Epivir:
• 150 and 300 mg
tablets
• 10 mg/mL oral
solution
Epivir:
• 150 mg BID, or 
• 300 mg once daily
• Take without regard to
meals.
Renal excretion: 70%
Dosage adjustment in
patients with renal
insufficiency is
recommended (see
Appendix B, Table 7).
5–7 hours/
18–22 hours
• Minimal toxicity
• Severe acute exacerbation of
hepatitis may occur in HBV-
coinfected patients who
discontinue 3TC.
Combivir
(3TC/ZDV)
Note: Generic
available
Combivir:
• (3TC 150 mg
plus ZDV 300
mg) tablet
Combivir:
• 1 tablet BID
Epzicom
(3TC/ABC)
Epzicom:
• (3TC 300 mg
plus ABC 600
mg) tablet
Epzicom:
• 1 tablet once daily
Trizivir
(3TC/ZDV/ABC)
Note: Generic
available
Trizivir:
• (3TC 150 mg
plus ZDV 300
mg plus ABC
300 mg) tablet
Trizivir:
• 1 tablet BID
Triumeq
(3TC/ABC/DTG)
Triumeq:
• (3TC 300 mg
plus ABC 600
mg plus DTG 50
mg) tablet
Triumeq:
• 1 tablet once daily
Stavudine
(d4T)
Zerit
Note: Generic
available
Zerit:
• 15, 20, 30, and
40 mg capsules
• 1 mg/mL oral
solution
Body Weight ≥60 kg: 
• 40 mg BID
Body Weight <60 kg: 
• 30 mg BID
Take without regard to
meals.
Note: WHO recommends
30 mg BID dosing
regardless of body
weight.
Renal excretion: 50%
Dosage adjustment in
patients with renal
insufficiency is
recommended (see
Appendix B, Table 7).
1 hour/
7.5 hours
• Peripheral neuropathy
• Lipoatrophy
• Pancreatitis
• Lactic acidosis/severe
hepatomegaly with hepatic
steatosis (rare but potentially life-
threatening toxicity)
• Hyperlipidemia 
• Insulin resistance/diabetes
mellitus
• Rapidly progressive ascending
neuromuscular weakness (rare)
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Appendix B, Table 1. Characteristics of Nucleoside Reverse Transcriptase Inhibitors  (Last updated
April 8, 2015; last reviewed April 8, 2015)  (page 4 of 5)
Generic Name
(Abbreviation)
Trade Name
Formulations DosingRecommendationsa Elimination
Serum/
Intracellular
Half-Lives
Adverse Eventsb
Tenofovir
Disoproxil
Fumarate
(TDF)
Viread
Also available as
a component of
fixed-dose
combinations.
Viread:
• 150, 200, 250,
and 300 mg
tablets
• 40 mg/g oral
powder
Viread:
• 300 mg once daily, or
• 7.5 level scoops once
daily (dosing scoop
dispensed with each
prescription; one level
scoop contains 1 g of
oral powder).
• Take without regard to
meals.
Mix oral powder with 2–4
ounces of a soft food that
does not require chewing
(e.g., applesauce,
yogurt). Do not mix oral
powder with liquid.
Renal excretion is
primary route of
elimination.
Dosage adjustment in
patients with renal
insufficiency is
recommended (see
Appendix B, Table 7).
17 hours/
>60 hours 
• Renal insufficiency, Fanconi
syndrome, proximal renal
tubulopathy
• Osteomalacia, decrease in bone
mineral density
• Severe acute exacerbation of
hepatitis may occur in HBV-
coinfected patients who
discontinue TDF.
• Asthenia, headache, diarrhea,
nausea, vomiting, and flatulence
Atripla
TDF/EFV/FTC
Atripla:
• (TDF 300 mg
plus EFV 600
mg plus FTC
200 mg) tablet
Atripla:
• 1 tablet at or before
bedtime
• Take on an empty
stomach to reduce side
effects.
Complera
TDF/RPV/FTC
Complera:
• (TDF 300 mg
plus RPV 25 mg
plus FTC 200
mg) tablet
Complera:
• 1 tablet once daily
• Take with a meal
Stribild
(TDF/EVG/c/FTC)
Stribild:
• (TDF 300 mg
plus EVG 150
mg plus COBI
150 mg plus
FTC 200 mg)
tablet
Stribild:
• 1 tablet once daily
• Take with food.
Truvada
(TDF/FTC)
Truvada:
• (TDF 300 mg
plus FTC 200
mg) tablet
Truvada:
• 1 tablet once daily
• Take without regard to
meals.
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Appendix B, Table 1. Characteristics of Nucleoside Reverse Transcriptase Inhibitors  (Last updated
April 8, 2015; last reviewed April 8, 2015)  (page 5 of 5)
Generic Name
(Abbreviation)
Trade Name
Formulations DosingRecommendationsa Elimination
Serum/
Intracellular
Half-Lives
Adverse Eventsb
Zidovudine
(ZDV)
Retrovir
Note: Generic
available
Also available as
a component of
fixed-dose
combinations.
Retrovir:
• 100 mg capsule
• 300 mg tablet
(only available
as generic)
• 10 mg/mL
intravenous
solution
• 10 mg/mL oral
solution
Retrovir:
• 300 mg BID, or
• 200 mg TID
• Take without regard to
meals.
Metabolized to GAZT
Renal excretion of
GAZT
Dosage adjustment in
patients with renal
insufficiency is
recommended (see
Appendix B, Table 7).
1.1 hours/
7 hours
• Bone marrow suppression:
macrocytic anemia or neutropenia
• Nausea, vomiting, headache,
insomnia, asthenia
• Nail pigmentation
• Lactic acidosis/severe
hepatomegaly with hepatic
steatosis (rare but potentially life-
threatening toxicity)
• Hyperlipidemia
• Insulin resistance/diabetes
mellitus
• Lipoatrophy
• Myopathy
Combivir
(ZDV/3TC)
Note: Generic
available
Combivir:
• (ZDV 300 mg
plus 3TC 150
mg) tablet
Combivir:
• 1 tablet BID
• Take without regard to
meals.
Trizivir
(ZDV/3TC/ABC)
Note: Generic
available
Trizivir:
• (ZDV 300 mg
plus 3TC 150
mg plus ABC
300 mg) tablet
Trizivir:
• 1 tablet BID
• Take without regard to
meals.
a For dosage adjustment in renal or hepatic insufficiency, see Appendix B, Table 7.
b Also see Table 14.
Key to Acronyms: 3TC = lamivudine; ABC = abacavir; BID = twice daily; c, COBI = cobicistat; d4T = stavudine; ddI = didanosine; DTG =
dolutegravir; EC = enteric coated; EFV = efavirenz; EVG = elvitegravir; FTC = emtricitabine; GAZT = azidothymidine glucuronide; HBV =
hepatitis B virus; HLA = human leukocyte antigen; HSR = hypersensitivity reaction; MI = myocardial infarction; RPV = rilpivirine; TDF =
tenofovir disoproxil fumarate; TID = three times a day; WHO = World Health Organization; ZDV = zidovudine 
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Appendix B, Table 2. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors  (Last
updated April 8, 2014; last reviewed April 8, 2015)  (page 1 of 2)
Note: DLV is not included in this table. Please refer to the DLV FDA package insert for related information.
Generic Name
(Abbreviation)
Trade Name
Formulations DosingRecommendationsa
Elimination/
Metabolic Pathway
Serum/
Half-Life Adverse Events
b
Efavirenz
(EFV)
Sustiva
Also available as
a component of
fixed-dose
combination.
Sustiva:
• 50 and 200 mg
capsules
• 600 mg tablet
Sustiva:
• 600 mg once daily, at or
before bedtime
• Take on an empty stomach
to reduce side effects.
Metabolized by CYPs
2B6 (primary), 3A4,
and 2A6
CYP3A4 mixed
inducer/inhibitor
(more an inducer than
an inhibitor)
CYP2C9 and 2C19
inhibitor; 2B6 inducer
40–55 hours • Rashc
• Neuropsychiatric symptomsd
• Increased transaminase levels
• Hyperlipidemia
• False-positive results with some
cannabinoid and benzodiazepine
screening assays reported.
• Teratogenic in non-human
primates and potentially
teratogenic during the first
trimester of pregnancy in humans
Atripla
(EFV/TDF/FTC)
Atripla: 
• (EFV 600 mg
plus FTC 200
mg plus TDF
300 mg) tablet
Atripla:
• 1 tablet once daily, at or
before bedtime 
Etravirine
(ETR) 
Intelence
• 25, 100, and
200 mg tablets
200 mg BID
Take following a meal.
CYP3A4, 2C9, and
2C19 substrate
3A4 inducer; 2C9 and
2C19 inhibitor
41 hours • Rash, including Stevens-
Johnson syndromec
• HSRs, characterized by rash,
constitutional findings, and
sometimes organ dysfunction
(including hepatic failure) have
been reported.
• Nausea
Nevirapine
(NVP)
Viramune or
Viramine XR
Generic available
for 200 mg tablets
and oral
suspension
• 200 mg tablet
• 400 mg XR
tablet
• 50 mg/5 mL oral
suspension
200 mg once daily for 14
days (lead-in period);
thereafter, 200 mg BID, or
400 mg (Viramune XR
tablet) once daily
Take without regard to
meals.
Repeat lead-in period if
therapy is discontinued for
>7 days.
In patients who develop mild-
to-moderate rash without
constitutional symptoms,
continue lead-in period until
rash resolves but not longer
than 28 days total.
CYP450 substrate,
inducer of 3A4 and
2B6; 80% excreted in
urine (glucuronidated
metabolites, <5%
unchanged); 10% in
feces
25–30 hours • Rash, including Stevens-
Johnson syndromec
• Symptomatic hepatitis,
including fatal hepatic necrosis,
has been reported:
• Rash reported in
approximately 50% of cases.
• Occurs at significantly higher
frequency in ARV-naive female
patients with pre-NVP CD4
counts >250 cells/mm3 and in
ARV-naive male patients with
pre-NVP CD4 counts >400
cells/mm3. NVP should not be
initiated in these patients
unless the benefit clearly
outweighs the risk.
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Appendix B, Table 2. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors  (Last
updated April 8, 2014; last reviewed April 8, 2015)  (page 2 of 2)
Note: DLV is not included in this table. Please refer to the DLV FDA package insert for related information.
Generic Name
(Abbreviation)
Trade Name
Formulations DosingRecommendationsa
Elimination/
Metabolic Pathway
Serum/
Half-Life Adverse Events
b
Rilpivirine
(RPV)
Edurant
Also available as
a component of
fixed-dose
combination.
Edurant:
• 25 mg tablet
Edurant:
• 25 mg once daily
• Take with a meal.
CYP3A4 substrate 50 hours • Rashc
• Depression, insomnia,
headache
• Hepatotoxicity
Complera
(RPV/TDF/FTC)
Complera:
• (RPV 25 mg
plus TDF 300
mg plus FTC
200 mg) tablet
Complera:
• 1 tablet once daily 
• Take with a meal.
a For dosage adjustment in renal or hepatic insufficiency, see Appendix B, Table 7.
b Also see Table 14.
c Rare cases of Stevens-Johnson syndrome have been reported with most NNRTIs; the highest incidence of rash was seen with NVP.
d Adverse events can include dizziness, somnolence, insomnia, abnormal dreams, depression, suicidality (suicide, suicide attempt or
ideation), confusion, abnormal thinking, impaired concentration, amnesia, agitation, depersonalization, hallucinations, and euphoria.
Approximately 50% of patients receiving EFV may experience any of these symptoms. Symptoms usually subside spontaneously after 2
to 4 weeks but may necessitate discontinuation of EFV in a small percentage of patients.
Key to Abbreviations: ARV = antiretroviral; BID = twice daily; CD4 = CD4 T lymphocyte; CYP = cytochrome P; DLV = delavirdine; EFV =
efavirenz; ETR = etravirine; FDA = Food and Drug Administration; FTC = emtricitabine; HSR = hypersensitivity reaction; NNRTI = non-
nucleoside reverse transcriptase inhibitor; NVP = nevirapine; RPV = rilpivirine; TDF = tenofovir disoproxil fumarate; XR = extended release
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Appendix B, Table 3. Characteristics of Protease Inhibitors  (Last updated April 8, 2015; last reviewed
April 8, 2015)  (page 1 of 4)
Generic Name
(Abbreviation)
Trade Name
Formulations Dosing Recommendationsa
Elimination/
Metabolic
Pathway
Serum
Half-Life Storage Adverse Events
b
Atazanavir
(ATV)
Reyataz
Also available
as a component
of fixed-dose
combination.
Reyataz:
• 100, 150,
200, and 300
mg capsules
• 50 mg single
packet oral
powder
In ARV-Naive Patients:
• (ATV 300 mg plus RTV 100
mg) once daily; or
• ATV 400 mg once daily
With TDF or in ARV-Experienced
Patients:
• (ATV 300 mg plus RTV 100
mg) once daily
With EFV in ARV-Naive Patients:
• (ATV 400 mg plus RTV 100
mg) once daily
Take with food.
For recommendations on dosing
with H2 antagonists and PPIs,
refer to Table 19a.
CYP3A4 inhibitor
and substrate; weak
CYP2C8 inhibitor;
UGT1A1 inhibitor
Dosage adjustment
in patients with
hepatic insufficiency
is recommended
(see Appendix B,
Table 7).
7 hours Room
temperature
(up to 25º C
or 77º F)
• Indirect
hyperbilirubinemia
• PR interval prolongation:
First degree
symptomatic AV block
reported. Use with
caution in patients with
underlying conduction
defects or on
concomitant medications
that can cause PR
prolongation.
• Hyperglycemia
• Fat maldistribution
• Cholelithiasis
• Nephrolithiasis
• Renal insufficiency
• Serum transaminase
elevations
• Hyperlipidemia
(especially with RTV
boosting)
• Skin rash
• Increase in serum
creatinine (with COBI)
Evotaz
(ATV/c)
Evotaz:
• (ATV 300 mg
plus COBI
150 mg)
tablet
Evotaz:
• 1 tablet once daily 
• Take with food.
With TDF:
• Not recommended for patients
with baseline CrCl< 70 mL/min
(see Appendix B, Table 7 for the
equation for calculating CrCl). 
ATV: as above
COBI: substrate of
CYP3A, CYP2D6
(minor); CYP3A
inhibitor
Darunavir
(DRV)
Prezista
Also available
as a component
of fixed-dose
combination.
• 75, 150, 600,
and 800 mg
tablets
• 100 mg/mL
oral
suspension
In ARV-Naive Patients or ARV-
Experienced Patients with No
DRV Mutations:
• (DRV 800 mg plus RTV 100
mg) once daily
In ARV-Experienced Patients
with One or More DRV
Resistance Mutations:
• (DRV 600 mg plus RTV 100
mg) BID
Unboosted DRV is not
recommended.
Take with food.
CYP3A4 inhibitor
and substrate
CYP2C9 inducer
15 hours
(when
combined
with RTV)
Room
temperature
(up to 25º C
or 77º F)
• Skin rash (10%): DRV
has a sulfonamide
moiety; Stevens-
Johnson syndrome,
toxic epidermal
necrolysis, acute
generalized
exanthematous
pustulosis, and
erythrema multiforme
have been reported.
• Hepatotoxicity
• Diarrhea, nausea
• Headache
• Hyperlipidemia
• Serum transaminase
elevation
• Hyperglycemia
• Fat maldistribution
• Increase in serum
creatinine (with COBI)
Prezcobix
(DRV/c)
Prezcobix:
• (DRV 800 mg
plus COBI
150 mg)
tablet
Prezcobix:
• 1 tablet once daily 
• Take with food.
Not recommended for patients
with one or more DRV resistance-
associated mutations.
With TDF:
• Not recommended for patients
with baseline CrCl< 70 mL/min
(see Appendix B, Table 7 for the
equation for calculating CrCl). 
DRV: As above
COBI: substrate of
CYP3A, CYP2D6
(minor); CYP3A
inhibitor
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Appendix B, Table 3. Characteristics of Protease Inhibitors  (Last updated April 8, 2015; last reviewed
April 8, 2015)  (page 2 of 4)
Generic Name
(Abbreviation)
Trade Name
Formulations Dosing Recommendationsa
Elimination/
Metabolic
Pathway
Serum
Half-Life Storage Adverse Events
b
Fosamprenavir
(FPV)
Lexiva (a prodrug
of APV)
• 700 mg tablet
• 50 mg/mL
oral
suspension
In ARV-Naive Patients:
• FPV 1400 mg BID, or
• (FPV 1400 mg plus RTV 100–
200 mg) once daily, or
• (FPV 700 mg plus RTV 100
mg) BID
In PI-Experienced Patients
(Once-Daily Dosing Not
Recommended):
• (FPV 700 mg plus RTV 100
mg) BID
With EFV:
• (FPV 700 mg plus RTV 100
mg) BID, or
• (FPV 1400 mg plus RTV 300
mg) once daily
Tablet:
• Without RTV tablet: Take
without regard to meals.
• With RTV tablet: Take with
meals.
Oral Suspension:
• Take without food.
APV is a CYP3A4
substrate, inhibitor,
and inducer.
Dosage adjustment
in patients with
hepatic insufficiency
is recommended
(see Appendix B,
Table 7).
7.7 hours
(APV)
Room
temperature
(up to 25º C
or 77º F)
• Skin rash (12% to
19%): FPV has a
sulfonamide moiety.
• Diarrhea, nausea,
vomiting
• Headache
• Hyperlipidemia
• Serum transaminase
elevation
• Hyperglycemia
• Fat maldistribution
• Possible increased
bleeding episodes in
patients with hemophilia
• Nephrolithiasis
Indinavir
(IDV)
Crixivan
100, 200, and
400 mg
capsules
• 800 mg every 8 hours
• Take 1 hour before or 2 hours
after meals; may take with skim
milk or a low-fat meal.
With RTV:
• (IDV 800 mg plus RTV 100–
200 mg) BID
• Take without regard to meals.
CYP3A4 inhibitor
and substrate
Dosage adjustment
in patients with
hepatic insufficiency
is recommended
(see Appendix B,
Table 7).
1.5–2
hours
Room
temperature
(15º to 30º
C or 59º to
86º F)
Protect from
moisture.
• Nephrolithiasis
• GI intolerance, nausea
• Hepatitis
• Indirect
hyperbilirubinemia
• Hyperlipidemia
• Headache, asthenia,
blurred vision, dizziness,
rash, metallic taste,
thrombocytopenia,
alopecia, and hemolytic
anemia
• Hyperglycemia
• Fat maldistribution 
• Possible increased
bleeding episodes in
patients with hemophilia
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Appendix B, Table 3. Characteristics of Protease Inhibitors  (Last updated April 8, 2015; last reviewed
April 8, 2015)  (page 3 of 4)
Generic Name
(Abbreviation)
Trade Name
Formulations Dosing Recommendationsa
Elimination/
Metabolic
Pathway
Serum
Half-
Life
Storage Adverse Eventsb
Lopinavir/
Ritonavir
(LPV/r)
Kaletra
Tablets:
• (LPV 200 mg
plus RTV 50
mg), or
• (LPV 100 mg
plus RTV 25
mg)
Oral Solution:
• Each 5 mL
contains
(LPV 400 mg
plus RTV 100
mg).
• Oral solution
contains 42%
alcohol.
• (LPV 400 mg plus RTV 100
mg) BID, or 
• (LPV 800 mg plus RTV 200
mg) once daily
Once-daily dosing is not
recommended for patients with
≥3 LPV-associated mutations,
pregnant women, or patients
receiving EFV, NVP, FPV, NFV,
carbamazepine, phenytoin, or
phenobarbital.
With EFV or NVP (PI-Naive or
PI-Experienced Patients):
• LPV/r 500 mg/125 mg tablets
BID (use a combination of 2
LPV/r 200 mg/50 mg tablets
plus 1 LPV/r 100 mg/25 mg
tablet to make a total dose of
LPV/r 500 mg/125 mg), or
• LPV/r 533 mg/133 mg oral
solution BID
Tablet:
• Take without regard to meals.
Oral Solution:
• Take with food.
CYP3A4 inhibitor
and substrate
5–6
hours
Oral tablet is
stable at room
temperature.
Oral solution
is stable at 2°
to 8° C (36° to
46° F) until
date on label
and is stable
for up to 2
months when
stored at room
temperature
(up to 25º C or
77º F). 
• GI intolerance, nausea,
vomiting, diarrhea
• Pancreatitis
• Asthenia
• Hyperlipidemia
(especially
hypertriglyceridemia)
• Serum transaminase
elevation
• Hyperglycemia
• Insulin
resistance/diabetes
mellitus
• Fat maldistribution
• Possible increased
bleeding episodes in
patients with hemophilia
• PR interval prolongation
• QT interval prolongation
and torsades de pointes
have been reported;
however, causality could
not be established.
Nelfinavir
(NFV)
Viracept
• 250 and 625
mg tablets
• 50 mg/g oral
powder
• 1250 mg BID, or
• 750 mg TID
Dissolve tablets in a small
amount of water, mix admixture
well, and consume immediately. 
Take with food.
CYP2C19 and 3A4
substrate—
metabolized to
active M8
metabolite; CYP3A4
inhibitor
3.5–5
hours
Room
temperature
(15º to 30º C
or 59º to 86º
F)
• Diarrhea
• Hyperlipidemia
• Hyperglycemia
• Fat maldistribution
• Possible increased
bleeding episodes in
patients with hemophilia
• Serum transaminase
elevation
Ritonavir
(RTV)
Norvir
• 100 mg tablet
• 100 mg soft
gel capsule
• 80 mg/mL
oral solution
Oral solution
contains 43%
alcohol.
As Pharmacokinetic Booster (or
Enhancer) for Other PIs: 
• 100–400 mg per day in 1 or 2
divided doses (refer to other
PIs for specific dosing
recommendations)
Tablet:
• Take with food.
Capsule and Oral Solution:
• To improve tolerability, take
with food if possible.
CYP3A4 >2D6
substrate; potent
3A4, 2D6 inhibitor;
Inducer of CYPs
1A2, 2C8, 2C9, and
2C19 and UGT1A1
3–5
hours
Tablets do not
require
refrigeration.
Refrigerate
capsules.
Capsules can
be left at room
temperature
(up to 25º C or
77º F) for up
to 30 days. 
Oral solution
should not be
refrigerated.
• GI intolerance, nausea,
vomiting, diarrhea
• Paresthesia (circumoral
and extremities)
• Hyperlipidemia (especially
hypertriglyceridemia)
• Hepatitis
• Asthenia
• Taste perversion
• Hyperglycemia
• Fat maldistribution
• Possible increased
bleeding episodes in
patients with hemophilia
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Appendix B, Table 3. Characteristics of Protease Inhibitors  (Last updated April 8, 2015; last reviewed
April 8, 2015)  (page 4 of 4)
Generic Name
(Abbreviation)
Trade Name
Formulations Dosing Recommendationsa
Elimination/
Metabolic
Pathway
Serum
Half-
Life
Storage Adverse Eventsb
Saquinavir
(SQV)
Invirase
• 500 mg tablet
• 200 mg
capsule
(SQV 1000 mg plus RTV 100
mg) BID
Unboosted SQV is not
recommended.
Take with meals or within 2
hours after a meal.
CYP3A4
substrate
1–2
hours
Room
temperature
(15º to 30º C
or 59º to 86º
F)
• GI intolerance, nausea, and
diarrhea
• Headache
• Serum transaminase elevation
• Hyperlipidemia
• Hyperglycemia
• Fat maldistribution
• Possible increased bleeding
episodes in patients with
hemophilia
• PR interval prolongation
• QT interval prolongation,
torsades de pointes have been
reported. Patients with pre-
SQV QT interval >450 msec
should not receive SQV.
Tipranavir
(TPV) 
Aptivus
• 250 mg
capsule
• 100 mg/mL
oral solution
(TPV 500 mg plus RTV 200 mg)
BID
Unboosted TPV is not
recommended.
With RTV Tablets: 
• Take with meals.
With RTV Capsules or Solution: 
• Take without regard to meals.
CYP P450 3A4
inducer and
substrate
CYP2D6
inhibitor;
CYP3A4, 1A2,
and 2C19
inducer
Net effect when
combined with
RTV (CYP3A4,
2D6 inhibitor)
6 hours
after
single
dose of
TPV/r
Refrigerate
capsules.
Capsules can
be stored at
room
temperature
(25º C or 77º
F) for up to 60
days.
Oral solution
should not be
refrigerated
or frozen and
should be used
within 60 days
after bottle is
opened.
• Hepatotoxicity: Clinical hepatitis
(including hepatic
decompensation and hepatitis-
associated fatalities) has been
reported; monitor patients
closely, especially those with
underlying liver diseases.
• Skin rash (3% to 21%): TPV
has a sulfonamide moiety; use
with caution in patients with
known sulfonamide allergy.
• Rare cases of fatal and nonfatal
intracranial hemorrhages have
been reported. Risks include
brain lesion, head trauma,
recent neurosurgery,
coagulopathy, hypertension,
alcoholism, and the use of anti-
coagulant or anti-platelet agents
(including vitamin E).
• Hyperlipidemia
• Hyperglycemia
• Fat maldistribution
• Possible increased bleeding
episodes in patients with
hemophilia
a For dosage adjustment in hepatic insufficiency, see Appendix B, Table 7.
b Also see Table 14.
Key to Acronyms: APV = amprenavir; ARV = antiretroviral; ATV = atazanavir; ATV/c = atazanavir/cobicistat; AV = atrioventricular; BID =
twice daily; COBI = cobicistat; CYP = cytochrome P; DRV = darunavir; DRV/c = darunavir/cobicistat; EFV = efavirenz; FPV =
fosamprenavir; GI = gastrointestinal; IDV = indinavir; LPV = lopinavir; LPV/r = lopinavir/ritonavir; msec = millisecond; NFV = nelfinavir; NVP
= nevirapine; PI = protease inhibitor; PK = pharmacokinetic; PPI = proton pump inhibitor; RTV = ritonavir; SQV = saquinavir; TDF =
tenofovir disoproxil fumarate; TID = three times a day; TPV = tipranavir
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Appendix B, Table 4. Characteristics of Integrase Inhibitors  (Last updated April 8, 2015; last
reviewed April 8, 2015)  
a For dosage adjustment in hepatic insufficiency, see Appendix, Table 7.
b Also see Table 14.
Key to Abbreviations: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ATV/r = atazanavir/ritonavir; BID = twice daily; c, COBI = cobicistat; CPK
= creatine phosphokinase; CrCl = creatinine clearance; CYP = cytochrome P; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; EVG =
elvitegravir; FPV/r = fosamprenavir/ritonavir; FTC = emtricitabine; HBV = hepatitis B virus; HSR = hypersensitivity reaction; INSTI = integrase strand
transfer inhibitor; LPV/r = lopinavir/ritonavir; RAL = raltegravir; TDF = tenofovir disoproxil fumerate; TPV/r = tipranavir/ritonavir; UGT = uridine diphosphate
gluconyltransferase
Generic Name
(Abbreviation)
Trade Name
Formulations Dosing Recommendationsa
Elimination/
Metabolic
Pathways
Serum
Half-
Life
Adverse Eventsb
Dolutegravir
(DTG)
Tivicay
Also available
as a component
of fixed-dose
combination.
• 50 mg tablet ARV-Naive or ARV-Experienced, INSTI-
Naive Patients:
• 50 mg once daily
ARV-Naive or ARV-Experienced, INSTI-
Naive Patients when CoAdministered
with EFV, FPV/r, TPV/r, or Rifampin: 
• 50 mg BID
INSTI-Experienced Patients with Certain
INSTI Mutations (See Product Label) or
with Clinically Suspected INSTI Resistance:
• 50 mg BID
Take without regard to meals.
UGT1A1
mediated
glucuronidation
Minor
contribution
from CYP3A4
~14
hours
• HSRs including rash, constitutional
symptoms, and organ dysfunction
(including liver injury) have been
reported.
• Insomnia
• Headache
Triumeq
DTG/ABC/3TC
Triumeq:
• (DTG 50 mg
plus 3TC 300
mg plus ABC
600 mg) tablet
Triumeq:
Take 1 tablet daily without regard to
meals.
Elvitegravir
(EVG)
Vitekta
Also available
as a component
of fixed-dose
combination.
85 and 150 mg
tablets
With Once Daily ATV/r or BID LPV/r:
• 85 mg once daily with food
With BID DRV/r, FPV/r, or TPV/r:
• 150 mg once daily with food
Unboosted EVG is not recommended.
CYP3A,
UGT1A1/3
substrate
~9
hours
• Nausea
• Diarrhea
Stribild
EVG/c/FTC/TDF
Stribild:
• (EVG 150 mg
plus COBI 150
mg plus FTC
200 mg plus
TDF 300 mg)
tablet
Stribild:
1 tablet once daily with food.
Not recommended for patients with
baseline CrCl< 70 mL/min (see Appendix
B Table 7 for the equation for calculating
CrCl). 
Not recommended for use with other
antiretroviral drugs.
EVG: As above
COBI: CYP3A,
CYP2D6
(minor); CYP3A
inhibitor
~13
hours
• Nausea
• Diarrhea
• New onset or worsening renal impairment
• Potential decrease in bone mineral density
• Severe acute exacerbation of hepatitis
may occur in HBV-coinfected patients who
discontinue FTC and TDF.
Raltegravir
(RAL)
Isentress
• 400 mg tablet
• 25 and 100 mg
chewable
tablets
• 100 mg single
packet for oral
suspension
400 mg BID
With Rifampin:
• 800 mg BID
Take without regard to meals.
UGT1A1-
mediated
glucuronidation
~9
hours
• Rash, including Stevens-Johnson syn-
drome, HSR, and toxic epidermal
necrolysis
• Nausea
• Headache
• Diarrhea
• Pyrexia
• CPK elevation, muscle weakness, and
rhabdomyolysis
• Insomnia
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Generic Name
(Abbreviation)
Trade Name
Formulation DosingRecommendation
Serum
Half-
Life
Elimination Storage Adverse Eventsa
Enfuvirtide
(T20)
Fuzeon
• Injectable;
supplied as
lyophilized
powder
• Each vial
contains 108
mg of T20;
reconstitute
with 1.1mL of
sterile water
for injection for
delivery of
approximately
90 mg/1 mL.
90 mg (1 mL)
subcutaneously BID
3.8
hours
Expected to
undergo
catabolism to its
constituent
amino acids,
with subsequent
recycling of the
amino acids in
the body pool
Store at room
temperature (up to
25º C or 77º F).
Re-constituted
solution should be
refrigerated at 2º to
8º C (36º to 46º F)
and used within 24
hours.
• Local injection site reactions
(e.g., pain, erythema,
induration, nodules and
cysts, pruritus, ecchymosis)
in almost 100% of patients
• Increased incidence of
bacterial pneumonia
• HSR (<1% of patients):
Symptoms may include rash,
fever, nausea, vomiting,
chills, rigors, hypotension, or
elevated serum
transaminases. Re-challenge
is not recommended.
Appendix B, Table 5. Characteristics of Fusion Inhibitor  (Last updated January 29, 2008; last
reviewed April 8, 2015)  
a Also see Table 14.
Key to Abbreviations: BID = twice daily; HSR = hypersensitivity reaction; T20 = enfuvirtide
Generic Name
(Abbreviation)/
Trade Name
Formulation DosingRecommendationsa
Serum 
Half-Life
Elimination/
Metabolic
Pathway
Adverse Eventsb
Maraviroc
(MVC)
Selzentry
150 and 300 mg
tablets
150 mg BID when given with
drugs that are strong CYP3A
inhibitors (with or without
CYP3A inducers) including
PIs (except TPV/r)
300 mg BID when given with
NRTIs, T20, TPV/r, NVP,
RAL, and other drugs that
are not strong CYP3A
inhibitors or inducers
600 mg BID when given with
drugs that are CYP3A
inducers, including EFV,
ETR, etc. (without a CYP3A
inhibitor)
Take without regard to
meals.
14–18 hours CYP3A4
substrate
• Abdominal pain
• Cough
• Dizziness
• Musculoskeletal symptoms
• Pyrexia
• Rash
• Upper respiratory tract
infections
• Hepatotoxicity, which may be
preceded by severe rash or
other signs of systemic allergic
reactions
• Orthostatic hypotension,
especially in patients with
severe renal insufficiency
Appendix B, Table 6. Characteristics of CCR5 Antagonist  (Last updated March 27, 2012; last
reviewed April 8, 2015)  
a For dosage adjustment in hepatic insufficiency, see Appendix, Table 7.
b Also see Table 14.
Key to Abbreviations: BID = twice daily; CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside
reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; T20 = enfuvirtide; TPV/r = tipranavir/ritonavir
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ARVs
Generic Name
(Abbreviation)
Trade Name
Usual Daily Dosea Dosing in Renal Insufficiencyb Dosing in Hepatic Impairment
NRTIs
Stribild should not be initiated in patients with CrCl <70 mL/min. Use of the following fixed-dose combinations is not recommended in patients
with CrCl <50 mL/min: Atripla, Combivir, Complera, Epzicom, Stribild, Triumeq, or Trizivir. Use of Truvada is not recommended in patients
with CrCl <30 mL/min. 
Abacavir
(ABC)
Ziagen
300 mg PO BID No dosage adjustment necessary Child-Pugh Score 5–6: 
• 200 mg PO BID (use oral solution)
Child-Pugh Score >6: 
• Contraindicated
Didanosine EC
(ddI)
Videx EC
Body Weight ≥60 kg:
• 400 mg PO once daily
Body Weight <60 kg:
• 250 mg PO once daily
No dosage adjustment necessary.
Didanosine Oral
Solution
(ddI)
Videx
Body Weight ≥60 kg: 
• 200 mg PO BID, or
• 400 mg PO once daily
Body Weight <60 kg: 
• 250 mg PO once daily, or
• 125 mg PO BID
No dosage adjustment necessary.
Emtricitabine
(FTC)
Emtriva
200 mg oral capsule once
daily 
or 
240 mg (24 mL) oral
solution once daily
No dosage recommendation.
Lamivudine
(3TC)
Epivir
300 mg PO once daily 
or
150 mg PO BID
No dosage adjustment necessary.
Appendix B, Table 7. Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic
Insufficiency  (Last updated May 1, 2014; last reviewed April 8, 2015)  (page 1 of 6)
See the reference section at the end of this table for creatinine clearance (CrCl) calculation formulas and criteria for Child-
Pugh classification.
Dose (Once Daily)
CrCl (mL/min) ≥60 kg <60 kg
30–59 200 mg 125 mg
10–29 125 mg 125 mg
<10, HDc, CAPD 125 mg 75 mg oral solution
Dose (Once Daily)
CrCl (mL/min) ≥60 kg <60 kg
30–59 200 mg 150 mg
10–29 150 mg 100 mg
<10, HDc, CAPD 100 mg 75 mg
Dose
CrCl (mL/min) Capsule Solution
30–49 200 mg q48h 120 mg q24h
15–29 200 mg q72h 80 mg q24h
<15 or on HDc 200 mg q96h 60 mg q24h
CrCl (mL/min) Dose
30–49 150 mg q24h
15–29 1 x 150 mg, then 100 mg q24h
5–14 1 x 150 mg, then 50 mg q24h
<5 or on HDc 1 x 50 mg, then 25 mg q24h
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ARVs
Generic Name
(Abbreviation)
Trade Name
Usual Daily Dosea Dosing in Renal Insufficiencyb Dosing in Hepatic Impairment
NRTIs, continued
Stavudine
(d4T)
Zerit
Body Weight ≥60 kg:
• 40 mg PO BID
Body Weight <60 kg:
• 30 mg PO BID
No dosage recommendation.
Tenofovir
Disoproxil
Fumarate
(TDF)
Viread
300 mg PO once daily No dosage adjustment necessary.
Emtricitabine
(FTC)
plus
Tenofovir Disoproxil
Fumarate
(TDF)
Truvada
1 tablet PO once daily No dosage recommendation.
Zidovudine
(AZT, ZDV)
Retrovir
300 mg PO BID No dosage recommendation.
NNRTIs
Delavirdine
(DLV)
Rescriptor
400 mg PO TID No dosage adjustment necessary. No dosage recommendation; use
with caution in patients with hepatic
impairment.
Efavirenz
(EFV)
Sustiva
600 mg PO once daily, at or
before bedtime
No dosage adjustment necessary. No dosage recommendation; use
with caution in patients with hepatic
impairment.
Efavirenz (EFV)
plus
Tenofovir Disoproxil
Fumarate
(TDF)
plus
Emtricitabine (FTC)
Atripla
1 tablet PO once daily Not recommended for use in patients with CrCl
<50 mL/min. Instead use the individual drugs of
the fixed-dose combination and adjust TDF and
FTC doses according to CrCl level.
Appendix B, Table 7. Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic
Insufficiency  (Last updated May 1, 2014; last reviewed April 8, 2015)  (page 2 of 6)
Dose
CrCl (mL/min) ≥60 kg <60 kg
26–50 20 mg q12h 15 mg q12h
10–25 or on HDc 20 mg q24h 15 mg q24h
CrCl (mL/min) Dose
30–49 300 mg q48h
10–29 300 mg twice weekly (every
72–96 hours)
<10 and not on
HD
No recommendation
On HDc 300 mg q7d
CrCl (mL/min) Dose
30–49 1 tablet q48h
<30 or on HD Not recommended
CrCl (mL/min) Dose
<15 or on HDc 100 mg TID or 300 mg once
daily
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ARVs
Generic Name
(Abbreviation)
Trade Name
Usual Daily Dosea Dosing in Renal Insufficiencyb Dosing in Hepatic Impairment
NNRTIs, continued
Etravirine
(ETR)
Intelence
200 mg PO BID No dosage adjustment necessary. Child-Pugh Class A or B: 
• No dosage adjustment
Child-Pugh Class C: 
• No dosage recommendation
Nevirapine
(NVP)
Viramune
or 
Viramune XR
200 mg PO BID 
or 
400 mg PO once daily
(using Viramune XR
formulation)
Patients on HD: 
• Limited data; no dosage recommendation.
Child-Pugh Class A: 
• No dosage adjustment
Child-Pugh Class B or C:
• Contraindicated
Rilpivirine
(RPV)
Edurant
25 mg PO once daily No dosage adjustment necessary. Child-Pugh Class A or B: 
• No dosage adjustment
Child-Pugh Class C: 
• No dosage recommendation
Rilpivirine (RPV) 
plus 
Tenofovir Disoproxil
Fumarate (TDF) 
plus 
Emtricitabine (FTC)
Complera
1 tablet PO once daily Not recommended for use in patients with
CrCl <50 mL/min. Instead use the individual
drugs of the fixed-dose combination and
adjust TDF and FTC doses levels according to
CrCl level.
Child-Pugh Class A or B: 
• No dosage adjustment
Child-Pugh Class C: 
• No dosage recommendation
PIs
Atazanavir
(ATV)
Reyataz
400 mg PO once daily 
or
(ATV 300 mg plus RTV 100
mg) PO once daily 
No dosage adjustment for patients with renal
dysfunction who do not require HD.
ARV-Naive Patients on HD:
• (ATV 300 mg plus RTV 100 mg) once daily
ARV-Experienced Patients on HD: 
• ATV or ATV/r not recommended
Child-Pugh Class B: 
• 300 mg once daily
Child-Pugh Class C: 
• Not recommended
RTV boosting is not recommended
in patients with hepatic impairment
(Child-Pugh Class B or C).
Atazanavir
(ATV)
plus
Cobicistat
(COBI)
Evotaz
1 tablet PO once daily If Used with TDF:
• Not recommended for use in patients with
CrCl <70 mL/min.
If Not Used with TDF:
• No dosage adjustment for patients with renal
dysfunction who do not require HD.
No dosage recommendation; not
recommended in patients with
hepatic impairment.
Appendix B, Table 7. Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic
Insufficiency  (Last updated May 1, 2014; last reviewed April 8, 2015)  (page 3 of 6)
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ARVs
Generic Name
(Abbreviation)
Trade Name
Usual Daily Dosea Dosing in Renal Insufficiencyb Dosing in Hepatic Impairment
PIs, continued
Darunavir
(DRV)
Prezista
ARV-Naive Patients and
ARV-Experienced Patients
with No DRV Resistance
Mutations: 
• (DRV 800 mg plus RTV
100 mg) PO once daily 
ARV-Experienced Patients
with at Least One DRV
Resistance Mutation:
• (DRV 600 mg plus RTV
100 mg) PO BID
No dosage adjustment necessary. Mild-to-Moderate Hepatic
Impairment:
• No dosage adjustment
Severe Hepatic Impairment:
• Not recommended
Darunavir
(DRV)
plus
Cobicistat
(COBI)
Prezcobix
1 tablet PO once daily (only
recommended for patients
without DRV-associated
resistance mutations)
If Used with TDF:
• Not recommended for use in patients with
CrCl <70 mL/min.
If Not Used with TDF:
• No dosage adjustment necessary.
Child-Pugh Class A or B: 
• No dosage adjustment
Child-Pugh Class C: 
• Not recommended
Fosamprenavir
(FPV)
Lexiva
1400 mg PO BID 
or 
(FPV 1400 mg plus RTV
100–200 mg) PO once
daily 
or
(FPV 700 mg plus RTV 100
mg) PO BID
No dosage adjustment necessary. PI-Naive Patients Only:
Child-Pugh Score 5–9:
• 700 mg BID
Child-Pugh Score 10–15:
• 350 mg BID
PI-Naive or PI-Experienced
Patients:
Child-Pugh Score 5–6: 
• (700 mg BID plus RTV 100 mg)
once daily
Child-Pugh Score 7–9: 
• (450 mg BID plus RTV 100 mg)
once daily
Child-Pugh Score 10–15: 
• (300 mg BID plus RTV 100 mg)
once daily
Indinavir
(IDV)
Crixivan
800 mg PO q8h No dosage adjustment necessary. Mild-to-Moderate Hepatic
Insufficiency Because of Cirrhosis: 
• 600 mg q8h
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ARVs
Generic Name
(Abbreviation)
Trade Name
Usual Daily Dosea Dosing in Renal Insufficiencyb Dosing in Hepatic Impairment
PIs, continued
Lopinavir/ritonavir
(LPV/r)
Kaletra
(LPV 400 mg plus RTV 100
mg) PO BID 
or 
(LPV 800 mg plus RTV 200
mg) PO once daily 
Avoid once-daily dosing in patients on HD. No dosage recommendation; use with
caution in patients with hepatic
impairment.
Nelfinavir
(NFV)
Viracept
1250 mg PO BID No dosage adjustment necessary. Mild hepatic impairment: 
• No dosage adjustment
Moderate-to-severe hepatic impairment:
• Do not use.
Ritonavir
(RTV)
Norvir
As a PI-Boosting Agent:
• 100–400 mg per day
No dosage adjustment necessary. Refer to recommendations for the
primary PI.
Saquinavir
(SQV)
Invirase
(SQV 1000 mg plus RTV
100 mg) PO BID
No dosage adjustment necessary. Mild-to-Moderate Hepatic Impairment:
• Use with caution.
Severe Hepatic Impairment:
• Contraindicated
Tipranavir
(TPV)
Aptivus
(TPV 500 mg plus RTV 200
mg) PO BID
No dosage adjustment necessary. Child-Pugh Class A:
• Use with caution
Child-Pugh Class B or C:
• Contraindicated
INSTIs
Dolutegravir
(DTG)
Tivicay
50 mg once daily 
or
50 mg BID
No dosage adjustment necessary. Child-Pugh Class A or B:
• No dosage adjustment
Child-Pugh Class C:
• Not recommended
Elvitegravir
(EVG)
Vitekta
85 mg or 150 mga once
daily
No dosage adjustment necessary. Child-Pugh Class A or B:
• No dosage adjustment
Child-Pugh Class C:
• Not recommended
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ARVs
Generic Name
(Abbreviation)
Trade Name
Usual Daily Dosea Dosing in Renal Insufficiencyb Dosing in Hepatic Impairment
INSTIs, continued
Elvitegravir (EVG) 
plus
Cobicistat (COBI) 
plus
Tenofovir Disoproxil
Fumarate (TDF) 
plus
Emtricitabine (FTC)
Stribild
1 tablet once daily EVG/c/TDF/FTC should not be initiated in
patients with CrCl <70 mL/min. 
Discontinue EVG/c/TDF/FTC if CrCl
declines to <50 mL/min while patient is on
therapy.
Mild-to-Moderate Hepatic Insufficiency:
• No dosage adjustment necessary
Severe Hepatic Insufficiency:
• Not recommended
Raltegravir
(RAL)
Isentress
400 mg BID No dosage adjustment necessary. Mild-to-Moderate Hepatic Insufficiency:
• No dosage adjustment necessary
Severe Hepatic Insufficiency:
• No recommendation
Fusion Inhibitor
Enfuvirtide
(T20)
Fuzeon
90 mg subcutaneous BID No dosage adjustment necessary. No dosage adjustment necessary
CCR5 Antagonist
Maraviroc
(MVC)
Selzentry
The recommended dose
differs based on
concomitant medications
and potential for drug-drug
interactions. See Appendix
B, Table 6 for detailed
dosing information.
CrCl <30 mL/min or on HD
Without Potent CYP3A Inhibitors or
Inducers:
• 300 mg BID; reduce to 150 mg BID if
postural hypotension occurs
With Potent CYP3A Inducers or Inhibitors:
• Not recommended
No dosage recommendations.
Concentrations will likely be increased in
patients with hepatic impairment.
Appendix B, Table 7. Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic
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a Refer to Appendix B, Tables 1–6 for additional dosing information
b Including with chronic ambulatory peritoneal dialysis and hemodialysis
c On dialysis days, take dose after HD session
Key to Abbreviations: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ATV = atazanavir; AZT = zidovudine; BID = twice daily;
CAPD = chronic ambulatory peritoneal dialysis; COBI, c = cobicistat; CrCl = creatinine clearance; CYP = cytochrome P; d4T = stavudine;
ddI = didanosine; DLV = delavirdine; DRV = darunavir; EC = enteric coated; DTG = dolutegravir; EFV = efavirenz; ETR = etravirine; EVG=
elvitegravir; FPV = fosamprenavir; FTC = emtricitabine; HD = hemodialysis; IDV = indinavir; LPV/r = lopinavir/ritonavir; MVC = maraviroc;
NFV = nelfinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP =
nevirapine; PI = protease inhibitor; PO = orally; q(n)d = every (n) days; q(n)h = every (n) hours; RAL = raltegravir; RPV = rilpivirine; RTV =
ritonavir; SQV = saquinavir; T20 = enfuvirtide; TDF = tenofovir disoproxil fumarate; TID = three times daily; TPV = tipranavir; XR =
extended release; ZVD = zidovudine
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Creatinine Clearance Calculation
Male: (140 - age in years) x (weight in kg)
72 x (serum creatinine)
Female: (140 - age in years) x (weight in kg) x (0.85)
72 x (serum creatinine) 
Child-Pugh Score
Component Points Scored
1 2 3
Encephalopathya None Grade 1–2 Grade 3–4
Ascites None Mild or controlled by diuretics Moderate or refractory despite diuretics
Albumin >3.5 g/dL 2.8–3.5 g/dL <2.8 g/dL
Total bilirubin or <2 mg/dL (<34 μmol/L) 2–3 mg/dL (34 μmol/L to 50 μmol/L) >3 mg/dL (>50 μmol/L)
Modified total bilirubinb <4 mg/dL 4–7 mg/dL >7 mg/dL
Prothrombin time
(seconds prolonged) or
<4 4–6 >6
International normalized
ratio (INR)
<1.7 1.7–2.3 >2.3
a Encephalopathy Grades
Grade 1: Mild confusion, anxiety, restlessness, fine tremor, slowed coordination
Grade 2: Drowsiness, disorientation, asterixis
Grade 3: Somnolent but rousable, marked confusion, incomprehensible speech, incontinence, hyperventilation
Grade 4: Coma, decerebrate posturing, flaccidity
b Modified total bilirubin used for patients who have Gilbert’s syndrome or who are taking indinavir or atazanavir
Child-Pugh Classification Total Child-Pugh Scorec
Class A 5–6 points
Class B 7–9 points
Class C >9 points
c Sum of points for each component
